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Abstract 
Bacterial resistance is a continuously evolving threat to our most common 
antibiotics; the β-lactams. Most recently, the production of β-lactamase 
enzymes by bacteria rendered many of our current antibiotics unusable 
threatening to plunge us into a ‘pre-antibiotic’ era. Metallo-β-lactamases 
(MBLs) play a key role in bacterial resistance to β-lactam antibiotics by 
efficiently catalysing the hydrolysis of the β-lactam amide bond. Since their 
discovery, the clinically relevant MBLs, Verona integrin-encoded metallo-β-
lactamase (VIM-2), Imipenemase (IMP-1), New Delhi metallo-β-lactamase 
(NDM-1) and Sao Paulo metallo-β-lactamase (SPM-1), have spread across 
the world with cases reported in almost all countries. 
This thesis describes a number of approaches to the identification of 
inhibitors of MBLs. A combination of structure-based drug design, chemical 
synthesis and biological evaluation has been used to rationally identify novel 
inhibitors of VIM-2, IMP-1, NDM-1 and SPM-1 which have also been co 
administered with a current β-lactam antibiotic and been found to re-
sensitise the bacteria to the antibiotic. Four novel classes of inhibitor have 
been investigated by taking different approaches to inhibitor discovery. 
A vHTS screening campaign was conducted to identify potential inhibitors 
from libraries of known compounds. The campaign identified some weak 
binding inhibitors. Boronic acid-based inhibitors were identified by using 
vHTS and de novo design respectively and were synthesised which gave 
IC50’s in the region of 10 nM against VIM-2 and NDM-1. Additionally, a new 
computational method for the identification of peptides which bind to 
enzymes has been developed which found Pro-Cys-Phe to be the most 
active peptide for binding to NDM-1 with an IC50 of 183 µM. This method 
could be applied to many other systems. In the final approach, de novo 
design using SPROUT led to the design of a novel thiol based inhibitor 
class. The inhibitor class has been co-crystallised in VIM-2 and gives IC50 
values in the range of 200 nM. The inhibitor class has also successfully 
shown a 100 fold recovery of the MIC of meropenem against NDM-1 
expressing bacteria.  
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Chapter 1 
Bacterial Resistance 
Bacterial infections cause seventeen million deaths per year worldwide and 
it is estimated that currently one third of the world’s population is likely to be 
infected by bacterial pathogens.1 Bacteria continue to develop resistance to 
new antibiotics with the result that antibiotics have a short and finite lifetime. 
Considerable research is therefore needed to find new antibiotics or ways to 
slow the development of resistance in bacteria.  
Beginning with the production of penicillin in the late 1930s and running right 
up until the discovery of daptomycin in 1987, was a period of time which 
generated almost all of the antibiotic classes which are used in the clinic 
today. This period, which was later known as the ‘golden age’ of antibacterial 
drug discovery, has been hailed as one of the most important advancements 
in modern medicine.2 However since 1987, the majority of large 
pharmaceutical companies have focussed their efforts on other therapeutic 
areas which has indirectly allowed bacteria to develop widespread 
resistance to our most commonly used antibiotics. 
The term ‘antibiotic’ was first used to classify natural products that inhibited 
the growth of, or killed microorganisms.3 This definition has now been 
extended to include synthetic and semi-synthetic antibacterial agents. These 
natural products were secondary metabolites of actinomycetes, microbes 
isolated from soil samples and marine deposits, a rich source of structurally 
complex chemical entities which are produced to protect the microbes from 
other bacteria. The use of nature’s natural products in herbal medicines has 
occurred for centuries, but isolating and characterising these compounds 
required modern techniques to produce the quantities required to satisfy 
medical need during the 20th century.  
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1.1 The structure of bacteria 
Bacteria are part of a large group of unicellular prokaryotic micro-organisms. 
Many bacteria have beneficial effects for humans. However, infection with 
others can have detrimental effects, and, in the most extreme cases can 
lead to death.  
 
Figure 1: Bacterial cell shapes, adapted from
4
 
Two main bacterial cell shapes are common; cocci which are spherical, and 
bacilli, which are rod shaped (Figure 1). Eubacteria and archaebacteria are 
the two subgroups bacteria can be divided into. The eubacteria subgroup 
includes Escherichia coli and Klebsiella pneumoniae. The archaebacteria 
are a diverse group of organisms which have very different cell walls and 
membranes compared to eubacteria. They include bacteria capable of 
existing in extreme conditions such as Sulfolobas and Pyroccus. This review 
concentrates on eubacteria as this encompasses most of the human 
pathogenic bacteria.  
Bacteria are small, single cell prokaryotic microorganisms which have a 
simple internal cell structure; however the cell surface is considerably more 
complex.5 Bacteria have no mitochondria or chloroplasts which are 
associated with energy production in eukaryotic cells, and additionally have 
a cell wall consisting of peptidoglycan. Peptidoglycan is a polymer of sugars 
and amino acids, unique to prokaryotic cells, that contributes to cell wall 
rigidity and shape. The cell wall is a tough multifunctional layer, protecting 
the cell from mechanical damage and osmotic lysis. The cell wall also acts 
- 4 - 
as a barrier to exclude various molecules, including polar drugs, via the 
cytoplasmic membrane. In certain bacteria, there can be a capsule formed 
around the bacterial cell formed of polysaccharide or another protein. Fibrils 
can be found on the cell surface which aid the adhesion of bacteria to 
surfaces. A flagellum will be present if the bacteria is required to move and 
become mobile (Figure 2).6 
 
Figure 2: The structural components of a bacterial cell.   
There are two subclasses of bacteria, which can be distinguished by their 
response to the Gram stain.7 Bacteria which are stained violet or blue by the 
crystal Gram stain are defined as Gram-positive bacteria. Their ability to 
retain the stain is due to the high content of peptidoglycan in their thick cell 
wall. Bacillus subtilis, Staphylococcus epidermidis, and Clostridium 
botulinum are all Gram-positive bacteria.  
Bacteria which are not stained via the Gram test but are stained by the 
counterstain (safranin) and appear red or pink are defined as Gram-negative 
bacteria. The result is due to the relative amounts of peptidoglycan found in 
the cell wall. Gram-positive bacteria has a thick peptidoglycan layer usually 
between 20-80 nm thick whereas Gram-negative bacteria have a much 
thinner peptidoglycan layer, about 7-8 nm thick (Figure 3). Gram-negative 
bacteria also have an additional lipopolysaccharide outer membrane, an 
orthogonal barrier to the cytoplasmic barrier, which excludes hydrophobic 
molecules with >600 Da molecular mass.  Escherichia Coli, Pseudomonas, 
and Stenotrophomonas are all Gram-negative bacteria.  
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Figure 3: The structure of the cell wall a) Gram-positive cell b) Gram-negative cell 
The great challenge for agents acting on Gram-negative bacteria is to 
penetrate both the outer and cytoplasmic membranes since different 
physiochemical properties are required to pass through each layer. This task 
is no easier for agents acting on Gram-positive bacteria since cell walls vary 
greatly between bacterial species. Not only do antibacterial agents require 
affinity for a certain biological target, but they need to be membrane 
permeable to accumulate inside bacterial cells and exert their function. This 
is the defining feature of antibiotics which sets them apart from other 
therapeutic drugs.  
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1.2 Antibacterial agents 
Fatalities from bacterial infections have become relatively rare occurrences 
in the developed world over the last 50 years. This is due to overall 
improvements in medication, increased levels of sanitation, good housing 
and better nutrition. Antibacterial agents have become key to fighting many 
bacterial infections which would have previously been life threatening. 
Antibacterial agents are defined as natural or synthetic chemical compounds 
used to impede the growth of, or kill, bacteria.8 If the compound is isolated 
from microbes, they are referred to as antibiotics. In 2009 the global 
antibiotic market generated an estimated $42 billion USD in sales. Experts 
predict with an average annual growth rate of ~4%, antibiotic sales could 
reach $60 billion USD by 2015.9  
From around 1987 the majority of large pharmaceutical companies focussed 
their research on other therapeutic areas. It was generally agreed that due to 
the large number of antibiotics available, it was not commercially viable to 
spend time and money researching new antibiotics. Antibacterial research is 
now returning as a focus of many pharmaceutical companies due to the 
increase in hospital acquired diseases and antibiotic resistance in the 
community, threatening a return to a ‘pre-antibiotic era’. Legislation has also 
been altered in order to help with the fast track and streamlining of approval 
of new antibacterial agents. In 2013 the FDA announced the Antibiotic 
Development to Advance Patient Treatment Act (ADAPT) which allows the 
approval of drugs to the market for the most serious cases of resistant 
bacterial infections which require a much smaller set of clinical testing data. 
1.2.1 History of antibacterial agents 
The first recognised antibacterial agent was salvarsan, an arsenic-containing 
compound used for the treatment of syphilis, discovered in 1909 by Paul 
Ehrlich, a pioneer of chemotherapy.10 This was an early example of his 
‘magic bullet’ theory, whereby a chemical agent could selectively cure a 
particular disease. The discovery of penicillin by Fleming in 1928 changed 
modern medicine, as penicillin was effective against a wide range of Gram-
positive bacteria.11 In 1935 Gerhard Domagk discovered the sulfonamides, 
the first effective drug administered against bacterial infections, for which 
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Domagk won the Nobel prize in 1939.12 These two discoveries marked the 
beginning of the golden age of antibacterial drug discovery (Figure 4). 
During this time actinomycetes provided a great source of antibacterial 
agents, discovered through the empirical screening of fermentation broths 
and extracts of microorganisms containing secondary metabolites which 
inhibited bacterial growth. Over 20 antibiotic classes used today were 
discovered from the actinomycetes during the ‘golden age’ of antibacterial 
drug discovery. During this period of high antibacterial agent discovery, 
clinicians were effectively able to deal with any bacterial resistance which 
arose.  
 
Figure 4: A timeline of the initial discoveries of antibiotic classes. Showing the key 
introductions of β-lactam antibiotics (blue) and the discovery void since the late 
1980s. Adapted from
13
 
Since the discovery of daptomycin in 1987, no new classes of antibiotics 
have been identified and successfully delivered to the clinic, leading to a 
period known as the ‘discovery void’ (Figure 4). The emphasis on 
discovering antibacterial agents with better whole cell activity and 
pharmacokinetic properties switched to finding analogues of previously 
identified classes rather than previous methods of identifying new 
antibacterial agents and classes from natural products. Eighteen of the 
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twenty newly approved antibiotics between 2000 and 2011 are analogues of 
either the β-lactam or quinolone classes. From 1995, a target-based 
approach was been employed by many companies looking to identify drugs 
specific to the desired bacteria. Screening of natural products was seen as 
time consuming and expensive. However, high throughput screening (HTS) 
and genomic methods have so far failed to deliver a drug to the market. As 
described by Spellberg et al.,14 the number of antibiotics accepted in the 
clinic has dropped but resistance has continued to rise. A review of recent 
literature suggests that the current rate of antibacterial drug discovery 
cannot meet  clinical needs.15  
1.2.2 Mechanisms of action 
Different antibacterial families have different mechanisms of action against 
bacteria; (Table 1).  
Table 1: Antibacterial classes and their enzyme targets 
Antibiotic Family Enzyme Target Source 
Date 
Discovered 
Inhibitors of cell wall biosynthesis 
   
Penicillins (β-lactams) Transpeptidase Actinomycete 1932 
Cephalosporins (β-lactams) Transpeptidase Fungus 1948 
Carbapenems (β-lactams) Transpeptidase Actinomycete 1976 
Glycopeptides Transpeptidase Actinomycete 1952 
Inhibitors of protein biosynthesis 
   
Tetracyclines 30S ribosome subunit Actinomycete 1945 
Aminoglycosides 30S ribosome subunit Actinomycete 1943 
Oxazolidinones 50S ribosome subunit Oxazolidinone 1990s 
Macrolides 50S ribosome subunit Actinomycete 1949 
Chloramphenicol 50S ribosome subunit Natural product derived 1949 
Inhibitors of DNA/RNA biosynthesis 
   
Fluoroquinolones DNA gyrase Synthetic 1962 
Novobiocin DNA gyrase Natural product derived 1955 
Rifamycins RNA polymerase Actinomycete 1957 
Inhibitors of cell membrane structure 
and function 
   
Lipopeptides n/a Actinomycete 1986 
Polymyxin n/a Natural product derived 1947 
Inhibitors of cell metabolism 
   
Sulfonamides Dihydropteroate synthase Synthetic 1932 
Trimethoprim Dihydrofolate reductase Synthetic 1950s 
Triclosan Fabl Synthetic 1972 
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The mechanisms in Table 1 show how bacteria are targeted by antibacterial 
agents. Below is a general description of the five bacterial targeting 
mechanisms: 
 Inhibition of bacterial cell wall synthesis: This leads to bacterial cell 
lysis and death. Mammalian cells do not have a cell wall composed of 
primarily peptidoglycan and are therefore not affected by these 
agents. 
 Disruption / inhibition of protein synthesis: The proteins and enzymes 
needed for bacterial cell survival are no longer produced, leading to 
cell death. 
 Inhibition of nucleic acid transcription and replication: This prevents 
cell division and or synthesis of essential proteins.    
 Interactions with the plasma membrane: Antibacterial agents interact 
with the plasma membrane of the bacterial cell to affect membrane 
permeability. 
 Inhibition of cell wall metabolism: Antibacterial agents which inhibit 
cell metabolism are termed antimetabolites. These compounds inhibit 
the metabolism of a microorganism, but not the metabolism of the 
host. This can be done by inhibiting an enzyme catalysed reaction 
which is present in the bacterial cell, but not in animal cells.  
1.2.3 β-lactam antibiotics 
Seventy years from their first use, β-lactam antibiotics remain the single 
most important type of antibiotic in the clinic in terms of sales9 and 
prescriptions.16 As one of the few antibiotic classes which show a broad-
spectrum activity, β-lactam antibiotics are of particular importance in the 
treatment of infections by Gram-negative pathogens. In particular these 
drugs have retained their importance as resistance to other broad spectrum 
antibiotics such as fluoroquinolones has increased.17 
β-Lactam antibiotics derive their name from their four-membered cyclic 
amide rings motif. The most well-known β-lactam antibiotics are the penicillin 
family which are classified as part of the penams (Figure 5). 
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Figure 5: β-lactam antibiotics: a) Cephalosporin 1.1, b) Monobactam 1.2, c) Carbapenem 
1.3, d) Penicillin 1.4, e) Amoxicillin 1.5. 
1.2.3.1 History of the β-lactam antibiotics 
In 1928, Fleming noted that a bacterial culture on the surface of an agar 
plate that had been left for several weeks open to air had become 
contaminated by a fungal colony. He noted that there was an area on the 
surface around the fungal growth where the bacterial colonies were dying. 
He concluded that the fungal colony was producing an antibacterial agent 
which was spreading to the surrounding area. Fleming set about identifying 
the fungus and showed it to be from the Penicillium genus and he termed 
the active agent ‘penicillin’.11  
Penicillin was first isolated in 1938 by Florey and Chain using processes 
such as freeze drying and chromatography which allowed for isolation under 
much milder conditions than previously had been available.18 By 1941 Florey 
and Chain had produced sufficient penicillin in order to enable the clinical 
trials and achieved spectacular success. The structure of penicillin was 
finally confirmed in 1945 when Dorothy Hodgkin successfully performed X-
ray crystallographic analysis. The first full synthesis was conducted by 
Sheehan in 1957 however this route was deemed commercially unviable.19 
Beechams isolated a biosynthetic intermediate of penicillin called 6-
aminopenicillanic acid which revolutionised the field of penicillins opening up 
a huge range of semi-synthetic penicillins. 
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Figure 6: The structure of cephalosporin C 1.6 
The second major group of β-lactam antibiotics is the cephalosporins. The 
first cephalosporin (cephalosporin C, Figure 6) was identified within a 
fungus obtained in the mid-1940s from sewer waters on the island of 
Sardinia. The first isolation was achieved in 1948 by workers at the 
University of Oxford but it was not until 1961 that the X-ray crystal structure 
was confirmed. As shown in Figure 5, the cephalosporin (1.1) structure has 
clear similarities to penicillin (1.4) with containing a bicyclic system and four 
membered β-lactam ring. The β-lactam ring in the cephalosporin is fused to 
a six membered ring rather than a five membered ring in the penicillins.  
1.2.3.2 Mechanism of action. 
β-lactam antibiotics act upon the peptidoglycan component of the cell wall of 
bacteria. The cell wall is a peptidoglycan structure consisting of peptide and 
sugar units (Figure 7). The structure of the wall consists of a parallel series 
of sugar backbones consisting of two types of sugar, (N-acetylmuramic acid 
(NAM) and N-acetylglucosamine (NAG)). Peptide chains are bound to the 
NAM sugars which contain both L-and D-amino acids. In the final stage of 
cell wall biosynthesis, the peptide chains are linked together by the 
displacement of D-alanine from one chain and glycine in another. This final 
stage is where the β-lactam antibiotics act by disrupting the cross-linking. 
This results in the wall becoming fragile and it can no longer prevent water 
continually entering the cell as a result of osmotic pressure causing the cell 
to swell and eventually burst.  The enzymes responsible for the cross linking 
reaction are known as the transpeptidase enzyme or Penicillin Binding 
Protein (PBPs). 
- 12 - 
 
Figure 7: Peptidoglycan structure of bacterial cell walls, adapted from
20
 
The transpeptidase enzymes are bound to the outer surface of the 
cytoplasmic membrane. In the cross-linking mechanism (Figure 8), a serine 
residue acts as a nucleophile to split the peptide bond between the two D-
Ala units (A). The terminal D-Ala departs leaving the peptide chain bound to 
the enzyme. The pentaglycyl moiety of another peptide chain now enters the 
active site and forms a new peptide bond with the D-Ala displacing the 
enzyme bound through the serine residue (B). The cell wall is then cross 
linked and much stronger (C).  
The β-lactam antibiotic has a conformation which is similar to the transition-
state conformation taken up by the D-Ala-D-Ala moiety during the cross-
linking reaction. The enzyme binds the β-lactam antibiotic to the active site in 
place of the D-Ala-D-Ala through the serine residue (D). The enzyme 
hydrolyses the β-lactam ring, however as the β-lactam is a cyclic molecule it 
is not split into two, so nothing leaves the active site. Subsequent hydrolysis 
of the β-lactam antibiotic does not occur as the antibiotic structure blocks 
access to the pentaglyine chain (F) and water (G).  
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Figure 8 : Mechanisms of transpeptidase cross-linking and penicillin inhibition, reproduced 
from
20
 
1.3 Bacterial resistance 
Hospital-acquired infections are a major and growing threat to public 
health.21 Multi-drug resistant bacteria compromise the ability to perform what 
are now considered routine surgical procedures. More worrying is the fact 
that these infections are becoming more prevalent in the community and are 
no longer solely a hospital-based problem.22 Bacterial resistance 
complicates treatments and increases the likelihood of death and financial 
cost. 
There are two broad resistance mechanisms seen: Inherent or natural 
resistance where the bacterium is inherently resistant to an antibiotic, or 
acquired resistance by genetic mutation or gene transfer. Acquired 
resistance can occur by vertical evolution which is a classical Darwinian type 
of evolution, or horizontal evolution, which involves genetic transfer between 
strains and species.  
These two broad classes of resistance can be subdivided into different 
mechanisms by which the resistance can arise (Figure 9):8, 23, 24  
Transpeptidase cross-linking 
Penicillin inhibition 
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1. Enzymic destruction or inactivation of the antibiotic – includes the 
most common modes of resistance to penicillins and cephalosporins. 
2. Alteration of the target site, or protection of a new site – this is seen 
in β-lactam antibiotics and others including glycopeptides. 
3. Reduced antibiotic uptake – this is important for tetracycline and β-
lactam antibiotics.   
4. Increased efflux of the antibiotic from the bacteria – this is often seen 
with macrolides, tetracyclines and quinolones. 
5. Over-expression of the drug target  
6. Acquisition of a replacement for the metabolic step initiated by the 
antibiotic – known examples include sulphonamides and trimethoprim 
 
Figure 9: Resistance mechanisms, adapted from
25
 
Many different classes of antibiotics have been administered to patients in 
the clinic to treat bacterial infections, and for each class at least one 
mechanism of resistance has been observed. Resistance has been 
observed within fifteen years for many antibiotics. (Table 2). Resistance to 
penicillin was observed soon after its introduction into the clinic in 1943 with 
the first cases of resistance reported in 1946. By the late 1960s, almost 80% 
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of people with a S. aureus infection were resistant to penicillin.26 Bacterial 
resistance has emerged at almost a parallel rate to the design and 
introduction to the clinic of new antibiotics which drastically reduced the 
efficiency of many antibiotics.8 This is increasingly worrying as no new 
antibiotic classes with Gram-negative activity are currently close to the 
clinic.17 Linezolid, an oxazolidinone, was the first entirely synthetically 
derived class to be introduced but resistance was seen in less than a year 
after its clinical introduction in 2000.26  
Table 2: Antibiotics and drug resistance 
Antibiotic Introduced Resistance observed 
Sulfonamides 1930s 1940s 
Penicillin 1943 1946 
Streptomycin 1943 1959 
Chloramphenicol 1947 1959 
Tetracycline 1948 1953 
Erythromycin 1952 1988 
Vancomycin 1956 1988 
Methicillin 1960 1961 
Ampicillin 1961 1973 
Cephalosporins 1960s late 1960s 
Linezolid 2000 2001 
 
There has been a steady decline in the number of FDA approved 
antibacterial agents, both acting against Gram-positive and Gram-negative 
bacteria, in the last 20 years. (Figure 10) 
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Figure 10: The decline of antibacterial drug approvals by the FDA, adapted from
14
  
It can be deduced that if a new highly effective antibiotic is found, its 
widespread usage will increase the chance of resistance developing.8   
The aim to reduce the amount of bacterial resistance to antibacterial agents 
can be approached from two directions:  
1. The rejuvenation of existing antibiotics by constant modification of 
existing antibiotics to stay ahead of resistance. 
2. The search for new drugs with novel modes of action as a result of 
identification of a biological target. 
Due to recent developments this report will focus on β-lactamase bacterial 
resistance and the methods being used to combat this form of bacterial 
resistance. 
0
2
4
6
8
10
12
14
16
18
1983-1987 1988-1992 1993-1997 1998-2002 2003-2008 2009-2012
N
u
m
b
e
r 
o
f 
n
e
w
 a
n
ti
b
ac
te
ri
al
 a
p
p
ro
va
ls
 
Year 
- 17 - 
Chapter 2 
β-lactamases 
Bacteria have developed resistance to β-lactam antibiotics by producing a 
specific family of enzymes, the β-lactamases. They catalytically hydrolyse 
the β-lactam antibiotics rendering them unable to inhibit peptidoglycan 
biosynthesis.  
The first β-lactamase enzyme was identified in Escherichia coli before the 
clinical use of penicillin.27 The enzyme was not thought to be clinically 
relevant, since penicillin was used to treat Staphylococcal and Streptococcal 
infections. β-Lactamase enzymes have mutated from the transpeptidase 
enzyme and therefore are quite similar in nature. Along with the ability to 
hydrolyse the β-lactam ring, the β-lactamase enzymes also possess the 
ability to hydrolyse the ester linkage to the enzyme to shed the hydrolysed 
moiety. This is so efficient that they can hydrolyse 1000 penicillin molecules 
per second (2.1, Figure 11). 
 
Figure 11: Structure of penicillin G (2.1) 
Many Gram-positive strains of bacteria are resistant to penicillin as they can 
produce β-lactamase enzymes which are released into the surrounding area 
to intercept the antibiotics before they reach the cell membrane. The enzyme 
eventually dissipates through the cell wall and is lost so the bacteria has to 
keep producing the enzyme in order to remain resistant. 
Most if not all Gram-negative bacteria produce β-lactamase enzymes which 
makes them more resistant to penicillin than Gram-positive bacteria. The 
released β-lactamase enzymes are trapped within the periplasmic space 
between the cell membrane and the outer cell membrane as they cannot 
permeate through the latter. As a result, β-lactam antibiotics which pass 
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through the outer membrane encounter a higher concentration of β-
lactamase than in Gram-positive bacteria.  
There are a number of β-lactamase enzymes which vary in their substrate 
selectivity. Penicillinases are selective to penicillin and cephalosporinases 
are selective to cephalosporins. There are also enzymes which are not 
selective between classes of β-lactam antibiotics. The differing levels of 
enzymes produced and the different affinities for each β-lactam antibiotic 
accounts for the varying susceptibility of different Gram-negative species to 
different β-lactam antibiotics. 
β-Lactamase enzymes have been grouped into four major classes (A-D) as 
defined by Ambler, based on amino acid sequence homology.28 Class A, C, 
and D belong to the serine-β-lactamase family as they use an active site 
serine as a nucleophile. Class B belongs to the metallo-β-lactamase family 
of enzymes which use zinc atoms in the active site to help ionize and 
coordinate a nucleophilic hydroxide ion to mediate hydrolysis.  
2.1 Serine-β-lactamases 
The serine β-lactamase class have evolved directly from the transpeptidase 
enzymes and are very similar in structure with active site lysine and serine 
residues helping to co-ordinate and hydrolyse the β-lactam antibiotics. The 
three classes of serine-β-lactamases (A, C and D) are described below: 
Class A29 serine-β-lactamases, often referred to as penicillinases, were the 
first β-lactamases to be identified in penicillin resistant isolates of bacteria 
and are still the most common β-lactamases today. In 1963, the plasmid-
borne class A resistant gene, TEM-1 was discovered. TEM-1 has spread 
through many different species of bacteria and spread throughout the globe. 
The TEM enzymes have demonstrated an ability to evolve resistance to 
molecules specifically designed to inhibit class A β-lactamases. 
Class C30 serine-β-lactamases are often termed cephalosporinases on 
account of their preference towards cephalosporins as a substrate even 
though they are also highly active against penicillins. Class C enzymes are 
the second most common class of serine-β-lactamase enzymes behind 
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class A. Class C enzymes are most commonly found in Gram-negative 
bacteria and are chromosomally encoded.  
Class D31 serine-β-lactamases are called oxicillinases because of their ability 
to hydrolyse oxacillin (Figure 12) and cloxacillin about three times faster 
than penicillins. Class D are the least well known serine-β-lactamases and 
have <20% amino acid identity with classes A and C. Almost 30 class D 
enzymes are known and have been designated OXA-1, OXA-2, etc. Class D 
enzymes have been found as dimeric enzymes. 
 
Figure 12: Antibiotics hydrolysed by serine-β-lactamases. a) penicillin, 2.2 b) cephalosporin 
2.3 and c) oxacillin 2.4. 
2.1.1 Hydrolysis mechanism 
In the serine β-lactamases, an active site serine is used to hydrolyse the β-
lactam ring (Scheme 1). A conserved Ser-X-X-Lys motif is conserved 
through all the serine β-lactamase enzymes. The lysine residue helps to co-
ordinate the antibiotic in position to enable nucleophilic attack by the serine 
residue, by forming a hydrogen bonding interaction with the carboxylic acid 
present in many antibiotics 2.6. The hydrolysed antibiotic is cleaved from the 
enzyme by hydrolysis of the formed ester bond by a water molecule 2.7. The 
enzyme then expels the antibiotic and is ready to accept another molecule 
for hydrolysis 2.8.  
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Scheme 1: Mechanism of hydrolysis of β-lactam antibiotics by serine-β-lactamases 
2.1.2 Serine-β-lactamase inhibitors 
A large number of class A enzyme inhibitors have been developed. These 
inhibitors have substantially extended the spectrum of activity of otherwise 
class A β-lactamase-susceptible partner penicillins. Examples already used 
in the clinic are Clavulanic acid (2.9)32, Tazobactam (2.10)33 and Sulbactam 
(2.11)34 (Figure 13). These inhibitors protect the β-lactam antibiotic from the 
activity of the β-lactamase and have widely been used for the treatment of 
human infections.  
 
Figure 13: Structures of serine-β-lactamase inhibitors: Clavulanic acid (2.9), Tazobactam 
(2.10), Sulbactam (2.11) and Avibactam (2.12). 
These inhibitors act as suicide inhibitors, covalently bonding to the active 
site serine residue. This re-structures the inhibitor molecule, creating a much 
more reactive species which is attacked by another amino acid in the active 
site, permanently inactivating it, and thus inactivating the enzyme.  
- 21 - 
An example of how clavulanic acid (2.9) inhibits a serine-β-lactamase (SHV-
1) is shown in Scheme 2.20 Clavulanic acid (2.9) covalently binds to the 
active site serine residue Ser-70 in the active site of the SHV-1 enzyme. 
Upon hydrolysis of the β-lactam to form the covalently bound species, the 
resulting cascade results in the formation of more reactive species which is 
attacked by the serine residue Ser-130. Hydrolysis of the bond to the Ser-70 
residue occurs but the inhibitor remains covalently bound to Ser-130 
permanently inactivating the SHV-1 enzyme. 
 
Scheme 2: Inhibition mechanism of SHV-1 serine-β-lactamase by clavulanic acid showing 
binding to key residues Ser-70 and Ser-130. 
Class C inhibitors are also being developed for use in the clinic. Avibactam 
(2.12, Figure 13)35 is in late stage clinical trials for the treatment of infections 
caused by bacteria expressing Class C β-lactamases. Avibactam is given in 
combination with a cephalosporin to combat the β-lactamase enzymes. 
Avibactam has also been shown to have activity against Class A and some 
Class D enzymes but not the Class B metallo-β-lactamases.  
There are very few examples of Class D inhibitors and as yet there are no 
reports of clinically useful inhibitors of the class B MBLs. 
 
- 22 - 
2.2 Metallo-β-lactamases (MBLs) 
Metallo-β-lactamases are divided into three subclasses B1, B2, and B3. 
Subclasses B1 and B3 contain two zinc ions in the active site while subclass 
B2 contains only one zinc ion.36 Subclass B1 β-lactamases are active in both 
the mono-zinc and di-zinc forms although binding of a second zinc atom 
improves activity. B2 are only active in the mono-zinc form, with the binding 
of a second zinc atom inhibiting the hydrolysis activity, and B3 are only 
active in the di-zinc form.37,38  
Each subclass has several different types of metallo-β-lactamase, many of 
which have several allelic variants.36 A value of at least 30% amino acid 
diversity is used as a cut off for classification of new metallo-β-lactamases.39   
MBLs are encoded either by genes which are part of the chromosomal 
framework in some bacterial species (resident metallo-β-lactamases) or by 
heterologous genes acquired by horizontal gene transfer (acquired metallo-
β-lactamases). Almost all acquired types belong to the B1 subclass. This 
implies B1 subclass MBLs have more mobile genetic elements than 
subclasses B2 and B3.  
Due to the broad nature of β-lactam antibiotics and the increase in number 
and spread of MBLs, it is desirable to produce metallo-β-lactamase inhibitors 
that can restore the activity of the β-lactam antibiotics against MBL-
producing bacteria. 
A few of the most prevalent MBLs for which potential inhibitors have been 
sought are Imipenemase (IMP-1),40 Verona integrin-encoded metallo-β-
lactamase (VIM-2)41 and Bacillus cereus β-lactamase.42 A common feature 
of many reported MBL inhibitors is the inclusion of metal chelators such as 
thiols40 and hydroxamic43 acids.  Problems are often seen as these inhibitors 
are not selective for the desired enzymes and bind to other metal centres in 
the body. Selective inhibitors have been found for individual enzymes such 
as NH-1,2,3-triazole inhibitors of VIM-241, however a broad spectrum 
inhibitor which is only selective for MBLs is still to be found.   
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2.2.1 The Spread of MBLs 
MBLs have become widespread throughout the world. (Figure 14).37 It is 
believed that the un-regulated prescription of β-lactam antibiotics in the 
developing world and the increased use of air travel has helped to facilitate 
transmission of the metallo-β-lactamase enzymes across the world. There is 
limited clinical data available from African countries leading to the lack of 
information on Figure 14 in this area of the world although it is predicted that 
MBLs will be present in these countries. 
IMP and VIM MBL isolates have been found to be the most widespread with 
most countries in the world seeing infections of bacteria expressing these 
enzymes. For NDM-1, although originally isolated in India and the UK, rapid 
spread has been seen across the world (see Section 2.3.1). There are 
limited cases of SPM-1 which have been identified, and these have been 
restricted to Brazil and central Europe. There are a number of reasons for 
this (see Section 2.4.1.3) 
 
Figure 14: The spread of key clinically relevant MBLs throughout the world, Adapted from.
9
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2.2.2 Hydrolysis mechanism 
 
Scheme 3: Schematic drawing of the proposed mechanism of β-lactam hydrolysis by NDM-
1, adapted from
44
 
In the proposed mechanism, Zn1 functions to orientate the substrate 
carbonyl bond, whereas Zn2 is required for interaction with the amide 
nitrogen of the substrate 2.1345 (Scheme 3). The shared hydroxide attacks 
the carbonyl carbon as the nucleophile. It is suggested (and supported by 
crystallographic evidence), that the hydroxide ion is generated from the 
bound water by the putative general base Asp-120.46 This results in a 
tetrahedral species which is short lived as the C-N bond breaks immediately 
with Zn2 acting as a Lewis acid to stabilise the charge on the nitrogen 
leaving group  2.14.38 The proton coming from the hydroxide is close to the 
nitrogen of the hydrolysed substrate and is acidic in its microenvironment 
bound to Asp-120 and is therefore easily transferred to the nitrogen. This 
mechanism appears plausible for all three subclasses of metallo-β-
lactamase. In the B1 and B3 subclasses when the Zn-Zn bond distance 
increases following hydrolysis there is a weakening in the interaction with the 
former amide nitrogen which leads to the departure of the product from the 
active site 2.15. The interatomic bond distance between Zn1 and Zn2 
returns to the shortened form as the enzyme returns to its apo form. This 
helps to make this mechanism catalytic so that one enzyme can turn over 
many molecules.   
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2.3 New Delhi metallo-β-lactamase 1 (NDM-1) 
New Delhi metallo-β-lactamase (NDM-1) is a broad spectrum β-lactamase 
that is able to inactivate all β-lactams except aztreonam, as is typical of 
metallo-β-lactamases.47 The first recorded case of an NDM-1 producing 
bacteria was reported in 2008 in a Swedish patient who had previously been 
hospitalised in New Delhi in 2007. The first case was found to be Klebsiella 
pneumonia from a urinary tract infection.48 NDM-1 has increasingly become 
a worldwide concern with reported cases in the UK, India and Pakistan.49 
The link between hospitalisation in India and Pakistan and development of 
infections in the UK was established in fourteen of thirty seven hospitalised 
patients in 2010.49 
NDM-1 is not only restricted to a single strain of bacteria and has been 
identified in a number of unrelated species, the most common of which have 
been found are E. coli and K. pneumonia.49 NDM-1 producers have recently 
also been reported in E. cloacae, Providencia rettgeri and Morganella 
morganii.50 NDM-1 producers cause a range of infections such as urinary 
tract, diarrhoea and soft tissue infections.51 
2.3.1 Spread of NDM-1 producers 
As of the 1st November 2010, around seventy cases of NDM-1- producing 
bacteria have been reported in the UK, one hundred and fifty in India and 
Pakistan,49 and four in Canada.52 Positive cases have not only been 
restricted to these countries as shown in Figure 15. Several fatal cases 
have been reported in UK, India and Belgium. In most cases, patients have 
been hospitalised in India, Pakistan or Bangladesh, or were of South Asian 
origin or had spent some time in that part of the world.51 It is suspected that 
overcrowding, poor sanitation, poor personal health and the sale of non-
prescribed antibiotics may all be factors in facilitating the spread of NDM-1.  
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Figure 15: Worldwide distribution of identified cases of NDM-1 producers (1
st
 December 
2010). Adapted from.
51
 
It is difficult to predict the rate of spread of the gene encoding NDM-1 within 
the less developed world. Exchange of the BlaNDM-1 gene between unrelated 
bacterial isolates and species has already been seen.53 It is suspected, like 
many other carbapenemases, that NDM-1 has a carrier state. It is important 
to estimate the amount of people who carry the inactive state and predict the 
genetic spread. It is predicted that like other carbapenemases NDM-1 will 
spread across the world due to the increased amount of human air travel.   
Bacteria become able to produce NDM-1 through the process of acquired 
resistance. This is when a particular microorganism gains the ability to resist 
the activity of a particular antimicrobial agent that it was previously 
susceptible to. This can result from mutation of genes involved in normal 
physiological processes and cellular structures (vertical evolution), from the 
acquisition of foreign resistance genes (horizontal evolution) or from a 
combination of these two mechanisms. The spread of NDM-1 is an example 
of horizontal evolution as genetic information is transferred between different 
bacterial species. Figure 16 describes the spread of the NDM-1 gene from 
the first isolate in K. pneumoniae in 2008. Genes for producing MBLs are 
transferred from the K. pneumoniae DNA. The genetic elements are spread 
easily to other strains of Enterobacteriacease or another K. pneumoniae.  
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NDM-1 has shown that it has all the properties necessary to turn organisms 
that contain it into ‘superbugs’. 54 There is increasing concern over how 
easily NDM-1 can spread between species through gene transcription.    
 
Figure 16: The origin and spread of NDM-1, adapted from
55
 
2.3.2 Structure of NDM-1 
A number of crystal structures of NDM-1 have recently become available: 
Apo-structure (PDB-ID: 3SPU),56 monometalated (PDB-ID: 3SPF)57 and 
containing a bound hydrolysed ampicillin molecule (PDB-ID: 3Q6X).38 All of 
the crystal structures are of good resolution, between 2-2.5 Å. The crystal 
structures are also in good agreement with the homology models which were 
generated before high resolution crystal structures were available.58   
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2.3.2.1 Overall structure 
NDM-1 is a single-chain polypeptide consisting of 270 amino acids.38 NDM-1 
adopts a characteristic metallo-β-lactamase αβ/βα fold as observed in the 
previously characterised VIM-2 and IMP-156 enzymes (Figure 17). The 
structure consists of two β-sheets (red); one is made up of seven antiparallel 
strands and the other five antiparallel strands. Each β sheet is flanked on its 
outer face by two α helices (cyan). A further α helix bridges the two β-sheets. 
NDM-1 shows about 32% sequence identity with VIM-2 and IMP-1. Notable 
variations are that the N-terminus of NDM-1 is much longer, forming two 
more β-strands but not part of the N-terminal β-sheet.  
In NDM-1 loop L3 appears to be more open than in VIM-2 and IMP-1 (see 
Section 2.4.2.1) (Figure 17). The open face suggests a broader profile of 
substrates can bind there. It has been found that the substrate binding face 
of this loop is more hydrophobic than in other metallo-β-lactamases. NDM-1 
is closely related to the B1 sub-class of metallo-β-lactamases as it has been 
found to be active in both the mono-zinc and di-zinc forms.59  
 
Figure 17: PDB entry 3Q6X shown with ribbon representation and coloured by secondary 
structure. α-helix (red), β-sheet (cyan), and loops (purple)  
 
 
Loop 3 Loop 10 
 
α           β             β          α  
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2.3.2.2 Active site of NDM-1 
The active site of NDM-1 is located at the bottom of a shallow groove 
enclosed by two important loops L3 and L10. In the same way as other 
subclass B1 metallo-β-lactamases, two zinc atoms are located in the active 
site. NDM-1 has a larger active site cleft than VIM-2 with a surface area of 
520 Å2 compared to 450 Å2. The larger surface area comes from the 
orientation of the L3 and L10 loops which are further away from the zinc 
active centre than in other metallo-β-lactamases. The large surface area 
allows for many more larger β-lactam substrates to be accommodated in the 
active site for hydrolysis (Figure 18b). 
In the zinc active centre, Zn1 is tightly coordinated with tetrahedral geometry 
by three histidine residues and a bridging water (His-120, His-122 and His-
189). Zn2 is coordinated in an octahedral environment by His-250 Cys-208, 
Asp-124 and three water molecules, one of which is the catalytic water 
which bridges to Zn1.60 The binding region is shown in Figure 18a.  
 
Figure 18: NDM-1 active site. a) amino acid residues binding to zinc atoms. b) SPROUT 
generated boundary surface of active site showing hydrophobic wall (green), 
hydrogen bond acceptor sites (red) and hydrogen bond donor sites (blue). 
It has been observed that NDM-1 has an enhanced positively charged 
electrostatic profile around Zn1 compared with VIM-2, which may serve to 
attract and orientate the negatively charged β-lactam carboxylate during 
hydrolysis.56  
The Zn-Zn interatomic bond distance is seen to be ~3.8 Å in the apo-
structures. Upon binding with a hydrolysed substrate it has been seen that 
the interatomic bond distance is substantially longer at ~4.6 Å. It has been 
a) b) 
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suggested that the larger Zn-Zn bond distance observed in the hydrolysed 
form of NDM-1 is required for the release of the hydrolysed substrate.38  
2.4 The other clinically relevant MBLs  
2.4.1 Spread 
2.4.1.1 Verona integron-encoded metallo-β-lactamase (VIM-2) 
VIM-2 has been identified in clinical isolates worldwide as shown in Section 
2.2.1. When focussing in on Europe, almost all European countries have 
seen an outbreak of VIM producing isolates. Spain and Italy have seen 
spread of VIM-2 outbreaks between hospitals. Greece shows a high 
prevalence of VIM enzymes within bacteria from patients (Figure 19). The 
blaVIM-2 gene has rapidly spread into many pathogenic bacteria with isolates 
found in E. coli and K. pneumoniae. As with NDM-1, blaVIM-2 is spread via 
horizontal gene transfer, giving acquired resistance to the bacteria that 
receive the gene. 
 
Figure 19: Locations of VIM in Europe. 
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2.4.1.2 Imipenemase (IMP-1) 
IMP-1 was initially isolated in the early 1990s from Pseudomonas 
aeruginosa and Serratia marcescens. Since this time IMP-1 has been 
detected in a number of different strains of bacterial isolates. Due to the 
ability of the blaIMP gene to spread rapidly by horizontal transfer, isolates 
have been identified across the globe.61 IMP-1, like the other MBL, exhibits 
broad substrate specificity, with high affinities for cephalosporin and 
carbapenems as opposed to penicillins. IMP-1 is considered to be one of the 
most clinically important MBL for several reasons: IMP variants hydrolyse all 
β-lactam containing antibiotics, except monobactams, including 
carbapenems like imipenem. The gene for IMP, blaIMP has rapidly spread 
into many pathogenic bacteria. IMP has spread across the globe but a high 
prevalence has been identified in Japan and Indonesia. The high prevalence 
in Japan can be partially attributed to the high population density which 
leads to ease of the spread of IMP (Figure 20). 
 
Figure 20: Worldwide spread of IMP metallo-beta lactamase. 
2.4.1.3 São Paulo metallo-β-lactamase (SPM-1) 
SPM-1 was purified for a highly resistant P. aeruginosa isolate from a 4 year 
old leukemic girl in São Paulo, Brazil.62 A subsequent screening program 
confirmed the presence of SPM-1-producing stains in a high proportion 
(~35%) of carbapenem-resistant isolates from seven geographically 
widespread Brazilian hospitals. This elevated SPM-1 to be viewed as 
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significantly clinically relevant. So far SPM-1 spread has been limited to 
South America and central Europe. (see Section 2.2.1) SPM-1 does have 
the potential to spread as rapidly as the other metallo-β-lactamase enzymes. 
2.4.2 Structural comparison 
2.4.2.1 VIM-2 and IMP-1 
VIM-263,64 and IMP-1 along with NDM-1 belong to the B1 subclass of the 
MBLs. The crystal structures reveal the αβ/βα sandwich seen in NDM-1 and 
feature a catalytic di-nuclear zinc binding site which lies at the interface of 
the two αβ domains. VIM-263,64 is the closest analogue to the NDM-1 
enzyme (~33%), and as for NDM-1, the active sites of VIM-2 and IMP-1 
contain two zinc atoms (Figure 21). The first Zn (Zn1 site) is coordinated in 
a tetrahedral geometry by three His residues and a bridging water molecule 
as in NDM-1. (His-116, His-119, His-196 and a bridging water in IMP-1 and 
His-116, His-118, His-196 and a bridging water in VIM-2) The second Zn 
(Zn2 site) is bound in an octahedral environment by an Asp, Cys, His, 
terminal water and a bridging water. (Asp-120, Cys-221, His-263, two 
terminally bound waters and the bridging water molecule in IMP-1 and Asp-
120, Cys-221, His-263, two terminal waters and a bridging water in VIM-2). 
The inter atomic Zn-Zn distance is very similar to NDM-1 at around 3.5-3.7 Å 
in length in the unbound form a distance which is seen to increase on 
binding of a substrate. 
 
Figure 21: Comparison of the co-ordination of the Zn ions in NDM-1, VIM-2 and IMP-1 
The active site of VIM-2 has a surface area of 450 Å2 which is slightly more 
closed than in NDM-1 which shows a larger surface area of 520 Å2. As seen 
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in Figure 22 in VIM-2, there is a Phe-61 residue which protrudes into the 
active site which is not present in NDM-1. This narrows the amount of space 
in the active site and reduces the overall surface area. IMP-1 has an even 
smaller active site surface area of 399 Å2. As is highlighted in Figure 22 
there is a significant reduction in the size of the active site cleft in IMP-1. The 
IMP-1 active site has almost a completely closed loop, which forms a 
hydrophobic pocket, increasing the affinity to hydrophobic molecules. The 
Trp-28 residue of the active site loop is seen to create a π stacking 
interaction with compounds helping to orientate them for hydrolysis in the 
active site.  
 
Figure 22: Overlays of the MBL active sites against NDM-1 (White with grey Zn). a) VIM-2 
showing key Phe-61 residue (Green) and b) IMP-1 showing key Trp-28 residue 
(Blue). 
2.4.2.2 SPM-1 
Unusually, SPM-1 has high sequence similarity with MBLs from both B1 and 
B2 subclasses. In solution SPM-1 is reported to have a Zn (II) ratio of 1.5 : 1 
however in the first available crystal structure there is only one zinc atom in 
the active site which is surrounded by three His residues, His-116, His-118, 
His-196 and a terminal water molecule  (PDB ID: 2FHX).62 The Cys residue 
which would be expected to bind the Zn2 atom has been oxidised (CSO-221, 
Figure 23). Brem et al. conducted a number of studies and concluded that in 
terms of its Zn (II) usage and catalytic mechanism, SPM-1 is best defined as 
a B1 MBL.65 However in terms of structure and in particular the flexible loop 
region, SPM-1 has features typical of a B2 enzyme. 
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Figure 23: Comparison of the active sites of NDM-1 and SPM-1 showing Single Zn 
occupancy in SPM-1 
The active site cleft is seen to be smaller than in other enzymes with a 
flexible loop covering part of the active site. The flexible loop is able to move 
into both a closed (PDB ID: 4BP0) and an open (PDB ID: 2FHX) form which 
enables or disables access to the active site of the molecule (Figure 24). 
The crystal structure of the closed form shows two zinc atoms present in the 
active site which again shows the strange nature of the SPM-1 enzyme 
having cross subclass characteristics. SPM-1 shows the lowest similarity to 
the active site of NDM-1.  
 
Figure 24: Overlay of NDM-1 (White) (PDB ID: 3Q6X) and SPM-1 in both closed (Red) 
(PDB ID: 4BP0) and open (Blue) (PDB ID: 2FHX) showing the enclosed active site of 
the SPM-1 enzyme in the closed form believed to be the cause of its differing 
properties to the other B1 MBLs. 
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2.5 Inhibitors of MBLs 
As NDM-1 is one of the most recent MBLs to be identified in bacteria from 
hospital acquired infections, there has been limited work conducted into 
finding new inhibitors. Currently there are no known clinically relevant 
inhibitors of the MBLs however there are a few classes of inhibitors in 
development. These include metal extractors, thiols and transition state 
mimics all of which are designed to be given in a combination with a current 
β-lactam antibiotic.  
2.5.1 Metal extractors 
The metal chelator EDTA (2.16) has been shown to inhibit NDM-1 by binding 
strongly to the zinc atoms present in the active site44 (Figure 25). However 
EDTA is non-selective in nature meaning it binds to other metal sites in the 
body as well as the NDM-1 enzyme which causes many potential issues with 
its use. 
 
Figure 25: Structures of metal extractors EDTA (2.16) and Aspergillomarasimine A (2.17) 
Aspergillomarasmine A (AMA, 2.17)66, has recently been identified as an  
NDM-1 inhibitor. It acts by coordinating to the zinc ions in the active site of 
the enzyme. This compound, which is similar structure to EDTA, acts as a 
‘suicide’ inhibitor by removing the zinc ions from the active site of the 
enzyme, leaving the enzyme unable to function. Wright et al., who identified 
AMA, showed it can overcome bacterial resistance in NDM-1 producers 
towards the carbapenem antibiotic meropenem. Although initial studies show 
promising results, limited selectivity data is available to show whether the 
molecule will be selective towards its target or have a detrimental effect by 
coordinating to other zinc-containing enzymes in the body. 
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2.5.2 Thiols 
Captopril (2.18, Figure 26) is one of the few compounds that effectively 
inhibit NDM-1. Chen et al. investigated scaling back captopril to simpler 
derivatives to identify the pharmacophore for NDM-1 inhibition. Captopril is a 
peptide mimic consisting of a proline residue and a 3-mercapto-2-
methylpropanoic acid subunit (2.19). They concluded that the captopril 3-
mercapto-2-methylpropanoic acid subunit demonstrated inhibitory activity 
against the NDM-1 enzyme. This highlighted the potential for thiol containing 
compounds which could bind strongly to zinc containing systems. Even the 
smallest of thiols have been seen to give an inhibitory effect such as 
mercaptoacetate (2.20) which was used to help elucidate the structure of B3 
MBL SMB-1.67 
 
Figure 26: Thiol-based inhibitors. a) Captopril (2.18) and active 3-mercapto-2-
methylpropanoic acid subunit (2.19). b) mercaptoacetate (2.20)  
Work has also been conducted into using cysteine-containing peptides. The 
3-mercapto-2-methylpropanoic acid subunit seen in captopril is a peptide 
mimic of cysteine so activity is also expected to be observed with cysteine. 
Page et al. showed that micromolar inhibition can be achieved against 
Bacillus cereus zinc β-lactamase using cysteine-containing peptides.42 This 
class of compound is discussed further in Chapter 6. 
Recently Klingler et al. showed that a number of existing FDA approved 
thiol-containing drugs can inhibit a range of  MBLs.68 The study found that 
four compounds DL-captopril (2.18), DL-Thiorphan (2.21, Figure 27) , 2,3-
Dimercaprol (2.22) and Tiopronin (2.23) showed micromolar levels of affinity 
against the MBLs. Further studies using thermal shift measurements 
confirmed that the inhibitors were co-ordinating to the zinc after observing 
higher melting temperatures than the enzyme with no inhibitor as the 
enzyme gained increased stability. This is in contrast to EDTA, which gave a 
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lower melting temperature due to the increased instability of the enzyme 
once the zincs had been abstracted. 
 
Figure 27: The structures of thiol based inhibitors DL-Thiorphan (2.21), 2,3-Dimecarpol 
(2.22) and Tiopronin (2.23) 
Rhodanines are known to inhibit class A and C β-lactamases and some 
PBP.69 Although rhodanines have often been identified as pan-assay 
interference compounds (PAINS),70 a recent report of a broadly active 
rhodanine based inhibitor claims the inhibitor to be an uncompetitive/non-
competitive submicromolar inhibitor of clinically relevant MBLs: VIM-2 (Ki = 
183 ± 24 nM) and IMP-1 (Ki = 930 ± 97 nM).71 The inhibitor is also seen to 
recover the activity of imipenem against clinical isolates of VIM-2, IMP-1 and 
NDM-1. Brem et al. conducted crystallographic and biological studies to 
elucidate the mechanism by which the inhibitor works.72 They showed the 
rhodanine (2.24) hydrolyses to form a thioenolate (2.25) active species 
which binds through the thiol to the zinc atoms (Figure 28).  
 
Figure 28: Rhodanine inhibitor (2.24) undergoes hydrolysis to give active thioenolate (2.25). 
2.5.3 Transition state mimics 
A number of ‘suicide’ inhibitors have been designed which mimic the β-
lactam antibiotics transition state on hydrolysis. Since β-lactam-containing 
antibiotics are peptide mimics and since β-lactamases catalyse peptide bond 
cleavage, researchers hypothesised that a tetrahedral transition state may 
be formed during the hydrolysis mechanism. It was thought that a chemically 
stable β-phospholactam transition state mimic may be a good inhibitor of the 
MBLs (2.26, Figure 29) Examples have seen β-phospholactams used to 
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inhibit ~50 % of NDM-1’s activity at 100 μM.73 Although inhibition through 
this type of mimic was seen it was significantly weaker than binding with 
metal chelators or thiols.  
The same principle has been applied with boron containing compounds 
forming a boronic acid transition state inhibitor (BATSI) (2.27, Figure 29).74 
In these compounds, the boronic acid acts as the tetrahedral intermediate.75 
These compounds have been shown to inhibit serine-β-lactamases and VIM-
2 in the nanomolar region but have yet to be tested against NDM-1, IMP-1 
and SPM-1 (See Chapter 6). 
 
Figure 29: Transition state β-lactamase inhibitors. Phospholactam (2.26) and BATSI (2.27) 
2.5.4 Other MBL inhibitors 
Recently Worthington et al. have identified a 2-aminoimidazole-derived small 
molecule (2.28) that is able to suppress resistance of a NDM-1 producing 
strain of K. pneumoniae76 (Figure 30). This small molecule is able to lower 
carbapenem MICs by up to 16 fold, while exhibiting little anti-bacterial 
activity itself. The molecule was derived by examination of previously 
reported inhibitors of MRSA, an example of drug repurposing.77 The 
mechanism of action of this compound has yet to be determined.  
 
Figure 30: 2-aminoimidazole scaffold (2.28) 
A study was carried out by Weide et al. to identify selective VIM-2 inhibitors41  
The most potent compound (Figure 31), a NH-1,2,3-triazole-based inhibitor 
(2.29), was found to have a Ki of 0.41 ± 0.03 µM activity against VIM-2. The 
same compound was seen to be inactive when screened against IMP-1. 
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Minond et al. discussed the click chemistry synthesis of these compounds 
and studied further derivatives to look for more potent inhibitors.78  
 
Figure 31: Selective VIM-2 inhibitor (2.29) identified by Weide et al. 
Toney et al. identified a number of 2,3-(S,S)-di-substituted succinic acid 
inhibitors (2.30).79 The identified best succinic acid inhibitor, which contained 
aromatic groups at R1 and R3, gave an IC50 value of 9 nM against IMP-1 
(Figure 32) It is expected that the aromatic portions form good π stacking 
interactions within the enclosed hydrophobic pocket. 
 
Figure 32: Succinic acid inhibitor (2.30) identified by Toney et al. 
As well as the described inhibitors above, which would be given in 
combination with a current β-lactam antibiotic, a number of combinations of 
non β-lactam containing drugs have been used to treat infections caused by 
NDM-1 producing bacteria, such as tigecycline and colistin. In 2011 Stone et 
al. reported a patient with calciphylaxis and co-infection with NDM-1 
producing E. coli and K. pneumoniae, both being susceptible to tigecycline 
and colistin.80 Colistin is an antimicrobial agent composed of a complex 
mixture of polymyxins which inhibits the cell membrane structure and 
function. Tigecycline is a glycylcycline with a wide spectrum of activity 
against bacteria, which inhibits protein biosynthesis. This work highlights that 
resistance was being observed when treatment was with tigecycline alone 
and that the colistin was required to fully treat the patient.81 
- 40 - 
Chapter 3 
Project goals 
The work presented in this thesis aims to rationally identify novel inhibitors of 
the clinically relevant metallo-β-lactamases, VIM-2, IMP-1, NDM-1 and SPM-
1, using a combination of structure-based drug design, chemical synthesis 
and biological evaluation.  
3.1 Molecular design stage 
 Understand the principles of structure-based drug design 
 Become proficient at using SPROUT modelling software and 
AutoDock, eHiTS and Glide docking programs  
 Use SPROUT to design novel inhibitors of the metallo-β-lactamases, 
NDM-1, VIM-2, IMP-1 and SPM-1. 
 Apply a consensus docking approach to the designed compounds. 
3.2 Chemical synthesis 
 Use modern organic synthesis to prepare the designed compounds 
 Produce libraries of analogues based upon hit compound(s) to enable 
SAR 
 Ensure all compounds are of suitable purity for biological evaluation 
3.3 Biological evaluation 
 An enzymatic assay will be used to determine the IC50 value of any 
potential inhibitors against each enzyme  
 Significantly potent inhibitors will be used in a cell based assay to 
determine if they rescue the Minimum Inhibitory Concentration (MIC) 
of meropenem against MBL producing bacteria. 
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When an IC50  value of better than 1 μM is achieved in the enzymatic assay, 
the inhibitors go on for MIC testing. 1 µM has been chosen as a cut off as 
captopril has an IC50 of 36 µM against NDM-1 and 12 µM against IMP-1. Any 
inhibitor designed specifically to interact with MBL would be expected to 
have a better potency than captopril against the enzymes. 
The inhibitors themselves should not have an MIC as they are not designed 
intentionally to be anti-bacterial but should give an MIC when used in 
combination with an established anti-bacterial agent such as meropenem. It 
would be expected that a compound would restore the meropenem MIC to 
less than 64 µg/ml before being taken further for in vivo testing.   
The design of new inhibitors goes through a number of cycles making 
improvements on compounds whose IC50’s and MICs fall below the desired 
acceptable ranges until a good inhibitor meeting the desired criteria is found. 
(Figure 33) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De Novo Design 
or vHTS 
Synthesis 
 
IC50 
determination 
MIC 
determination 
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IC50 <1 μmol 
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MIC < 64 µg/ml 
MIC > 64 µg/ml 
Figure 33: Flow diagram of biological testing protocol for potential MBL inhibitors. 
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Screening of the compounds to determine the IC50’s was conducted by a 
collaborating partner; Dr Jürgen Brem at the University of Oxford. The 
enzymes used in the assays were expressed and purified by a collaborating 
partner; Dr James Spencer at the University of Bristol.  
The enzymatic assay is based upon the hydrolysis of chromogenic 
cephalosporin nitrocefins as a reporter of enzyme inhibition (ie. assaying at 
multiple substrate/inhibitor concentrations and / or analysing the complete 
time course for the hydrolysis reaction.)82 (see Appendix A1.1) The reaction 
is monitored at 485 nm as this is the absorbance band of the hydrolysed 
nitrocefin. The absorbance seen is due to the n π* electronic transition in 
the di-nitro benzene ring seen in the nitrocefin. (Figure 34)  
 
 
 
Figure 34: Hydrolysis of nitrocefin showing the change in λmax between the hydrolysed and 
unhydrolysed forms. 
Compounds which displayed an IC50 of less than 1 µM against the enzymes 
in the enzymatic assay were sent to Dr James Spencer at the University of 
Bristol where they were tested against NDM-1-producing bacteria with 
antibacterial agent meropenem to determine the recovery in the MIC. The 
broth dilution method was used according to standard Clinical Laboratory 
Standards Institute (CLSI)83 protocols were used to determine MICs. (see 
Appendix A1.2) 
λmax 390 nm λmax 486 nm 
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Part 2 
Results and Discussion 
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Chapter 4 
Application of vHTS to inhibitor discovery.84 
Virtual High-Throughput Screening (vHTS) both reduces the time and the 
cost of identifying potential inhibitors for a given target. In virtual screening, 
available databases of compounds are searched to identify novel hit 
molecules.85 The potential molecules predicted using vHTS can be used to 
obtain a highly focussed library of compounds to be assayed against the 
protein target.86 Libraries generated using vHTS have been shown to give hit 
rates of 20-30% which is much higher than the hit rates of traditional HTS 
which generally give a hit rate of less than 1%.87 Two of the vHTS packages 
used at Leeds are AutoDock88 and eHiTS.89 
Recent advances in computation technology have made the docking of very 
large collections of small molecules into a desired molecular target a very 
rapid and time efficient process. Some libraries which are available for 
screening are the ZINC library90, chemnavigator library91 and the 
Chembridge compound library92. Some of the most prominent pieces of 
docking software currently in use for virtual screening include AutoDock88, 
Glide93, Gold94, Dock95, FRED96 and eHiTS89. A selection from these 
programs is discussed below in the context of their recent use in 
antibacterial drug discovery. In a typical vHTS (Figure 35), a library of 
>10,000 compounds is docked using one of the docking programs. Very 
large libraries such as the ZINC database may be pre-screened using a 
program such as Pipeline Pilot.97 Conditions such as the Lipinski rules98 can 
be used to reduce the computational time required to dock the whole library 
by removing molecules that don’t match the desired criteria. From the results 
generated by the scoring function in such programs, the top 10% of the 
‘virtual hits’ is usually then visually inspected to assess synthetic 
accessibility, as well as calculate physiochemical properties such as cLogP. 
From these, a small library of compounds will be synthesised or purchased 
and screened against the enzyme. If an active compound is identified, a 
SAR study can be conducted around this molecule.   
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Figure 35: Typical vHTS screening protocol based upon using the Peakdale molecular 
screening library of 27,000 compounds
99
 
4.1 Docking programs 
4.1.1 AutoDock 
AutoDock is a suite of automated docking tools designed to predict how 
small molecules bind to a protein of known three-dimensional structure.100 
AutoDock consists of two main programmes: ‘autodock’ which carries out 
the docking of the desired ligand to a set of grids describing the protein. The 
grids are pre-calculated in ‘autogrid’ from a designated grid box as shown in 
Figure 36. In ‘autodock’ the ligand explores six spatial degrees of freedom, 
rotation and translation, and an arbitrary number of torsional degrees of 
freedom within the grid. After docking, AutoDockTools can be used to 
visualise and analyse the results.88  
AutoDock uses a Lamarckian genetic algorithm to generate a range of 
docking poses that can be clustered together based on energetic similarity. 
A number of studies have shown that, rather than the lowest energy cluster, 
the most populated cluster of docked ligand conformations are better 
predictors of the native state.101 The clustering of results is displayed in bar 
chart form (Figure 36). 
 
 
27,000 Compounds 
100 
Lead  
Series 
AutoDock 
Compound Selection 
Enzyme Assay 
SAR/Analogue Synthesis 
1 Active Compound 
Hit Identification 
Lead 
Optimisation 
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Figure 36: AutoDock results generation. a) Formation of a grid box. b) AutoDock tools 
results clustering. 
4.1.2 eHiTS  
eHiTS (designed and released by SimBioSys)102 takes a unique approach to 
docking, by having an innovative algorithm and novel scoring function.89 The 
approach breaks ligands into rigid fragments and connecting flexible chains. 
Each rigid fragment is docked independently and exhaustively within the 
receptor. A post-match algorithm finds all the matching solutions and 
reconstructs the original molecules (Figure 37). The solutions generated are 
automatically ‘scored’ by the eHiTS scoring function. This scoring function is 
based upon the interactions made between surface points on the receptor 
and ligand. Complementary surface points give a positive score while 
repulsive points give negative scores. Scoring components include hydrogen 
bonding, hydrophobicity, VDW contact energy, steric clash and entropy lost 
due to restricted rotatable bonds. Recent examples of the use of eHiTS 
include the identification of inhibitors of BACE-1103 and the bacterial leucine 
transporter, LeuT respectively.104  
eHiTS has also been previously been used in the identification of  inhibitors 
for staphylococcal pyruvate kinase. Work in the Cherkasov group focussed 
on discovering inhibitors of methicillin-resistant Staphylococcus aureus 
(MRSA).105 An in-house collection of 255 chemically diverse compounds that 
were selected from the ZINC library using “antibiotic like” criteria106 were 
screened in a MRSA pyruvate kinase enzymatic assay and docked using 
eHiTS (PDB ID: 3TOT). The molecular docking used eHiTS operating with 
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the standard parameters. eHiTS successfully identified the selection of 
inhibitors which were found to be the most active in the enzymatic assay.  
 
 
 
 
 
Figure 37: Schematic representation of eHiTS docking. 
4.1.3 Glide  
Glide93,107 is an add-on to the Schrödinger package Maestro. Glide 
approximates a complete systematic search of the conformational, 
orientation, and positional space of the docked ligand. In this search, an 
initial rough positioning and scoring phase that dramatically narrows the 
search space is followed by torsionally flexible energy optimization on an 
OPLS-AA108 non-bonded potential grid for a few hundred surviving candidate 
poses. The very best candidates are further refined via a Monte Carlo 
sampling of pose conformation;109 in some cases, this is crucial to obtaining 
an accurate docked pose. Selection of the best pose uses a model energy 
function that combines empirical and force-field based terms. 
Glide has been used  by the Legler group in the design of inhibitors of 
Francisella tuarensis.110 This facultative intracellular Gram-negative 
bacterium is responsible for the disease tularemia. Without treatment, the 
mortality rate can be as high as 5-15% for type A strains and 30-60% for the 
severe systemic and pneumonic forms of the disease.  
1. Ligand is 
divided into rigid 
fragments and 
flexible chains 
2. Rigid fragments 
are independently 
docked 
everywhere in the 
active site. 
3. eHiTS finds 
solutions and 
reassembles the 
molecule 
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4.2 Program choice 
The choice of docking program is important as each utilises a different 
docking algorithm as described in Sections 4.1.1-4.1.3.  
In order to investigate the best docking algorithm to use for docking proteins 
containing zinc atoms, as is the case for the MBLs, 4 known zinc binding 
ligands from crystal structures were sourced from the Protein Databank.111 
The selected zinc-containing crystal structures were chosen to cover a range 
of different ways ligands bind directly to the zinc atoms. (e.g. hydroxamic 
acid or thiol). The following crystal structures were selected: 
1. 2FV9- TNF-alpha converting enzyme (TACE) complex112 
2. 2HOC- Human carbonic anhydrase complex113  
3. 2IWE- Structure of a cavity mutant CH117G of Pseudomonas 
aeruginosa azurin114  
4. 3B92- Novel thiol based TACE inhibitor115  
Each of the four ligands as well as ampicillin (from 3Q6X38) were re-docked 
into their native crystal structure using eHiTS, glide93 and AutoDock 
respectively to see which docking program provided the closest match to the 
observed native co-crystallised ligand.  
 
Figure 38: Novel thiol inhibitor in PDB ID: 3B92 a) crystal structure (cyan) b) eHiTS docked 
pose (pink) c) Glide docked pose (yellow) d) AutoDock docked pose (grey). 
A B 
C D 
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When conducting re-docking of the ligands into the native crystal structure 
using eHiTS. It was observed that the bond lengths between the zinc atoms 
of the enzyme active site and heteroatoms on the ligands from which binding 
occurs were consistently in the region of 1-1.5 Å (Figure 38b). This 
observed bond length for a covalent bond to a zinc atom is unrealistically 
small with typical bond lengths observed in crystal structures to be around 
1.8-2.5 Å.116 From these results, it can be deduced that eHiTS was not 
parameterised adequately for docking to proteins containing zinc atoms and 
therefore would not be suitable to use for vHTS.  
The Glide docking algorithm provided more reasonable docking poses.  
However many of the poses involved the ligands binding at other locations 
within the active site rather than making a direct contact to the zinc atom as 
observed in the actual co-crystal structures. (Figure 38c). Overall Glide 
recognised the zinc atoms in the active site but would preferentially bind to 
other locations in the active site rather than by the zinc as observed in the 
native crystal structures.  
 
Figure 39: Overlay of ampicillin co-crystalized in NDM-1 (PDB ID: 3Q6X) (Cyan) and 
docked ampicillin (Grey) 
The AutoDock docking algorithm gave the closest docking results to the 
native crystal structures. The bond lengths of the carboxylic acid of the 
ampicillin to the Lys-211 and carboxylic acid formed by the hydrolysis of the 
β-lactam ring to Zn1, predicted by AutoDock, were in a similar range to those 
seen in the crystal structures. AutoDock was the only programme to re-dock 
the hydrolysed ampicillin back into the crystal structure in a very similar 
position to that seen in the native crystal structure. The only observed 
change is the position of the phenyl ring where AutoDock places this deep 
into the active site pocket minimising solvent interactions whereas in the 
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native crystal structure the phenyl ring is positioned up away from the base 
of the active site. (Figure 39). The decision was then taken that AutoDock 
would be the programme used to conduct vHTS of compound libraries and 
used to dock new SPROUT designs. 
4.3 Protocol for vHTS screening using AutoDock 
In this work, the same protocol was used for all vHTS screening runs using 
AutoDock. The protocol is described below: 
1. A crystal structure of the target protein is chosen from the Protein 
Databank.111 Suitable crystal structures are those that have been 
resolved to less than 3 Å and have a co-crystallised small molecule 
inhibitor which can be used to define the screening volume of the 
enzyme. 
2. The active site was defined using SPROUT (see Section 7.2.1). A 10 
Å cut of the protein surrounding the active site was designated as the 
protein receptor. 
3. A library of three-dimensional structures of commercially available 
compounds is created from the two-dimensional structures provided 
by the chemical supplier using the Corina software.117 These were 
used as the ligand file for AutoDock screening. Suitable databases 
include the Peakdale Molecular99, Chembridge92, Maybridge118 and 
KeyOrganics119 databases.   
4. At Leeds, AutoDock is run on an array of parallel processors which 
enables ~27,000 compounds to be screened against a particular 
protein in around 48 hours. 
5. Once the AutoDock run was complete, any structures which have a 
score value of less than -7.000 in AutoDock were then analysed using 
SPROUT. 
6. These structures were scored in the HIPPO module. Structures which 
had a score better than -5.50 using SPROUT were then evaluated to 
assess the predicted H-bonding and hydrophobic interactions within 
the protein. It was preferable for compounds to be making at least 
one H-bonding interaction with the protein, as well as a hydrophobic 
interaction. 
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The following factors are important when considering compounds for 
purchase/ synthesis prior to actual screening: 
LogP: The partition coefficient P is a measure of the differential solubility of 
a compound in octanol and water. The log ratio of the concentrations of the 
solute in the solvent is called LogP. In the context of drug-like substances, 
hydrophobicity is related to absorption, bioavailability, hydrophobic drug-
receptor interactions, metabolism and toxicity. The preferred limits for 
compounds LogP are in the range of +5.5 to -0.5.98 
Toxicity: Evaluation of lead compounds using the Advanced Chemistry 
Development, Inc.(ACD/Percepta)120 examined each molecule for toxicity 
and gave it an overall toxicity value based upon its predicted mutagenicity, 
tumourogenicity, irritating and teratogenic effects. 
The ACD/Percepta Platform provides prediction and modelling of 
physicochemical (pKa, logD, Solubility), ADME (Blood-Brain Barrier121 CYP 
450 Regioselectivity) and toxicity (Genotoxicity, hERG Inhibition) endpoints 
by the use of a number of computational algorithms. From the results the 
user has the ability to design or modify structures to attain a desired property 
profile.  
Solubility: The aqueous solubility of a compound significantly affects its 
absorption and distribution characteristics. Typically, a low aqueous solubility 
goes along with poor absorption. ACD/Percepta120 gives an estimated LogS 
value for each compound by incremental addition of each atom’s solubility. 
LogS is an estimate of the solubility measured in mol dm-3. More than 80% 
of drugs on the market have an estimated LogS value greater than -4. 
Molecular Weight: Compounds with high molecular weights are less likely 
to be absorbed. Over 80% of all marketed drugs have a molecular weight 
below 450 g mol-1. 
Promiscuity122: A promiscuous drug is a term used for drugs that may bind 
to many different molecular targets or receptors in the body, and so tend to 
have a wide range of effects and the potential for adverse drug reactions.123  
At micromolar and sometimes submicromolar concentrations, many drug-like 
organic molecules aggregate into colloid-like particles in aqueous media, 
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termed ‘colloidal aggregation’. These aggregates can block off protein 
targets from their desired substrate, thereby inhibiting them. Aggregating 
inhibitors are often unrelated chemically, although they typically share 
certain physical properties. Like colloids and vesicles, they are sensitive to 
assay conditions, the presence or absence of adjuvants, such as detergents 
or serum proteins, and target concentration.  
Pharmaceutical companies try to make new drugs as selective as possible 
to minimise binding to undesired targets and hence reduce the occurrence of 
side effects and risk of adverse reactions. 
Once a short list of compounds has been identified the desired compounds 
can be purchased from the supplier and tested for enzyme inhibition. 
Several vHTS screenings were conducted against NDM-1 were carried out 
and are discussed in sections 4.4 and 4.5. 
4.4 Molecular docking of the Peakdale Molecular screening 
collection 
Molecular docking was conducted using the method described in Section 
4.3, using the Peakdale Molecular99 database as the ligand files and the 
NDM-1 crystal structure PDBID: 3Q6X.38 A set of ten possible inhibitors of 
NDM-1 was identified from the Peakdale Molecular database for purchase. 
Details of compound structures and predicted binding affinities are shown in 
Appendix A2.2. 
4.4.1 Preliminary ‘hit’ molecule 
Compound 4.1 (Figure 40) was identified from a preliminary biological 
evaluation, which was conducted at the University of Bristol by Dr. James 
Spencer. The preliminary biological evaluation was to give an indication of 
an inhibitory effect but not to quantify it. Of the top ten scoring compounds 
from the vHTS runs only compound 4.1 showed inhibition at 100 μM. 
Compound 4.1 showed limited solubility in 10% DMSO solution. 
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Figure 40: Structure of inhibitor 4.1 identified from Peakdale screen 
Figure 41 shows that the main interactions between the ‘hit’ molecule and 
NDM-1 are predicted to come from the coumarin portion of the molecule 
interacting through the carbonyl to Gln-123 and the sulfonyl to Lys-211, Asn-
220 and Zn2 respectively. The indole portion of the scaffold is seen to 
extend into a hydrophobic region of the binding site and is therefore a good 
place to investigate the effects of substituents in this region and attempt to 
make the molecule more soluble and more potent.   
 
Figure 41: Binding interactions of 4.1 in a) 2D skeletal representation and b) 3D 
representation 
In order to confirm these results, a re-synthesis of the hit molecule 4.1 was 
conducted as shown below (Scheme 4). 
Coumarin 4.2 was reacted with chlorosulfonic acid to form sulfonyl chloride 
4.3. The reaction proceeded with moderate yields due to the formation of the 
undesired isomer with the sulfonyl chloride group on the 8 position of the 
coumarin (41%). In order to form nitro indole 4.5, a Fisher indole synthesis124 
was conducted from hydrazine 4.4 and butan-2-one in moderate yield (52%). 
Nitro indole 4.4 was reduced under an atmosphere of hydrogen to produce 
amine 4.6 in high yield (83%). Finally sulfonyl chloride 4.3 and amine 4.6 
were coupled in the presence of base to produce 4.1 in good yield 
(70%)(Scheme 4). 
MC = Main chain 
SC = Side chain 
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Scheme 4: Synthetic route to 4.1  
4.4.2 SAR investigation 
The ‘Hit’ molecule 4.1 was re-examined in SPROUT125 to look at the 
predicted interactions with NDM-1 and sites of potential interactions where a 
SAR investigation could be conducted to increase potency and solubility. 
SPROUT identified three potential areas where a structure activity 
relationship exploration could be conducted around 4.1 with the aim of 
identifying a more potent inhibitor (Figure 42)  
 
Figure 42: Areas for SAR investigation of 4.1 
All synthesised compounds (4.13-4.18, 4.20, 4.22, 4.25, 4.27) were 
biologically evaluated against NDM-1 by Dr Jürgen Brem at the University of 
Oxford, and the results are reported in Section 4.4.2. IC50 values were 
determined on compounds which showed less than 30% residual enzyme 
activity at 100 μM. 
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4.4.2.1 Structure activity relationship of the N-aryl ring substituent. 
The first SAR series containing compounds (4.13-4.18) was designed to 
examine the effects of changing the electron density of the aromatic ring 
attached directly to the amine side of the sulfonamide (previously the indole 
in 4.1).  
Compound 4.13 was synthesised as an analogue of 4.1 with the methyl 
groups on the indole portion of the molecule removed in an attempt to 
reduce the hydrophobicity of the molecule and make it more soluble in the 
assay without reducing the potency. Compounds 4.14-4.18 are simpler 
analogues of 4.1 looking at the effects of changing the electron density of 
the ring. 
 
Scheme 5: Synthetic route to compounds 4.13-4.18  
The synthesis of compounds (4.13-4.18) investigating the N-aryl substituent 
was conducted as shown in Scheme 5. Each amine (4.7-4.12) was coupled 
to sulfonyl chloride 4.3 in the presence of base to produce compounds 4.13-
4.18 respectivly in good yields (90-68%)(Scheme 5) 
Biological evaluation of compounds 4.13-4.18 against NDM-1 was 
conducted by Dr Jürgen Brem at the University of Oxford using the nitrocefin 
based assay described in Appendix A1.1. 
From the residual activity it appears that the addition of electron withdrawing 
groups (rendering the aromatic ring electron deficient) helps to slightly 
increase the potency (Table 3). The substitution to a pyridine ring helps to 
both increase the potency and solubility (as in compound 4.15). Although 
there is a significant reduction in the residual activity it is not below the 
desired level of <30% and therefore the IC50 of the compound was not 
calculated. 
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Table 3: SAR Study of N-aryl ring substituent of 4.1 against NDM-1 
Compound Number Structure RA[%], 100 μM 
4.1 
 
83 
4.13 
 
86 
4.14 
 
89 
4.15 
 
40 
4.16 
 
89 
4.17 
 
81 
4.18 
 
92 
 
4.4.2.2 Structure activity relationship of the dihedral angle of the linker. 
The second series of compounds was designed to investigate the role of the 
dihedral angle of the N-aryl ring from the coumarin in order to explore if there 
are specific π stacking interactions occurring within the binding site due to 
the position of these groups.  
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The nitrogen from the sulfonamide was substituted for a carbon (4.20) and 
an oxygen (4.22). The substitutions were conducted in order to change the 
dihedral angle due to the change in bond angles around the individual 
atoms.  
The synthesis of compound 4.20 investigating the role of the dihedral angle 
of the N-aryl ring from the coumarin where the nitrogen was substituted for a 
carbon was conducted as shown in Scheme 6. Benzyl bromide (4.19) was 
coupled to sulfonyl chloride 4.3 in the presence of base to produce 
compound 4.20 in moderate yield (29%)(Scheme 6). 
 
Scheme 6: Synthetic route to compound 4.20  
The synthesis of compound 4.22 investigating the role of the dihedral angle 
of the N-aryl ring from the coumarin where the nitrogen was substituted for a 
oxygen was conducted as shown in Scheme 7. Phenol (4.21) was coupled 
to sulfonyl chloride 4.3 in the presence of base to produce compound 4.22 in 
good yield (73%)(Scheme 7). 
 
Scheme 7: Synthetic route to compound 4.22  
Biological evaluation of compounds 4.20 and 4.22 against NDM-1 was 
conducted by Dr Jürgen Brem at the University of Oxford using the nitrocefin 
based assay described in Appendix A1.1. 
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Table 4: SAR investigation of linker against NDM-1 
Compound Number Structure RA[%], 100 μM 
4.14 
 
83 
4.20 
 
95 
4.22 
 
98 
 
It can be seen that substitution of the sulfonamide nitrogen for an oxygen or 
a carbon has a negative effect on the potency of the compound (Table 4). 
The dihedral angle created by the sulfonamide must be required for good 
binding. 
4.4.2.3 Structure activity relationship of the aryl sulfonyl group. 
The third series was designed to investigate the importance of the predicted 
interaction between the coumarin carbonyl to the main chain amine of the  
Gln-123 residue.  
Compound 4.27 was therefore designed to remove this interaction 
completely and compound 4.25 to change the nature of the bonding due to 
the tautomerisation to the hydroxyquinoline. The synthesis of compound 
4.25 investigating the importance of the predicted interaction between the 
coumarin carbonyl to the main chain amine of the Gln-123 residue by 
changing the nature of the bonding was conducted as shown in Scheme 8.  
1,2-dihydroquinolin-2-one 4.23 was reacted with chlorosulfonic acid to form 
sulfonyl chloride 4.24. The reaction proceeded with moderate yields due to 
the formation of the undesired isomer with the sulfonyl chloride group on the 
8 position of the quinoline (39%). Sulfonyl chloride 4.24 and amine 4.6 were 
coupled in the presence of base to produce 4.25 in moderate yield 
(31%)(Scheme 8). 
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Scheme 8: Synthetic route to compound 4.25  
The synthesis of compound 4.27 investigating the importance of the 
predicted interaction between the coumarin carbonyl to the main chain 
amine of the Gln-123 residue by completely removing the interaction was 
conducted as shown in Scheme 9. Benzene sulfonyl chloride (4.26) was 
coupled to amine 4.6 in the presence of base to produce compound 4.27 in 
good yield (57%)(Scheme 9). 
 
Scheme 9: Synthetic route to compounds 4.27  
Biological evaluation of compounds 4.25 and 4.27 against NDM-1 was 
conducted by Dr Jürgen Brem at the University of Oxford using the nitrocefin 
based assay described in Appendix A1.1.  
Table 5: SAR investigation of coumarin portion of 4.1 against NDM-1 
Compound Number Structure RA[%], 100 μM 
4.1 
 
83 
4.25 
 
82 
4.27 
 
93 
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The substitution of the coumarin to  2-hydroxyquinoline  and a simple phenyl 
ring appeared to have no effect upon binding to the enzyme (Table 5). The 
residual activity of the enzyme remained almost constant for all of the 
compounds. 
4.4.3 Biological evaluation of the hits identified from the Peakdale 
Molecular screening collection 
Biological evaluation of the identified potential inhibitors against NDM-1 was 
conducted by Dr Jürgen Brem at the University of Oxford using the nitrocefin 
based assay described in Appendix A1.1. 
The top four results from the biological evaluation of the selected inhibitors 
from the Peakdale molecular library against NDM-1 are shown in Table 6.  
As the residual activity was greater than 30% at 100 μM in all cases, no IC50 
values were determined. Although these compounds showed some activity 
against the enzyme, they were not pursued due to the activity levels being 
well above the desired levels of less than 30% residual activity at 100 μM. 
Table 6: Peakdale molecular potential inhibitors and residual activities against NDM-1 
Inhibitor Structure RA[%], 100 μM 
4.28 
 
75 
4.29 
 
78 
4.30 
 
80 
4.1 
 
83 
- 61 - 
 
4.5 Molecular docking of the Chembridge screening 
collection 
Screening was conducted using the method described in Section 4.3, using 
the Chembridge92 database as the ligand files and the NDM-1 crystal 
structure 3Q6X.38 A set of eight possible inhibitors of NDM-1 was identified 
from the Chembridge database, for purchase. Details of compound 
structures and predicted binding affinities are shown in Appendix A2.1. 
4.5.1 Biological evaluation of the hits identified from the 
Chembridge screening collection  
Biological evaluation of the identified potential inhibitors against NDM-1 was 
conducted by Dr Jürgen Brem at the University of Oxford using the nitrocefin 
based assay described in Appendix A1.1. 
The top three results from the biological evaluation of the selected inhibitors 
from the Chembridge diversity library against NDM-1 are shown in Table 7.  
Table 7: Chembridge identified compounds and their residual activity against NDM-1 
Inhibitor Structure RA[%], 100 μM 
4.31 
 
81 
4.32 
 
81 
4.33 
 
82 
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As the residual activity was greater than 30% in all cases, no IC50 values 
were determined. Although these compounds showed some activity against 
the enzyme, they were not pursued due to the activity levels being well 
below the desired levels of lower than 30% residual activity. 
4.6 Conclusions  
An extensive vHTS campaign was carried out in an attempt to identify novel 
inhibitors of NDM-1. Initial evaluation of a number of docking algorithms 
using known zinc binding ligands determined AutoDock to be the best 
program to use for docking studies investigating MBLs . Biological evaluation 
at the University of Bristol of the top 10 scoring compounds from the 
Peakdale molecular compound library lead to the identification of a moderate 
hit from which a limited SAR investigation was conducted. When the initial 
putative inhibitors were re-screened along with the Chembridge compounds 
and SAR series at the University of Oxford, some inhibition was seen 
against NDM-1. However there was not significant enough inhibition to 
warrant a more detailed SAR investigation to be carried out around these 
compounds. 
One of the limitations of the vHTS screening approach is that AutoDock 
relies upon a single high-resolution crystal structure. It is important to take 
into account that a protein, when in solution, is flexible and will often undergo 
conformational changes upon substrate binding. A number of studies have 
shown the importance of allowing both the protein and the ligand to have 
free movement in binding.126 Increasing the protein flexibility also rapidly 
increases the computational time to process the dockings and therefore 
most programs, such as AutoDock, only allow the ligand to be flexible. It 
would not be possible, with the current computational power available, to 
conduct high throughput docking where both the ligand and protein are 
allowed to move. 
Therefore if vHTS was to be used further in the identification of inhibitors of 
MBLs it would be sensible to use a number of crystal structures and select  
compounds which are identified as hits for a number of them. Further 
avenues to investigate would be to look at known inhibitors of the MBLs and 
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subject them to development (Chapter 6) and the design of de novo 
compounds which would be specifically designed for this biological target 
(Chapter 7). Both of these methods of compound identification would move 
away from the restrictions imposed by using a commercially available library 
for screening.  
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Chapter 5 
Boronic acid inhibitors 
Traditionally due to a common belief that boron and boron-containing 
compounds are toxic, many medicinal chemists in both industry and 
academia have overlooked using boron in drug molecules and have only 
used them as molecular tools.127 The belief that boron is a toxic element is 
thought to have come from the fact that boric acid is an ingredient in ant 
poisons. It has however been proven that boric acid has a median lethal 
dose (LD50) of 2660 mg/kg (rat, oral) which is comparable to regular table 
salt (NaCl) which has a LD50 of 3000 mg/kg (rat, oral).
128 People have also 
questioned the toxicity of boron from the side effects of taking Bortezomib, 
which is marketed as Velcade (Figure 43).129 Velcade is the only boron-
based therapeutic on the market, widely prescribed for the treatment of 
multiple myeloma. Velcade was slow to be taken into the clinic due to the 
high rate of side effects such as peripheral neuropathy in 30% of patients. 
Myelosuppression causing neutropenia and thrombocytopenia can also 
occur and can be dose limiting. The side effects are however usually mild 
relative to the side effects of bone marrow transplantation and other 
treatment options available for patients with this type of cancer. Recent 
studies have shown that the side effects of taking Velcade are not from the 
presence of a boron atom but the mechanism of action.130  
 
Figure 43: The structure of the boronic acid-based drug Velcade (5.1) 
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Boron-containing compounds have begun to receive increased attention 
over the past few years as potential drugs. This interest comes from a better 
understanding of the unique electronic properties of boron, which for 
example, allow it to act as a transition-state mimetic for the tetrahedral 
intermediate of peptide bond cleavage observed in the β-lactamase 
enzymes.  
Boron contains an empty p-orbital which makes it a strong electrophile and a 
Lewis acid. Boron can easily form dative bonds with nucleophiles which 
changes the structure from being uncharged in a trigonal-planar geometry to 
an anionic tetrahedral geometry (Figure 44).131 The formation of dative 
bonds to inhibitors in the β-lactamase active site provides additional binding 
affinity of the inhibitor to the enzyme. The advantage of a dative bond is that 
they provide stronger binding than non-covalent and hydrophobic 
interactions but are reversible, unlike many covalent bonds generated by 
‘suicide inhibitors’ such as EDTA. The formation of the tetrahedral geometry 
allows inhibitors to be designed which mimic the tetrahedral transition state 
in the hydrolysis of β-lactams. The formation of the dative covalent bond 
makes this type of inhibitor a reversible competitive inhibitor which is 
preferable to ‘suicide inhibitors’ are which are often non-selective in nature 
and co-ordinate to a wide number of sites.  
 
Figure 44: Trigonal-planar boronic acid species forms dative bond with nucleophile to 
generate tetrahedral structure 
In addition to boronic acids, which has been explored by numerous research 
groups, the benzoxaboroles, a class of compounds wherein the boron atom 
is incorporated into a heteroaromatic ring system, have provided a number 
of interesting anti-inflammatory, antifungal and antibacterial drug candidates 
(see Section 5.1). 
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5.1 Known boron-containing drugs 
The first natural product found to contain boron was Boromycin (5.2, Figure 
45), a polyether macrolide antibiotic active against Gram positive bacteria.132 
It is effective against most Gram-positive bacteria, but is ineffective against 
Gram negative bacteria. Boromycin kills bacteria by negatively affecting the 
cytoplasmic membrane, resulting in the loss of potassium ions from the cell. 
The discovery of boromycin led to scientists realising that boron could be 
incorporated into clinically administered drugs. 
 
Figure 45: Natural product Boromycin (5.2) 
There has also been research into the use of boronic acids as electrophiles 
targeting enzymes such as arginase133 (5.3) and serine proteases (a class 
which includes the serine-β-lactamases) (5.4)131 (Figure 46).  
 
Figure 46: Boronic acid containing therapeutics clinical trials. a) Arginase inhibitor (5.3), b) 
beta-lactamase inhibitor (5.4). 
The oxaboroles were first synthesised and characterised by Torssell et al. 
and were found to possess a high hydrolytic stability.134 The oxaborole class 
of compounds have recently seen an upsurge in interest with almost half of 
the publications and patents based on this class of compound having 
appeared after 2005. The physical properties of the oxaboroles differ from 
- 67 - 
simple aryl-boronic acids mainly in their pKa. Cyclising the boron into an 
oxaborole ring reduces the pKa by 1-2 pKa units. A compound of this class 
which is on the market is AN2690 (5.5). AN2690 (Figure 47), which is 
commercially marketed as Tavaborole, was the result of a medicinal 
chemistry program conducted at Anacor Pharmaceuticals.135 Tavaborole 
was designed to be a small, water soluble antifungal agent that could 
penetrate human toe and finger nails to treat onychomycosis.   
 
Figure 47: The structure of Tavaborole 
5.2 Boron containing β-lactamase inhibitors 
Several years ago it was recognised that boronic acid-containing 
compounds could be developed as β-lactamase inhibitors. The boronic acid-
containing inhibitors do not contain a β-lactam ring and can therefore not be 
hydrolysed136 however due to the nature of the boron element they have the 
ability to accept a pair of electrons from a nucleophile in the active site of the 
β-lactamase to form a strong dative covalent bond giving good binding 
affinity. However this research has mainly focused on the serine-β-
lactamases, in particular the Class C β-lactamase, AmpC, where a variety of 
boronic acids have been tested for their biological activity.137 Compound 5.6 
(Figure 48), identified by Anacor, has a Ki of 35 nM against AmpC. 
Compound 5.4 (Figure 46), a glycylboronic acid bearing a side chain of 
ceftazidime, has proven to be a competitive reversible inhibitor of CTX-M β-
lactamases giving a Ki’s of 15 and 4 nM against CTX-M-9 and CTX-M-16 
respectively. 
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Figure 48: Anacor AmpC inhibitor (5.6). 
In 2000, Burns et al. patented a large number of boronic acid based 
inhibitors which act on the β-lactamase enzymes.138 Each of the compounds 
was screened against SHV-5, KPC-2 and CTX-M-15 (Class A), P99 AmpC 
(Class C), VIM-2 (Class B) and OXA-23 (Class D) in enzymatic assays.  
Almost all of the inhibitors show low nano-molar IC50 values against the 
CTX-M-15, P99 AmpC and KPC-2 enzymes. There was a significant 
increase in the IC50 values against VIM-2, SHV-5 and OXA-23 enzymes with 
almost no activity seen against the OXA-23 enzymes. The results for VIM-2 
range from 22 nM through to no inhibition being seen at all. The low nano-
molar IC50 values raised the question of whether, with further modification, 
these compounds could become potent pan MBL enzyme inhibitors. The 
compounds were identified as good potential inhibitors and therefore a 
synthesis was required in order that the compounds could be screened 
against the panel of clinically relevant MBLs. The synthetic route which was 
used to make the boronic acid based inhibitors in the patent is shown in 
Scheme 10.  
The synthesis begins with a tert-butyl protection of acid 5.7 followed by 
reaction of the boronic acid with (+)-pinanediol to form 5.8. A homologation 
was then conducted on 5.8 to produce 5.9. Molecule 5.9 was then converted 
to compound 5.11 via intermediate 5.10 by conducting a homologation 
before introducing the amine using lithium hexamethyldisilane. The TMS 
groups were then removed before an amide coupling was conducted 
yielding 5.11. Finally a global deprotection was conducted using BCl3 to yield 
boronic acid inhibitor 5.12.  
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Scheme 10: The synthetic route to produce the boronic acid-based inhibitors
138
 
The patent does not confirm how the compounds bind to the VIM-2 enzyme 
and there has been no co-crystal structures published in the literature of this 
class of compound binding to the MBLs.  
5.3 Targeting the MBLs with boron-containing inhibitors 
Initial biological screening data against VIM-2, from the patent by Burns et 
al, suggests that this boron containing inhibitor class could be strongly active 
against the MBLs as well as the serine-β-lactamases. The aim was to 
identify, using a number of in silico techniques, a small sample of five 
strongly binding boronic acid-containing inhibitors which would be 
synthesised and screened against the panel of clinically relevant MBLs. Any 
of the boronic acid containing compounds which show good activity against 
the MBLs will be co-crystallised in an MBL in order to investigate how the 
boronic acid based inhibitors bind to the MBL enzymes.  
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The five boronic acid-based inhibitors were selected using the following 
reasoning: The first compound (5.13) was selected because it gave the best 
biological result against the VIM-2 MBL with an IC50 of 22 nM in the patent 
(see Section 5.3.1). The next two compounds (5.14 and 5.15) were selected 
as the best predicted binding compounds from docking the 45 compounds 
stated in the patent into the active site of NDM-1 (see Section 5.3.2). The 
final two compounds (5.17 and 5.18) were identified using de novo design, 
building up from a scaled down portion of the boronic acid with the aim of 
increasing the binding affinity of the inhibitor to the MBL compared to 
inhibitor compound 5.13 (see Section 5.3.3).  
5.3.1 VIM-2 active compound 
Compound (5.13, Figure 49) was selected because it reported the best 
biological result against the VIM-2 MBL with an IC50 of 22 nM in the patent. It 
is expected that by having good biological activity against VIM-2 there will 
also be good biological activity against the other clinically relevant MBLs. 
 
Figure 49: Structure of compound 5.13 with IC50 of 22 nM against VIM-2 
Molecular docking of compound 5.13 was conducted as part of the docking 
of the 45 patented compounds, as described in Section 5.3.2. Compound 
5.13 is predicted to bind to both zinc atoms and a number of residues within 
VIM-2 (Figure 50). The free carboxylic acid is predicted to bind to the side 
chain amine of Lys-211, main chain amide of Asn-220 and Zn2. The 
hydroxyl group binds to Zn1 along with the boronic acid group which also 
has interactions with the main chain amides of Gln-123 and Asp-124. The 
docking poses do not show the free amine making any contacts with the 
enzyme. It is however expected that the free amine would bind to the side 
chain carboxylic acid of Glu-152 which is located in close proximity to the 
free amine.  
- 71 - 
 
Figure 50: Docking of compound 5.13 into NDM1 showing key binding contacts: a) 3D 
spatial representation, b) 2D representation (PDB ID: 3Q6X). 
5.3.2 Docking of patented compounds 
In silico docking of the 45 compounds described in the patent, into the NDM-
1 enzyme (PDB ID: 3Q6X), was conducted to identify the two compounds 
which gave the best predicted AutoDock88, 100 and SPROUT125 binding 
scores. The compounds would be biologically screened after synthesis 
against the panel of clinically relevant MBLs to see if these compounds 
exhibit strong inhibitory effects. The procedure for molecular docking was 
carried out as described below. 
The following protocol was used: 
1. Each of the 45 boronic acid based inhibitors were constructed in 
maestro.139 The resulting structures were then fully energy minimised 
using the multiple minimisation tool (MM). 
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2. Each compound was then docked using the AutoDock program and 
docked into the di-zinc containing active site of the crystal structure of 
NDM-1 (PDB ID: 3Q6X38). 
3. The resulting docking ‘poses’ were scored, both within AutoDock and 
also using the SPROUT scoring function for comparison. 
The top two results, compound 5.14 and 5.15 (Figure 51), were selected 
based upon consideration of the best AutoDock score, AutoDock pose 
clustering and SPROUT score respectively.  
 
Figure 51: Structure of best scoring compounds (5.14 and 5.15) identified from docking to 
NDM-1 in AutoDock 
Compound 5.14 contains a piperazine unit in place of the free amine of 
compound 5.13. Compound 5.14 is predicted to bind in a slightly different 
position to 5.13 with the boronic acid now being the key binding portion of 
the molecule as it binds to main chain amide of Asn-220, side chain amine of 
Lys-211 and Zn2 (Figure 52). The hydroxyl group can be seen to bind to 
main chain amide of Asn-220. The carbonyl of the amide bond is placed 
between the two zinc atoms binding to both. The piperazine binds to the side 
chain carboxylic acid of the Glu-152 residue which the free amine of 5.13 did 
not bind to in the predicted docking pose.  
Compound 5.15 is predicted to bind in almost identical position to compound 
5.14 (Figure 53). The amine-containing alkyl chain is positioned down 
deeper into the active site of the NDM-1 enzyme than the piperazine amine 
of compound 5.14 and therefore, as well as picking up the side chain 
carboxylic acid of the Glu-152 residue, there is also an interaction with the 
side chain carboxylic acid of the Asp-223 residue. From the patent, the IC50 
against VIM-2 is 47 nM for compound 5.15 and 510 nM for compound 5.14 
which could show that making this extra interaction is key to good potency.  
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Figure 52: Docking of compound 5.14 into NDM1 showing key binding contacts: a) 3D 
spatial representation, b) 2D representation (PDB ID: 3Q6X). 
 
Figure 53: Docking of compound 5.15 into NDM1 showing key binding contacts: a) 3D 
spatial representation, b) 2D representation (PDB ID: 3Q6X). 
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5.4.3 De novo design of novel compounds. 
Two compounds were to be made with the use of de novo design to attempt 
to increase the potency of the boron-containing inhibitors against the MBLs. 
A scaled back fragment of compound 5.13 disconnected at the amide bond 
leaving an amine was used as the starting point for de novo design (5.16, 
Figure 54). This was selected as the fragment 5.16 was a common motif 
seen in all of the boronic acid based inhibitors from the patent. The aim was 
to grow out from this free amine using the SPROUT de novo design program 
in an attempt to pick up further interactions within the binding site therefore 
increasing the potency of the inhibitor (see Section 7.2 for explanation of 
SPROUT). Once designed the molecules would be synthesised and 
screened against the panel of clinically relevant MBLs. 
 
Figure 54: Scaled back starting point for de novo design (5.16) 
A number of SPROUT runs were conducted growing from the free amine of 
fragment 5.16 out into the active site of NDM-1. A number of runs were 
conducted attempting to bind fragment 5.16 to a number of residues in the 
active site including Glu-152 where previous interactions have been see in 
the docking of patented compounds 5.14 and 5.15. The SPROUT runs 
identified a selection of 30 potential inhibitor compounds which were re-
docked into the active site of NDM-1 (PDB ID: 3Q6X) using AutoDock to 
increase confidence in the predicted binding pose. The results of the 
AutoDock dockings were visually inspected to identify the top two scoring 
compounds. The two compounds predicted to bind the best, 5.17 and 5.18, 
were selected for synthesis (Figure 55).  
 
Figure 55: De novo designed boronic acid based inhibitors (5.17 and 5.18) 
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Compound 5.17 was predicted to bind mainly through the boronic acid which 
is predicted to bind to main chain amide of Asn-220, the side chain amine of 
Lys-211 and Zn2 (Figure 56). There are further binding interactions 
predicted from the amide nitrogen to the carboxylic acid side chain of Asp-
124 and the amide carboxylate to the side chain amide of Asn-220. Finally 
the free amine is predicted to bind the side chain carboxylic acid of the Glu-
152 residue as seen in previous examples.  
 
 
Figure 56: Docking of SPROUT identified compound 5.17 into NDM1 showing key binding 
contacts: a) 3D spatial representation, b) 2D representation (PDB ID: 3Q6X). 
Compound 5.18 has a rather different predicted binding pose when 
compared to the other boronic acid compounds. The boronic acid is now 
expected to bind to side chain carboxylic acid of Asp-124, main chain amide 
of Asp-124 and main chain amide of Gln-123.  The carbonyl of the amide is 
predicted to bind to the side chain amide of Asn-220 (Figure 57). The 
carboxylic acid is predicted to bind to both the side chain amine of Lys-211 
and the main chain amide of Asn-220. The final predicted contact is from the 
phenol to the Zn1 atom. The cyclohexyl group lies up against the 
hydrophobic wall of the NDM-1 active site. 
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Figure 57: Docking of SPROUT identified compound 5.18 into NDM1 showing key binding 
contacts: a) 3D spatial representation, b) 2D representation (PDB ID: 3Q6X). 
5.5 Synthetic route development 
In order to produce the compounds required for biological evaluation and 
crystallisation studies, some synthetic route development work was required 
to make the reasonable quantities of the desired compounds. 
The first change that was made to the route described in the patent by Burns 
et al was the choice of starting material. Rather than using 3-
(dihydroxyboranyl)-2-methoxybenzoic acid (5.7) which costs >£500 per g 
(Combi-blocks) a switch was made to 3-bromo-2-methoxy benzoic acid 
(5.19) which costs ~£75 per g (Sigma-Aldrich). This change in starting 
material changed the first few steps of the synthesis as the boronic acid was 
now needed to be introduced to the starting molecule. Although there is an 
increase in the number of synthetic steps the developed route is preferred as 
it uses cheaper starting materials. Many of the steps show slightly improved 
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yields over the patent route. The complete modified synthetic route is shown 
in Scheme 11.  
 
Scheme 11: Synthetic route to boronic acid based inhibitors 
The first reaction, protecting the acid (5.19) as a tert-butyl ester (5.20) was 
initially conducted as described in the patent (Scheme 12). This reaction 
provided low conversion to yield ester 5.20 (12%). In order avoid the use of 
2-methylpropene gas and to use milder conditions, the reaction was 
repeated with the use of oxalyl chloride to form the acid chloride and then 
reaction with t-BuOH (Scheme 12). The reaction gave an improved yield of 
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ester (62%). This route was therefore chosen as the preferred route to be 
used. 
 
Scheme 12: Formation of tert-butyl ester (5.20) 
The second reaction was a one pot conversion of dibromomethane to the 
pinacol boronate (5.21) (Scheme 13).140 This was conducted via the addition 
of n-BuLi to a mixture of dibromomethane and triisopropylborate to form the 
triisopropyl borate intermediate. This was then hydrolysed with methane 
sulfonic acid to form the boronic acid and trans-esterified with pinacol to form 
5.21. Compound 5.21 is isolated rather than proceeding straight to 5.22 as 
5.21 is easier to purify using distillation to remove the salts and reaction by-
products. The product was formed in moderate yield (40%). The second 
stage was a transesterification of 5.21 with (+)-pinanediol which was 
conducted over 18 h to give 5.22 in good yield (71%).141  
 
Scheme 13: Formation of pinaneboron species (5.22) 
The joining of 5.20 and 5.22 to form coupled product 5.23 was conducted by 
lithium halogen exchange on 5.20 before the addition of the borane species 
5.22. Presumably, the reaction proceeds via a Matteson type homologation 
(Scheme 14).142 The lithiated 5.20 attaches to 5.22 to form a borate complex 
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which rearranges on warming to give the product 5.9. Typically, the reaction 
gives  low to moderate yields (~40-50%).  
 
Scheme 14: Mattesen type homologation of 5.20 and 5.22 to form compound 5.9 
The next step was another Matteson type homologation of 5.9 to 5.23.142 
The reaction was initially conducted as described in the patent using 
chloroiodomethane but this afforded low yield (20%). The reaction was then 
conducted using the conditions described by Inglis et al. at Oxford using 
freshly produced LDA, DCM and ZnCl2.
141 The ZnCl2 catalyses the 
rearrangement giving improved diastereoselection. The altered conditions 
gave an improved yield of product (95%, Scheme 15). The introduction of 
the TMS amine by a SN2 reaction via the use of LiHMDS was conducted as 
described in the patent to yield amine 5.10 in moderate yield (63%).   
 
Scheme 15: Homologation and amine introduction to give 5.10 
 
- 80 - 
Removal of the TMS groups from 5.10 proved difficult to monitor so was 
assumed to proceed with quantitative conversion to the free amine. The 
amide coupling with different carboxylic acids, to give compounds 5.24-5.27 
respectively, was conducted using HATU as the coupling agent. The amide 
coupling reactions proceeded in low yield (40-14%, Scheme 16). A number 
of different coupling agents were tested including EDC/HOBt, T3P and the 
use of an acid chloride. However, all of these methods gave significantly 
lower yields than the HATU conditions.   
 
Scheme 16: Amine deprotection and amide coupling 
In order to produce compounds 5.14 and 5.15 an extra step was required in 
the synthetic route. An SN2 reaction was carried out on the bromine of 
compound 5.25 with 1-Boc piperazine and N-Boc-ethylenediamine 
respectively in the presence of base (Scheme 17) to give compounds 5.28 
and 5.29 respectively in low yield (18-17%)   
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Scheme 17: SN2 reaction of compound 5.25 with amine X to form compounds 5.28 and 
5.29 
The global deprotection of the protecting groups from compounds 5.24, 
5.26-5.29 to give compounds 5.13-5.15, 5.17 and 5.18 was attempted as 
described in the patent with the exception of substituting BCl3 with BBr3. 
Additionally an alternative deprotection method used in a second patent by 
Burns et al. using 3N HCl was tested. However, in this case no deprotected 
product was seen using LCMS.143 The deprotected inhibitors were purified 
using reverse phase C18 biotage column chromatography in low yield  (13-
1%). (Scheme 18). 
 
Scheme 18: Global deprotection of compounds 5.24, 5.26-5.29 
Compounds 5.13-5.15, 5.17-5.18 were formed in low quantities as the HCl 
salt. Due to the low quantities produced a satisfactory 13C NMR spectrum 
was unable to be obtained for characterisation. 
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5.6 Biological evaluation 
Biological evaluation of the identified potential inhibitors of NDM-1 was 
conducted by Dr Jürgen Brem at the University of Oxford using the nitrocefin 
based assay described in Appendix A1.1. 
The results of the biological evaluation against NDM-1 are reported in Table 
8. 
Table 8: Biological evaluation of boronic acid based compounds against VIM-2, IMP-1 and 
NDM-1 
Compound 
Number 
Structure 
IC50 VIM-2 
(µM) 
IC50 IMP-1 
(µM) 
IC50 NDM-1 
(µM) 
5.13 
 
0.003 ± 0.058 10.0 ± 0.09 0.029 ± 0.020 
5.14 
 
0.014 ± 0.045 16.3 ± 0.13 0.040 ± 0.021 
5.15 
 
0.002 ± 0.114 26.0 ± 0.13 0.004 ± 0.052 
5.17 
 
0.011 ± 0.029  32.0 ± 0.11 0.687 ± 0.068  
5.18 
 
0.051 ± 0.035 27.6 ± 0.12 2.04 ± 0.028 
 
Generally all of the boronic acid based inhibitors 5.13-5.15, 5.17-5.18 
exhibited < 50 µM inhibition against the MBL enzymes. Inhibitor 5.15 was 
the most potent  inhibitor against VIM-2 and NDM-1 giving IC50’s of 2 nM and 
4 nM respectively.  
The five boronic acid-containing inhibitors (5.13-5.15, 5.17-5.18) have poorer 
IC50’s against IMP-1 than against the other MBL enzymes. The IC50’s for 
IMP-1 are in the micro-molar range as opposed to IC50’s in the nano-molar 
range observed for the other enzymes. This is rationalised by the much 
more enclosed active site of the IMP-1 enzyme when compared to the active 
sites of VIM-2 and NDM-1 (see Section 2.4.2.1). In comparison to IMP-1 the 
IC50’s of each inhibitor against NDM-1 and VIM-2 are in a similar range to 
each other.  
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A trend is visible within the IMP-1 IC50 data showing that the shorter in length 
the inhibitor molecule the better the inhibition the enzyme. The same trend is 
not observed in either the VIM-2 or NDM-1 IC50 results. 
The cyclohexyl containing compound 5.18, which does not have the free 
amine is predicted to bind to Glu-152 in NDM-1 as seen in compounds 5.13-
5.15 and 5.17, has weaker IC50’s against all of the MBL enzymes. This 
shows that the amine in this position has a positive effect on the binding 
affinity of the boronic acid-containing inhibitors.  
Poorer IC50 values are observed for the SPROUT derived compounds 5.17 
and 5.18 which contain a cyclohexyl ring in the place of an aryl ring next to 
the amide bond. This implies either that a positive π-stacking interaction is 
being formed between the MBL enzyme side wall and the aromatic ring in 
compounds 5.13-5.15, there is not enough space in the active site to 
accommodate the cyclohexyl ring, or the direction of the amine emanating 
from the cyclohexyl ring compared to coming off of an aryl ring has a large 
effect on the binding affinity. This effect is more prominent in NDM-1 than 
the other enzymes.  
5.7 Conclusions  
Boron has been shown to be a useful atom which can be used in medicinal 
chemistry and is slowly beginning to be incorporated into a number of 
therapeutics including inhibitors of the β-lactamases. Traditionally boron was 
avoided due to the perception it was toxic but now many of these 
misconceptions are being dispelled leading to boron being viewed as 
another useful atom to use in medicinal chemistry.  
Using the patent by Burns et al. as a starting point five compounds were 
identified for synthesis by the use of vHTS and de novo design. A number of 
significant changes were made to the synthetic route in order to both reduce 
the overall cost of the synthesis and to improve the yields on a number of 
steps.  
The compounds were biologically screened against the enzymes showing 
pan inhibition across the panel of MBL enzymes. IMP-1 gave significantly 
poorer IC50’s for the inhibitors with low micro-molar results for each inhibitor 
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compared to nano-molar results for each inhibitor against the VIM-2 and 
NDM-1. Inhibitor 5.15 gave IC50’s of 2 nM, 26 µM and 4 nM against VIM-2, 
IMP-1 and NDM-1 respectively.  
The results backed up the predictions with each of the five inhibitors being 
active against the panel of MBL enzymes. The de novo designed inhibitors 
5.17 and 5.18 did not provide any extra binding affinity compared to the 
compound identified from the patent (5.13) and the vHTS identified 
compounds (5.14-5.15). It is predicted this is due to the cyclohexyl portion of 
the molecule and 5.18 having no free amine which could bind to the Gln-152 
residue in NDM-1. 
A crystal structure of compound 5.13 in VIM-2 is currently being solved by Dr 
Michael MacDonough at the University of Oxford who will be looking to see 
how the boronic acid binds to the enzyme. From this data more active 
inhibitors can be designed and synthesised. The availability of a crystal 
structure will greatly increase the accuracy of the structure based drug 
design techniques. 
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Chapter 6 
Cysteine-containing peptides  
Inhibition of enzymes by peptides and the evolution of peptide ligands to 
small molecule mimetics is a common approach in drug discovery, with 
several notable successes. Some well-known examples where peptides or 
peptide mimetics have been used in drug discovery include Captopril144 
(ACE inhibitor), Epifibatide145 (anticoagulant) and Ziconotide146 (N-type Ca 
channel blocker). 
Peptides would therefore seem to be ideal drug leads with a large number of 
advantages to the use of peptides as drugs including: high potency, high 
selectivity, broad range of targets, potentially lower toxicity than small 
molecules, low accumulation in tissue and high chemical and biological 
diversity. However there are also a large number of disadvantages to 
peptides including: poor metabolic stability due to protease cleavage of the 
peptide backbone, poor membrane permeability, poor oral bioavailability, 
high production cost, rapid clearance and sometimes poor solubility. A large 
number of peptide based drugs fail in clinical trials before making it to the 
clinic.147 
6.1 Methods of identifying the active peptides 
The starting point for peptide and peptide mimetic research is the 
identification of a peptide that is active in the relevant assay. There are a 
number of techniques which could be used to probe peptide binding to the 
enzyme target. These included phage display, peptide microarrays and HTS.  
Phage display is a technique used for the study of protein–protein, protein–
peptide, and protein–DNA interactions.  The technique uses bacteriophages 
(viruses that infect bacteria) to connect proteins with the genetic information 
that encodes them.148 In this method, a gene which encodes the protein (or 
in this case peptide) of interest is inserted into a phage coat protein gene, 
causing the phage to "display" the peptide on its outside while containing the 
gene for the peptide on its inside, resulting in a connection between 
genotype and phenotype.149 The displaying phages are then screened 
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against the enzyme, in order to detect interactions between the displayed 
peptide and the enzyme. In this way, large libraries of proteins can be 
screened and amplified in a process called in vitro selection, which is 
analogous to natural selection. Figure 58 shows the sequence of identifying 
a hit from Phage display screening.150  
 
Figure 58: Phage display screening sequence based upon identification of trimer peptides 
against a MBL, adapted from
150
 
A second technique is the peptide microarray (also referred to as peptide 
spot array) which is a collection of peptides displayed on a solid surface of 
silica or glass, which is often termed a ‘peptide chip’.151 A peptide microarray 
is assembled directly on the surface of the peptide chip by in situ synthesis. 
Synthesis on a chip allows the parallel synthesis of tens of thousands of 
peptides providing larger peptide libraries with relatively low synthesis 
costs.152 Peptide chips are then used by scientists in biochemistry to study 
binding properties, functionality and kinetics of protein-protein interactions. 
Peptide microarrays are often used to profile an enzyme to find key residues 
for binding. Figure 59 shows an example row on a peptide microarray for 
trimer peptides.  
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Figure 59: Simplified representation of a peptide microarray for the identification of trimer 
peptides which would bind to a MBL. Each colour represents a different amino acid. 
High Throughput Screening (HTS) has become an important way of 
screening peptides and proteins against a biological target. HTS significantly 
reduces the cost and time required to identify active molecules from a large 
library of compounds. In the case of peptides a large library can be screened 
in a short amount of time against the target. HTS does, however, have some 
disadvantages when compared to the other techniques. These include 
storage of a large number of compounds as well as the cost of the run. HTS 
is, however, used by a number of researchers against a wide range of 
biological targets with a large number of compounds.  
As HTS is a commonly used process to identify new peptides, there is no 
reason why this process could not be switched to vHTS for all the 
advantages set out in Section 4.1. Computational libraries of peptides could 
be constructed and docked into crystal structures in significantly smaller 
timescales with greatly reduced cost over traditional HTS. The 
computationally generated peptide libraries could be made into more 
bespoke libraries by applying filters such as ensuring one residue type such 
as Cys is present in all the peptides (see Section 6.3). This chapter of work 
describes the process of converting the standard HTS protocol into a vHTS 
protocol with its application to the NDM-1 enzyme. 
6.2 Peptides as inhibitors of MBLs  
Captopril, an angiotensin-converting-enzyme inhibitor (ACE inhibitor), is a 
known peptide mimic of a Cys-Pro di-peptide.144 ACE indirectly increases 
blood pressure by causing blood vessels to constrict. For this reason, drugs 
known as ACE inhibitors (such as captopril) are used to lower blood 
pressure.153 ACE is a zinc-containing enzyme which makes it interesting to 
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potentially screen its inhibitors against the MBLs. D-captopril was screened 
against IMP-1 and NDM-1 and has been shown to exhibit moderate 
inhibition of NDM-1 with an IC50 of 36 μM and IMP-1 with an IC50 of 12 μM.  
A crystal structure of D-captopril co-crystalised in IMP-1 was obtained by 
Brem et al.154 at the University of Oxford. The key feature in the binding of 
captopril is the sulfur displacing the bridging water between the zinc atoms 
and forming a strong zinc-sulfur bond to both zincs (Figure 60). A secondary 
interaction is seen from the carboxylic acid group of the captopril to the Lys-
161 residue.   
From this knowledge it was decided to include cysteine in each designed 
putative inhibitor peptide, due to the potential to form a strong zinc-sulfur 
bond similar to that seen in captopril. 
        
Figure 60: Captopril co-crystallised in IMP-1 Brem et al. Unpublished data
154
 
Page et al. at the University of Huddersfield, screened a small number of 
substituted thiols and cysteinyl dipeptides as potential inhibitors of Bacillus 
cereus zinc β-lactamase. The simplest thiol, N(2-mercaptoethyl)-
phenylacetamide, was found to be a competitive inhibitor of the enzyme. 
Competitive inhibition was also seen for all the other compounds tested. The 
thiol group was observed to be necessary for inhibition as removal of the 
group led to a significant decrease in potency. This work confirmed the key 
nature of the zinc-sulfur interaction and that cysteine-containing dipeptides 
have a moderate binding affinity to MBL enzymes.  
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In the current study the length of the peptide will be investigated to see if a 
di-, tri- or tetramer peptide length gives the best binding to the target. This 
work focuses on targeting the peptide for the NDM-1 system so slightly 
weaker binding would be expected due to the larger active site than the 
Bacillus cereus zinc β-lactamase enzyme investigated by Page et al. The full 
range of di-, tri- and tetramer cysteine containing peptides will be docked to 
identify the best binding compounds rather than only docking a small 
selection of each length of peptide. 
6.3 Peptide library generation  
A computational library containing all of the possible molecular structures of 
the L-amino acid-containing trimer peptides was required. This study was 
initially performed on the L-amino acid enantiomers because this absolute 
configuration represents the majority of peptides in vivo. The required 
conditions were that there was one cysteine residue in the trimer peptide 
and the other two residues could consist of any of the other 19 common 
amino acids. Multiple cysteine residues were not allowed due the toxicity of 
many thiol containing compounds. The generated library would contain 
1,083 trimer peptides. The library was first created using a Python155 script 
(Appendix A3.1), written by Joshua Meyers (MChem student at the 
University of Leeds), which generated all possible trimers meeting the 
criteria firstly as three letter code (Figure 61, A) and then in SMILES 
strings156 (B). The SMILES strings were then fed into Openeye’s BABEL157 
program which converted the SMILES strings into 2D structures in SDF file 
format (C)(Appendix A3.2). The 2D structures were then converted into 
lowest energy 3D conformers using the OMEGA158 programs (D)(Appendix 
A3.3). The same process was repeated for the di-peptides and tetramer 
peptides respectively. 
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Figure 61: Schematic of peptide library production 
6.4 Docking protocol 
The computational library of trimers was docked into the crystal structure of 
NDM-1 (PDB ID: 3Q6X38) using AutoDock 4.2 (see Section 4.1.1). 
AutoDock, uses a Lamarckian genetic algorithm to generate a range of 
docking poses. The resulting docking poses were scored, both within 
AutoDock and also using the SPROUT scoring function for comparison. 
Figure 62 below shows the correlation between the two scores for both the 
tri- and tetra-peptides respectively. The scores have been normalised to 
allow a direct comparison of the two scoring functions, with the best scoring 
peptide being normalised to one. It can be seen that there is a possible weak 
correlation between the two scores with almost no correlation when looking 
at the tri-peptides but a clearer correlation with the tetra-peptides. The major 
variances are seen due to the different weighting of different components in 
the scoring functions. This highlights the need for a consensus approach 
when interpreting the results taking into account both scores to find the best 
inhibitors.     
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Figure 62: Graphs comparing the AutoDock and SPROUT scores of the top 40 hits of the 
tri- and tetra-peptides. 
6.5 Docking results  
The docking of the di-, tri- and tetramer peptides respectively were 
conducted as described in Section 6.4. The results of the docking studies 
can be seen in Appendix A4.1-A4.3. Overall the dipeptides gave the weakest 
binding scores which was to be expected due to the lower molecular weight 
of these systems. As the task was to look for the best binding peptides and 
the trimers and tetramers gave a significant enhancement on the binding, 
the di-peptides were not investigated any further.   
Initially it appeared that the scores of both the trimer and tetramer peptides 
are very similar, however considering that the tri-peptides have a lower 
molecular weight, and that a greater average number of possible docking 
poses were found than in the four membered peptides, the tri-peptides 
performed significantly better. Visual inspection of the docking poses for the 
tri- and tetramer peptides revealed that the tri-peptide molecules docked 
deep into the pocket making contacts with residues in the pocket whereas 
the tetra-peptides often protrudes into the solvent exposed region of the 
open cavity (Figure 63). Taking these results into account, it was decided to 
progress the trimer peptides only. 
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Figure 63: Example docking of a trimer 6.1 (cyan) and tetramer 6.2 (magenta) showing the 
tetramer extending up into open space 
It was observed that in almost all of the top ten trimer peptides, a Pro 
attached to a Cys is a common feature. It is predicted that this motif 
orientates the binding functional groups on the peptide towards the Lys and 
Zn thus reducing the energy required for binding. An example of this is 
shown by the docking of compound 6.1 (Figure 63) 
In a large number of the docking results, the sulfur atom within the cysteine 
residue is not predicted to make a direct contact with the zinc atom and is 
placed into the solvent-exposed region of the cavity rather than in a position 
to make a direct contact to the zinc atoms. This issue stems from one of the 
limitations in the AutoDock docking parameters where the zinc is assumed 
to have zero charge. Docking also only provides a score of a pre-covalent 
event, therefore not taking into account the strength of a covalent bond that 
could be formed from sulfur to the zinc atoms. It is predicted that upon 
binding, there would be rotation of the molecule to place the sulfur in a 
position where it can make a strong covalent bond with the zinc atoms. Part 
of the visual inspection of the results ensures that with rotation, a zinc-sulfur 
bond could be formed without disruption of the other bonds already 
predicted to take place. 
Figure 64 shows a high scoring example where the sulfur is in a good 
orientation to make a zinc-sulfur bond. However, this bond is not taken into 
account in the score of the docking pose.  
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Figure 64: 2D and 3D representations of trimer peptide 6.3 (Pro-Trp-Cys) docked into 
NDM-1. PDB ID: 3Q6X 
The ten worst binding trimer peptides were identified in order to synthesise 
them along with the top ten to ensure that the screening identifying pre-
covalent inhibitors was sucessful, and the formation of the zinc-sulfur bond is 
not the exclusive factor contributing to the binding affinity of the inhibitors. 
The predicted worst ten trimer peptides contained a number of charged 
functional groups such as Asp and Arg which gave poor scores. Predictions 
implied that many of them would have problems reaching the active site to 
form binding interactions. Figure 65 shows an example of the poor binding 
peptide 6.4. 
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Figure 65: Poor binding peptide 6.4 (Arg-Arg-Cys) 
6.6 Biological evaluation 
The ten trimer peptides which gave the strongest predicted binding were 
identified for synthesis along with the ten trimer peptides which gave the 
weakest predicted binding.  
The selected trimer peptides were synthesised using Solid Phase Peptide 
Synthesis (SPPS)159 and purified using preparative mass-directed HPLC. 
Biological evaluation against NDM-1 was conducted at the University of 
Oxford in a nitrocefin based fluorescence assay as described in Appendix 
A1.1.  
The results of biological screening for the top ten scoring trimers are shown 
in Table 9. 
Table 9: Top 10 scoring trimer peptides and their biological activity against NDM-1  
Compound 
No. 
Sequence RA [%],  100 μM 
6.5 Pro-Ile-Cys 100 ± 2.3 
6.6 Asn-Pro-Cys 77 ± 11.5 
6.7 Pro-Pro-Cys 100 ± 2.8 
6.8 Pro-Trp-Cys 100 ± 10.6 
6.9 Pro-Cys-Phe 59 ± 4.3 
6.10 Cys-Pro-Phe 100 ± 12.2 
6.11 Cys-Gly-Trp 100 ± 7.8 
6.12 Cys-Pro-Trp 100 ± 4.0 
6.13 Cys-Phe-Tyr 64 ± 1.9 
6.14 Cys-Pro-Tyr 100 ± 2.4 
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Peptide 6.9 and Peptide 6.13 showed moderate inhibition of the NDM-1 
enzyme. Both contain a Cys-Pro motif and an aromatic-containing amino 
acid residue. Compounds 6.9 and 6.13 displayed IC50 values against NDM-1 
of 183 ± 0.1 μM and 219 ± 0.1 μM respectively. Peptide 6.6 showed low 
inhibition of the NDM-1 enzyme however this was not deemed significant for 
IC50 determination. No inhibition was seen for the other top-scoring peptides 
which exhibited 100% residual activity (RA) at 100 µM. 
The predicted ten worst peptides were also biologically evaluated against 
NDM-1 and the results are shown below in Table 10. 
Table 10: Worst Scoring compounds and their biological results against NDM-1 
Compound 
No. 
Sequence  RA [%], 100 μM 
6.15 Cys-Arg-Arg 100 ± 2.5 
6.16 Arg-Cys-Arg 100 ± 6.9 
6.17 Gln-Cys-Arg 100 ± 6.2 
6.18 Lys-Cys-Arg 100 ± 12.1 
6.19 Asp-Cys-Asp 88 ± 5.9 
6.20 Arg-Arg-Cys 100 ± 4.2 
6.21 Cys-Lys-Glu 100 ± 5.4 
6.22 Cys-Arg-Glu 100 ± 3.5 
6.23 Lys-Cys-Gln 100 ± 2.8 
6.24 Arg-Cys-Tyr 100 ± 3.0 
 
Overall it is observed that there is poorer binding with these peptides than 
the best binding top ten with all compounds apart from 6.19 exhibiting 100% 
residual activity at 100 µM against NDM-1. This indicates that the screening 
is broadly consistent with the predictions. The peptide based inhibitors have 
been identified in their pre-covalent docking state. The docking predictions 
does not take into account the strength of the zinc sulfur bond and therefore 
should distinguish between strong and weak binding inhibitors by the other 
binding interactions with the active site. The results show that the formation 
of the zinc-sulfur bond is not the exclusive factor in the inhibitors binding 
affinity as some of the top scoring peptides are biologically active.  
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Compound 6.19 gives a slightly anomalous result with higher than predicted 
inhibition relative to the other peptides. This is potentially rationalised by the 
preference of the Asp residues to bind strongly to the Lys-211 residue found 
in the active site. Figure 66 shows the predicted contact made by compound 
6.19. 
 
Figure 66: Binding of compound 6.19 to the Lys-211 in the active site 
6.7 D and DL combination trimers 
The research into thiol- and cysteinyl peptide inhibitors by Page et al. 
suggested that, for dipeptides in the BCII model system, that the strongest 
binders have a D absolute stereochemistry at the cysteine residue and at the 
C-terminal chiral centre respectively. The above process was therefore 
repeated using libraries of just D-amino acids and of all DL combinations. 
The virtual libraries of all D-amino acids (1,083 compounds) and the DL 
combinations (8,432 compounds) were produced as described in Section 
6.3. The four top scoring peptides were identified by docking each of the 
libraries into the crystal structure of NDM-1 using AutoDock. The docking 
results can be found in Appendix A4.5. As with the all L amino acid trimers, 
the common Cys-Pro motif was observed in many of the high scoring 
compounds. It was also noted that all of the four top scoring trimer peptides 
consisted of all D-amino acids. From the research by Page et al. these 
would therefore be expected to give better binding than the already tested L-
amino acid trimers. The top scoring peptide was 6.25 which is shown in 
Figure 67. 
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Figure 67: Best binding DL combination trimer peptide 6.25 
The top four peptides were then synthesised and biologically evaluated 
against the NDM-1 enzyme at the University of Oxford 
The results of the biological evaluation are shown below in Table 11. 
Table 11: Top scoring D and DL combination trimers and their biological activity against 
NDM-1 
Compound 
No. 
Sequence RA[%], 100 μM 
6.25 D-Cys-D-Phe-D-Tyr 91 ± 3.6 
6.26 D-Pro-D-Trp-D-Cys 72 ± 5.7 
6.27 D-Cys-D-Pro-D-Tyr 84 ± 5.1 
6.28 D-Pro-D-Cys-D-Phe 77 ± 3.2 
 
Given the limited range of the activities it is hard to draw firm conclusions 
from the results. However, generally the all D- absolute stereochemistry 
containing peptides 6.25-6.28 show better inhibition of the NDM-1 enzyme at 
100 µM than the all L- absolute stereochemistry peptides.  
The all L-absolute stereochemistry peptides 6.9 and 6.13 exhibit the best 
overall inhibition at 183 µM and  219 µM against NDM-1 respectively   
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6.8 Peptide mimics 
After a strong binding peptide has been identified using one of the 
techniques described in Section 6.1, a peptide mimic can be designed. 
Designing a peptide mimic involves deconstructing the original peptide and 
reassembling the essential features on a new mimetic scaffold that retains 
the ability to interact with the enzyme target, but circumvents the problems 
associated with a natural peptide. By this process, the peptide is reduced to 
its ‘information content’, the basis for a pharmacophore model that defines 
the critical features and their arrangement in space. This model supports the 
re-assembly of the critical elements and non-peptide variants on a modified 
scaffold that presents the optimized pharmacophore to the receptor. The 
optimized peptide-hybrid may be valuable as a lead, in addition to its role as 
a tool for further evolution to a mimetic.  
For the peptides identified as active in the current research, a study was 
conducted to find compounds from a known commercial library which are 
similar in structure and electron density to the identified peptide but without 
the biological liabilities of peptides. The virtual screening of the Zinc 
database’s ‘Drug like molecules’ against the peptide 6.25 was conducted 
using the shape similarity software ROCS160 and electron density 
comparison software EON.161  
6.8.1 ROCS160  
ROCS stands for Rapid Overlay of Chemical Structures and is a ligand-
based docking software, marketed by OpenEye, which uses shape 
comparison to identify potential inhibitors from large databases of 
compounds. ROCS works on the idea that molecules similar in shape to 
active molecules are more likely to be active molecules than randomly 
selected molecules. ROCS considers 3D similarity and chemical functionality 
such as hydrogen bond acceptors and donors, positive and negative 
charges. Results are ranked based upon the ROCS scoring function which 
includes the shape and chemical similarity.  
 
- 99 - 
6.8.2 EON161  
EON is a program designed to compare the electrostatics of a compound to 
a database of known compounds to find similarity matches. EON compares 
electrostatic potential maps of pre-aligned molecules and determines the 
Tanimoto measures for the comparison. The results from the top slice of the 
ROCS result can be directly used as the input file for the EON run.  
6.8.3 Process for identifying peptide mimics 
A three-dimensional library of the Zinc databases ‘Drug-Like Molecules’ 
collection was created from the available two-dimensional structure library 
using the OMEGA software.162 The Zinc ‘Drug-Like’ library contains 
1,064,843 compounds. The ‘Drug-Like’ library is based upon the Lipinski rule 
of 5 being applied to the full zinc library database.163 This library was used 
for comparison to the query molecule 6.25. ROCS was used to identify the 
top 1000 compounds which scored highly. The results were visually 
inspected in VIDA164, OpenEye’s molecular modelling visualising software, 
to ensure there were no major variations from 6.25. Figure 68 shows an 
overlay of one of the library compounds with the desired query.  
 
Figure 68 ROCS and EON screening identified compound 6.29: a) overlay of 6.29 (cyan) 
onto query molecule 6.25 (green). b) 2D structures of 6.25 and 6.29 
The electrostatic comparison was conducted using EON which identified the 
top 50 compounds with the best electrostatic overlay to query molecule 6.25. 
a) b) 
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The top 50 compounds were visually inspected using SPROUT to ensure 
there were no surface boundary violations. 
6.8.4 Compound results  
The top six scoring compounds are shown in Figure 69.  
 
Figure 69: Structures of the top six scaffold hopping results (6.29-6.34) 
From all of the selected compounds it is clear to see that ROCS and EON try 
to mimic the peptide backbone but do not mimic the side chain containing 
the thiol. When looking at the electrostatic map generated in VIDA there are 
no interactions around the thiol. This would be an issue if the thiol was 
wanted to be included as part of the designed inhibitor. An inhibitor could 
however be designed that does not require this functionality and therefore 
forms a cover over the active site zincs preventing the β-lactam from 
reaching the active site. Further research is therefore required to find a good 
peptide mimetic for this peptide structure if direct binding to the zinc is 
required as has previously been suggested. 
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6.9 Conclusions  
A new method coupling in silico predictions to peptide screening to identify 
strong binding peptides to biological targets by making custom-built peptide 
libraries has been developed which could be a great improvement on the 
current methods of peptide identification. The method has been shown to 
work by identifying active peptides against the MBL NDM-1.  
When docking to NDM-1 it was observed that trimer peptides provide the 
best predicted binding scores when compared with di and tetramer peptides. 
The L-amino acid trimer peptides give moderate activity against the NDM-1 
enzyme with the best giving an IC50 of 183 μM. This result is not as good as 
was initially hoped for but does show moderate binding to the enzyme which 
could be further developed into a drug compound.  
The all D-absolute stereochemistry peptides are in general better inhibitors 
of the NDM-1 enzyme however due to the tight range of the results a firm 
conclusion on the extent of the improved binding affinity cannot be drawn. 
The best L-amino acid trimer had better inhibitory activity than the all D-
trimers however was still a way off the inhibitory activity of known peptide 
mimic captopril.  
There are still a number of limitations to this technique including the zinc 
atoms being given no charge in the docking runs but the zinc atoms in the 
MBLs are known to be in the 2+ charged state. Docking is also only 
conducted on a single crystal structure which is deemed to be rigid. In the 
biological environment the enzyme would have much more movement 
however as previously this would greatly increase the computational time 
required to complete the dockings.  
There is a great potential that this method could be used to identify binding 
peptides for a large number of different biological targets. The libraries can 
be made to be tailored for each individual task increasing the chance of 
getting a hit which can be further developed into a peptide mimetic drug. 
This coupled with the reduced time to identify the hits and the reduced cost 
of compound production and storage needing to only make the best 
identified compounds makes this a very attractive hit finding method. 
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Chapter 7 
De novo designed inhibitors  
The term de novo means starting from the beginning or anew. De novo drug 
design is an iterative process in which the three-dimensional structure of the 
receptor is used to design new inhibitor molecules.165 The inhibitor molecule 
is designed from scratch to bind in the active site. Fragments are docked 
into sub-sites, and then joined to create full molecules. These molecules are 
scored and ranked in silico based on the interactions present with the target 
protein.84 The top scoring lead molecules can be taken on for full synthesis 
reducing the overall number of compounds produced saving both time and 
money. 
The first examples of software produced specifically for de novo drug design 
were reported in the early 90s. Developments in computing power and 
increased availability to high-resolution crystal structures has led to the 
development of more programs to conduct de novo design.166  The use of 
such programs has been increasing as people look for easy starting points 
for lab synthesis and aim to reduce the time and cost spent conducting high 
throughput screening to produce a hit compound. A general description of 
the steps involved in de novo design is given in Scheme 19. 
 
Scheme 19: General summary of the de novo process to obtain a biologically active 
compound. 
Chemical space167 is defined as the total number of possible small organic 
molecules and is estimated to exceed 1060. When designing new molecules 
from scratch it is possible to come up with almost infinite possibilities. 
Therefore, design of molecules must be constrained to those which fit 
certain spatial and electronic characteristics which will allow them to bind 
favourably within the target protein. 
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The first step carried out by many de novo design programs is the analysis 
of the target site of the desired protein. Some programs, such as 
SPROUT168 and LUDI169, identify regions where favourable interactions 
could form between an appropriately functionalised ligand and the protein by 
looking for hydrogen bond donors and acceptors and hydrophobic residues 
in the protein structure. Other programs such as GRID170 and LigBuilder171 
use a grid-based approach moving probe fragments around a grid of points 
in the binding site and calculating the energy at each position to determine 
regions where favourable interactions might occur. 
Once a binding site has been identified and analysed to identify possible 
interactions, building blocks are chosen to begin designing new ligands. The 
type of building blocks used varies from program to program. A number of  
programs such as SPROUT, have a database of small, simple fragments 
such as aromatic rings and linker fragments such as amides or alkyl chains 
which can be combined to give a wide range of structures. Other programs 
can take known molecules, break them down into functional groups and 
dock these within the binding site. 
The ways in which building blocks are connected varies immensely between 
programs. Some programs start from a single fragment positioned in the 
binding site and grow out from there by directly linking fragments to the start 
fragment one at a time. Others start with several building blocks positioned 
in favourable positions in the binding site and then connect them using linker 
fragments, e. g. SPROUT168. Once an appropriately sized small molecule 
has been produced further improvements to the structure might be carried 
out by evolution or substitution at various positions. This is often conducted 
with the use of the programs scoring function  
An essential part of any de novo design software is a method for determining 
the relative binding affinity of the designed structures which is often referred 
to as the scoring function. Most programs contain methods for calculating 
the free energy of the designed structures within the protein binding site as a 
way of predicting the binding affinity and thus determining which putative 
ligands designed by the program are the most promising candidates. Often 
structures generated by de novo design can be complex and difficult to 
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synthesise, so many de novo design packages include a method for 
analysing the complexity or synthetic accessibility of the designed structures. 
Several detailed reviews cover the different software tools available which 
provide a more detailed account of the various techniques used and their 
application to different areas of drug discovery.166, 172 This report focuses 
upon the SPROUT package which has been employed in the project work. 
7.1 SPROUT 
SPROUT was created at the Institute for Computer Applications in Molecular 
Sciences (ICAMS) at the University of Leeds. SPROUT is a unique program 
that uses a multidirectional tree search to build up templates from functional 
groups that are predicted to have the best possible interactions with the 
target site.168,125b SPROUT has already been used successfully to design 
inhibitors of a number of enzymes such as Dihydroorotate dehydrogenase 
(DHODH)173 and RNA polymerase (RNAP).174  
A problem in de novo design is the generation of a large number of 
structures. SPROUT uses many constraints such as steric and electrostatic 
properties on the molecule to limit the number of structures generated.  
 
Figure 70: Overview of the components of SPROUT. 
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7.2 Components of SPROUT 
SPROUT consists of a series of individual modules, each of which controls a 
section of the overall process outlined in Figure 70. These are as follows; 
 CANGAROO – Definition of constraints for primary structure 
generation i.e. receptor volume, boundary 
 HIPPO – Analysis of localities for favourable interaction (target sites) 
 ELEFANT – Docking of atoms or fragments (as defined by the user) 
into chosen target sites 
 SPIDER – Connection of target sites using user defined spacer 
templates to produce molecular scaffolds 
 ALLIGATOR – Scoring and ranking output 
7.2.1 CANGAROO 
CANGAROO stands for Cleft ANalysis by Geometry 
based Algorithm Regardless Of the Orientation. In this 
module the primary constraints are defined. The X-ray 
crystal structure of the target protein is imported into the module (i.e. pdb). 
CANGAROO identifies potential binding pockets or clefts based upon the 
protein surface curvature. The user then selects the desired cleft in which 
structure generation is to occur and reassigns this as a receptor site 
comprising of a set distance (usually 10 Å) from the centre of the cleft. In the 
ideal case the X-ray crystal structure will contain a known ligand co-
crystallised within the protein. (Figure 71). The receptor site can then be 
assigned as the area directly around the ligand. The ligand is then removed 
from the receptor leaving and empty pocket for de novo structure generation.  
 
Figure 71: Cangaroo identification of active site in NDM-1. a) Hydrolysed ampicillin 
(Orange) bound in the active site (Grey) identified as binding cavity. b) 10 Å cut 
around the cavity defined as the receptor (Red). 
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7.2.2 HIPPO 
HIPPO stands for Hydrogen-bonding Interaction site 
Prediction as Positions with Orientations. In this module 
the interaction sites within the receptor are identified. 
The receptor is analysed for its electrostatic and hydrophobic features which 
are determined by the amino acids found on the receptor surface. A 
boundary surface is added to the receptor based upon van der Waals radii of 
each protein atom and this is coloured as follows; red for an area where 
hydrogen bond donors exist in the protein, blue for an area where hydrogen 
bond acceptors exist in the protein, purple for a complex hydrogen bonding 
area (i.e overlapping acceptor and donor sites) and green for a non-polar 
hydrophobic area. HIPPO then creates a loci around each polar atom in the 
receptor defining an area of space where a favourable polar contact might 
be made if a complementary moiety in the generated structure were placed 
there. This locus is calculated based on statistical analysis of H-bonding 
geometry in published crystal structures. As with the boundary surface 
colouring, areas around H-acceptors in the receptor are coloured blue and 
around H-bond donors coloured red. (Figure 72). HIPPO also has the ability 
to create a spherical site which is a user defined area within the receptor in 
which ready-made fragments which are not part of the template library can 
be docked. This is useful if the user wishes to grow from a known core or 
part of an existing ligand. 
   
Figure 72: Hippo identification of surface interaction sites. a) Donor and acceptor site loci 
generation. b) SPROUT generated surface of NDM-1 active site showing identified 
interaction sites. 
a) b) 
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7.2.3 ELEFANT 
ELEFANT stands for ELEction of Functional groups and 
ANchoring them to Target sites. Atoms and fragments 
are selected from the SPROUT template library based 
upon complementarity to the target sites generated in HIPPO. (Figure 73) 
The choice of fragments and atoms to be included are defined by the user. 
All available conformations are considered for flexible fragments whilst atom 
hybridisation governs the directional nature of fragment growth. 
 
Figure 73: Template fragments available in the SPROUT Elefant module 
7.2.4 SPIDER 
SPIDER stands for Structure Production with Interactive 
DEsign of Results. Structures are generated by joining 
the fragments docked in the ELEFANT module to 
produce scaffolds. The fragments are connected in a stepwise manner 
where violations of the primary constraints is monitored at each step. The 
SPROUT template library is again used to define the spacers, which controls 
the potential combinatorial explosion of results. In the connection of two 
starting fragments, templates (as chosen by the user) are added 
simultaneously to each starting fragment in the direction of the other 
fragment (as governed by joining rules creating ‘partial skeletons’) As 
mentioned above, a final solution is found when an overlapping template 
common to both partial skeletons is found. The newly created scaffold 
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connecting the two sites is now grown in the same way towards the 
remaining receptor target sites to produce the final ligand.   
 
Figure 74: Example tree diagram of connections made in SPIDER module of SPROUT 
7.2.5 ALLIGATOR 
ALLIGATOR stands for Analyse Lots of LIGAnds, 
Test and Order Results. This module sorts out the 
generated results into sets by various user imposed 
criteria. This enables easy identification of groups of molecules which 
contain either desired or undesired characteristics. The module assigns 
each new scaffold a score which is then used to rank the output in order to 
predict binding affinity and identify the molecules with the best potential for 
good in vitro binding. The SPROUT score attempts to estimate binding 
affinity through considering the combined contribution of hydrogen bonding, 
hydrophobic interactions, van der Waals interactions and the number of 
rotatable bonds. These estimates are derived from real-life measurements 
involving ligand-protein complexes making this an empirical scoring function. 
Ligand and receptor desolvation is not considered in the SPROUT scoring 
function. (Scheme 20). 
 
 
Scheme 20: SPROUT scoring function components 
Naturally, it is unrealistic to expect a scoring function to predict the 
experimental potency of a ligand to any great degree of accuracy, however, 
the SPROUT scores serves more as a ranking system, directing the user to 
the ligands which have the most potential to show activity. 
ΔGScore = ΔGhbonds + ΔGhydrophobic + ΔGVdW + ΔGrotatable 
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7.3 Compound selection 
A SPROUT run was conducted which involved all of the steps described in 
Section 7.2. This yielded a selection of possible inhibitors scaffolds of which 
the top ten-scoring motifs were docked back into the NDM-1 active site (PDB 
ID: 3Q6X) using AutoDock to ensure the compounds bound as expected 
from the SPROUT design. Visual inspection of the docking poses generated 
for the top ten SPROUT-designed compounds led to the identification of 
structure 7.1 as a potential NDM-1 enzyme inhibitor which gave a SPROUT 
score of  -6.90 (7.1, Figure 75).  
 
Figure 75: Designed compound (7.1) docking into the NDM-1 active site (PDB ID: 3Q6X): 
Visualised in SPROUT and 2D representation 
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Compound 7.1 was predicted to bind via the carboxylic acid to the side chain 
amine of the Lys-211 residue. The amine on the amine / hydroxyl containing 
carbon was predicted to bind to Zn1 and the hydroxyl was bound to the side 
chain carbonyl of the Asn-220 residue. Further interactions predicted 
involving with the amine attached to the 5-membered ring binding to the side 
chain carbonyl of the Gln-123 residue and the hydroxyl on the five 
membered ring being bound to the main chain amide of the Gln-123 residue 
respectively (Figure 75).  
The identified structure (7.1) was quite complex so it was decided to scale 
the fragment down to the ‘war head’ which would bind directly to the zinc 
(7.2). Direct binding to the zinc atoms blocks them off from the β-lactam 
antibiotic. The β-lactam antibiotic should therefore not be hydrolysed by the 
enzyme and should be able to have its desired effect on its bacterial target. 
It was seen that SPROUT had placed an amine and a hydroxyl on the same 
carbon. This functionality is hydrolytically unstable therefore it was decided 
to focus on only one of these interactions (7.3). The alcohol was selected 
due to ease of the proposed synthetic route (Scheme 22). The molecule 
was then simplified to contain a phenyl ring rather than a cyclopentadiene 
ring as in (7.4) (Scheme 21).  
 
Scheme 21: Formation of the ‘war head’ fragment (7.4) from the SPROUT identified 
compound (7.1). 
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Compound 7.4 was predicted to bind from the carboxylic acid to the side 
chain amine of the Lys-211 residue and Zn2, from the hydroxyl to the Zn1 
and Zn2 atoms and to form an edge to face π stacking interaction with the 
Trp-93 residue located in the hydrophobic wall of the NDM-1 active site. 
(Figure 76) 
 
Figure 76: 'War head' fragment 7.4 docked into the active site of NDM-1 (PDB ID: 3Q6X) 
7.3.1 Synthesis of SPROUT-generated compound 
The synthesis of the SPROUT-derived alcohol compound 7.4 was 
conducted by use of a Suzuki cross coupling reaction175 of 7.5 and phenyl 
boronic acid to form compound 7.6, followed by lactone hydrolysis using 
base to afford compound 7.4 (Scheme 22). Both reactions proceeded in 
good yield (>65%).  
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Scheme 22: Synthetic route to hydroxide compound (7.4) 
7.3.2 First generation de novo designed inhibitors 
A structure activity relationship investigation (SAR) was conducted on the 
phenyl ring attached to the ‘war head’ group to see if changing the sterics 
and electronics around this ring had an effect on the binding affinity (Position 
X, Figure 77). A further example (7.11) was included to investigate the role 
of variation in dihedral angle within the biphenyl unit introduced by the 
introduction of an ortho chloro group.  
 
Figure 77: Position of SAR investigation around compound 7.4 
The compounds were synthesised by altering the phenyl boronic acid used 
in the Suzuki cross coupling step.(Scheme 23)  
 
Scheme 23: Synthetic route to SAR compounds based upon lead compound 7.4 
The synthesised compounds were biologically evaluated against NDM-1 by 
Dr Jürgen Brem at the University of Oxford. The results of the biological 
evaluation are shown in Table 12. 
 
 
X = 
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Table 12: Biological screening results of hydroxide compounds against NDM-1 
Compound Number X RA [%], 100 µM 
7.4 
 
93 
7.7 
 
56 
7.8 
 
98 
7.9 
 
95 
7.10 
 
70 
7.11 
 
74 
7.12 
 
49 
7.13 
 
97 
 
None of the tested compounds gave a residual activity measurement of less 
than 30% at 100 μM therefore no IC50 measurements were determined. 
Overall there was no significant trend in the data. Increasing the 
hydrophobicity of the inhibitor is seen to weakly increase the inhibitory effect 
of the compound against the enzymes. This weak trend is observed in the 
SPROUT score however due to the low biological activity this effect was not 
investigated further.  
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7.3.3 Structure activity relationship investigation of the zinc 
binding group 
Along with the investigation of substituents on the phenyl ring attached to the 
‘war head’ group an investigation was conducted into the effects of changing 
the alcohol (7.4) into a thiol (7.21) (Figure 78). 
 
Figure 78: Site of heteroatom substitution on compound 7.4 
7.3.3.1 Thiol-based compound synthesis 
In light of the known ability of sulfur to bind strongly to zinc, the thiol 
containing version of alcohol 7.4 was synthesised. It was predicted that the 
thiol containing compound (7.21) should provide a much stronger binding 
affinity to the MBL enzymes when compared to alcohol 7.4. Compound 7.21 
is predicted to retain the binding of the carboxylic acid to the Lys-211 residue 
and the edge to face π-stacking interactions with Trp-93 located within the 
hydrophobic wall of the active site as seen for compound 7.4 (Figure 79 and 
Figure 80).  
 
Figure 79: 2D representation of the docking pose of compound 7.21 into NDM-1 (PDB ID: 
3Q6X) showing the predicted strong zinc sulfur bond  
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Figure 80: 3D representation of the docking pose of compound 7.21 into NDM-1 (PDB ID: 
3Q6X) showing the predicted strong zinc sulfur bond  
The thiol-based inhibitor (7.21) was synthesised as shown in Scheme 24 by 
first conducting a Suzuki reaction between 7.5 and phenyl boronic acid 
which gave 7.6 in high yield (75%). The next step was a lactone opening of 
7.6 using BBr3 and NaI which gave ester 7.22 in low yield (31%). The final 
stage was the introduction of the thiol group by displacement of the iodine 
within 7.15 with thiourea and then the global hydrolysis to afford the product 
7.21 (81%). 
 
Scheme 24: Initial synthesis of compound 7.21 
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Due to the use of a base hydrolysis in the final step, a portion of disulfide 
product was formed along with the desired mono thiol product. Purification to 
isolate pure mono thiol 7.21 proved unsuccessful. Column chromatography 
and recrystallisation attempts led to increased disulfide formation and the 
depletion of mono sulfide 7.21. In order to gain an indication as to if the thiol 
was binding to the enzyme with better affinity than compound 7.4, compound 
7.21 was initially tested as part of a 4:1 ratio of mono to di sulfide. 
7.3.3.3 Biological evaluation of thiol based compound 7.21 
Compound 7.21 was biologically evaluated against NDM-1 by Dr Jürgen 
Brem at the University of Oxford. The result of the biological evaluation are 
shown in Table 13. 
 
Table 13: SAR study of R group against NDM-1 
Compound Number R  RA [%], 100 µM 
7.4 OH 93 
7.21 SH 12 
 
From Table 13 we can see that the thiol-based inhibitor 7.21 was much a 
more potent inhibitor of NDM-1 than the alcohol 7.4. An IC50 was then 
determined for the thiol compound 7.21 against IMP-1. Figure 81 shows the 
IC50 curves for D-captopril and compound 7.21 against IMP-1. There is an 
observed IC50 of 12.2 ± 2 μM for captopril and 1.1 ± 0.2 μM for compound 
7.21. 
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Figure 81: IC50 curves for D-captopril and compound 7.21 against IMP1 
The inhibitory activity of compound 7.21 was also investigated in the 
presence of NDM-1 where it gave an IC50 of 24 ± 0.2 μM. D-captopril had an 
IC50 of 36 ± 0.4 μM against NDM-1. These results were very promising and 
therefore crystallisation of the inhibitor bound to VIM-2 was attempted along 
with further development of the synthetic route. 
7.4 Crystallographic investigation of the binding of inhibitor 
7.21 to VIM-2 
In an attempt to confirm the binding mode of compound 7.21 a crystal 
structure was obtained of compound 7.21 co-crystallised in VIM-2 by Dr 
Michael MacDonough at the University of Oxford (Figure 82). 
A strong zinc sulfur bond was observed in the active site as expected. 
Rather unexpectedly, there was a through-water interaction from the 
carboxylic acid to the Asp-117 residue. Originally this carboxyl group had 
been predicted to bind to Arg-205 in the active site which is similar to the 
Lys-211 residue in the NDM-1 enzyme (Figure 80). There is a face to face 
π-stacking interaction with the tyrosine residue Tyr-67 in the loop region. It is 
observed that the Arg-205 residue which is normally found located in the 
active site near to the zinc atoms has moved out away from the zinc atoms 
to accommodate the inhibitor in the active site. There was a significant 
R
A
 %
 
R
A
 %
 
Log [inhibitor]  (μM) Log [inhibitor]  (μM) 
IC50 for D-captopril against IMP-1 IC50 for compound 7.21 against IMP-1 
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dihedral angle observed within the biphenyl unit which was not observed in 
the docking predictions (Figure 83).  
 
Figure 82: Crystal structure of small molecule inhibitor in the VIM-2 active site showing key 
interactions 
 
Figure 83: 2D Representation of the binding of compound 7.21 in the VIM-2 active site 
showing key interactions 
7.5 Thiol-containing inhibitors: route development. 
In order to attempt to reduce the formation of the disulfide and provide a 
sample of pure thiol compound 7.21, a route development campaign was 
conducted. The first alteration to the route was to use aqueous 2M HCl for 
the final hydrolysis ensuring protonation of the thiol after the reaction and 
therefore preventing the disulfide formation (Scheme 25). However after 24 
hours under reflux with dilute HCl no deprotection of the methyl ester was 
seen. This deprotection problem was seen as a key problem as the 
carboxylic acid was required for strong binding in the active site.  
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Scheme 25: The final steps of the synthesis of compound 7.21 using acid hydrolysis 
conditions 
A second synthetic route was developed which would hopefully remove the 
problem of disulfide formation (Scheme 26). The route was also designed to 
move the diversification point to much later in the synthesis. The trityl 
protecting group was introduced after hydrolysis of the thiourea adduct and 
methyl ester to form compound 7.24 which could be easily separated from 
the disulfide via column chromatography. After this, the Suzuki reaction of 
compound 7.24 and phenyl boronic acid to form 7.25 could be conducted 
before removal of the trityl group using Reagent K (87% TFA, 3% 
ethanedithiol, 5% thioanisole, 5% H2O) to afford compound 7.21.  
 
Scheme 26:Synthetic route to palladium contaminated palladium product 
When thiol compound 7.21 was produced using the synthetic route set out in 
Scheme 26 erroneous results were observed in the assay showing weak 
binding when compared to captopril and the previous mono/disulfide 
mixture. Most analytical techniques showed that the desired product 7.21 
had been formed and isolated in high purity, However, microanalysis was 
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conducted on the product and it showed the presence of a metal due to a 
very large deviation to the expected percentage composition. The thiol-
containing compound 7.21 was retaining the palladium from the Suzuki 
cross coupling reaction. A new synthetic route was therefore required 
avoiding the exposure of the thiol to metals.   
The final route shown in Scheme 27 which proved to be the most successful 
involves first a Suzuki cross coupling reaction between 7.5 and phenyl 
boronic acid which proceeds in good yield to give compound 7.6 (67%).  
Then a ring opening of the lactone 7.6 using TMSI which proceeded in high 
yield compared to the previous BBr3 route to give iodide 7.26 (62%). The 
iodine containing intermediate was characterised by 1H NMR, IR and MS. 
Full characterisation of 7.26 was not possible due to the degradation of the 
product by the loss of iodine in solution. The final two-part reaction was the 
introduction of the thiol group by nucleophilic displacement of the iodine 
within compound 7.26 by thiourea. The product of which was recrystallized 
before hydrolysis of the thiourea adduct with base to afford the desired 
product 7.21 in good yield (81%).  
 
Scheme 27: Synthetic route to thiol based inhibitors featuring TMSI ring opening step. 
Compound 7.21 was proved to be the thiol as opposed to disulfide (7.27) 
using NMR analysis. Conversion of the mono to disulfide can be monitored 
using the shift in the retention time within the HPLC and the change in the 1H 
NMR spectrum of the reaction mixture (Figure 85).  
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Biological evaluation of pure 7.21, produced by the route described in 
Scheme 27, gave a residual activity of < 1 % against IMP-1 at 100 µM. The 
IC50 of compound 7.21 against IMP-1 was calculated to be 232 nM.  
The disulfide (7.27, Figure 84) was prepared using the conditions described 
by Niwa et al.176 The disulphide (7.27) was biologically screened against 
IMP-1 and exhibited low inhibitory activity with a residual activity of 94% at 
100 µM. The IC50 of disulfide 7.27 was therefore not determined as the 
residual activity was > 50%. The results of the biological evaluation confirm 
the mono thiol 7.21 to be the active inhibitor species. 
 
Figure 84: The structure of disulfide 7.27 
Before compound 7.21 could be considered for microbiological testing to see 
if it helped to recover the MIC of meropenem, the stability of the thiol in 
DMSO needed to be established. The stability of compound 7.21 needed to 
be established in DMSO because DMSO as the solvent used to dissolve 
compounds for the bacterial cell based assay. Compound 7.21 was found to 
be stable in DMSO up to 4 days by conducting NMR studies at relevant 
intervals. The NMR studies monitored the disappearance of the CH2 and SH 
peaks, which show distinctive coupling to each other, and the appearance of 
the CH2 singlet of the disulfide (Figure 85). 
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Figure 85: 
1
H NMR spectra of key regions for determination of thiol or disulfide production. 
Thiol: 4.13 (2H, d, J 7.4, CH2SH), 2.86 (1H, t, J 7.4, CH2SH).                           
Disulfide: 4.25 (4H, s, CH2S) 
7.6 Second generation de novo designed inhibitors 
As observed in the crystal structure of 7.21 co-crystallised in VIM-2 (Figure 
82), it is believed that adding an electron withdrawing group onto the phenyl 
ring attached to the ‘war head’ group would increase the binding affinity.  
This is due to increased face to face π-stacking interactions with the electron 
rich Tyr-67 residue. A structure activity relationship study was conducted to 
confirm this hypothesis (Figure 86).   
 
Figure 86: Location of SAR variation for thiol series 
Thiol 
Disulfide 
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The phenyl group of compound 7.21 was also substituted for a bromine 
(7.41) to see if this had negative effects on the binding affinity due to the loss 
of the π-stacking interactions. Two examples were included which contained 
5 membered rings (7.36 and 7.38) to see what effect changing from a 6 
membered ring had on the binding affinity. Scheme 28 shows the synthetic 
route to the thiol based compounds.  
 
Scheme 28: Synthetic route to compounds 7.28-7.41 based around thiol compound 7.21 
Due to the observed dihedral angle in the crystal structure of compound 7.21 
co-crystallised in VIM-2. Substituents were placed in the ortho position of the 
phenyl ring attached to the ‘war head’ group (Position X, Figure 86) to 
explore the role of the dihedral angle of the biphenyl ring system to 
investigate if changing the dihedral angle effects the binding affinity (7.28 
and 7.33). Substituents were also placed in the meta and para positions of 
the phenyl group, attached to the ‘war head’ group (Position X, Figure 86), 
to investigate if placing substituents around the ring changed the binding 
affinity (7.28, 7.29 and 7.30). 
Compounds containing strong electron withdrawing groups, such as nitro 
groups and carboxylic acids, gave very poor yields for the Suzuki coupling 
reaction (<30%). The compounds also proved be very water soluble leading 
to problems with isolation of the iodine containing intermediate compounds 
following opening of the lactone with TMSI.  A number of impurities from this 
step were then carried through the introduction of the thiol and hydrolysis 
steps lead to significantly impure final thiol compounds. Although purification 
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attempts through column chromatography and recrystallization were made, 
no compounds containing electron withdrawing groups could be obtained in 
high enough purity for biological testing. There was therefore no compounds 
containing electron withdrawing groups, such as nitro or carboxylic acids, 
that were tested against the MBL enzymes.  
Generally, there is no clear trend from the SAR study, and it has been 
observed that changing the electron density on the phenyl ring of 7.21 has 
no real effect on the potency of the molecules (Table 14).  
It is also observed that putting groups into the ortho position (7.28, 7.33 and 
7.40) on the phenyl ring does not affect the binding affinity of the compounds 
to the IMP-1 enzyme implying the dihedral angle of the biphenyl unit does 
not have a large contribution to the binding affinity. However, In placing 
groups in the ortho position does lower the IC50 of the compounds against 
the VIM-2 enzyme. This result suggests that the increase in the dihedral 
angle of the biphenyl unit is favourable for binding to the VIM-2 enzyme.  
Substitution of the phenyl ring for five membered rings (7.36 and 7.38) 
shows no significant change in the binding affinity of the inhibitors. This 
implies that the π-stacking interaction is not a major component of the 
binding affinity. Substitution of the phenyl ring for a bromine shows no 
change to the binding affinity for VIM-2. However, for IMP-1 there is a 
significant increase in the IC50 indicating that a bromine is not tolerated as 
well within this enzyme. 
Placing groups onto the phenyl ring, attached to the ‘war head’ group, in the 
meta position lowers the IC50 of the inhibitor compounds towards the VIM-2 
enzyme. In general increasing the hydrophobicity of the inhibitors causes 
them to exhibit stronger binding to the VIM-2 enzyme (7.33 and 7.35). The 
same effect is not observed for the IMP-1 enzyme where placing groups into 
the meta position weakens the binding affinity. Compound 7.30 exhibits the 
best IC50 against IMP-1 and contains a chloro group  in the para position. 
This is potentially rationalised by the more enclosed active site seen in the 
IMP-1 enzyme compared to the VIM-2 enzyme (see Section 2.4.2.1)  
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Table 14: Biological evaluation results of thiol series SAR study 
Compound 
Number 
X RA [%], 100 
µM (VIM-2) 
IC50 VIM-2 
(μM) 
IC50 IMP-1 
(μM) 
7.21 
 
< 1 0.234 ± 0.044 0.232 ± 0.043  
7.28 
 
< 1 0.180 ± 0.098 0.309 ± 0.067 
7.29 
 
< 1 0.072 ± 0.059 0.147 ± 0.057 
7.30 
 
< 1 0.109 ± 0.039 0.069 ± 0.052 
7.31 
 
< 1 0.207 ± 0.069 0.397 ± 0.089 
7.32 
 
< 1 0.231 ± 0.030 0.307 ± 0.094 
7.33 
 
< 1 0.045 ± 0.031 0.378 ± 0.062 
7.34 
 
< 1 0.459 ± 0.073 1.723 ± 0.047 
7.35 
 
< 1 0.071 ± 0.031 0.220 ± 0.035 
7.36 
 
< 1 0.365 ± 0.023 0.393 ± 0.035 
7.37 
 
< 1 N.A. N.A 
7.38 
 
1.25 0.174 ± 0.127 0.189 ± 0.049 
7.39 
 
< 1 0.184 ± 0.165 0.323 ± 0.037 
7.40 
 
< 1 0.158 ± 0.089 0.480 ± 0.045 
7.41  
< 1 0.170 ± 0.018 0.804 ± 0.030 
N.A. = Not determined due to limited solubility 
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The thiolactone (7.64) was also synthesised and biologically evaluated. This 
could investigate if the thiolactone ring could be hydrolysed under the 
conditions of the assay to give inhibitor 7.21. The idea being that this method 
could be used to produce a pro-drug to help with the administration of the 
compound with the thiol ‘war head’ masked until hydrolysed by the enzyme. 
To so synthesise 7.64, compound 7.21 was refluxed in TFA to afford 
thiolactone 7.64 in good yield (99%) (Scheme 29). 
 
Scheme 29: Synthesis of thiolactone 7.64 
Additionally, compound (7.67) with the thiol group directly on the aromatic 
ring and a spacer to the carboxylic acid moiety, was also prepared and 
screened to probe the importance of the spatial arrangement of the groups.  
To synthesise 7.67, boronic acid 7.65 was oxidised to thiolactone 7.66 with 
hydrogen peroxide in good yield (97%). Thiolactone 7.66 was then 
hydrolysed using base to yield compound 7.67 in good yield (93%) (Scheme 
30). 
 
Scheme 30: Synthesis of compound 7.67 
Neither of these compounds (7.64 and 7.67) gave significant inhibitory 
activity in the presence of the NDM-1 enzyme. The thiolactone 7.64 gave a 
residual activity (RA) of 90% at 100 µM against NDM-1, which is significantly 
higher than the RA of 7.21 which is < 1% at 100 µM against NDM-1. No IC50 
was determined for 7.64 against the MBLs as the RA was above 30%. The 
observed RA implies that 7.64 is not being hydrolysed rapidly by the NDM-1 
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enzyme. The results however do not confirm if hydrolysis is occurring slowly 
or not at all. Further biological evaluation would be required to establish this.  
Compound 7.67 has a RA of 92% at 100 µM against NDM-1, which is 
significantly higher than the RA of 7.21 of < 1% at 100 µM against NDM-1. 
No IC50 was determined 7.67 against the MBLs as the RA was above 30%. 
This shows that the spatial arrangement of the thiol in relation to the 
benzene and carboxylic acid is important to the observed binding affinity of 
7.21.  
7.6 Microbiology results 
As the compounds (7.21, 7.28-7.41) had shown significant activity against 
the enzyme in the enzymatic assay, a selection of these compounds was 
sent to Dr James Spencer, at the University of Bristol, to see if they had any 
effect on restoring the MIC of meropenem against MBL producing bacterial 
strains.  
Microbiological screening was conducted by Dr James Spencer, at the 
University of Bristol, as described in Appendix A1.2 (Table 15).  
Initial tests of the MBL-producing bacteria with meropenem in the absence of 
inhibitor gave an MIC >128 μg/ml. Testing also showed that inhibitor 7.21 
had no antibacterial effect on the enzyme alone. This confirmed that the 
inhibitor was suitable in terms of investigation into possible co-administered 
with a β-lactam antibiotic to achieve the desired effects.   
Encouragingly, all the compounds, apart from 7.34, showed restoration of 
the MIC of meropenem against the NDM-1-producing strains when using 
100 μg/ml of inhibitor. Compound 7.38 was seen to be the best, showing 
restoration of the MIC of meropenem to 8 μg/ml against K. pneumoniae. 
Unfortunately when using  a lower concentration (10 μg/mL) of inhibitor no 
significant change in the MIC of meropenem was observed.  
There could be a number of reasons for no restoration of the MIC of 
meropenem being observed at lower concentrations (10 μg/ml). With 
compounds 7.21, 7.28-7.41 all displaying IC50’s in the nanomolar region 
against both VIM-2 and IMP-1 enzymatic assays some restoration of the 
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meropenem MIC would be expected at this concentration. The first reason 
for no MIC restoration to be observed is that the thiol-containing compounds 
may have limited permeability through the outer membrane of the Gram 
Negative bacterial call wall. The second is that the compounds could be 
making it into the cell however are being effluxed out of the cell by efflux 
pumps. Further biological evaluation looking into efflux knockouts and 
membrane damaged bacteria will be required to be conducted to provide a 
conclusive answer to the lack of restoration of the MIC at lower 
concentrations.  
Table 15: Determination of Meropenem MIC against bacterial strains when administered 
with designed inhibitors 
Compound 
Number 
Structure Meropenem MIC (μg/mL) 
NDM-1 producing K. 
pneumoniae (ATCC 5055) 
Meropenem MIC (μg/mL) 
NDM-1 producing E. coli 
(MG1655) 
7.21 
 
32 16 
7.41  64 32 
7.34 
 
>128 >128 
7.35 
 
32 32 
7.36 
 
64 32 
7.37 
 
64 32 
7.38 
 
8 16 
7.39 
 
16 64 
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7.7 Drug Metabolism and PharmoKinetics studies (DMPK)  
Before committing to full in vivo studies, compound 7.21 was sent to the 
DMPK group at Shanghai ChemPartner Co., Ltd for aqueous solubility and 
metabolic stability testing.177  
ChemPartner state that aqueous solubility values less than 10 µM suggest 
compounds show low solubility, solubility values between 10 µM and 80 µM 
suggest compounds show moderate solubility and solubility values higher 
than 80 µM suggest compounds show high solubility. Compound 7.21 
recorded an aqueous solubility of 88.45 µM in phosphate buffer solution 
(PBS, pH 7.4) with an RSD of 0.06. This indicates that compound 7.21 has 
high solubility at this pH.    
For a metabolic study with human liver microsomes, ChemPartner state that 
T½ values where T½ > 120 min suggest compounds are stable in human liver 
microsomes, where T½ = 30-120 min suggest compounds show moderate 
metabolism in human liver microsomes, and where T½ < 30 min suggest 
compounds are susceptible to metabolism in human liver microsomes. 
Compound 7.21 recorded a T½ = 82.28 mins which suggests that the 
compound is showing moderate metabolism in human liver microsomes. 
Compound 7.21 recorded an intrinsic predicted clearance rate of 21.13 
(mL/min/kg). Ideally before progressing compound 7.21 into more in vivo 
studies, further modifications would be required to remove the metabolic 
susceptibility of the compound and increase the half-life.   
7.8 Drug delivery 
In order to overcome the potential limited permeability of the inhibitors 
through the outer membrane of Gram negative bacteria, the idea of ‘co-
drugging’ was employed. The principle has been used in a number co-drugs, 
for example a quinolone drug attached to a cephalosporin through an ester 
linker has been investigated (7.68, Figure 87). Upon hydrolysis of the β-
lactam, the resulting cascade results in the release of the carboxylic acid 
leaving the alkene containing hydrolysed cephalosporin (Figure 88).  
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Figure 87: Structure of a cephalosporin-quinolone co-drug (7.68) 
 
Figure 88: The hydrolysis cascade of a cephalosporin - quinalone co-drug (7.68) releasing 
the quinalone (7.70) 
The aim in the present study was to couple compound 7.21 to a 
cephalosporin to help 7.21 permeate through the outer membrane of the 
Gram negative bacterial call wall. Once through, hydrolysis of the β-lactam in 
the co-drug will occur in the active site of the MBL which then releases the  
inhibitor following the cascade reaction. The inhibitor could then bind to the 
active site of the MBL preventing further β-lactam antibiotics administered 
with the co-drug from being hydrolysed. The inhibitor molecule 7.21 was 
coupled onto the cephalosporin cephlatin (7.71) using the SN2 displacement 
of the acetate group by the thiol of the inhibitor (Scheme 31).  
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Scheme 31: Coupling of compound 7.21 onto ceflatin 7.71 to form compound 7.72 
The product 7.72 was predicted to undergo fragmentation in a similar 
manner to the previously described co-drugs following  hydrolysis of the β-
lactam ring as shown in Figure 89. 
 
Figure 89: Hydrolysis cascade of cephalosporin containing compound 7.21 to release 
compound 7.21. 
The synthesis of 7.72 was conducted as described in Scheme 31. 
Compound 7.72 was then sent for testing in the enzymatic and 
microbiological assays (Table 16).  
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Table 16: Biological data for cephalosporin containing compound 7.72 
Compound 
Number 
Structure RA [%], 100 
µM VIM-2 
RA [%], 100 
µM NDM-1 
7.72 
 
13.4 2.7 
 
The initial biological screens at 100 µM against VIM-2 and NDM-1 show 
promising reduction in the activity. The residual activity is larger than for 7.21 
alone. Further biological testing is required to establish the IC50 of the co-
drug inhibitor and if the 7.72 can successfully restore the MIC of meropenem 
against NDM-1 producing bacteria to a greater extent than 7.21 alone. 
Further testing is also required to establish what is the active compound 
giving the reduction residual activity. It could be from 7.72 itself or from the 
release of 7.21 by hydrolysis. 
7.9 Conclusions  
A novel inhibitor class has been created using de novo structure based drug 
design which can be co-administered with current antibiotics restoring some 
of their activity against the bacteria. Results in tests with clinical isolates of 
MBL-producing bacteria have seen a restoration of the MIC of meropenem 
from >128 ug/mL to 8 ug/mL when administered with designed inhibitors. 
Additionally a number of these inhibitors have shown strong inhibition of the 
VIM-2 and IMP-1 enzymes in the enzymatic assays at around 200 nM.   
In general, sulfur-containing drugs have often been avoided in medicinal 
chemistry due to side effect such as Stevens–Johnson syndrome,178 a form 
of toxic epidermal necrolysis and a life-threatening skin condition. However 
we should not shy away from the use of sulfur containing compounds as a 
number have been seen to be successful in the clinic. An example of which 
is ticagrelor, which is marketed as Brilinta,179 a platelet aggregator inhibitor. 
Further toxicity studies are required for the MBL inhibitors described in this 
thesis but initial testing against bacteria has been promising. Initial DMPK 
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studies show that one of the designed inhibitors is highly soluble in aqueous 
media but is susceptible to metabolic degradation by liver microsomes. 
Further development would be required to overcome this aspect.  
Unlike a number of MBL inhibitors which have previously been discovered, 
this class of inhibitor is not a metal extractor and does not function by pulling 
the zincs out of the enzyme, but instead by chelating to them within the 
active site. This has been observed via crystallography and is consistent 
with the observations of Klingler et al.68 who state that thiol compounds 
chelate and do not extract the zinc atoms out of the enzyme. There is still a 
question over the selectivity of the compounds over other metal-containing 
systems such as ACE which captopril is the known inhibitor. Due to limited 
access to an ACE assay and selectivity panel this has not been further 
investigated.     
Further research should be conducted into overcoming the high loading 
required to rescue the activity. As suggested the high loading could be 
required due to poor permeability of the outer membrane or from efflux. A 
number of studies could be conducted looking at efflux knockouts and 
membrane permeating peptides to see what is causing the lower than 
optimally desired responses.   
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Chapter 8 
In silico assay evaluation82 
8.1 Introduction to MBL assays 
A number of different screening methods for in vitro detection of β-
lactamases have been reported in the literature.180  Current assays in use for 
β-lactamase enzymes include the use of chromogenic cephalosporin-based 
substrates such as nitrocefin181 and CENTA,182 cephalosporin based 
fluorogenic substrates,183 bioluminescent probes184 and fluorescence 
resonance energy transfer (FRET)-based substrates.185  
Widespread use of these types of compounds in HTS for MBL detection is 
often avoided due to their long and often difficult synthesis and the high 
costs associated with these substrates. These substrates often suffer from 
poor recognition by the MBLs due to the high diversity of the enzyme family. 
Additionally, the MBL family of enzymes vary in sequence, structure and 
substrate specificity therefore making it hard to use a single substrate for 
broad MBL activity screening.  
Collaborators at the University of Oxford aimed to develop in vitro assay 
procedures suitable for a range of clinically relevant enzymes. The clinically 
relevant enzymes chosen were New Delhi metallo-β-lactamase (NDM-1),38 
Verona interon-encoded metallo-β-lactamase (VIM-2),64 Imipenemase (IMP-
1)79 and Sao Paulo metallo-β-lactamase (SPM-1).62 The substrates tested 
against the panel of MBLs were Nitrocefin181 (8.1), CENTA182 (8.2), 
Imipenem (8.3), and an in-house fluorogenic compound 8.4 (Figure 90). 
Each substrate was biologically evaluated against the panel of MBLs to 
identify the best substrate. (See Section 8.3.2 for NDM-1, IMP-1 and VIM-2 
and see Section 8.3.3 for SPM-1)  
To understand and rationalise the substrate binding constants of Nitrocefin 
(8.1), CENTA (8.2), Imipenem (8.3) and compound 8.4 for the different 
MBLs, in silico docking studies were performed to predict binding modes of 
the substrates to the enzymes. The in silico studies were conducted at the 
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University of Leeds and the results were compared against the in vitro 
biological evaluation data.  
 
Figure 90: 2D Structures of Nitrocefin (8.1), CENTA (8.2), Imipenem (8.3) and fluorogenic 
compound 8.4 
8.2 Docking protocol 
The in silico docking studies were conducted using AutoDock88, 100 and 
SPROUT125 as described below. 
The following protocol was used: 
1. Nitrocefin (8.1), CENTA (8.2), Imipenem (8.3), and compound 8.4, in 
substrate form were constructed in maestro.139 The resulting 
structures were then fully energy minimised using the multiple 
minimisation tool (MM). 
2. Each compound was then imported into the SPROUT125 programme 
and docked into the di-zinc containing active site of the crystal 
structure of NDM-1 (PDB ID: 3Q6X38). 
3. SPROUT scores were taken of the resulting docking ‘poses’ (these 
are generated as negative log numbers such that a value of, say -6, 
corresponds- very approximately- to a predicted binding affinity of 1 x 
10-6 M, i.e. µM). 
4. These docking results were also independently assessed via 
repeating the docking procedure again using AutoDock88, 100 which 
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utilises a different docking algorithm to that used within the SPROUT 
software. Again, the resulting docking ‘poses’ were scored, both 
within AutoDock and also using the SPROUT scoring function for 
comparison. 
5. The procedure was repeated for IMP-1 (PDB ID: 1JJT79), SPM-1 
(PDB ID: 2FHX62) and VIM-2 (PDB ID: 1KO364). 
8.3 In silico docking studies 
8.3.1 Docking to IMP-1, NDM-1 and VIM-2 
The predicted enzyme-substrate complex structures show some similarities 
in terms of orientation of the substrates within the binding cavity (Figure 
91a). Both Nitrocefin (8.1) and CENTA (8.2) are predicted to bind in almost 
identical orientations having the C-4 carboxylic acid of the cephalosporin-
derived thiazine ring positioned between the two zinc atoms of IMP-1 
(Figure 91b). A similar situation can be seen in the NDM-1 and VIM-2 
enzymes. 
 
Figure 91: a) Overlay of Nitrocefin (8.1, green), Imipenem (8.3, yellow), CENTA (8.2, blue) 
and compound 8.4 (pink) structures modelled in the active site of IMP-1 (PDB ID: 
1JJT); b) Overlay of Nitrocefin (8.1, green) and CENTA (8.2, blue). 
Differences are found in the binding of the C-3’ nitrophenyl ring systems (see 
Figure 92 and Figure 93). In the case of Nitrocefin (8.1), the ortho-nitro 
group is positioned to form a hydrogen bond with Lys-161. This hydrogen 
bond does not occur in the case of CENTA (8.2). However, the carboxylic 
acid on the thiophenol ring of CENTA (8.2) is able to form a hydrogen bond 
with the indole nitrogen of Trp-28. (Figure 91b) 
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Figure 92: Binding of Nitrocefin (8.1) to IMP-1 (PDB ID: 1JJT): a) 2D Binding 
representation, b) 3D spatial representation 
 
Figure 93: Binding of CENTA (8.2) to IMP-1 (PDB ID: 1JJT): a) 2D Binding representation, 
b) 3D spatial representation 
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Both Imipenem (8.3) and compound 8.4 have dissimilar zinc-binding 
orientations when compared to Nitrocefin (8.1) and CENTA (8.2). In the case 
of Imipenem (8.3), the β-lactam carbonyl is positioned between the two zinc 
atoms (Figure 94), whereas for compound 8.4, coordination to the di-zinc 
atoms is predicted to occur via the C-4 carboxylic acid of the cephalosporin-
derived thiazine ring and the β-lactam carbonyl respectively (Figure 95). 
Both Imipenem (8.3) and compound 8.4 are predicted to coordinate to Lys-
161 through their C-3/C-4 carboxylic acids located on the thiazolidine and 
thiazine rings, respectively. This mode of binding, unlike the binding mode 
predicted for Nitrocefin (8.1) and CENTA (8.2) in which the C-4 carboxylate 
is positioned between the two zincs, is the predicted mode of productive 
substrate binding to MBLs.186  
Fluorogenic compound 8.4 has the strongest predicted binding when 
compared to the other substrates. This is predicted to be due to an extra 
hydrogen bond between Glu-199 and the coumarin motif of the molecule. 
Nitrocefin (8.1) shows weak bonding to Glu-199 through its nitro groups. 
Imipenem (8.3) and CENTA do not bind to Glu-199 at all.  
 
 
 
Figure 94: Binding of Imipenem (8.3) to IMP-1 (PDB ID: 1JJT): a) 2D Binding 
representation, b) 3D spatial representation 
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Figure 95: Binding of compound 8.4 to IMP-1 (PDB ID: 1JJT): a) 2D Binding representation, 
b) 3D spatial representation 
Although in-depth structural analyses are required, the modelling results 
suggest that the cephalosporins may bind to the active site in more than one 
orientation, including non-catalytically productive ones. Overall, these results 
emphasize the importance of experimentally determining optimal MBL-
substrate combinations, and the need for X-ray crystallography of MBL-
substrate complexes. 
8.3.2 Comparison to biological results 
After analysis of the obtained substrate-enzyme models, the different 
docking poses, calculated using AutoDock 4 and SPROUT, were scored and 
compared to the substrate binding constants (KM) (Table 17). Full docking 
analysis data can be found in Appendix A5.1. 
From the biological evaluation of the substrates against the panel of MBL 
enzymes it was noticed that IMP-1 had much stronger binding interactions 
with all of the substrates than NDM-1 or VIM-2 which had similar binding 
scores to each other. IMP-1’s much more closed active site, which includes 
a large hydrophobic region created by the closed L3 loop, is predicted to 
account for this increase in binding affinity. The in silico docking scores of 
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the substrates backs up this result predicting stronger binding for the IMP-1 
enzyme compared to VIM-2 and NDM-1. 
As seen in Section 2.4.2, the active sites of VIM-2 and NDM-1 have a 
calculated RMS similarity of 1.652 and as expected exhibit similar 
characteristics to each other in the in vitro and in silico studies.   
Table 17: Docking scores for different substrates 
Enzyme Substrate 
Normalized 
AutoDock 
Score 
Normalized 
SPROUT Scorea 
KM-values 
(M) 
IMP-1 CENTA  1.9 1.20 17.1 
  Imipenem  1.25 1.23 42.7 
  Nitrocefin  1.83 1.30 55.7 
  8.4 1.92 1.35 15.2 
NDM-1 Imipenem  1.03 0.95 111.2 
  CENTA  1.18 1.01 34.6 
  Nitrocefin  1.12 1.15 8.8 
  8.4 1.33 1.34 4.0 
VIM-2 Imipenem  1.23 0.76 37.8 
  CENTA  1.15 0.81 26.1 
 Nitrocefin 1.00 1.00 7.2 
 8.4 1.33 1.14 6.3 
 
a 
Note, higher normalised score equates to tighter predicted binding. Scores are ranked 
based on the normalized SPROUT scores going from the lowest score to the highest score.  
Assessment of the AutoDock scoring data showed no clear correlations 
between the calculated pre-hydrolysis enzyme-substrate complexes and the 
experimentally obtained binding constants. In contrast to AutoDock, the 
SPROUT scoring data showed good correlation for NDM-1 and VIM-2; 
however less of a correlation was found for IMP-1. This is a clear example of 
where the use of a consensus scoring approach is advantageous when 
performing docking studies.187 
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For all three enzymes the highest ranking ligand in terms of SPROUT and 
AutoDock score is compound 8.4 which was also measured to have the 
highest binding affinity for all three enzymes. The broad correlation found, 
may reflect, in part, different Zn-binding modes as well as variation in the 
orientation of the side-chains of Imipenem (8.3), Nitrocefin (8.1), CENTA 
(8.2) and compound 8.4 (Figure 91-Figure 95). 
8.3.3 Docking to SPM-1 
Relatively poor KM values were obtained for all substrates when biologically 
evaluated against SPM-1 (PDB ID: 2FHX) when compared to the other MBL 
enzymes. (Table 18, unpublished data). A similarly poor predicted binding 
affinity can be seen in the in silico studies where the AutoDock and 
SPROUT predicted binding scores are not comparable to the other MBL 
enzymes and are significantly lower. (Appendix A5.1)   
The flexible loop region identified in Section 2.4.2.2 which has been seen to 
have an open and closed state is predicted to be the reason for the 
significant difference in binding affinity when compared to the other MBLs. In 
the closed form the flexible loop is predicted to be preventing access to the 
zinc atoms. (Figure 96)  
 
Figure 96: X-ray crystal structures of  SPM-1 showing the flexible loop region in the open 
form (Blue, PDB ID: 2FHX) and closed form (Red, PDB ID: 4BP0
188
). 
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Table 18: Docking scores for different substrates against SPM-1 
Enzyme Substrate 
Normalized 
AutoDock 
Score 
Normalized 
SPROUT 
Scorea 
KM-values 
(µM) 
SPM-1 Imipenem 0.63 0.66 330.9 
 
CENTA  -0.42 0.88 25.3 
 
Nitrocefin -0.33 0.90 16 
  8.4 -1.25 1.02 2.5 
 
a 
Note, higher normalised score equates to tighter predicted binding. Scores are ranked 
based on the normalized SPROUT scores going from the lowest score to the highest score.  
Further studies on the SPM-1 enzyme should look at the identified flexible 
loop to see if molecular dynamics can explain the effects of this loop on the 
rate of hydrolysis when compared to the other enzymes. 
8.4 Tetrahedral intermediates and hydrolysis products 
8.4.1 NDM-1, IMP-1 and VIM-2 
In an attempt to further understand the hydrolysis mechanism, the in silico 
docking of the tetrahedral hydrolysis intermediate and the hydrolysed 
product were conducted. (Figure 97) (Appendix A5.2 and A5.3)  
 
Figure 97: 2D structures of nitrocefin a) pre-hydrolysed substrate (8.1), b) tetrahedral 
intermediate (8.5) and c) hydrolysed substrate (8.6). 
a) 
b) 
c) 
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In general for NDM-1, IMP-1 and VIM-2  the best predicted binding scores 
come from the hydrolysed products of the substrates (Figure 98). In the 
hydrolysed form the newly formed carboxylic acid now binds to the side 
chain amine of the Asn-167 residue. The carboxylic acid that was bound to 
the Asn-167 residue is now bound to the Asn-167 residue and Zn1 atom. 
The extra interactions lead to a much stronger predicted binding energy for 
the hydrolysed product that the pre-hydrolysis substrate. 
The pre-hydrolysis substrates give the next best predicted binding scores 
which shows that binding to the enzyme is favourable. In general the lowest 
scores are for the tetrahedral intermediate, which may be representative of 
the energy barrier for hydrolysis and also could be an indicator as to why the 
hydrolysis of the reaction is catalytic (Figure 99). The formation of the 
tetrahedral intermediate removes the binding interaction seen from the β-
lactam carbonyl to the Asn-167 residue. The loss of this bond and the 
increase in space required to accommodate the tetrahedral intermediate 
reduces the binding energy.  
 
 
 
Figure 98: Hydrolysed nitrocefin docked into the active site of the IMP-1 (PDB ID: 1JJT): a) 
2D binding representation, b) 3D spatial representation 
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Figure 99: Tetrahedral intermediate in the hydrolysis of nitrocefin docked into IMP-1  (PDB 
ID: 1JJT).  
Figure 100 shows the proposed energy profile for the hydrolysis of the 
substrates by the MBL enzymes showing the activation energy needed to 
pass through the tetrahedral intermediate and the lower energy hydrolysis 
product. 
As seen with the pre-hydrolysis substrates, there is much stronger binding to 
the IMP-1 enzyme than to the other MBL enzymes. This is attributed to the 
more enclosed active site which gives stronger hydrophobic interactions 
between the active site wall and the substrates. There is a good correlation 
between the VIM-2 and NDM-1 results for all of the states and this is 
comparable to the results seen in the in vitro assays.  
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Figure 100: Proposed energy profile for the hydrolysis of substrates by MBL enzymes 
based upon in silico predicted binding scores 
8.4.2 SPM-1 
The predicted in silico binding scores of the substrates to the SPM-1 enzyme 
are significantly lower than to the other MBL enzymes.  
The binding predictions from AutoDock give some unexpected results 
(Appendix A5.2 and A5.3). A number of positive binding energies were 
observed. This implies that energy is required to place the substrate into this 
position and would be highly disfavoured. An example of this is the positive 
score of 2.00 for the binding of pre-hydrolysed nitrocefin to SPM-1. All of the 
AutoDock scores for each substrate docked into the SMP-1 enzyme are 
much lower scoring then for any of the other enzymes which indicates poor 
binding. This was also observed in the biologically measured KM values in 
Table 18 however not to the extreme seen in the AutoDock scores.   
The SPROUT predicted binding scores for each substrate are more 
consistent in value with the binding scores of the substrates to the other 
MBL enzymes. However they show the pre-hydrolysis substrate to give the 
tightest binding followed by the hydrolysed substrate and the most unfavored 
being the intermediate. This gives an indication that hydrolysis of the 
substrates may not be as favourable as with the other enzymes. The 
SPROUT scores also show stronger binding of imipenem to the SMP-1 
enzyme rather than compound 8.4 as seen with all the other MBLs. This 
could be due to the flexible loop restricting the larger substrates from 
reaching the active site as easily.   
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A molecular dynamics studies of the flexible loop region of the SMP-1 
enzyme would be required in order to fully understand why the scores are so 
different. However, as more crystal structures of SPM-1 enzyme become 
available researchers will gain a better understanding of the enzyme as a 
whole and especially the flexible loop region where it should be possible to 
establish whether the open or closed state is preferred.  
8.5 Conclusions 
The in silico SPROUT docking scores generally show a better correlation 
with the in vitro obtained kinetic parameters (specifically KM values) 
compared to the docking scores obtained by AutoDock 4.  It should however 
be noted that these studies are based upon a single crystal structure for 
each enzyme. This means that the docking does not take into account 
movement of any loops or changes in the inter atom distance between the 
zinc atoms which is widely reported in the literature especially with SPM-1. 
As more crystallographic data becomes available there will be an increase 
the accuracy of the docking predictions. Further studies on the SPM-1 
enzyme should look at the identified flexible loop to see if molecular 
dynamics can explain the effects of this loop on the rate of hydrolysis when 
compared to the other enzymes. 
Overall compound 8.4 provides the strongest binding to all of the enzymes in 
pre-hydrolysis substrate, tetrahedral intermediate and hydrolysed product 
forms. The stronger binding means that lower concentrations of substrate 
are required when conducting the assays which would save on the amount 
of substrate required for HTS screens and costs associated with producing 
substrate. Fluorogenic compound 8.4 provides good activity against all of the 
tested clinically relevant MBLs which shows it would be a good broad 
spectrum substrate to use in enzymatic assays. 
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Chapter 9 
Conclusions and future work 
This thesis reports on the molecular design, synthesis and biological 
evaluation of metallo-β-lactamase inhibitors which could be co-administered 
with current β-lactam antibiotics restoring the activity of the antibiotic against 
its bacterial target. The initial aim was to rationally identify novel inhibitors of 
the clinically relevant MBLs, VIM-2, IMP-1, NDM-1 and SPM-1, using a 
combination of structure-based drug design, chemical synthesis and 
biological evaluation.  
Four classes of inhibitor compound were successfully identified using a 
range of in silico techniques. 
9.1 vHTS identified inhibitors 
An extensive vHTS campaign was carried out in an attempt to identify novel 
inhibitors of NDM-1. Using AutoDock running on an array of parallel 
processors, ten compounds were identified from the Peakdale Molecular 
screening library and, eight compounds were identified from the Chembridge 
chemical library compounds. A series of compounds investigating the effects 
of changing the sterics and electronics around one of the Peakdale hits was 
synthesised and assessed biologically at the University of Oxford. Some 
inhibition was seen against NDM-1. However the degree of inhibition was 
not considered sufficient to warrant a more detailed SAR investigation to be 
carried out around these compounds. To improve the study, more crystal 
structures of each enzyme should be used to provide a consensus of which 
identified inhibitors are the most likely to be active in the enzymatic assay. 
9.2 Boronic acid inhibitors 
A series of boronic acid-containing inhibitors were identified from a patent as 
potent inhibitors of MBLs. Five target compounds were identified through a 
combination of vHTS of the compounds contained in the patent, and a de 
novo design approach. The synthetic route described in the patent was 
modified to increase the yields with moderate success. When screened in 
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the biological assays, the boronic acid based inhibitors gave IC50s in the 
region of 10 nM against VIM-2 and NDM-1 and 10 µM against IMP-1. The 
boronic acid-based inhibitors showed pan inhibition across the panel of MBL 
enzymes although much weaker binding was observed to the IMP-1 
enzyme. A crystal structure of one of the compounds co-crystallised in one 
of the MBLs will help to elucidate how the boronic acid compounds bind to 
the active site of the MBLs. Although a crystal structure is not yet available 
the conducted docking studies gave a good insight into how the boronic 
acid-based inhibitors are predicted to bind.  
9.3 Cysteine-containing peptides 
A new method to identify strong-binding peptides via the docking of custom 
built virtual peptide libraries to MBLs has been developed which could be a 
great improvement on the current methods of inhibitor peptide identification. 
The method has been shown to work by identifying active peptides against 
NDM-1. Initially the study was carried out using only L-amino acids with the  
best L-amino acid trimer peptides giving moderate activity against the NDM-
1 enzyme with an IC50 of 183 μM. Generally, improvements were seen when 
using peptides consisting of combinations of D and L amino acids however 
the best L-amino acid trimer was the most biologically active against NDM-1. 
Further testing is required to confirm this finding. A ROCs overlay screen 
was conducted with the zinc ‘drug like’ molecules screening library using the 
best scoring peptide as a template. Many of the compounds identified did 
not contain a strong zinc binding group and therefore would not make good 
peptide mimic drugs for this system. More screening libraries could be used 
or a better overlay based upon a crystal structure of the peptide bound into 
the active site.   
9.4 De novo designed thiol-based inhibitors 
De novo design successfully identified a novel small thiol-containing 
fragment. An investigation was conducted looking at the effects of changing 
the sterics and electronics of the lead molecule. This lead to the 
identification of a series of fragment molecules which are active against the 
MBLs. Evaluation in the enzymatic assays showed that the lead compound 
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had IC50’s of 234 nM and 232 nM against VIM-2 and IMP-1 respectively, 
which is the most potent inhibitor discovered using a fragment based 
approach. The small thiol-containing fragment was successfully co-
crystallised in VIM-2 leading to better understanding of the binding mode. In 
the bacterial cell assay, the thiol based inhibitor was seen to restore some of 
the activity of meropenem recovering the MIC of meropenem against NDM-1 
producing isolates from >128 ug/mL to 8 ug/mL. There was moderately high 
loading of the inhibitor to see the restoration in the MIC which could be down 
to penetration of the outer membrane or from removal from the cell by efflux. 
Modifications to the molecule in future work may help to overcome this. 
DMPK studies also showed the thiol molecule to be highly soluble in 
aqueous media but does show susceptibility to metabolic degradation by 
human liver microsomes. Initial studies have been conducted with the idea 
of co-drugging the inhibitor attached to a β-lactam antibiotic. However, and 
perhaps not surprisingly, early studies with the co-drug described are not 
promising. 
Studies are still required to investigate improving the drugability of all the 
identified inhibitor compounds. Getting the compounds into Gram negative 
bacteria still poses a considerable challenge, a challenge that has been the 
downfall to many antibacterial drug leads over the years. With the presence 
of elements such as sulfur and boron, full toxicity studies on these 
compounds will be required in order to ensure that they will have no adverse 
effects when administered in vivo. 
9.5 The future direction of MBL research 
The results described in this thesis provide a significant advancement of 
knowledge in the field as a whole. As yet no inhibitors of the MBLs have 
progressed to the clinic. This thesis reports a number of non-metal extracting 
compounds which have shown the ability to bind strongly to the MBLs and, 
in the case of the de novo fragments, potentiate the effect of meropenem on 
MBL producing bacteria. The successful identification of these novel tool 
compounds paves the way for other scientists to continue to develop 
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compounds which can be co-administered with our current β-lactam 
antibiotics prolonging their lifetime. 
The de novo designed inhibitors offer the most promising lead. Given more 
time to expand on the research contained in this thesis, studies would focus 
on establishing a strong SAR. Efforts would also be concentrated on 
continuing to minimise the potential toxicity problems within the current leads 
by considering moving towards other zinc binding groups such as carboxylic 
acids and / or imidazole in place of the thiol moiety. Further microbiological 
studies would focus on how to ensure these inhibitors penetrate bacterial 
cells and rationalising why the current inhibitors only exhibit moderate 
potentiation in the cellular assay-despite their strong inhibition in the 
enzymatic assay. The principle of co-drugging to overcome penetration 
difficulties should be investigated further by coupling the inhibitors to 
different cephalosporins.  
The boronic acid-containing inhibitors, which were found to exhibit strong 
binding to the MBLs, are some of the most potent MBL inhibitors known. 
Future research should focus on establishing the mode of binding of these 
compounds through crystallisation studies. Finding out more about how they 
bind will aid future development efforts to translate these systems to the 
clinic. Microbiological studies should be conducted taking the compounds 
into the cells with current β-lactam antibiotics to see if there is potentiation of 
the antibiotic against the MBL producing bacteria.  
When used to identify peptide-based inhibitors for the MBLs the vHTS-
derived peptide library approach ultimately proved to be unsuccessful. 
However, the principle of generation of such bespoke libraries should be 
further investigated using a number of different biological systems.   
Further work should focus on the SPM-1 MBL which was briefly introduced 
in this thesis. The flexible loop area within this enzyme poses a particular 
challenge to designing a suitable inhibitor. As with the other clinically 
relevant MBLs spread of SPM-1 is expected to grow rapidly over the next 
few years. Future work on MBL inhibition should aim to design novel 
inhibitors which can specifically target the SPM-1 enzyme  
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9.6 The future of structure-based drug design and 
antibacterial resistance 
As computational power increases, more accurate molecular screening will 
become available with hopefully, programs becoming capable to deal with 
the movement of the enzyme. This will allow for substantial increases in the 
accuracy of predictions and lower the need to synthesise large libraries of 
compounds which both reduces the cost and time of projects. 
There is a major pressing need to either discover new antibiotics or to 
protect our current spectrum of antibacterial agents to avoid the return to a 
‘pre-antibiotic’ era. The structure-based drug design approach outlined in 
this research offers rapid progression from target to lead compound at much 
reduced costs to the standard drug discovery approach. Progress is being 
made in identifying inhibitors of the MBLs but there are still some challenges 
nevertheless however challenging the fight against antibacterial resistance 
must go on.  
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Chapter 10 
Experimental 
10.1 General procedures and instrumentation. 
All reactions were carried out under nitrogen unless otherwise specified. All 
reagents were obtained from commercial sources without further purification. 
All solvents were distilled before use or obtained dry from commercial 
suppliers; EtOAc refers to ethyl acetate and Petrol to Petroleum ether (bp. 
40-60 °C). Analytical TLC was performed using silica gel pre-coated plates 
(Merck) and visualised by UV irradiation. Flash column chromatography was 
carried out on silica gel 60 (230-400 mesh, Merck). Solvents were removed 
under reduced pressure using a Buchi rotary evaporator at diaphragm pump 
pressure. Samples were freed of remaining traces of solvents under high 
vacuum. 
1H and 13C NMR spectra were measured on a Bruker DPX300 Fourier 
transform spectrometer or a Bruker Avance 500 using an internal deuterium 
lock. Chemical shifts were reported in parts per million (ppm) downfield from 
TMS in δ units and coupling constants are given in hertz (Hz). TMS as 
defined as 0 ppm for 1H NMR spectra and the centre line of the triplet CDCl3 
was also defined as 77.10 ppm for 13C NMR spectra. When displaying the 
1H NMR data the following abbreviations will be used; s= singlet, d= doublet, 
t= triplet, q= quartet, qi=quintet, m= multiplet, app= apparent. 
High resolution mass spectra (HRMS) was recorded in house using a 
Micromass GCT Premier, using electron impact ionization (EI) or a Bruker 
MaXis Impact Time of Flight spectrometer, using electron spray ionization 
(ES). All quoted masses refer to the 79Br isotope.  
Infrared spectra were recorded as thin films using sodium chloride plates or 
solid samples on a Perkin Elmer Spectrum One FT-IR spectrophotometer or 
Bruker Alpha Platinum ATR FT-IR spectrophotometer. The vibrational 
frequencies are reported in wavenumbers (cm-1).  
Melting points were determined on a Reichert Hot Stage apparatus. Melting 
points obtained were unchanged. 
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Elemental analysis was carried out using a Carlo Erba 1108 Elemental 
Analyzer. Determination of chlorine, bromine, fluorine, iodine and sulfur were 
carried out using the Schoniger Oxygen Flask combustion method followed 
by the relevant titration for the particular halogen.  
HPLC analyses were carried out on an Agilent 1290 Infinity system using a 
Supelco Ascentis Express C18, 50 x 2.1 mm, 2.7 micron column and diode 
array as a detector. A gradient of water and acetonitrile (5-95%) was used at 
a flow rate of 0.5 mL/min over 5 minutes. 
Preparative HPLC was conducted on an Agilent mass directed prep. LCMS 
using a XBridge C18, 19 × 100 mm, 5 micron column and positive ion 
electrospray ioniozation. A gradient of water and acetonitrile (5-95%) was 
used at a flow rate of 20mL/min over 8 minutes. 
LC-MS analysis was performed on a Bruker Daltronics instrument running 
on a gradient of increasing acetonitrile (5-95%) in water containing 0.1% 
formic acid at 1 mL min-1 on a 50 × 20 mm C18 reverse phase column and 
positive ion electrospray ionization. 
Specific rotation measurements were recorded using a Schmidt and 
Haensch Polartronic H532 polarimeter, using a 100 mm cell and the Sodium 
D line (589 nm). [α]D are reported in units of 10
-1 deg dm2g-1.  
10.2 General experimental methods 
Method A: Suzuki couplings 
The boronic acid (1.1 eq) was added to a stirred solution of 5-
bromophthalide (1.0 eq), potassium carbonate (1.0 eq) and tetrakis 
(triphenylphosphine) palladium (0) (0.05 eq) in THF (4 mL) and water (2 mL). 
The reaction mixture was heated to reflux for 12 h. The reaction mixture was 
filtered through celite and concentrated in vacuo. The residue was diluted 
with water (20 mL) and extracted in DCM (3 × 20 mL). The combined 
organics were dried (MgSO4) and concentrated in vacuo to give an off-
white/yellow solid, which was purified using flash column chromatography to 
afford the coupled products which were used without further purification. 
Method B: Lactone hydrolysis 
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2M NaOH (aq) (2.5 mL) was added to a stirred solution of the benzofuranone 
(1.0 eq) in methanol (5 mL). The reaction mixture was heated to reflux for 4 
h. The reaction mixture was concentrated in vacuo. The residue was diluted 
with water (10 mL) and acidified with 2M HCl (aq) to ~pH 2. The precipitate 
was filtered and washed with cold water (5 mL) and cold ethyl acetate (5 
mL). The collected solid was dried to afford the hydrolysed product as an off-
white solid without further purification.   
Method C: Lactone opening forming iodide 
The desired benzofuranone (1.0 eq) was dissolved in DCM (4.5 mL). TMSI 
(1.5 eq) was added and the reaction was refluxed under nitrogen for 3 h. 
After this time the mixture was cooled to room temperature and quenched 
with water (3 mL). The precipitate was isolated by filtration and washed with 
water (2 × 10 mL) to give the desired product as an off-white solid which was 
used without further purification.  
Method D: Introduction of Thiol189 
A mixture of thiourea (1.1 eq) in THF (3 mL) was heated to reflux. To this 
was added the iodine containing open lactone product (1.0 eq). The reaction 
mixture was heated to reflux for 16 h under an atmosphere of nitrogen. The 
reaction mixture was cooled to room temperature. The mixture was then 
concentrated in vacuo. The residue was re-suspended in 2M NaOH (aq) (5 
mL) and the solution refluxed for 3 h. The reaction mixture acidified with 2M 
HCl (aq) to ~pH2. The colourless precipitate was isolated by filtration.  
Method E: TMS group deprotection and HATU Peptide coupling 
The desired TMS protected amine (1.2-2.0 eq) was dissolved in THF (20 
mL) and to this was added anhydrous MeOH (2 mL). The reaction mixture 
was stirred at room temperature for 2 h. The reaction mixture was 
concentrated in vacuo to afford a pale brown oil which was taken forward to 
the next step without further purification. 
The desired carboxylic acid (1.0 eq) and HATU (1.1 eq) was dissolved in 
DCM (30 mL). The reaction mixture was cooled to 0 °C and Et3N (1.5 eq) 
was added drop-wise. The reaction mixture was stirred at 0 °C for 30 mins 
and then at room temperature for 1 h. The solution was then cooled to −20 
°C and the desired amine (1.2-2.0 eq) was added drop-wise. The reaction 
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was allowed to warm to room temperature overnight. After this time the 
reaction was quenched with water (50 mL). The aqueous layer was 
extracted with EtOAc (3 × 50 mL).  The combined organics were dried 
(MgSO4) and concentrated in vacuo to give the desired amide, which was 
purified using flash column chromatography to afford the coupled products. 
Method F: SN2 reaction in the synthesis of boronic acid-containing 
inhibitors 
3-[(2R)-2-[4-(bromomethyl)-benzoylamino]-2-[(3aS,4S,6S,7aR)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]-ethyl]-2-
methoxy benzoic acid tert-butyl ester (1.0 eq) was dissolved in CH3CN:DMF 
(1:1, 10 mL) and the desired amine (1.0 eq) was added. Na2CO3 (1.1 eq) 
was added and the solution heated to 70 °C for 3 h. The reaction was cooled 
to room temperature and extracted with EtOAc (3 × 20 mL). The organics 
were washed with water (3 × 20 mL) and brine (20 mL), dried (MgSO4) and 
concentrated in vacuo to afford the crude product. The crude product was 
purified by mass directed HPLC to afford the desired product as an oil. 
Method G: Boronic acid global deprotection. 
Boron tribromide (1M in DCM, 7.0 eq) was added drop-wise to a solution of 
boronic acid species (1.0 eq) in DCM (10 mL) at −78 °C. The reaction 
mixture was stirred at −78 °C for 1 h before warming to room temperature 
and quenched with water (6 mL). The DCM layer was evaporated in situ. 
Water (75 mL) was added and the mixture was extracted with diethyl ether 
(3 × 50 mL). The aqueous layer was concentrated to ~5 mL and the pH 
adjusted to ~pH1 with 2M HCl (aq). The product was purified by biotage 
chromatography on a C18 reverse phase cartridge eluting with 2:98 
Isopropanol-water to afford the desired product as a colourless solid.  
- 157 - 
10.3 Synthesis of ‘Peakdale screen hit molecule’ 
Synthesis of 2-oxo-2H-chromene-6-sulfonyl chloride (4.3)190 
A solution of coumarin (1.00 g, 6.85 mmol) in 
chlorosulfonic acid (4.2) (20 mL) was refluxed for 15 
mins. After cooling to room temperature the mixture 
was poured into ice and water (200 mL). The solution 
was extracted with chloroform (3 × 100 mL), dried over MgSO4, and 
concentrated in vacuo to give the crude product as a colourless solid. The 
crude product was purified by flash column chromatography eluting with 3:1 
DCM–Petrol. The title compound (4.3) was isolated after recrystallization 
from DCM as colourless plates. (0.68 g, 2.81 mmol, 41%)  m.p.: 115.6-117.4 
°C (from DCM) [lit.190 m.p. 113-115 °C] ; Rf: 0.41 (3:1 DCM–Petrol); δH (300 
MHz, CDCl3): 8.24 (1H, d, J 2.1, 5-H), 8.20 (1H, dd, J 8.7 and 2.1, 7-H), 7.82 
(1H, d, J 9.3, 4-H), 7.58 (1H, d, J 8.7, 8-H), 6.64 (1H, d, J 9.3, 3-H); δC (75 
MHz, CDCl3): 188.6 (C=O), 161.1 (C4a), 147.1 (C6), 141.8 (C4), 134.0 
(C8a), 130.0 (C8), 127.6 (C5), 119.3 (C7), 118.7 (C3); νmax/ cm
-1 (solid): 
3458, 3084, 1734, 1370; HPLC: Tr= 2.77 (100% rel. area); m/z (EI): (Found: 
M+, 243.9607. C9H5ClO4S requires M, 243.9597).  
Synthesis of 2,3-dimethyl-7-nitroindole (4.5)191 
2-nitrophenyl hydrazine (4.4) (1.00 g, 6.54 mmol) and butan-
2-one (0.58 mL, 6.54 mmol) were dissolved in methanol (10 
mL) and to this was added ceric ammonium nitrate (0.72 g, 
1.31 mmol). The solution was refluxed under an atmosphere 
of nitrogen for 16 h. The reaction was cooled to room temperature and 
poured into water (50 mL). The crude product was extracted with ethyl 
acetate (2 × 50 mL). The extracts were washed with water (20 mL), dried 
(MgSO4) and concentrated in vacuo. The crude product was re-suspended 
in conc. HCl (10 mL) and refluxed for 12 h. The reaction mixture was 
concentrated in vacuo. The residue was re-suspended in DCM (20 mL) and 
water (20 mL). The aqueous layer was extracted with DCM (2 × 20 mL). The 
organics were concentrated in vacuo to yield a dark brown powder which 
was recrystallized from acetone to afford the title compound (4.5) as pale 
brown plates. (0.64 g, 3.38 mmol, 52%)  m.p.: 94.4-96.2 °C (from acetone)  
- 158 - 
[lit.191 m.p. 95-96 °C (from acetone)]; Rf: 0.38 (1:1 Petrol−EtOAc); δH (300 
MHz, CDCl3): 9.43 (1H, brs, NH), 8.00 (1H, d, J 7.7, 4-H), 7.71 (1H, d, J 7.7, 
6-H), 7.10 (1H, app. t, J 7.7  5-H), 2.32 (3H, s, CH3-3), 2.18 (3H, s, CH3-2);  δC 
(75 MHz, CDCl3): 133.6 (C3a), 133.3 (C2), 128.9 (C3), 125.9 (C6), 118.3 
(C4), 118.0 (C5), 108.5 (C7a), 11.6 (CH3-3), 8.37 (CH3-2); νmax/ cm
-1 (solid): 
3409, 2916, 1512, 1364; HPLC: Tr= 3.46 (92% rel. area); m/z (EI): (Found: 
M+, 190.0741. C10H10N2O2 requires M, 190.0742).  
Synthesis of 2,3-dimethyl-7-aminoindole (4.6) 
2,3-dimethyl-7-nitroindole (4.5) (0.50 g, 2.63 mmol) was 
dissolved in methanol (25 mL). To this was added (10%) 
palladium on carbon (0.14 g, 0.13 mmol). The reaction was 
placed under an atmosphere of hydrogen and stirred at room 
temperature for 12 h. The reaction mixture was filtred through celite and 
concentrated in vacuo. The product was re-suspended in DCM (20 mL) and 
washed with water (20 mL) and brine (20 mL). The organics were 
concentrated in vacuo to yield a pale brown powder which was recrystallized 
from chloroform to afford the title compound (4.6) as colourless needles. 
(0.35 g, 2.18 mmol, 83%). m.p.: 123.6-124.3 °C (decomp) [lit.192 m.p. 126 °C 
(decomp)]; Rf: 0.52 (19:1 DCM–MeOH); δH (300 MHz, CDCl3): 7.60 (1H, brs, 
NH), 7.00 (1H, d, J 7.1, 4-H), 6.90 (1H, app. t, J 7.1, 5-H), 6.51 (1H, d, J 7.1, 
6-H), 3.50 (2H, brs, NH2), 2.32 (3H, s, CH3-3), 2.20 (3H, s, CH3-2); δC (75 
MHz, CDCl3): 130.6 (C2), 130.0 (C7), 125.9 (C3a), 119.8 (C5), 110.2 (C4), 
108.2 (C6), 108.0 (C7a), 11.5 (CH3-3), 8.70 (CH3-2); νmax/ cm
-1 (solid): 3406, 
2918, 1580; HPLC: Tr= 1.64 (100% rel. area); m/z (EI): (Found: M
+, 
160.0997. C10H12N2 requires M, 160.1000).  
Synthesis of 7-aminoindole (4.7) 
7-Nitroindole (0.50 g, 3.09 mmol) was dissolved in methanol (25 
mL). To this was added (10%) palladium on carbon (0.15 g, 0.15 
mmol). The reaction was placed under an atmosphere of 
hydrogen and stirred at room temperature for 12h. The reaction 
mixture was filtered through celite and concentrated in vacuo. The product 
was re-suspended in DCM (20 mL) and washed with water (20 mL) and 
brine (20 mL). The organics were concentrated in vacuo to yield an off-white 
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powder which was recrystallized in chloroform to afford the title compound 
(4.7) as colourless needles. (0.36 g, 2.72 mmol, 88%). m.p.: 95.2-96.6 °C 
(CHCl3)  [lit.
193 m.p.94-95 °C (CHCl3)]; Rf: 0.55 (19:1 DCM–MeOH); δH (300 
MHz, CDCl3): 8.10 (1H, brs, NH), 7.19 (1H, d, J 7.1, 4-H), 7.04 (1H, d, J 2.7, 
2-H), 6.94 (1H, app. t, J 7.1, 5-H), 6.57 (1H, d, J 7.1, 6-H), 6.50 (1H, d, J 2.7, 
3-H), 3.6 (2H, brs, NH2); δC (75 MHz, CDCl3): 130.9 (C7), 128.9 (C3a), 126.9 
(C7a), 124.1 (C2), 120.6 (C5), 112.8 (C4), 108.7 (C6), 103.4 (C3); νmax/ cm
-1 
(solid): 3375, 3216, 2735; HPLC: Tr= 1.11 (100% rel. area); m/z (EI): (Found: 
M+, 132.0690. C8H8N2 requires M, 132.0687).  
Synthesis of N-(2,3-dimethyl-1H-indol-7-yl)-2-oxo-chromene-6-
sulfonamide (4.1) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) 
(0.10 g, 0.41 mmol), 2,3-dimethyl-7-
aminoindole (4.6) (66 mg, 0.41 mmol) and 
pyridine (0.03 mL, 0.41 mmol) were stirred in 
DCM (5 mL) under and atmosphere of nitrogen 
for 16 h. The reaction mixture was washed with water (10 mL), dried 
(MgSO4) and concentrated in vacuo to yield the crude product as a pale 
brown powder. The crude product was purified using flash column 
chromatography, eluting with 1:1 Petrol–EtOAc. The title compound (4.1) 
was isolated by recrystallization from toluene as pale brown microcrystals. 
(0.11 g, 0.29 mmol, 70%) m.p.: 198.4-199.5 °C (from toluene); Rf: 0.36 (1:1 
Petrol–EtOAc); δH (300 MHz, CDCl3): 8.70 (1H, brs, indole-NH), 7.89 (1H, d, 
J 2.1, 5-H), 7.88 (1H, d, J 9.3, 8-H), 7.60 (1H, d, J 9.3, 4-H), 7.27 (1H,d, J 
7.6, 4’-H), 7.26 (1H, dd, J 9.3 and 2.1, 7-H), 6.79 (1H, app. t, J 7.6  5’-H), 
6.62 (1H, brs, NH), 6.48 (1H, d, J 9.3, 3-H), 6.23 (1H, d, J 7.6, 6’-H), 2.40 
(3H, s, CH3-3), 2.21 (3H, s, CH3-2); δC (75 MHz, CDCl3): 159.4 (C=O), 156.5 
(C8a), 142.4 (C4), 134.2 (C6), 132.4 (C4a), 131.8 (C3’a), 131.5 (C7’a), 
130.3 (C5), 127.9 (C8), 118.9 (C5’), 118.6 (C7), 118.2 (C3), 118.0 (C6’), 
117.8 (C4’ and C7), 117.6 (C2’), 107.5 (C3’), 11.7 (CH3-3), 8.52 (CH3-2); νmax/ 
cm-1 (solid): 3422, 3220, 2915, 1731, 1324, 1148; HPLC: Tr= 3.17 (100% rel. 
area); m/z (ES): (Found: [M-H]-, 367.0758. C19H16N2O4S requires [M-H], 
367.0770).  
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Synthesis of N-(1H-indol-7-yl)-2-oxo-chromene-6-sulfonamide (4.13) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.10 
g, 0.41 mmol), 1H-indol-7-amine (4.7) (54 mg, 
0.41 mmol) and pyridine (0.03 mL, 0.41 mmol) 
were stirred in DCM (5 mL) under and 
atmosphere of nitrogen for 16 h. The reaction 
mixture was washed with water (10 mL), dried (MgSO4) and concentrated in 
vacuo to yield the crude product as a pale brown powder. The crude product 
was purified using flash column chromatography eluting with 1:1 Petrol–
EtOAc. The title compound (4.13) was isolated by recrystallization from 
toluene as pale brown microcrystals. (0.12 g, 0.34 mmol, 83%) m.p.: 160.3-
161.8 °C (from toluene); Rf: 0.48 (1:1 Petrol–EtOAc); (Found: C, 60.1; H, 
3.55; N, 8.0; S, 9.2; C17H12N2O4S requires C, 59.9; H, 3.55; N, 8.2; S, 9.4%); 
δH (300 MHz, CDCl3):  9.20 (1H, brs, NH indol), 7.74 (1H, d, J 8.2, 8-H), 7.73 
(1H, s, NH), 7.58 (1H, d, J 9.9, 4-H), 7.55 (1H, d, J 7.7, 4’-H), 7.36 (1H, dd, J 
8.2 and 2.1, 7-H), 7.35 (1H, d, J 2.1, 2’-H), 6.84 (1H, app. t, J 7.7, 5’-H), 6.59 
(1H, d, J 2.1, 5-H), 6.48 (1H, d, J 9.9, 3-H), 6.46 (1H, d, J 2.1, 3’-H), 6.30 
(1H, d, J 7.7, 6-H’); δC (75 MHz, CDCl3): 188.8 (C=O), 160.9 (C8a), 142.3 
(C4), 136.5 (C6), 131.1 (C4a) 130.3 (C8), 127.9 (C7), 125.5 (C7’a and C3’a), 
125.4 (C4’), 120.6 (C5’), 119.7 (C6’), 118.5 (C3), 118.4 (C2’), 117.9 (C3’), 
122.1 (C7’), 102.9 (C5); νmax/ cm
-1 (solid): 3432, 3173, 1717, 1599, 1321, 
1110; HPLC: Tr= 2.75 (100% rel. area); m/z (ES): (Found: [M-H]
-, 339.0450. 
C17H12N2O4S requires [M-H], 339.0445).  
Synthesis of 2-oxo-N-phenyl-2H-chromene-6-sulfonamide (4.14) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.10 g, 
0.41 mmol), aniline (4.8) (0.05 mL, 0.41 mmol) and 
pyridine (0.03 mL, 0.41 mmol) were stirred in DCM (5 
mL) under and atmosphere of nitrogen for 16 h. The 
reaction mixture was washed with water (10 mL), 
dried (MgSO4) and concentrated in vacuo to yield the crude product as a 
brown powder. The crude product was purified using flash column 
chromatography eluting with 1:1 Petrol–EtOAc. The title compound (4.14) 
was isolated by recrystallized from toluene as yellow microcrystals. (98 mg, 
0.33 mmol, 79%) m.p.: 131.7-133.4 °C (from toluene) [lit.194  m.p.132 °C 
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(from benzene)]; Rf: 0.74 (1:1 Petrol–EtOAc); (Found: C, 59.3; H, 3.75; N, 
4.6; S, 10.6; C15H11NO4S requires C, 59.8; H, 3.68; N, 4.7; S, 10.6%); δH 
(300 MHz, CDCl3): 7.96 (1H, d, J 2.2, 5-H), 7.88 (1H, dd, J 8.8 and 2.2, 7-H), 
7.68 (1H, d, J 9.3, 4-H), 7.38 (1H, d, J 8.8, 8-H), 7.26 (2H, t, J 7.1, 5’-H and 
3’-H), 7.18 (1H, t, J 7.1, 4’-H), 7.08 (2H, d, J 7.1, 6’-H and 2’-H), 6.94 (1H, 
brs, NH), 6.51 (1H, d, J 9.3, 3-H);  δC (75 MHz, CDCl3): 159.4 (C=O), 156.4 
(C8a), 142.5 (C4), 135.8 (C6), 135.2 (C1’), 130.2 (C7), 129.6 (C6’ and C2’), 
127.8 (C5), 126.1 (C4’), 122.0 (C5’ and C3’), 118.8 (C4a), 118.3 (C3), 117.0 
(C8); νmax/ cm
-1 (solid): 3408, 3160, 2872, 2818, 1714, 1621, 1344, 1160; 
HPLC: Tr= 2.53 (100% rel. area); m/z (ES): (Found: [M-H]
-, 300.0343 
C15H11NO4S requires [M-H], 300.0336).  
Synthesis of 2-oxo-N-(pyridine-3-yl)-2H-chromene-6-sulfonamide (4.15) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.10 g, 
0.41 mmol), 3-aminopyridine (4.9) (39 mg, 0.41 
mmol) and pyridine (0.03 mL, 0.41 mmol) were stirred 
in DCM (5 mL) under and atmosphere of nitrogen for 
16 h. The reaction mixture was washed with water 
(10 mL), dried (MgSO4) and concentrated in vacuo to yield the crude product 
as a yellow solid. The crude product was purified using flash column 
chromatography eluting with 1:1 Petrol–EtOAc. The title compound (4.15) 
was isolated by recrystallized from toluene as off-white microcrystals. (0.10 
g, 0.33 mmol, 82%) m.p.: 183.6-185.3 °C (from toluene); Rf: 0.45 (1:1 
Petrol–EtOAc); (Found: C, 55.5; H, 3.40; N, 8.9; S, 10.3; C14H10N2O4S 
requires C, 55.6; H, 3.33; N, 9.3; S, 10.6%); δH (300 MHz, DMSO-d6): 10.72 
(1H, brs, NH), 8.32 (1H, d, J 2.7, 2’-H), 8.29 (1H, d, J 4.4, 6’-H), 8.21 (1H, d, 
J 2.5, 5-H), 8.17 (1H, d, J 9.3, 4-H), 7.92 (1H, dd, J 8.8 and 2.5, 7-H), 7.59 
(1H, d, J 8.8, 8-H), 7.52 (1H, dd, J 8.2 and 2.7, 4’-H), 7.29 (1H, dd, J 8.2 and 
4.4, 5’-H), 6.61 (1H, d, J 9.3, 3-H);  δC (75 MHz, DMSO-d6): 159.0 (C=O), 
155.9 (C8a), 145.4 (C6’), 143.3 (C4), 141.9 (C2’), 134.8 (C6), 134.0 (C3’), 
129.4 (C7), 127.7 (C5 and C4), 124.1 (C5’), 119.0 (C4a), 117.9 (C8 and C3); 
νmax/ cm
-1 (solid): 3462, 3061, 2856, 2774, 1737, 1603, 1471, 1164, 826; 
HPLC: Tr= 1.32 (100% rel. area); m/z (ES): (Found: [M-H]
-, 301.0284. 
C14H10N2O4S requires [M-H], 301.0289).  
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Synthesis of 2-oxo-N-(2,4,6-trimethylphenyl)-2H-chromene-6-
sulfonamide (4.16) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.10 
g, 0.41 mmol), 2,4,6 trimethyl aniline (4.10) (0.06 
mL, 0.41 mmol) and pyridine (0.03 mL, 0.41 mmol) 
were stirred in DCM (5 mL) under an atmosphere of 
nitrogen for 16 h. The reaction mixture was washed 
with water (10 mL), dried (MgSO4) and 
concentrated in vacuo to yield the crude product as a yellow powder. The 
crude product was purified using flash column chromatography eluting with 
1:1 Petrol–EtOAc. The title compound (4.16) was isolated by recrystallized 
from toluene as off-white microcrystals. (96 mg, 0.28 mmol, 68%) m.p.: 
170.4-171.9 °C (from toluene); Rf: 0.68 (1:1 Petrol–EtOAc); (Found: C, 63.2; 
H, 5.10; N, 4.1; S, 9.2; C18H17NO4S requires C, 63.0; H, 4.99; N, 4.1; S, 
9.3%); δH (300 MHz, CDCl3): 7.91 (1H, d, J 2.2, 5-H), 7.88 (1H, dd, J 8.8 and 
2.2, 7-H), 7.68 (1H, d, J 9.3, 4-H), 7.40 (1H, d, J 8.8, 8-H), 6.84 (2H, s, 5’-H 
and 3’-H), 6.53 (1H, d, J 9.3, 3-H), 6.25 (1H, brs, NH), 2.25 (3H, s, CH3-4’), 
2.00 (6H, s, CH3-6’ and CH3-2’); δC (75 MHz, CDCl3): 159.4 (C=O), 156.3 
(C8a), 142.5 (C4), 138.1 (C6), 137.4 (C6’ and C2’), 137.1 (C4’), 130.3 (C7), 
129.7 (C5’ and C3’), 129.3 (C1’), 127.4 (C5), 118.7 (C4a), 118.3 (C3), 117.8 
(C8), 20.9 (CH3-4’), 18.7 (CH3-6’ and CH3-2’); νmax/ cm
-1 (solid): 3244, 1744, 
1600, 1309, 1153; HPLC: Tr= 3.05 (100% rel. area); m/z (ES): (Found: [M-
H]-, 342.0798. C18H17NO4S requires [M-H], 342.0806).  
Synthesis of N-(4-nitrophenyl)-2-oxo-2H-chromene-6-sulfonamide (4.17) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.10 g, 
0.41 mmol), 4 nitro aniline (4.11) (57 mg, 0.41 mmol) 
and pyridine (0.03 mL, 0.41 mmol) were stirred in 
DCM (5 mL) under and atmosphere of nitrogen for 16 
h. The reaction mixture was washed with water (10 
mL), dried (MgSO4) and concentrated in vacuo to 
yield the crude product as a yellow powder. The 
crude product was purified using flash column chromatography eluting with 
1:1 Petrol–EtOAc. The title compound (4.17) was isolated by recrystallization 
from toluene as yellow microcrystals. (0.11 g, 0.30 mmol, 74%) m.p.: 221.7-
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222.9 °C (from toluene) [lit.194  m.p.220 °C (from benzene)]; Rf: 0.35 (1:1 
Petrol–EtOAc); (Found: C, 52.1; H, 3.00; N, 7.8; S, 9.0; C15H10N2O6S 
requires C, 52.0; H, 2.91; N, 8.1; S, 9.3%); δH (300 MHz, DMSO-d6): 8.36 
(1H, d, J 2.2, 5-H), 8.16 (1H, d, J 9.8, 4-H), 8.12 (2H, d, J 9.3, 5’-H and 3’-H), 
8.00 (1H, dd, J 8.8 and 2.2, 7-H), 7.60 (1H, d, J 8.8, 8-H), 7.33 (2H, d, J 9.3, 
6’-H and 2’-H), 6.63 (1H, d, J 9.8, 3-H); δC (75 MHz, DMSO-d6): 159.0 
(C=O), 156.2 (C8a), 143.7 (C4’), 143.3 (C4), 142.6 (C1’), 134.7 (C6), 129.5 
(C7), 127.8 (C5), 125.4 (C5’ and C3’), 119.1 C4a), 118.1 (C8, C6’ and C2’), 
117.9 (C3); νmax/ cm
-1 (solid): 3423, 3159, 2448, 1736, 1724, 1595, 1521, 
1347, 1226, 1162; HPLC: Tr= 2.65 (100% rel. area); m/z (ES): (Found: [M-
H]-, 345.0198. C15H10N2O6S requires [M-H], 345.0187).  
Synthesis of N-(3-chlorophenyl)-2-oxo-2H-chromene-6-sulfonamide 
(4.18) 
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.10 
g, 0.41 mmol), 3-chloro aniline (4.12) (0.04 mL, 
0.41 mmol) and pyridine (0.03 mL, 0.41 mmol) 
were stirred in DCM (5 mL) under and atmosphere 
of nitrogen for 16 h. The reaction mixture was 
washed with water (10 mL), dried (MgSO4) and concentrated in vacuo to 
yield the crude product as a pale yellow powder. The crude product was 
purified using flash column chromatography eluting with 1:1 Petrol–EtOAc. 
The title compound (4.18) was isolated by recrystallization from toluene as 
colourless microcrystals. (0.12 g, 0.37 mmol, 90%) m.p.: 167.1-168.8 °C 
(from toluene); Rf: 0.72 (1:1 Petrol–EtOAc); (Found: C, 53.5; H, 3.10; Cl, 
10.7; N, 4.2; S, 9.4; C15H10ClNO4S requires C, 53.7; H, 3.00; Cl, 10.6; N, 4.2; 
S, 9.6%); δH (300 MHz, DMSO-d6): 10.75 (1H, brs, NH), 8.25 (1H, d, J 2.2, 
5-H), 8.17 (1H, d, J 9.9, 4-H), 7.92 (1H, dd, J 8.8, and J 2.2, 7-H), 7.57 (1H, 
d, J 8.8, 8-H), 7.25 (1H, app. t, J 8.2, 5’-H), 7.14 (1H, t, J 1.6, 2’-H), 7.09 
(2H, m, 6’-H and 4’-H), 6.61 (1H, d, J 9.9, 3-H); δC (75 MHz, DMSO-d6): 
159.0 (C=O), 155.9 (C8a), 143.3 (C4), 138.9 (C6), 134.9 (C1’), 133.4 (C3’), 
131.0 (C5’), 129.4 (C7), 127.7 (C5), 124.0 (C4’), 119.3 (C2’), 119.0 (C4a), 
118.1 (C6’), 117.8 (C3); νmax/ cm
-1 (solid): 3185, 2970, 1738, 1723, 1373, 
1217; HPLC: Tr= 2.93 (100% rel. area); m/z (ES): (Found: [M-H]
-, 333.9938 
C15H10ClNO4S requires [M-H], 333.9946).  
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Synthesis of 6-benzylsulfonyl-2H-chromen-2-one (4.20) 
A stirred mixture of 2-oxo-2H-chromene-6-sulfonyl 
chloride (4.3) (0.10 g, 0.41 mmol), sodium bicarbonate 
(69 mg, 0.82 mmol) and sodium sulfite (0.10 g, 0.82 
mmol) in water (2 mL) was heated at 100 °C under an 
atmosphere of nitrogen for 1 h. The reaction was 
cooled to 50 °C, treated with tetra-n-butyl ammonium iodide (10 mg) and 
benzyl bromide (4.19) (0.05 mL, 0.45 mmol) and re-heated to 70 °C for 18 h. 
The reaction was cooled, treated with water (5 mL) and extracted with DCM 
(3 × 10 mL). The extracts were dried (MgSO4) and concentrated in vacuo to 
yield the crude product as a colourless solid. The crude product was purified 
using flash column chromatography eluting with 2:1 Petrol–EtOAc. The title 
compound (4.20) was isolated without further purification as a colourless 
powder. (36 mg, 0.12 mmol, 29%) m.p.: 182.3-184.0 °C; Rf: 0.73 (2:1 Petrol–
EtOAc); δH (300 MHz, CDCl3): 7.70 (1H, app s, 5-H), 7.64 (1H, dd, J 8.7 and 
2.2, 7-H), 7.63 (1H, d, J 9.8, 4-H), 7.36 (1H, d, J 8.7, 8-H), 7.32-7.30 (1H, m, 
4’-H), 7.28 (2H, t, J 7.1, 5’-H and 3’-H), 7.10 (2H, d, J 7.1, 6’-H and 2’-H), 
6.52 (1H, d, J 9.8, 3-H), 4.36 (2H, s, CH2); δC (75 MHz, CDCl3): 159.1 (C=O), 
157.0 (C8a), 142.2 (C4), 133.8 (C6), 131.6 (C7), 130.8 (C6’ and C2’), 129.2 
(C5), 129.1 (C4’), 128.8 (C5’ and C3’), 127.8 (C1’), 118.7 (C4a), 118.5 (C3), 
117.7 (C8); νmax/ cm
-1 (solid): 3446, 3084, 2928, 2455, 1979, 1732, 1601, 
1313; HPLC: Tr=  2.59 (100% rel. area); m/z (ES): (Found: [M-H]
-, 299.0377. 
C16H12O4S requires [M-H], 299.0384).  
Synthesis of phenyl 2-oxo-2H-chromene-6-sulfonate (4.22)  
2-oxo-2H-chromene-6-sulfonyl chloride (4.3) (0.48 
g, 1.96 mmol), phenol (4.21) (0.19 g, 1.96 mmol) 
and pyridine (0.16 mL, 1.96 mmol) were stirred in 
DCM (10 mL) under and atmosphere of nitrogen 
for 16 h. The reaction mixture was washed with water (20 mL), dried 
(MgSO4) and concentrated in vacuo to yield the crude product as a yellow 
powder. The crude product was purified using flash column chromatography 
eluting with 1:1 Petrol–EtOAc. The title compound (4.22) was isolated by 
recrystallization from toluene as pale pink needles. (0.43 g, 1.43 mmol, 73%) 
m.p.: 148.6-149.9 °C (from toluene); Rf: 0.80 (1:1 Petrol–EtOAc); δH (300 
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MHz, DMSO-d6): 8.39 (1H, d, J 2.3, 5-H), 8.19 (1H, d, J 7.9, 4-H), 8.00 (1H, 
dd, J 8.8 and 2.3, 7-H), 7.64 (1H, d, J 8.8, 8-H), 7.45-7.30 (3H, m, 5’-H, 4’-H 
and 3’-H), 7.06 (2H, d, J 7.7, 6’-H and 2’-H), 6.68 (1H, d, J 7.9, 3-H); δC (75 
MHz, DMSO-d6): 158.9 (C=O), 157.1 (C8a), 148.9 (C7), 143.2 (C4), 131.0 
(C6), 130.1 (C5’ and C3’), 129.4 (C5), 127.6 (C6’), 122.1 (C6’ and C2’), 
119.5 (C4a), 118.4 (C8), 118.1 (C3); νmax/ cm
-1 (solid): 1700, 1353, 1231, 
1079; HPLC: Tr= 2.15 (100% rel. area); m/z (ES): (Found: MH
+,  303.0310. 
C15H10O5S requires MH, 303.0322). 
Synthesis of 2-oxo-1,2-dihydroquinoline-6-sulfonyl chloride (4.24) 
A solution of 1,2-dihydroquinolin-2-one (4.23) (0.20 g, 
1.38 mmol) in chlorosulfonic acid (5 mL) was refluxed 
for 15 mins. After cooling to room temperature the 
mixture was poured into ice and water (50 mL). The 
solution was extracted with chloroform (3 × 50 mL), dried (MgSO4), and 
concentrated in vacuo to yield the crude product as a pale yellow powder. 
The crude product was purified using flash column chromatography eluting 
with 1% MeOH:CHCl3. The title compound (4.24) was isolated by 
recrystallization from DCM as colourless plates. (0.13 g, 0.54 mmol, 39%) 
m.p.: >250 °C (from DCM); Rf: 0.52 (1:99 MeOH–CHCl3); δH (300 MHz, 
DMSO-d6): 7.97 (1H, d, J 9.3, 4-H), 7.91 (1H, d, J 1.6, 5-H), 7.70 (1H, dd, J 
8.2  and J 1.6, 7-H), 7.26 (1H, d, J 8.2, 8-H), 6.49 (1H, d, J 9.3, 3-H); δC (75 
MHz, DMSO-d6): 162.0 (C=O), 141.8 (C6), 140.7 (C4), 138.7 (C8a), 128.1 
(C7), 124.8 (C5), 121.8 (C4a), 114.6 (C8); νmax/ cm
-1 (solid): 3156, 2921, 
1815, 1660, 1371, 1166; HPLC: Tr= 0.49 (100% rel. area); m/z (EI): (Found: 
M+, 242.9761 C9H6ClO3S requires M, 242.9757).   
Synthesis of N-(2,3-dimethyl-1H-indol-7-yl)-2-oxo-1,2- 
dihydroquinoline-6-sulfonamide (4.25) 
2-Oxo-1,2-dihydroquinoline-6-sulfonyl 
chloride  (4.24) (0.10 g, 0.42 mmol), 2,3-
dimethyl-7-aminoindole (4.6) (67 mg, 0.42 
mmol) and pyridine (0.03 mL, 0.42 mmol) 
were stirred in DCM (5 mL) under and atmosphere of nitrogen for 16 h. The 
reaction mixture was washed with water (10 mL), dried (MgSO4) and 
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concentrated in vacuo to yield the crude product as a yellow powder. The 
crude product was purified using flash column chromatography eluting with 
1:1 Petrol–EtOAc. The title compound (4.25) was isolated by recrystallization 
from toluene as yellow microcrystals. (50 mg, 0.13 mmol, 31%) m.p.: > 250 
°C (from toluene); Rf: 0.09 (1:1 Petrol–EtOAc); δH (300 MHz, DMSO-d6): 
12.08 (1H, brs, quinolone-NH), 10.35 (1H, brs, indole-NH), 9.70 (1H, brs, 
sulphonamide-NH), 8.07 (1H, d, J 1.8, 5-H), 7.98 (1H, d, J 9.7, 4-H), 7.80 
(1H, dd, J 8.3 and 1.8, 7-H), 7.34 (1H, d, J 8.3, 8-H), 7.10 (1H, d, J 7.3, 4’-
H), 6.73 (1H, app. t, J 7.3 5’-H), 6.65-6.58 (2H, m, 6’-H and 3-H), 2.28 (3H, 
s, CH3-C3’), 2.08 (3H, s, CH3-C2’); δC (125 MHz, DMSO-d6): 161.8 (C=O), 
141.5 (C7’), 139.9 (C4), 132.8 (C8a), 131.6 (C6), 130.6 (C7’a), 129.1 (C2’), 
128.1 (C7), 127.5 (C5), 123.3 (C5’), 120.4 (C3’a), 118.3 (C4a), 118.2 (C8), 
115.7 (C4’), 114.8 (C6’), 113.8 (C3), 105.8 (C3’), 11.1 (CH3-C3’), 8.16 (CH3-
C2’); νmax/ cm
-1 (solid): 3395, 1677, 1353, 1231, 1079; HPLC: Tr= 2.40 (91% 
rel. area); m/z (ES): (Found, MH+, 368.1069. C19H17N3O3S requires MH, 
368.1063). 
Synthesis of N-(2,3-dimethyl-1H-indol-7-yl)benzenesulfonamide (4.16) 
Benzenesulfonylchloride (0.07 mL, 0.56 mmol), 2,3-
dimethyl-7-aminoindole (90 mg, 0.56 mmol) and 
pyridine (4.6) (0.05 mL, 0.56 mmol) were stirred in 
DCM (5 mL) under and atmosphere of nitrogen for 16 h. The reaction 
mixture was washed with water (10 mL), dried (MgSO4) and concentrated in 
vacuo to yield the crude product as a pale yellow powder. The crude product 
was purified using flash column chromatography eluting with 1:1 Petrol–
EtOAc. The title compound (4.16) was isolated by recrystallization from 
toluene as colourless microcrystals. (12 mg, 0.04 mmol, 2%) m.p.: 169.8-
171.6 °C (from toluene); Rf: 0.86 (1:1 Petrol–EtOAc); δH (300 MHz, CDCl3): 
8.71 (1H, brs, indole NH), 7.64 (2H, d, J 7.1, 6-H and 2-H), 7.49 (1H, t, J 7.1, 
4-H), 7.40 (2H, t, J 7.1, 5-H and 3-H), 7.32 (1H, d, J 7.7, 4’-H), 6.80 (1H, 
app. t, J 7.7, 5’-H), 6.48 (1H, brs, NH), 6.24 (1H, d, J 7.7, 6’-H), 2.39 (3H, s, 
CH3-C3’), 2.20 (3H, s, CH3-C2’); δC (75 MHz, CDCl3): 137.8 (C1), 133.1 
(C4), 132.2 (C2’), 131.7 (C7’a), 131.6 (C3’a), 128.9 (C5 and C3), 127.4 (C6 
and C2), 118.8 (C5’), 118.5 (C3’), 117.6 (C6’), 117.4 (C4’), 107.4 (C7’), 11.7 
(CH3-C3’), 8.56 (CH3-C2’); νmax/ cm
-1 (solid): 3371, 3269, 1229, 1160, 1093; 
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HPLC: Tr= 3.27 (100% rel. area); m/z (ES): (Found: MNa
+, 323.0824. 
C16H16N2O2S requires MNa, 323.0825).  
10.4 Synthesis of boronic acid based inhibitors 
Synthesis of tert-butyl 3-bromo-2-methoxybenzoate (5.20) 
3-Bromo-2-methoxybenzoate (5.19) (0.50 g, 2.17 mmol) 
was dissolved in DCM (10 mL). To this was added oxalyl 
chloride (0.37 mL, 4.34 mmol) and cat. DMF (2 drops) and 
the reaction mixture was stirred for 1 h. The reaction mixture 
was concentrated in vacuo. The residue was dissolved in tert-butanol and 
refluxed for 16 h. The solvent was removed in vacuo. The crude product was 
purified by flash column chromatography eluting with 3:1 Petrol–EtOAc. The 
appropriate fractions were collected, combined and concentrated to afford 
the title compound (5.20) as a colourless oil which was used without further 
purification (0.29 g, 1.02 mmol, 47%) Rf: 0.84 (3:1 Petrol–EtOAc); δH (300 
MHz, CDCl3): 7.68 (2H, app. d, J 7.7, 6-H and 4-H), 7.02 (1H, app. t, J 7.7, 
5-H), 3.93 (3H, s, OCH3), 1.59 (9H, s, CH3); δC (75 MHz, CDCl3): 164.8 
(C=O), 156.2 (C2), 136.5 (C4), 130.4 (C6), 128.9 (C1), 124.9 (C5), 118.9 
(C3), 82.1 (C(CH3)), 62.0 (OCH3), 28.2 ((CH3)3); νmax/ cm
-1 (oil): 2978, 1721, 
1590, 1463, 1302; m/z (ES): (Found: MNa+, 309.0098. C12H15BrO3 requires 
MNa, 309.0097).   
Synthesis of 2-(bromomethyl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane140 (5.21) 
To a mixture of triisopropyl borate (20.0 g, 110 mmol), 
dibromomethane (8.60 mL, 120 mmol) and THF (150 mL) 
was added n-butyllithium (1.6M n-hexane solution, 63.6 mL, 
100 mmol) at −100 °C (external temperature) over 1.5 h. The reaction 
mixture was stirred at the same temperature for 1.5 h, and then the reaction 
mixture was stirred at room temperature for 2 h. After the mixture was 
cooled at 0 °C (external temperature), to the reaction mixture was added 
methanesulfonic acid (6.50 mL, 100 mmol), and then the reaction mixture 
was stirred at room temperature for 1 h. After the mixture was cooled to 0 °C 
(external temperature), to the reaction mixture was added pinacol (12.0 g, 
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100 mmol), and then the reaction mixture was stirred at room temperature 
for 1 h. After the solvent was concentrated, the resulting residue was distilled 
under reduced pressure (80-82 °C, 40 mmHg), to obtain the title compound 
(5.21) as a colourless oil. (16.0g, 72.4 mmol, 72%)  Rf: 0.37 (19:1 
Petrol−EtOAc); δH (300 MHz, CDCl3): 2.57 (2H, s, CH2), 1.27 (12H, s, CH3); 
δC (75 MHz, CDCl3): 84.6 (CH2), 24.7 (CH3); νmax/ cm
-1 (oil): 2922, 1415, 
1338, 1286, 1144, 1029; m/z (ES): (Found: [M-Br]+, 141.0833. C7H14BBrO2 
requires [M-Br], 141.0837).   
Synthesis of (3aS,4S,6S,7aR)-2-(bromomethyl)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole141 (5.22) 
A mixture of 2-(bromomethyl)-4,4,5,5-tetramethyl-1,3,2 
dioxaborolane (5.21) (0.40 g, 1.18 mmol) and (+)-
Pinanediol (0.62 g, 3.62 mmol) in THF (10 mL) was stirred 
at room temperature for 18 h. The reaction mixture was concentrated in 
vacuo. The residue was partitioned between EtOAc (10 mL) and water (10 
mL). The organics were separated and the aqueous extracted with further 
EtOAc (2 × 10 mL). The combined organics were dried (MgSO4) and 
concentrated in vacuo to yield the crude product as a pale brown oil.  The 
crude product was by flash column chromatography eluting with 3:1 Petrol–
EtOAc. The appropriate fractions were collected, combined and 
concentrated to afford the title compound (5.22) as a colourless oil which 
was used without further purification (0.29 g, 1.02 mmol, 47%) Rf: 0.50 (19:1 
Petrol−EtOAc); δH (300 MHz, CDCl3): 4.37 (1H, dd, J 9.0 and 2.0, 7a-H), 
2.63 (2H, s, CH2Br), 2.36 (1H, ddt, J 14.5, 9.0 and 2.0, 7*-H), 2.22-2.29 (1H, 
m, 8-H), 2.08 (1H, app. t, J 5.5, 4-H), 1.87-1.96 (2H, m, 7*-H and 6-H), 1.42 
(3H, s, CH3-C3a), 1.30 (3H, s, CH3-5b), 1.20 (1H, d, J 11.0, 8-H), 0.85 (3H, 
s, CH3-5a) ; δC (75 MHz, CDCl3): 86.7 (C3a), 78.6 (C7), 51.2 (C4), 39.3 (C6) 
38.2 (C5), 35.2 (C7), 28.7 (C3a-CH3), 27.2 (C5b-CH3), 26.5 (C8), 23.9 (C5b-
CH3), 10.1 (CH2Br); νmax/ cm
-1 (oil): 2922, 1725, 1415, 1338; m/z (ES): 
(Found: [M-Br]+,  193.1198. C11H18BBrO2 requires [M-Br], 193.1120). [α]D = + 
35.2° (c 0.50, CHCl3).  
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Synthesis of 2-methoxy-3-([(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-
4,6-methano-1,3,2-benzodioxaborol-2-yl]methyl) benzoic acid tert-butly 
ester (5.9) 
To a stirred solution of tert-butyl 3-bromo-2-
methoxybenzoate (5.20) (2.63 g, 9.19 mmol) in 
THF (50 mL) was added n-butyllithium (1.6M 
n-hexane solution, 5.77 mL, 9.19 mmol) drop 
wise at -100 °C. The solution was stirred at −100 °C for 1 h. 
(3aS,4S,6S,7aR)-2-(bromomethyl)-3a,5,5-trimethylhexahydro-4,6-methano-
1,3,2-benzodioxaborole (5.22) (3.00 g, 11.0 mmol) was added and the 
reaction mixture was stirred at −100 °C for 2 h. The mixture was then 
allowed to warm to room temperature with stirring overnight. The mixture 
was concentrated in vacuo. The residue was diluted with water (50 mL) and 
extracted in DCM (3 × 50 mL). The combined organics were dried (MgSO4) 
and concentrated in vacuo to yield the crude product as a pale yellow oil. 
The crude product was by flash column chromatography eluting with 19:1 
Petrol–EtOAc. The appropriate fractions were collected, combined and 
concentrated to afford the title compound (5.9) as a colourless oil which was 
used without further purification (2.79 g, 6.98 mmol, 76%). Rf: 0.85 (19:1 
Petrol−EtOAc); δH (300 MHz, CDCl3): 7.52 (1H, dd, J 7.6 and 1.8, 6-HAr), 
7.33 (1H, dd, J 7.6 and 1.8, 4-HAr), 7.02 (1H, app. t, J 7.6, 5-HAr), 4.27 (1H, 
dd, J 8.7 and 2.0, 7a-H), 3.81 (3H, s, OCH3), 2.32 (2H, s, CH2B), 2.32-2.24 
(1H, m, 7*-H), 2.22-2.14 (1H, m, 8-H), 2.03 (1H, app. t, J 5.1, 4-H), 1.91-1.87 
(1H, m, 6-H), 1.82 (1H, dd, J 14.2 and 2.1, 7*-H), 1.59 (9H, s, C(CH3)3), 1.38 
(3H, s, CH3-C3a), 1.27 (3H, s, CH3-5b), 1.19 (1H, d, J 10.8, 8-H), 0.83 (3H, 
s, CH3-5a); δC (75 MHz, CDCl3): 166.0 (C=O), 157.4 (C2-Ar), 134.2 (C6-Ar), 
134.0 (C3-Ar), 128.4 (C5-Ar), 126.4 (C1-Ar), 123.3 (C4-Ar), 85.8 (C3a), 81.0 
(C(CH3)3), 77.9 (C7), 61.5 (OCH3), 51.3 (C4), 41.3 (C6), 39.5 (C5), 38.2 
(C7), 28.6 (C3a-CH3), 28.2 (C(CH3)3), 27.1 (C5b-CH3), 24.0 (C8), 22.6 (C5a-
CH3), 11.4 (br, CH2B); νmax/ cm
-1 (oil): 2977, 2925, 2869, 1700, 1278, 1135; 
HPLC: Tr= 2.79 (93% rel. area); m/z (ES): (Found: MH
+, 401.2505. 
C24H34BClO5 requires MH, 401.2498). [α]D = + 12.4° (c 0.50, CHCl3).   
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Synthesis of 2-methoxy-3-((2S)-2-chloro-2-[(3aS,4S,6S,7aR)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]ethyl) 
benzoic acid tert-butly ester (5.23) 
 Lithium diisopropylamide (LDA) was prepared 
fresh by addition of n-butyllithium (1.6M n-hexane 
solution, 0.98 mL, 1.50 mmol) to a solution of 
diisopropylamine (0.21 mL, 1.50 mmol) in THF (3.5 
mL) at -100 °C under a nitrogen atmosphere. The 
mixture was stirred at −100 °C for 10 mins before warming to ca. −20 °C. In 
a separate flask a mixture of 2-methoxy-3-([(3aS,4S,6S,7aR)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]methyl) benzoic 
acid tert-butly ester (5.9) (0.50 g, 1.25 mmol), DCM (0.32 mL, 5.00 mmol) in 
THF (22.5 mL) was stirred at −100 °C under nitrogen. To this was added the 
LDA solution over 30 mins. Stirring was continued at −100 °C for 30 mins 
before addition of 1M ZnCl2 solution in ether (2.00 mL, 2.00 mmol). The 
resulting mixture was left to warm to room temperature overnight. The 
mixture was concentrated in vacuo and sat. NH4Cl solution (50 mL) was 
added and the resulting mixture stirred for 10 mins. The mixture was 
extracted with hexane (3 × 25 mL). The organics were combined, dried 
(MgSO4) and concentrated in vacuo to afford the title compound (5.23) as a 
pale yellow oil (0.51 g, 1.14 mmol, 91%) Rf: 0.52 (19:1 Petrol−EtOAc); δH 
(300 MHz, CDCl3): 7.63 (1H, dd, J 7.7 and 1.8 6-HAr), 7.39 (1H, dd, J 7.7 
and 1.8, 4-HAr), 7.06 (1H, app. t, J 7.7, 5-HAr), 4.36 (1H, dd, J 8.5 and 2.1, 
7a-H), 3.86 (3H, s, OCH3), 3.74 (1H, t, J 8.2, ClCH), 3.20 (2H, dd, J 14.1 and 
8.2 CH2Ar), 2.45-2.27 (1H, m, 7*-H), 2.25-2.18 (1H, m, 8-H), 2.06 (1H, app. 
t, J 5.5, 6-H), 1.95-1.83 (2H, m, 7*-H and 4-H), 1.59 (9H, s, (CH3)3), 1.38 
(3H, s, C3a-CH3), 1.28 (3H, s, C5b-CH3), 1.10 (1H, d, J 11.2, 8-H), 0.83 (3H, 
s, C5a-CH3); δC (75 MHz, CDCl3): 165.7 (C=O), 158.3 (C2-Ar), 134.4 (C6-
Ar), 132.7 (C3-Ar), 130.3 (C5-Ar), 126.4 (C1-Ar), 123.2 (C4-Ar), 86.8 (C3a), 
81.3 (C(CH3)3), 78.5 (C7), 62.3 (OCH3), 51.2 (C4), 41.2 (br, ClCH), 39.4 
(C6), 38.2 (C5), 35.1 (C7), 35.0 (CH2Ar), 28.3 (C3a-CH3), 28.2 (C(CH3)3), 
27.0 (C5b-CH3), 26.8 (C8), 24.0 (C5a-CH3); νmax/ cm
-1 (oil): 2971, 2921, 
2871, 1700, 1466, 1369, 1239, 1135; m/z (ES): (Found: MH+, 449.2233. 
C24H34BClO5 requires MH, 449.2268).  [α]D = + 52.1° (c 0.50, CHCl3). 
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Synthesis of 2-methoxy-3-((2R)-2-[bis(trimethylsilyl)amino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]ethyl) benzoic acid tert-butly ester (5.10) 
To a stirred solution of 2-methoxy-3-((2S)-2-
chloro-2-[(3aS,4S,6S,7aR)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]ethyl) benzoic acid tert-
butly ester (5.23) (0.45 g, 1.00 mmol) in THF 
(17.5 mL) at −100 °C was added a solution of 
LiHMDS (1M in THF, 1.1 mL) in THF (7 mL) over 30 mins. The resulting 
mixture was left to warm to room temperature with stirring overnight. The 
mixture was concentrated in vacuo and re-suspended in hexane (50 mL) 
with stirring for 1 h. The suspension was filtered through celite and the celite 
was washed with further hexane (2 × 25 mL). The filtrate was concentrated 
in vacuo to afford the title compound (5.10) as dense pale yellow oil which 
was used without further purification. (0.33 g, 0.58 mmol, 58%) Rf: 0.71 (19:1 
Petrol−EtOAc); δH (300 MHz, CDCl3): 7.48 (1H, dd, J 7.6 and 1.8, 6-HAr), 
7.27 (1H, dd, J 7.6 and 1.8, 4-HAr), 6.94 (1H, app. t, J 7.6, 5-HAr), 4.18 (1H 
dd, J 8.7 and 1.9, 7a-H), 3.77 (3H, s, OCH3), 3.15 (1H, dd, J 13.2 and 6.6, 
CH2Ara), 2.89 (1H, dd, J 8.4 and 6.6, NCH), 2.49 (1H, dd, J 13.2 and 8.4, 
CH2Arb), 2.28-2.13 (1H, m, 7*-H), 2.10-2.03 (1H, m, 8-H), 1.93 (1H, app. t, J 
5.6, 4-H), 1.83-1.75 (1H, m, 6-H), 1.70-1.62 (1H, m, 7*-H), 1.54 (9H, s, 
C(CH3)3), 1.30 (3H, s, C3a-CH3), 1.20 (3H, s, C5b-CH3), 0.94 (1H, d, J 10.8, 
8-H), 0.76 (3H, s, C5a-CH3), -0.01 (18H, s, TMS); δC (75 MHz, CDCl3): 165.3 
(C=O), 157.5 (C2-Ar), 134.9 (C6-Ar), 134.0 (C3-Ar), 128.2 (C5-Ar), 125.6 
(C1-Ar), 121.8 (C4-Ar), 84.7 (C3a), 80.1 (C(CH3)3), 77.3 (C7), 61.0 (OCH3), 
50.5 (C4), 41.2 (NCH), 35.1 (C7), 35.0 (CH2Ar), 27.7 (C3a-CH3), 27.3 
(C(CH3)3), 26.2 (C5b-CH3), 25.4 (C8), 23.1 (C5b-CH3); νmax/ cm
-1 (oil): 2977, 
2925, 2869, 1700, 1287, 1135; m/z (ES): (Found: [M-2TMS]+, 430.2783. 
C30H52BNO5Si2 requires [M-2TMS], 430.2760). [α]D = + 20.1° (c 0.50, 
CHCl3).  
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Synthesis of 3-[(2R)-2-[4-(tert-Butoxycarbonylamino-methyl)-
benzoylamino]-2-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-
methano-1,3,2-benzodioxaborol-2-yl]-ethyl]-2-methoxy-benzoic acid 
tert-butyl ester. (5.24) 
Preparation was via general 
method E using 4-Boc 
(aminomethyl)benzoic acid 
(0.50 g, 1.99 mmol)  and 2-
methoxy-3-((2R)-2-
[bis(trimethylsilyl)amino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]ethyl) benzoic acid tert-butly ester (5.10) (1.70 g, 3.98 
mmol)  to afford the title compound (5.24) as a yellow glassy solid which was 
used without further purification (0.55 g, 0.84 mmol, 42%). m.p.: 73.8-75.5 
°C; Rf: 0.21 (3:1 Hexane−EtOAc); δH (500 MHz, CDCl3): 7.73 (2H, d, J 8.2 2’-
HAr and 6’-HAr), 7.61 (1H, dd, J 7.7 and 1.7, 6-HAr), 7.48 (1H, brs, CONH), 
7.38 (1H, dd, J 7.7 and 1.7, 4-HAr), 7.34 (2H, d, J 8.2, 3’-HAr and 6’-HAr), 
7.09 (1H, t, J 7.7, 5-HAr), 4.94 (1H, brs, BOC-NH), 4.36 (2H, app. s, CH2N), 
4.31 (1H, d, J 7.6, 7a-H), 3.83 (3H, s, OCH3), 3.09 (1H, t, J 5.4, NCH), 2.99 
(2H, d, J 5.4, CH2Ar), 2.44-2.30 (1H, m, 7*-H), 2.29-2.12 (1H, m, 8-H), 2.06 
(1H, app. t, J 10.9, 6-H), 1.98-1.86 (2H, m, 7*-H and 4-H), 1.61 (9H, s, 
C(CH3)3), 1.58 (1H, d, J 10.9, 8-H), 1.48 (9H, s, BOC-CH3), 1.46 (3H, s, C3-
CH3), 1.30 (3H, s, C5b-CH3), 0.90 (3H, s, C5a-CH3); δC(75 MHz, CDCl3): 
170.1 (CONH), 165.8 (C=O), 157.6 (C=O BOC), 135.8 (C4’-Ar), 134.8 (C6-
Ar and C1’-Ar), 129.8 (C4-Ar), 128.0 (C5’-Ar, C3’-Ar and C3-Ar), 127.5 (C6’-
Ar and C2’-Ar), 124.2 (C5-Ar and C1-Ar), 83.7 (C3a), 81.5 (C(CH3)3), 76.7 
(C7a), 62.3 (OCH3), 52.4 (C4), 45.0 (CH2CB), 40.2 (C6), 38.2 (C5), 36.7 
(CH2N), 32.8 (C7), 28.3 (C3-CH3), 28.2 ((CH3)3), 27.4 (C5a-CH3), 26.7 (C8), 
24.3 (C5b-CH3); νmax/ cm
-1 (solid): 3272, 2971, 2870, 1700, 1502, 1388, 
1228; m/z (ES): (Found: MH+, 663.4033. C37H51BN2O8 requires MH, 
663.3811). [α]D = − 22.3° (c 0.50, CHCl3). 
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Synthesis of 3-[(2R)-2-(4-(Aminomethyl)benzoylamino)-2-borono-ethyl]-
2-hydroxy-benzoic acid hydrochloride. (5.13) 
Preparation was via general method G 
using 3-[(2R)-2-[4-(tert-
Butoxycarbonylamino-methyl)-
benzoylamino]-2-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-
1,3,2-benzodioxaborol-2-yl]-ethyl]-2-methoxy-benzoic acid tert-butyl ester 
(5.24) (50 mg, 0.08 mmol) to afford the title compound (5.13) as a colourless 
solid which was used without further purification (3.8 mg, 0.01 mmol, 13%). 
m.p.: > 250 °C; Rf: 0.05 (9:1 DCM−MeOH); δH (500 MHz, MeOD-d4): 8.39 
(1H, brs, CONH), 8.0-7.85 (2H, app. m, 6’-H and 2’-H), 7.82 (1H, d, J 7.8, 6-
H), 7.62-7.50 (2H, app. m, 5’-H and 3’-H), 7.38-7.28 (1H, app. m, 4-H), 6.97-
6.78 (1H, app. m, 5-H), 4.20 (2H, s, CH2NH2), 3.52 (1H, app. s, NCH), 3.09 
(2H, app. s, CH2); νmax/ cm
-1 (solid): 3388, 2913, 1597, 1481, 1337; m/z (ES): 
(Found: [M-H2O+H]
+, 341.1312. C17H19BN2O6 requires [M-H2O+H], 
341.1306. [α]D = − 75.4° (c 0.10, MeOH). 
Synthesis of 3-[(2R)-2-[4-(bromomethyl)-benzoylamino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]-ethyl]-2-methoxy benzoic acid tert-butyl ester. 
(5.25) 
Preparation was via general method 
E using 4-bromomethylbenzoic acid 
(0.99 g, 4.64 mmol)  and 2-methoxy-
3-((2R)-2-[bis(trimethylsilyl)amino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]ethyl) benzoic 
acid tert-butly ester (3.19 g, 5.57 mmol)  to afford the title compound (5.25) 
as a yellow glassy solid which was used without further purification (0.50 g, 
0.80 mmol, 14%). m.p.: 93.7-95.2 °C; Rf: 0.32 (3:1 Hexane−EtOAc); δH (500 
MHz, CDCl3): 7.72 (2H, d, J 7.8, 2’-HAr and 6’-HAr), 7.61 (1H, d, J 6.9, 6-
HAr), 7.44 (3H, app. d, J 7.8, CONH, 3’-HAr and 5’-HAr), 7.36 (1H, d, J 6.9, 
4-HAr), 7.10 (1H, t, J 6.9, 5-HAr), 4.48 (2H, s, CH2Br), 4.32 (1H, d, J 9.0, 7a-
H), 3.84 (3H, s, OCH3), 3.15 (1H, t, J 6.9, NCH), 3.00 (2H, d, J 6.9, CH2Ar), 
2.48-2.29 (1H, m, 7*-H), 2.25-2.16 (1H, m, 8-H), 2.07-1.99 (1H, m, 6-H), 
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1.97-1.83 (2H, m, 7*-H and 4-H), 1.62 (9H, s, C(CH3)3), 1.52 (1H, d, J 7.4, 8-
H), 1.74 (3H, s, C3-CH3), 1.28 (3H, C5b-CH3), 0.89 (3H, s, C5a-CH3); δC 
(125 MHz, CDCl3): 169.5 (HNC=O), 165.8 (C=O), 157.6 (C2-Ar), 142.5 (C4’-
Ar), 135.5 (C1’-Ar), 134.7 (C6-Ar), 129.9 (C4-Ar), 129.4 (C3-Ar), 129.3 (C6’-
Ar and C2’-Ar), 128.1 (C5’-Ar and C3’-Ar), 124.2 (C5-Ar), 84.1 (C3a), 81.5 
(C7a), 77.0 (C(CH3)3),62.3 (OCH3), 52.5 (C4), 45.0 (brs, NCH), 38.2 (C5), 
36.5 (CH2C), 32.6 (C7), 32.0 (CH2Br), 29.1 (C3-CH3), 27.4 (C5a-CH3), 26.6 
(C8), 24.2 (C5b-CH3); νmax/ cm
-1 (solid): 2720, 1700, 1367, 1039, 1003; m/z 
(ES): (Found: MH+, 626.2780. C32H41BBrNO6 requires MH, 626.2283. [α]D = 
+ 14.3° (c 0.50, CHCl3). 
Synthesis of 2-methoxy-3-[(2R)-2-((4-Boc-piperazinylmethyl)-
benzoylamino)-2-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-
methano-1,3,2-benzodioxaborol-2-yl]-ethyl] benzoic acid tert-butyl 
ester. (5.28) 
Preparation was via 
general method F using 3-
3-[(2R)-2-[4-
(bromomethyl)-
benzoylamino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]-ethyl]-2-methoxy benzoic acid tert-butyl ester (5.25) 
(0.41 g, 0.65 mmol)  and 1-Boc-piperazine (0.12 g, 0.65 mmol) to afford the 
title compound (5.28) as a red oil which was used without further purification 
(80 mg, 0.11 mmol, 17%). Rf: 0.14 (3:1 Hexane−EtOAc); δH (500 MHz, 
CDCl3): 7.72 (2H, d, J 8.1, 6’-HAr and 2’-HAr), 7.61 (1H, dd, J 7.3 and 1.3, 6-
HAr), 7.45 (1H, brs, CONH), 7.39 (2H, d, J 8.1, 5’-HAr and 3’-HAr), 7.38 (1H, 
dd, J 7.3 and 1.3, 4-HAr), 7.10 (1H, app.t, J 7.3, 5-HAr), 4.31 (1H, d, J 9.0, 
7a-H), 3.83 (3H, s, OCH3), 3.54 (2H, s, CH2), 3.46-3.39 (4H, m, 5-HPip and 
3-HPip), 3.09 (1H, t, J 6.3, NHC), 3.00 (2H, d, J 6.3, CH2C), 2.43-2.31 (5H, 
m, 6-HPip, 2-HPip and 7*-H), 2.24-2.14 (1H, m, 8-H), 2.08-2.00 (1H, m, 6-
H), 1.95-1.86 (2H, m, 7*-H and 4-H), 1.61 (9H, s, C(CH3)3), 1.48 (3H, s, C3-
CH3), 1.46 (9H, s, BOC), 1.30 (C5a-CH3), 1.26 (1H, d, J 7.4, 8-H), 0.89 (3H, 
s, C5b-CH3); δC (125 MHz, CDCl3): 170.3 (NHC=O), 165.8 (C=O), 154.8 
(BOC C=O), 143.8 (C4’-Ar), 135.9 (C1’-Ar), 134.8 (C6-Ar), 129.8 (C4-Ar), 
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129.9 (C6’-Ar, C2’-Ar and C3-Ar), 127.8 (C5’-Ar and C3’-Ar), 127.7 (C1-Ar), 
124.1 (C5-Ar), 83.7 (C3a), 81.5 (C(CH3)3), 79.6 (BOC C), 77.0 (C7a), 62.5 
(CH2), 62.3 (OCH3) 52.9 (C6-Pip, C5-Pip, C3-Pip and C2-Pip), 52.4 (C4), 
45.0 (brs, NCH), 40.2 (C6), 38.2 (CH2C), 36.8 (C5), 32.8 (C7), 29.2 (C3-
CH3), 28.3 (C(CH3)3 × 2), 27.3 (C5a-CH3) 26.7 (C8), 24.2 (C5b-CH3);  νmax/ 
cm-1 (oil): 2850, 1700, 1390, 1252, 1030; m/z (ES): (Found: MH+, 732.4394. 
C41H58BN3O8 requires MH, 732.4397). [α]D = − 65.6° (c 0.50, CHCl3). 
Synthesis of 3-[(2R)-2-borono-2-(4-(1-piperazinylmethyl)benzoylamino)-
ethyl]-2-hydroxy-benzoic acid hydrochloride. (5.14) 
Preparation was via general 
method G using 2-methoxy-3-
[(2R)-2-((4-Boc-piperazinylmethyl)-
benzoylamino)-2-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-
1,3,2-benzodioxaborol-2-yl]-ethyl] benzoic acid tert-butyl ester (5.28) (50 mg, 
0.07 mmol) to afford the title compound (5.14) as an off-white glassy solid 
which was used without further purification (0.7 mg, 2.00 µmol, 2%). m.p.: 
36.3-37.6 °C; Rf: 0.08 (9:1 DCM−MeOH); δH (500 MHz, MeOD-d4): 8.28 (1H, 
brs, CONH), 7.75-7.70 (2H, app. m, 6’-H and 2’-H), 7.61 (1H, d, J 7.6, 6-H), 
7.44-7.36 (2H, app. m, 5’-H and 3’-H), 7.23-7.18 (1H, app. m, 4-H), 6.84-
6.78 (1H, app. m, 5-H), 4.47 (2H, brs, B(OH)2), 3.55 (2H, s, CH2N), 3.36 (1H, 
brs, CHN), 3.13-3.04 (4H, m, 5’’-H and 3’’-H), 2.96 (2H, app. s, CH2), 2.58-
2.50 (4H, m, 6’’-H and 2’’-H); νmax/ cm
-1 (solid): 3358, 1670, 1610, 1478, 
1018; m/z (ES): (Found: [M-H2O+H]
+, 410.1891. C21H26BN3O6 requires [M-
H2O+H], 410.1895. [α]D = − 46.0° (c 0.05, MeOH). 
Synthesis of 3-[(2R)-2-[((Boc-ethylamine)methyl)-benzoylamino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]-ethyl]-2-methoxy benzoic acid tert-butyl ester. 
(5.29) 
Preparation was via 
general method F 
using 3-[(2R)-2-[4-
(bromomethyl)-
benzoylamino]-2-
[(3aS,4S,6S,7aR)-
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3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]-ethyl]-2-
methoxy benzoic acid tert-butyl ester (5.25) (0.60 g, 0.96 mmol) and N-Boc-
ethylenediamine (0.15 g, 0.96 mmol) to afford the title compound (5.29) as a 
pale brown oil which was used without further purification (0.12 g, 0.17 
mmol, 18%). Rf: 0.18 (3:1 Hexane−EtOAc); δH (500MHz, CDCl3): 7.67 (2H, 
d, J 7.6, 6’-HAr and 2’-HAr), 7.51 (1H, dd, J 6.5 and 1.3, 6-HAr), 7.36 (2H, d, 
J 7.6, 5’-HAr and 3’-HAr), 7.29 (1H, dd, J 6.5 and 1.3, 4-HAr), 7.01 (1H, app. 
t, J 6.5, 5-HAr), 5.86 (1H, brs, BOCNH), 4.20 (1H, d, J 7.7, 7a-H), 3.99 (2H, 
s, ArCH2NH), 3.76 (3H, s, OCH3), 3.26 (2H, d, J 5.5, CH2C), 3.10 (1H, brs, 
NH), 2.95-2.85 (4H, m, HNCH2 and CH2NH), 2.31-2.24 (1H, m, 7*-H), 2.13-
2.06 (1H, m, 8-H), 1.96-1.91 (1H, m, 6-H), 1.85-1.77 (2H, m, 7*-H and 4-H), 
1.54 (9H, s, C(CH3)3), 1.41 (1H, d, J 7.4, 8-H), 1.34 (3H, s, C3-CH3), 1.30 
(9H, s, BOC C(CH3)3), 1.20 (3H, s, C5a-CH3), 0.78 (3H, s, C5b-CH3); δC 
(100MHz, CDCl3): 169.8 (NHC=O), 166.3 (BOC C=O), 165.9 (C=O), 157.8 
(C2-Ar), 135.3 (C1’-Ar), 134.6 (C6-Ar), 130.0 (C6’-Ar and C2’-Ar), 129.9 (C3-
Ar), 129.7 (C4-Ar), 128.5 (C5’-Ar and C3’-Ar), 126.8 (C1-Ar), 124.0 (C5-Ar), 
84.0 (C3a), 81.5 (C(CH3)3 × 2), 76.7 (C7a), 62.2(OCH3), 52.2 (C4), 50.6 
(CH2NH), 47.4 (CH2NH), 45.0 (brs HCN), 40.1 (C6), 38.2 (C5), 36.4 (CH2C), 
32.4 (ArCH2NH), 29.1 (C3-CH3), 28.3 (C(CH3)3 × 2), 27.3 (C5a-CH3), 24.2 
(C5b-CH3); νmax/ cm
-1 (oil): 2920, 2914, 1700, 1652, 1080, 730 m/z (ES): 
(Found: MH+, 706.4222. C39H56BN3O8 requires MH, 706.4240). [α]D = − 
147.0° (c 0.50, CHCl3). 
Synthesis of 3-[(2R)- 2-[(4-(2-amino-ethylamino)-methyl)benzoylamino]-
2-borono-ethyl]-2-hydroxy-benzoic acid hydrochloride. (5.15) 
Preparation was via general 
method G using 3-[(2R)-2-
((Boc-ethylamine)-
benzoylamino)-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]-ethyl]-2-methoxy benzoic acid tert-butyl ester (5.29) 
(0.10 g, 0.14 mmol) to afford the title compound (5.15) as a yellow glassy 
solid which was used without further purification (0.5 mg, 1.00 µmol, 1%). 
m.p.: 44.7-45.9 °C; Rf: 0.12 (9:1 DCM−MeOH); δH (500 MHz, MeOD-d4): 
8.28 (1H, brs, CONH), 7.75-7.71 (2H, app. m, 6’-H and 2’-H), 7.70 (1H, d, J 
- 177 - 
7.6, 6-H), 7.44-7.41 (2H, m, 5’-H and 3’-H), 7.24-7.18 (1H, app. m, 4-H), 
6.84-6.78 (1H, app. m, 5-H), 4.47 (2H, brs, B(OH)2), 3.75 (2H, s, CH2N), 
3.39 (1H, app. s, NCH), 2.96 (2H, app. s, CH2Ar), 2.86 (2H, app. t, J 5.7, 
Ethyl CH2), 2.68 (2H, app. t, J 5.7, Ethyl-CH2); νmax/ cm
-1 (solid): 2892, 1717, 
1662, 1530, 1389, 921; m/z (ES): (Found: [M-H2O+H]
+, 384.1725. 
C19H24BN3O6 requires [M-H2O+H], 384.1729. [α]D = − 15.4 ° (c 0.10, MeOH). 
Synthesis of 3-[(2R)-2-[4-(tert-Butoxycarbonylamino-methyl)-cyclohexyl 
formamido]-2-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-
1,3,2-benzodioxaborol-2-yl]-ethyl]-2-methoxy-benzoic acid tert-butyl 
ester. (5.26) 
Preparation was via general 
method E using 4-BOC 
aminomethylcyclohexyl 
carboxylic acid (0.36 g, 1.40 
mmol)  and 2-methoxy-3-
((2R)-2-
[bis(trimethylsilyl)amino]-2-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-
methano-1,3,2-benzodioxaborol-2-yl]ethyl) benzoic acid tert-butly ester 
(5.10) (0.80 g, 1.40 mmol) to afford the title compound (5.26) as a colourless 
oil which was used without further purification (0.15 g, 0.22 mmol, 16%). Rf: 
0.18 (3:1 Hexane−EtOAc); δH (500 MHz, CDCl3): 7.58 (1H, dd, J 7.9 and 1.4, 
6-HAr), 7.32 (1H, dd, J 7.9 and 1.4, 4-HAr), 7.08 (1H, app. t, J 7.9, 5-HAr), 
6.85 (1H, brs, CONH), 4.56 (1H, brs, BOC NH), 4.23 (1H, d, J 6.0, 7a-H), 
3.81 (3H, s, OCH3), 2.97 (2H, t, J 7.1, CH2NH), 2.84 (2H, d, J 8.9, CH2C), 
2.39-2.32 (1H, m, 7*-H), 2.20-2.11 (2H, m, 8-H and 1’-H), 2.03-1.99 (1H, m, 
6-H), 1.97-1.80 (6H, m, 7*-H, 4-H, 6’-H and 2’-H), 1.65-1.63 (1H, m, 4’-H), 
1.61 (9H, s, C(CH3)3) 1.50 (1H, d, J 7.7, 8-H), 1.46 (9H, s, CH3 BOC), 1.48-
1.37 (4H, m, 5’-H and 3’-H), 1.40 (3H, s, C3-CH3), 1.28 (3H, s, C5a-CH3), 
0.89 (3H, s, C5b-CH3); δC (100MHz, CDCl3): 179.3 (HNC=O), 165.8 
(tBuOC=O), 157.7 (C2-Ar), 156.0 (BOC C=O), 135.6 (C1-Ar), 134.5 (C6-Ar), 
129.5 (C4-Ar), 127.1 (C3-Ar), 123.8 (C5-Ar), 83.5 (C3), 81.3 (C(CH3)3 × 2), 
76.4 (C7a), 62.0 (OCH3), 52.6 (C4), 46.4 (CH2N), 45.0 (NCH), 41.4 (C1’), 
40.3 (C6), 38.2 (C5), 37.8 (C4’), 36.8 (CH2C), 32.5 (C7), 29.6 (C6’ and C2’), 
29.4 (C3-CH3), 28.4 (BOC C(CH3)3), 28.3 (C5’ and C3’), 28.2 (C(CH3)3), 27.4 
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(C5a-CH3), 26.6 (C8), 24.1 (C5b-CH3); νmax/ cm
-1 (oil): 2973, 2925, 1698, 
1365, 1228; HPLC: Tr= 3.11 (100% rel. area); m/z (ES): (Found: MH
+, 
669.4285. C37H57BN2O8 requires MH, 669.4287). [α]D = − 9.04° (c 0.50, 
CHCl3). 
Synthesis of 3-[(2R)-2-[4-(aminomethyl)-cyclohexylformido]-2-borono-
ethyl]-2-hydroxy-benzoic acid hydrochloride. (5.17) 
Preparation was via general method G 
using 3-[(2R)-2-[4-(tert-
Butoxycarbonylamino-methyl)-
cyclohexyl formamido]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]-ethyl]-2-methoxy-benzoic acid tert-butyl ester (5.26) 
(50 mg, 0.07 mmol) to afford the title compound (5.17) as a colourless solid 
which was used without further purification (2.2 mg, 0.01 mmol, 8%). m.p.: 
49.2-50.1 °C; Rf: 0.05 (9:1 DCM−MeOH); δH (500 MHz, MeOD-d4): 8.36 (1H, 
brs, HNC=O), 7.71 (1H, app. s, 6-HAr), 7.20 (1H, app. s, 4-HAr), 6.86 (1H, 
app. s, 5-HAr), 4.47 (2H, brs, B(OH)2), 3.16 (1H, brs, HCN), 2.83 (2H, s, 
CH2), 2.67 (2H, dd, J 7.0 and 1.8, CH2NH2), 2.19 (1H, app. s, 1’-H), 1.74-
1.63 (4H, m, 6’-H and 2’-H), 1.50-1.43 (1H, m, 4’-H), 1.35-1.20 (2H, m, 5a’-H 
and 3a’-H), 0.95-0.87 (2H, m, 5b’-H and 3b’-H); νmax/ cm
-1 (solid): 2928, 
2858, 1718, 1595, 1427, 1227; m/z (ES): (Found: [M-H2O+H]
+, 347.1782. 
C17H25BN2O6 requires [M-H2O+H], 347.1776. [α]D = − 46.0 ° (c 0.10, MeOH). 
Synthesis of 3-[(2R)-2-[cyclohexylformamido]-2-[(3aS,4S,6S,7aR)-
3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]-
ethyl]-2-methoxy-benzoic acid tert-butyl ester. (5.27) 
 Preparation was via general method E 
using cyclohexane carboxylic acid (0.24 g, 
1.80 mmol)  and 2-methoxy-3-((2R)-2-
[bis(trimethylsilyl)amino]-2-
[(3aS,4S,6S,7aR)-3a,5,5-
trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]ethyl) benzoic 
acid tert-butly ester (5.10) (1.25 g, 2.20 mmol) to yield the title compound 
(5.27) as a yellow glassy solid (0.14 g, 0.26 mmol, 14%); m.p.: 135-138 °C; 
Rf: 0.16 (3:1 Hexane–EtOAc); δH (500 MHz, CDCl3): 8.04 (1H, s, NH), 7.63 
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(1H, dd, J 7.7, 1.6, 6-HAr), 7.37 (1H, dd, J 7.7, 1.6, 4-HAr), 7.12 (1H, app. t, 
J 7.7, 5-HAr), 4.30 (1H, d, J 6.5, 7a-H), 3.85 (3H, s, OCH3), 2.92-2.87 (3H, 
m, CH2C and NCH), 2.39 (1H, t, J 2.5, 1`-H), 2.32-2.30 (1H, m, 7*-H), 2.21-
2.18 (2H, m, 2`-H, 6`-H), 2.07 (1H, t, J 3.3, 16-H), 1.94-1.90 (4H, m, 2`-H, 
3`H, 5`-H, 6`H), 1.81 (2H, d, J 12.5, 6-H, 8-H), 1.72-1.69 (1H, m, 7*-H), 1.64 
(9H, s, C(CH3)3), 1.56 (1H, d, J 10.1, 4`-H), 1.46 (3H, s, C3-CH3), 1.40 (1H, 
d, J 6.8, 8-H), 1.32 (3H, s, C5a-CH3), 1.30-1.25 (2H, m, 5’-H and 3’-H), 1.25-
1.20 (1H, m, 4`H), 0.91 (3H, s, C5b-CH3); δC (125 MHz, CDCl3): 180.5 
(NHC=O), 165.0 (C=O), 158.0 (C2-Ar), 136.0 (C1-Ar), 134.7 (C6-Ar), 129.7 
(C4-Ar), 127.5 (C3-Ar), 124.1 (C5-Ar), 83.1 (C3a), 81.5 (C(CH3)), 77.3 (C4), 
76.3 (C7a), 62.2 (OCH3), 52.6 (C4), 45.0 (brs, NCH), 40.5 (C1`), 40.3 (C6), 
38.2 (C5), 37.0 (CH2), 32.8 (C7*), 29.2 (C3-CH3), 28.8 (C6` and C2`), 28.2 
(C(CH3)3), 27.4 (C5a-CH3), 26.7 (C4), 25.5 (C5`, C4’ and C3`), 24.2 (C5b-
CH3); νmax/ cm
-1 (solid): 3197, 3072, 2975, 2929. 2896, 2856, 1717, 1590; 
m/z (ES): (Found: MH+, 540.3513. C31H46BNO6 requires MH, 540.3513). [α]D 
= + 10.2° (c 0.50, CHCl3). 
Synthesis of 3-[(2R)-2-borono-2-[cyclohexylformido]-ethyl]-2-hydroxy-
benzoic acid hydrochloride. (5.18) 
Preparation was via general method G using 
3-[(2R)-2-[cyclohexylformamido]-2-
[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-
4,6-methano-1,3,2-benzodioxaborol-2-yl]-ethyl]-2-methoxy-benzoic acid tert-
butyl ester (5.27) (50 mg, 0.08 mmol) to afford the title compound (5.18) as a 
colourless solid which was used without further purification (1.9 mg, 0.01 
mmol, 7%). m.p.: > 250 °C; Rf: 0.08 (9:1 DCM−MeOH); δH (500 MHz, MeOD-
d4): 7.64 (1H, d, J 7.6, 6-HAr), 7.12 (1H, d, J 7.6, 4-HAr), 6.78 (1H, app. t, J 
7.6, 5-HAr), 3.07 (1H, app. s, NCH), 2.73 (2H, dd, J 15.5 and 7.1, CH2), 
2.16-2.08 (1H, m, 1-H), 1.45-1.30 (4H, m, 6-H and 2-H), 1.23-1.15 (2H, m, 4-
H), 1.11-0.92 (4H, m, 5-H and 3-H); δC (125 MHz, MeOD-d4): 185.0 
(NHC=O), 169.1 (COOH), 157.2 (C2-Ar), 136.4 (C4-Ar), 131.1 (C6-Ar), 
129.1 (C3-Ar), 122.2 (C5-Ar), 118.6 (C1-Ar), 45.0 (br, NCH), 40.1 (C1), 32.3 
(CH2), 29.5 (C6 and C2), 26.2 (C4), 25.6 (C5 and C3); νmax/ cm
-1 (solid): 
2929, 2855, 1713, 1596, 1185; HPLC: Tr= 1.78 (90% rel. area); m/z (ES): 
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(Found: [M-H2O+H]
+, 318.1516. C16H22BNO6 requires [M-H2O+H], 318.1510. 
[α]D = − 32.0° (c 0.10, MeOH). 
10.5 Peptide synthesis 
10.5.1 General procedure for oligomer formation-single coupling 
Fmoc-protected pre-loaded Wang resin was loaded onto a CEM microwave 
peptide synthesizer after being swelled for a total of 30 min in DMF. A series 
of washes (3 × DMF), deprotection (2 × 20% Piperidine/DMF, total of 10 min 
at rt) and further washes (5 × DMF) prepared the resin for coupling. Fmoc 
protected amino acids were dissolved in DMF, delivered to the reaction 
vessel and reacted with HCTU and DIPEA at room temperature for 90 min.  
Each trimer peptide was then deprotected (5 × 20% Piperidine/DMF, total 10 
min at room temperature), washed (5 × DMF, total 10 min at rt, 5 × DCM, 
total 10 min at room temperature and 3 × MeOH, total 6 min at rt) and 
cleaved from the resin (2 × Reagent K (87% TFA, 3% 1,2-ethanedithiol, 5% 
thioanisol, and 5% H2O),  3 h total at room temperature). The resulting 
solution was concentrated in vacuo and triturated with ether to afford the 
desired crude peptide. 
Peptides were purified by mass directed HPLC eluting with 5-95% MeOH in 
water.   
10.5.2 (L)-Amino acid trimers 
Pro-Ile-Cys (6.5)  
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.5) was formed as 
colourless microcrystals (6.5 mg, 0.02 mmol, 13%). 
m.p.: 210.2 °C (depcomp); Rf: 0.05 (19:1 
DCM−MeOH); δH (500 MHz, D2O): 4.38 (1H, t, J 7.4, 
PRO-CH), 4.32 (1H, t, J 6.1, CYS-CH), 4.18 (1H, d, J 7.8, ILE-CH), 3.42-
3.38 (1H, m, PRO-5a-H), 3.38-3.31 (1H, m, PRO-5b-H), 2.86 (2H, dd, J 14.0 
and 5.4, CH2SH), 2.48-2.36 (1H, m, PRO-3a-H), 2.19-1.95 (3H, m, PRO-4-H 
and PRO-3b-H), 1.85 (1H, m, CH-CH3), 1.45-1.40 (1H, m, CH2-CH3), 1.24-
1.12 (1H, m, CH2-CH3), 0.90 (3H, d, J 6.8, CH3), 0.83 (3H, t, J 7.4, CH3-
CH2); δC (75 MHz, D2O): 175.7 (PRO C=O), 172.5 (ILE C=O), 169.7 (CYS 
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C=O), 59.6 (PRO-CH), 59.2 (ILE-CH), 56.5 (CYS-CH) 46.6 (C5), 35.8 (CH-
CH3), 29.9 (C3), 26.3 (CH2SH), 24.6 (C4) 23.7 (CH2-CH3), 14.8 (CH3-CH), 
10.2 (CH3-CH2); νmax/ cm
-1 (solid): 3093, 2968, 2875, 1750, 1640, 1420; m/z 
(ES): (Found: MH+, 332.1639. C14H25N3O4S requires MH, 332.1639). [α]D = 
− 41.1° (c 0.10, H2O). 
Asn-Pro-Cys (6.6)  
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.6) was formed 
as a pale yellow oil (14 mg, 0.04 mmol, 27%). Rf: 0.04 
(19:1 DCM−MeOH); δH (500 MHz, D2O): 4.65 (1H, 
dd, J 6.8 and 4.3, ASN-CH), 4.58 (1H, dd, J 6.8 and 
4.8, CYS-CH), 4.55-4.44 (1H, m, PRO-CH), 3.72-3.60 
(2H, m, PRO-5-H), 3.38 (1H, dd, J 14.1 and 4.3, ASN-CH2-C=Oa), 3.05 (1H, 
m, CH2-SHa), 3.00 (1H, dd, J 14.1 and 4.3, ASN-CH2-C=Ob) 2.80 (1H, dd, J 
14.1 and 6.8, CH2-SHb), 2.29 (1H, t, J 19.1 PRO-3a-H), 2.19-1.93 (3H, m, 
PRO-4-H and PRO-3b-H); δC (125 MHz, D2O): 174.0 (ASN C=O), 173.7 
(C=O-NH2), 172.8 (CYS C=O), 167.7 (PRO C=O), 60.8 (PRO-CH), 52.2 
(CYS-CH), 48.8 (ASN-CH), 48.0 (C5), 38.5 (CH2-C=O), 34.3 (CH2SH), 29.4 
(C3), 24.6 (C4); νmax/ cm
-1 (oil): 3200, 2950, 1630, 1240; m/z (ES): (Found: 
MH+, 333.1229. C12H20N4O5S requires MH, 333.1227). [α]D = + 200.8° (c 
0.10, H2O). 
Pro-Pro-Cys (6.7) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.7) was formed 
as a dark yellow oil (6.2 mg, 0.02 mmol, 12%). Rf: 
0.07 (19:1 DCM−MeOH). δH (500 MHz, D2O): 4.65-
4.55 (1H, m, PRO-CH) 4.55-4.45 (1H, m, PRO-CH’), 
4.45-4.35 (1H, m, CYS-CH), 4.10 (1H, m, PRO-5a’-H), 3.70-3.00 (5H, m, 
PRO-5b’-H, PRO-5-H and CH2SH) 2.58-2.47 (1H, m, PRO-3a-H), 2.35-2.15 
(2H, m, PRO-3b-H and PRO-3a’-H), 2.12-1.80 (5H, m, PRO-4-H, PRO-4’-H 
and PRO-3b’-H); δC (125 MHz, D2O): 168.5 (PRO C=O and CYS C=O), 60.8 
(PRO-CH), 59.3 (CYS-CH), 45.6 (C5), 27.3 (CH2SH and C3), 22.8 (C4); 
νmax/ cm
-1 (oil): 3400, 2950, 2900, 1675, 1490; m/z (ES): (Found: MH+, 
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316.1327. C13H21N3O4S requires MH, 316.1326). [α]D = + 187.6° (c 0.10, 
H2O).  
Pro-Trp-Cys (6.8) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.8) was formed 
as a pale brown oil (26 mg, 0.07 mmol, 14%). Rf: 
0.07 (19:1 DCM−MeOH). δH (500 MHz, D2O): 7.39 
(1H, d, J 7.8, 4’-H), 7.23 (1H, d, J 8.7, 7’-H), 7.18-
6.95 (3H, m, 6’-H, 5’-H and 2’-H), 4.68-4.53 (1H, m, TRP-CH), 4.54-4.39 
(1H, m, CYS-CH), 4.19 (1H, dd, J 20.1 and 14.1, PRO-CH), 3.26-2.68 (6H, 
m, CH2Ar, CH2SH and PRO-5-H), 2.41-2.17 (1H, m, PRO-3a-H), 2.10-1.71 
(3H, m, PRO-4-H and PRO-3b-H); δC (75 MHz, D2O): 172.6 (PRO-C=O), 
168.9 (TRP-C=O), 163.0 (CYS-C=O), 136.2 (C8’), 129.8 (C2’), 126.7 (C9’), 
124.5 (C6’), 121.9 (C5’), 118.2 (C4’), 111.9 (C7’), 108.5 (C3’), 59.5 (TRP-CH 
and PRO-CH), 55.0 (CYS-CH), 46.8 (C5), 37.9 (C3), 29.8 (CH2SH), 27.0 
(C4), 23.6 (CH2Ar); νmax/ cm
-1 (oil): 3330, 2950, 1675, 1210; LCMS: (Tr = 
1.32, m/z (ES): (Found: MH+, 404.6. C19H24N4O4S requires MH, 404.6)). [α]D 
= + 220.1° (c 0.10, H2O). 
Pro-Cys-Phe (6.9) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.9) was 
formed as colourless microcrystals (2.7 mg, 0.01 
mmol, 5%). m.p.: 219.3 °C (decomp.); Rf: 0.05 
(19:1 DCM−MeOH). δH (500 MHz, D2O): 7.30 (2H, 
app. t, J 6.4, 5’-H and 3’-H), 7.25 (1H, t, J 6.4, 4’-H), 7.20 (2H, d, J 6.4, 6’-H 
and 2’-H), 4.75-4.66 (1H, m, CYS-CH), 4.59-4.45 (1H, m, PHE-CH), 4.35-
4.28 (1H, m, PRO-CH), 3.42-3.26 (2H, m, PRO-5-H), 3.25-3.09 (2H, m, 
CH2Ar), 2.98-2.76 (1H, m, CH2SHa), 2.74-2.69 (1H, m, CH2SHb), 2.35-2.25 
(1H, m, PRO-3a-H), 1.98-1.87 (2H, m, PRO-4-H), 1.82 (1H, dd, J 13.3 and 
6.7, PRO-3-Hb); δC (125 MHz, D2O): 170.5 (PRO-C=O), 170.3 (PHE-C=O), 
169.3 (CYS-C=O), 137.1 (C1’), 129.4 (C6’ and C2’), 128.7 (C5’ and C3’), 
127.0 (C4’), 59.8 (PRO-CH), 59.7 (CYS-CH), 51.0 (PHE-CH), 46.6 (C5), 
38.9 (CH2Ar), 29.9 (C3), 25.3 (CH2SH), 23.9 (C4); νmax/ cm
-1 (solid): 3350, 
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3100, 2995, 2495, 1650, 1590, 1470; m/z (ES): (Found: MH+, 366.1490. 
C17H23N3O4S requires MH, 366.1482. [α]D = + 180.8° (c 0.10, H2O). 
Cys-Pro-Phe (6.10) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.10) was 
formed as colourless microcrystals (1.2 mg, 3.29 
µmol, 2%). m.p: 145.4-146.9 °C Rf:  0.05 (19:1 
DCM−MeOH). δH (500 MHz, D2O): 7.36 (2H, t, J 
7.4, 3’-H and 5’-H), 7.30 (1H, t, J 7.4, 4’-H), 7.26 
(2H, app. t, J 7.4, 6’-H and 2’-H), 4.59 (1H, s, PHE-CH), 4.33-4.24 (1H, m, 
PRO-CH), 4.00-3.86 (1H, m, CYS-CH), 3.50 (2H, dd, J 18.0 and 8.5 PRO-5-
H), 3.58-3.42 (3H, m, CH2Ar and CH2SHa), 3.06 (1H, dd, J 14.0 and 8.0, 
CH2HSb), 2.33-2.27 (1H, m, PRO-3a-H), 2.05-1.98 (1H, m, PRO-3b-H), 1.88 
(2H, dd, J 20.9 and 8.5, PRO-4-H); δC (75 MHz, D2O): 170.0 (PRO-C=O), 
171.7 (PHE-C=O), 165.7 (CYS-C=O), 135.2 (C1’), 129.5 (C6’ and C2’), 
129.2 (C5’ and C3’), 127.8 (C4’), 59.2 (PRO-CH), 56.2 (CYS-CH), 55.0 
(PHE-CH), 45.7 (C5), 39.6 (CH2Ar), 36.4 (C3), 28.3 (CH2SH), 21.8 (C4); 
νmax/ cm
-1 (solid): 3420, 3250, 3110, 1620, 1430; m/z (ES): (Found: MH+, 
366.1484. C17H23N3O4S requires MH, 366.1482). [α]D = + 476.8° (c 0.10, 
H2O). 
Cys-Gly-Trp (6.11) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.11) was formed as 
colourless microcrystals (8.0 mg, 0.02 mmol, 16%). Rf: 
0.13 (19:1 DCM−MeOH). δH (500 MHz, D2O): 7.57 (1H, 
dd, J 20.2 and 7.7, 4-H), 7.41 (1H, d, J 24.7 and 8.1, 7-H) 
7.23-7.02 (3H, m, 6-H, 5-H and 2-H), 4.78-4.70 (1H, m, 
GLY-CH2), 4.54 (1H, dd, J 7.2 and 5.5, TRP-CH), 4.20 
(1H, dd, J 7.5 and 5.8, CYS-CH), 3.35-3.24 (1H, m 
CH2Ara), 3.22-3.08 (2H, m, CH2Arb and CH2SHa), 2.98 (1H, d, J 5.8 
CH2SHb); δC (125 MHz, D2O): 176.5 (CYS-C=O), 169.8 (GLY-C=O), 168.4 
(TRP-C=O), 136.2 (C8), 127.2 (C9), 124.5 (C2), 121.9 (C6), 119.4 (C5), 
118.5 (C4), 112.0 (C7), 109.5 (C3), 54.8 (CYS-CH), 54.4 (TRP-CH), 42.4 
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(GLY-CH2), 27.1 (CH2Ar) 24.8 (CH2SH); νmax/ cm
-1 (solid): 3255, 3000, 2500, 
1600, 1530, 1500, 1420; m/z (ES): (Found: MH+, 365.1275. C16H20N4O4S 
requires MH, 365.1239). [α]D = + 604.7° (c 0.10, H2O). 
Cys-Pro-Trp (6.12) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.12) was formed 
as a purple oil (13 mg, 0.03 mmol, 26%). Rf: 0.10 (19:1 
DCM−MeOH). δH (500 MHz, D2O): 7.58 (1H, dd, J 20.8 
and 7.6, 4’-H), 7.40 (1H, dd, J 16.4 and 7.4, 7’-H), 7.24-
6.98 (3H, m, 5’-H, 6’-H and 2’-H), 4.70-4.59 (1H, m, 
CYS-CH), 4.58-4.49 (1H, m, TRP-CH), 4.48-4.36 (1H, 
m, PRO-CH), 3.64-3.57 (1H, m, 5-Ha), 3.45-3.05 (4H, m. 5-Hb, CH2Ar and 
CH2SHa), 2.95-2.86 (1H, m, CH2SHb), 2.23-2.04 (1H, m, 3-Ha), 1.98-1.77 
(2H, m, 4-H), 1.77-1.72 (1H, m, 3-Hb); δC (75 MHz, D2O): 175.2 (TRP-C=O), 
174.3 (PRO-C=O), 166.6 (CYS-CH), 136.2 (C8’), 129.8 (C2’), 126.9 (C9’), 
121.9 (C6’), 119.3 (C5’), 111.9 (C7’), 108.9 (C3’), 60.7 (CYS-CH and PRO-
CH), 50.8 (TRP-CH), 47.9 (C5), 38.0 (CH2Ar), 29.0 (C3), 26.6 (CH2SH), 24.5 
(C4); νmax/ cm
-1 (oil): 3400, 2890, 1670, 1500, 1220; LCMS: (Tr = 1.40, m/z 
(ES): (Found: MH+, 404.1. C19H24N4O4S requires MH, 404.1)). [α]D = + 
194.4° (c 0.10, H2O). 
Cys-Phe-Tyr (6.13) 
Preparation was via the general method outlined 
in Section 10.5.1. The title compound (6.13) was 
formed as colourless microcrystals (12 mg, 0.03 
mmol, 23%). Rf: 0.12 (19:1 DCM−MeOH). δH (500 
MHz, D2O): 8.24 (1H, brs, COOH), 7.26 (2H, app. 
t, J 7.4, 5-H and 3-H), 7.25 (1H, t, J 7.4, 4-H), 7.20 
(2H, d, J 7.4, 6-H and 2-H), 7.01 (2H, d, J 8.3, 6’-H and 2’-H), 6.72 (2H, d, J 
8.3, 5’-H and 3’-H), 4.87 (1H, t, J 7.6, PHE-CH), 4.40 (1H, dd, J 8.9 and 4.8, 
CYS-CH), 4.00 (1H, t, J 5.7, TYR-CH), 2.92-2.71 (6H, m, PHE-CH2, TYR-
CH2 and CYS-CH2), 2.65 (1H, s, SH); δC (75 MHz, D2O): 175.7 (PHE C=O), 
171.6 (TYR C=O), 167.3 (CYS C=O),154.2 (C4’), 136.2 (C1), 130.6 (C6’ and 
C2’), 129.1 (C6 and C2), 128.8 (C1’), 128.8 (C5 and C3), 127.2 (C4), 115.3 
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(C3’ and C5’), 55.2 (PHE-CH), 55.0 (CYS-CH), 54.1 (TYR-CH), 37.0 (PHE-
CH2), 36.5 (TYR-CH2), 25.0 (CH2SH); νmax/ cm
-1 (solid): 3280, 3050, 2500, 
1600, 1510, 1220; m/z (ES): (Found: MH+, 432.1584. C21H25N3O5S requires 
MH, 432.1587). [α]D = + 310.0° (c 0.10, H2O). 
Cys-Pro-Tyr (6.14) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.14) was 
formed as colourless microcrystals (16 mg, 0.04 
mmol, 33%). m.p.: 157.3-154.2 °C Rf: 0.09 (19:1 
DCM−MeOH). δH (500 MHz, D2O): 7.07 (2H, dd, J 
7.4 and 2.1, 5’-H and 3’-H), 6.79 (2H, dd, J 7.4 and 
2.1, 6’-H and 2’-H), 4.63 (1H, d, J 6.5, CYS-CH), 
4.47 (1H, t, J 6.8, TYR-CH), 4.45-4.40 (1H, m, PRO-CH), 3.75-3.63 (1H, m, 
PRO-5a-H), 3.63-3.49 (1H, m, PRO-5b-H), 3.38 (1H, dd, J 14.9 and 3.4, 
CH2SHa), 3.10-2.81 (3H, m, CH2Ar and CH2SHb), 2.18 (1H, dt, J 12.4 and 
6.1, PRO-3a-H), 1.98-1.84 (2H, m, PRO-4-H), 1.78 (1H, dt, J 12.4 and 6.1, 
PRO-3b-H); δC (75 MHz, D2O): 175.2 (TYR-C=O), 172.8 (PRO-C=O), 166.7 
(CYS-C=O), 154.4 (C4’), 130.6 (C6’ and C2’), 128.3 (C1’), 115.4 (C5’ and 
C3’), 60.8 (PRO-CH), 54.6 (CYS-CH), 50.8 (TYR-CH), 47.9 (C5), 38.7 (C3), 
35.8 (CH2), 29.2 (C4), 24.5 (CH2SH); νmax/ cm
-1 (solid): 3420, 3050, 2500, 
1670, 1500, 1250; m/z (ES): (Found: MH+, 382.1432. C17H23N3O5S requires 
MH, 382.1431). [α]D = + 238.8° (c 0.10, H2O). 
Cys-Arg-Arg (6.15) 
Preparation was via the general 
method outlined in Section 10.5.1. 
The title compound (6.15) was 
formed as a colourless oil (6.1 mg, 
0.02 mmol, 12%). Rf: 0.02 (19:1 
DCM−MeOH). δH (500 MHz, D2O): 
4.40-4.31 (2H, m, CYS-CH and ARG-CH), 4.29-4.19 (1H, m, ARG-CH), 3.35 
(1H, dd, J 14.0 and 6.4, CH2SHa), 3.21-3.17 (4H, m, CH2NH × 2), 3.17-3.09 
(1H, m, CH2SHb), 1.91-1.78 (2H, m, ARG-CH-CH2), 1.78-1.66 (2H, m, ARG-
CH-CH2), 1.66-1.54 (4H, m, CH2CH2CH2 × 2); δC (75 MHz, D2O): 173.0 
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(ARG C=O), 172.4 (ARG C=O), 167.9 (CYS C=O), 156.9 (ARG-CN3 × 2), 
53.6 (CYS-CH), 53.0 (ARG-CH), 51.8 (ARG-CH), 40.6 (CH2NH ×2), 28.5 
(CHCH2), 27.9 (CHCH2), 24.7 (CH2SH), 24.4 (CH2CH2CH2 × 2); νmax/ cm
-1 
(oil): 3500-3000, 1670, 1440, 1190, 1100; m/z (ES): (Found: MH+, 433.2221. 
C15H31N9O4S requires MH, 433.2220). [α]D = + 430.8° (c 0.10, H2O). 
Arg-Cys-Arg (6.16) 
Preparation was via the general method 
outlined in Section 10.5.1. The title 
compound (6.16) was formed as a colourless 
oil (37 mg, 0.09 mmol, 74%). Rf: 0.03 (19:1 
DCM−MeOH). δH (500 MHz, D2O): 4.73-4.69 
(1H, m, CYS-CH), 4.40-4.28 (1H, m, ARG-
CH), 4.10-3.96 (1H, m, ARG-CH), 3.26-3.05 
(5H, m, CH2SHa and CH2NH × 2), 2.99 (1H, 
dd, J 14.3 and 8.6, CH2SHb), 1.98-1.83 (3H, m, ARG-CH-CH2 and ARG-CH-
CH2b) 1.82-1.69 (1H, m, ARG-CH-CH2a), 1.69-1.51 (4H, m, CH2CH2CH2 × 
2); δC (125 MHz, D2O): 175.0 (ARG-C=O), 171.4 (ARG-C=O), 169.6 (CYS-
C=O), 156.9 (ARG-CN3 × 2), 52.7 (ARG-CH and CYS-CH), 40.6 (CH2NH × 
2), 27.9 (CH2CH2CH × 2), 24.6 (CH2SH) 23.6 (CH2CH2CH2 × 2); νmax/ cm
-1 
(oil): 3500-3000, 2495, 1650, 1480, 1200, 1110; LCMS: (Tr = 0.13, m/z (ES): 
(Found: MH+, 434.2. C15H31N9O4S requires MH, 434.2)). [α]D = + 50.0° (c 
0.10, H2O). 
Gln-Cys-Arg (6.17) 
Preparation was via the general method 
outlined in Section 10.5.1. The title compound 
(6.17) was formed as a pale yellow oil (34 mg, 
0.08 mmol, 69%). Rf: 0.03 (19:1 DCM−MeOH). 
δH (500 MHz, D2O): 4.73-4.65 (1H, m, CYS-
CH), 4.45-4.28 (1H, m, ARG-CH), 4.12-4.00 
(1H, m, GLN-CH), 3.28-3.06 (3H, m, CH2NH 
and CH2SHa), 3.05-2.91 (1H, m, CH2SHb), 2.37 (1H, dt, J 10.2 and 6.9, 
CH2CONH2), 2.12 (1H, t, J 7.7, GLN-CH-CH2a), 2.07-1.96 (1H, m, GLN-CH-
CH2b), 1.96-1.84 (1H, m, ARG-CH-CH2a), 1.79-1.68 (1H, m, ARG-CH-
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CH2b), 1.68-1.50 2H, m, CH2CH2CH2); δC (75 MHz, D2O): 182.2 (CONH2), 
176.7 (GLN-C=O), 174.9 (ARG-C=O), 171.2 (CYS-C=O), 156.7 (ARG-CN3), 
56.7 (GLN-CH), 52.7 (CYS-CH), 52.3 (ARG-CH), 40.3 (CH2NH), 29.2 
(CH2CONH2), 27.2 (GLU-CH2CH), 26.6 (ARG-CH-CH2), 25.3 (CH2SH), 24.4 
(CH2CH2CH2); νmax/ cm
-1 (oil): 3250, 3020, 2500, 1600, 1220, 1200; m/z 
(ES): (mass not found). [α]D = + 40.1° (c 0.10, H2O). 
Lys-Cys-Arg (6.18) 
Preparation was via the general method 
outlined in Section 10.5.1. The title compound 
(6.18) was formed as a pale yellow oil (35 mg, 
70%). Rf: 0.02 (19:1 DCM−MeOH). δH (500 
MHz, D2O): 4.71-4.54 (1H, m, CYS-CH), 4.45-
4.24 (1H, m, ARG-CH), 4.11-3.93 (1H, m, LYS-
CH), 3.20-3.11 (3H, m, CH2SHa and CH2NH), 
3.05-2.85 (3H, m, CH2SHb and CH2NH2), 1.92-
1.81 (3H, m, LYS-CH2CH and ARG-CH-CH2a), 1.80-1.69 (1H, m, ARG-CH-
CH2b), 1.68-1.58 (4H, m, CH2CH2NH2 and CH2CH2NH), 1.47-1.30 (2H, m, 
LYS-CHCH2CH2); δC (75 MHz, D2O): 174.7(LYS-C=O), 171.3 (ARG-C=O), 
169.7 (CYS-C=O), 156.7 (ARG-CN3), 58.2-58.6 (ARG-CH, LYS-CH, CYS-
CH), 40.5 (CH2NH2), 39.0 (CH2NH), 30.4 (LYS-CH-CH2), 27.6 (ARG-CH2-
CH), 23.7 (ARG-CH2CH2CH2), 20.9 (LYS-CH2CH2CH2); νmax/ cm
-1 (oil): 3420, 
3005, 1670, 1220, 1190; LCMS: (Tr = 0.25, m/z (ES): (Found: MH+, 406.2. 
C15H31N7O4S requires MH, 406.2)). [α]D = + 73.4° (c 0.10, H2O). 
Asp-Cys-Asp (6.19) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.19) was formed as 
a colourless oil (36 mg, 0.10, mmol, 73%). Rf: 0.01 (19:1 
DCM−MeOH). δH (500 MHz, D2O): 4.71 (1H, d, J 7.5, 
ASP-CH), 4.67 (1H, dd, J 8.7 and 5.1, ASP-CH), 4.31 (1H, 
dd, J 12.1 and 7.2, CYS-CH), 3.17 (1H, dd, J 14.3 and 
5.1, CH2COOHa), 3.11-2.99 (2H, m, CH2SH) 2.99-2.84 
(3H, m, CH2COOHb and CH2COOH’); δC (75 MHz, D2O): 174.2 (ASP-C=O), 
173.5 (CYS-C=O), 171.5 (ASP-C=O), 170.9 (COOH), 170.8 (COOH), 52.5 
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(CYS-CH), 49.4 (ASP-CH), 49.2 (ASP-CH), 38.6 (CH2COOH), 34.1 
(CH2COOH), 33.7 (CH2SH); νmax/ cm
-1 (oil): 3400-2700, 1670, 1220, 1190, 
1000; m/z (ES): (Found: MH+, 352.0810. C11H17N3O8S requires MH, 
352.0809). [α]D = + 21.6° (c 0.10, H2O).  
Arg-Arg-Cys (6.20) 
Preparation was via the general method 
outlined in Section 10.5.1. The title 
compound (6.20) was formed as a pale 
brown oil (21 mg, 0.05 mmol, 41%). Rf: 0.01 
(19:1 DCM−MeOH). δH (500 MHz, D2O): 
4.71-4.63 (1H, m, CYS-CH), 4.37 (1H, t, J 
7.0, ARG-CH), 4.00 (1H, t, J 6.4 ARG-CH), 
3.25 (1H, dt, J 19.6 and 9.9, CH2SHa), 3.21-3.09 (4H, m, CH2NH × 2) 3.07-
2.89 (1H, m, CH2SHb), 1.89-1.77 (3H, m, ARG-CH2CH and ARG-CH-CH2a), 
1.77-1.68 (1H, m, ARG-CH-CH2b), 1.68-1.51 (4H, m, CH2CH2CH2 × 2); δC 
(75 MHz, D2O): 173.7 (ARG-C=O), 173.1 (ARG-C=O), 169.4 (CYS-C=O), 
156.9 (ARG CN3 × 2), 53.6 (CYS-CH), 52.6 (ARG-CH), 52.2 (ARG-CH), 40.7 
(CH2NH × 2), 28.3 (CH2CH × 2), 24.5 (CH2SH), 23.6 (CH2CH2CH2 × 2); νmax/ 
cm-1 (oil): 3400-2700, 1675, 1550, 1200; m/z (ES): (Found: [M+2H]2+, 
217.6187. C15H31N9O4S requires [M+2H]
2+, 217.6182). [α]D = + 139.5° (c 
0.10, H2O).  
Cys-Lys-Glu (6.21) 
Preparation was via the general method 
outlined in Section 10.5.1. The title 
compound (6.21) was formed as a 
colourless oil (16 mg, 0.04 mmol, 32%). 
Rf: 0.06 (19:1 DCM−MeOH). δH (500 
MHz D2O): 4.43-4.29 (3H, m, CYS-CH, LYS-CH and GLU-CH), 3.31 (1H, dd, 
J 14.9 and 5.1, CH2SHa), 3.11 (1H, dd, J 14.9 and 7.9, CH2SHb), 2.92 (2H, 
t, J 7.6, CH2NH2), 2.43 (2H, dt, J 13.9 and 8.5, CH2COOH), 2.15 (1H, td, J 
15.1 and 7.4, GLU-CH-CH2a), 1.94 (1H, dt, J 15.1 and 7.4, GLU-CH-CH2b), 
1.80-1.67 (2H, m, LYS-CH2CH), 1.63 (2H, app. t, J 7.4, CH2CH2NH2), 1.42-
1.36 (2H, m, CH2CH2CH); δC (75 MHz, D2O): 176.9 (GLU-C=O), 174.8 (LYS-
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C=O), 173.0 (COOH), 167.7 (CYS-C=O), 53.7 (LYS-CH), 52.0 (CYS-CH), 
51.5 (GLU-CH), 39.2 (CH2NH2), 37.4 (CH2COOH), 30.6 (LYS-CH-CH2), 29.8 
(NH2CH2CH2) 26.3 (GLU-CH-CH2), 25.7 (CH2SH), 21.8 (CH2CH2CH2); νmax/ 
cm-1 (oil): 3000, 1650, 1230, 1150; m/z (ES): (Found: MH+, 379.1649. 
C14H26N4O6S requires MH, 379.1646). [α]D = + 296.6° (c 0.10, H2O). 
Cys-Arg-Glu (6.22) 
Preparation was via the general method 
outlined in Section 10.5.1. The title 
compound (6.22) was formed as a  
colourless oil (23 mg, 0.06 mmol, 45%). Rf: 
0.04 (19:1 DCM−MeOH). δH (500 MHz D2O): 
4.44-4.31 (3H, m, CYS-CH, ARG-CH and 
GLU-CH), 3.32 (1H, dd, J 14.9 and 5.2, CH2SHa), 3.22-3.04 (3H, m, 
CH2SHb and CH2NH), 2.44 (2H, t, J 7.1, CH2COOH), 2.23-2.09 (1H, m, 
GLU-CH-CH2a), 2.05-1.86 (1H, m, GLU-CH-CH2b), 1.84-1.67 (2H, m, ARG-
CH-CH2), 1.661.55 (2H, m, CH2CH2NH); δC (75 MHz, D2O): 177.0 (GLU-
C=O), 175.0 (ARG-C=O), 172.7 (COOH), 167.7 (CYS-C=O), 156.7 (ARG-
CN3), 53.5 (ARG-CH), 52.2 (CYS-CH), 51.5 (GLU-CH), 40.5 (CH2NH), 37.4 
(CH2COOH), 30.0 (LYS-CH2-CH), 28.3 (NHCH2CH2) 25.8 (CH2SH), 24.2 
(GLU-CH2-CH); νmax/ cm
-1 (oil): 3300, 3050, 2600, 2480, 1670, 1460; m/z 
(ES): (Found: MH+, 407.1711. C14H26N6O6S requires MH, 407.1707). [α]D = 
+ 402.9° (c 0.10, H2O). 
Lys-Cys-Gln (6.23) 
Preparation was via the general method 
outlined in Section 10.5.1. The title 
compound (6.23) was formed as 
colourless microcrystals (1.3 mg, 3.45 
µmol, 3%). m.p.: 165.6-167.2 °C; Rf: 
0.14 (19:1 DCM−MeOH). δH (500 MHz, D2O): 4.77-4.63 (1H, m, CYS-CH), 
4.45-4.28 (1H, m, GLN-CH), 4.08-3.95 (1H, m, LYS-CH), 3.20 (1H, dd, J 
14.2 and 5.4, CH2SHa), 3.00 (1H, dd, J 14.2 and 5.4, CH2SHb), 2.95-2.86 
(2H, m, CH2NH2), 2.40-2.27 (2H, m, CH2CONH2), 2.21-2.12 (1H, m, GLN-
CH2CHa), 2.06-1.80 (1H, m, GLN-CH-CH2b), 1.87 (2H, dd, J 15.1 and 6.9, 
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LYS-CH-CH2), 1.72-1.57 (2H, m, CH2CH2NH2), 1.49-1.31 (2H, m, 
CH2CH2CH); δC (75 MHz, D2O): 177.9 (CON2), 174.4 (GLN-C=O), 171.2 
(LYS-C=O), 169.7 (CYS-C=O), 52.8 (LYS-CH and CYS-CH), 52.5 (GLN-
CH), 38.9 (CH2NH2), 38.8 (CH2CONH2) 31.1 (LYS-CH2CH), 30.3 (GLN-
CH2CH), 26.5 (CH2CH2NH2) 26.3 (CH2SH), 20.9 (CH2CH2CH); νmax/ cm
-1 
(solid): 3250, 3220, 3090, 2940, 1680, 1510; LCMS: (Tr = 0.13, m/z (ES): 
(Found: MH+, 377.6. C14H27N5O4S requires MH, 377.5)). [α]D = + 277.0° (c 
0.10, H2O). 
Arg-Cys-Tyr (6.24) 
Preparation was via the general 
method outlined in Section 
10.5.1. The title compound 
(6.24) was formed as a glassy 
solid (9.2 mg, 0.02 mmol, 18%). 
m.p.: 84.2-85.4 °C; Rf: 0.11 (19:1 DCM−MeOH). δH (500 MHz D2O): 7.06 
(2H, dd, J 16.4 and 8.4, 2-H and 6-H), 6.72 (2H, dd, J 16.4 and 8.4, 3-H and 
5-H), 4.82 (1H, dd, J 9.3 and 5.0, CYS-CH), 4.56-4.39 (1H, m, TYR-CH), 
3.99 (1H, t, J 6.3, ARG-CH), 3.29-2.97 (4H, m, CH2SH and CH2NH), 2.97-
2.71 (2H, m, CH2Ar), 1.81 (2H, d, J 6.8, ARG-CH-CH2) 1.42 (1H, d, J 6.6, 
CH2CH2CH2); δC (125 MHz, D2O): 176.0 (ARG-C=O), 170.5 (TYR-C=O), 
169.2 (CYS-C=O), 156.8 (ARG-CN3), 154.4 (C4), 130.8 (C6 and C2), 128.8 
(C1), 115.4 (C5 and C3), 55.7 (ARG-CH), 52.8 (CYS-CH), 52.7 (TYR-CH), 
40.4 (CH2NH), 36.6 (CH2Ar), 28.2 (CH2CH), 25.5 (CH2SH), 23.4 
(CH2CH2CH2); νmax/ cm
-1 (solid): 3500-2700, 1670, 1500, 1260; m/z (ES): 
(Found: MH+, 441.1917. C18H28N6O5S requires MH, 441.1915). [α]D = + 
42.4° (c 0.10, H2O). 
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10.5.3 (DL)-Combination amino acid trimers  
D-Pro-D-Trp-D-Cys (6.25) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.25) was 
formed as a purple oil (40 mg, 0.10 mmol, 80%). 
Rf: 0.08 (19:1 DCM-MeOH). δH (500 MHz, D2O): 
7.53 (1H, d, J 7.7, 4’-H), 7.39 (1H, d, J 7.9, 7’-H), 
7.23-6.96 (3H, m, 5’-H, 6’-H and 2’-H), 4.63 (1H, t, J 7.6, TRP-CH), 4.46-
4.38 (1H, m, CYS-CH), 4.26-4.18 (1H, m, PRO-CH), 3.30-2.82 (6H, m, 
CH2SH, 5-CH2 and CH2Ar), 2.34-2.30 (1H, m, 3-CH2a), 2.08-1.75 (3H, m, 4-
CH2 and 3-CH2b); δC (75 MHz, D2O): 174.1 (PRO-C=O), 172.9 (TRP-C=O), 
169.3 (CYS-C=O), 136.3 (C8’), 129.9 (C2’), 126.9 (C9’), 122.2 (C6’), 119.4 
(C5’), 118.1 (C4’), 112.1 (C7’), 108.7 (C1’), 59.6 (PRO-CH), 55.0 (TRP-CH), 
52.6 (CYS-CH), 46.7 (C5), 31.9 (C3), 29.9 (CH2SH), 23.7 (C4), 22.3 
(CH2Ar); νmax/ cm
-1 (oil): 3262, 3011, 2921,1660, 1515, 1174, 1012; m/z 
(ES): (Found: [M-H]-, 403.1433. C19H24N4O4S requires [M-H], 403.1445). [α]D 
= + 15.2° (c 0.10, H2O). 
D-Cys-D-Phe-D-Tyr (6.26) 
Preparation was via the general method outlined 
in Section 10.5.1. The title compound (6.26) was 
formed as colourless microcrystals (37 mg, 0.09 
mmol, 74%). m.p.: 183.4 °C (decomp); Rf: 0.10 
(19:1 DCM−MeOH). δH (500 MHz, D2O): 7.33-
7.18 (3H, m, 3-H, 5-H and 4-H), 7.12 (2H, d, J 6.5, 
2-H and 6-H), 6.97 (2H, d, J 7.9, 6’-H and 2’-H), 6.70 (2H, d, J 7.9, 5’-H and 
3’-H), 4.66 (1H, t, J 7.4 PHE-CH), 4.47 (1H, dd, J 8.9 and 5.1, CYS-CH), 
4.16 (1H, s, TYR-CH), 3.16-2.70 (6H, m, CH2SH, PHE-CH2Ar and TYR-
CH2Ar); δH (125 MHz, D2O): 174.3 (PHE-C=O), 171.8 (CYS-C=O), 167.4 
(TYR-C=O), 154.4 (C4’), 136.1 (C1), 130.6 (C5 and C3), 129.3 (C6’ and 
C2’), 128.9 (C6 and C2), 128.4 (C1’), 127.4 (C4), 115.6 (C5’ and C3’), 55.0 
(PHE-CH), 54.2 (CYS-CH), 51.4 (TYR-CH), 37.7 (PHE-CH2), 36.1 (TYR-
CH2), 14.2 (CH2SH); νmax/ cm
-1 (solid): 3241, 3013, 2912, 1660, 1515, 1174; 
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LCMS: (Tr = 1.55, m/z (ES): (Found: MH+, 431.1. C21H25N3O5S requires MH, 
431.2)). [α]D = − 69.2° (c 0.10, H2O). 
D-Cys-D-Pro-D-Tyr (6.27) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.27) was formed as 
colourless microcrystals (44 mg, 0.12 mmol, 88%). m.p.: 
164.2-165.7 °C; Rf: 0.14 (19:1 DCM−MeOH). δH (500 
MHz D2O): 7.07 (2H, t, J 8.6 2’-H and 6’-H), 6.77 (2H, t, J 
8.6 3’-H and 5’-H), 4.60-4.45 (2H, m, TYR-CH and CYS-
CH), 4.47-4.36 (1H, m, PRO-CH), 3.69 (1H, t, J 5.5, 
PRO-5a-H), 3.54 (1H, t, J 5.5 PRO-5b-H), 3.40 (1H, dd, J 
16.1 and 5.5, CH2Ara), 3.15-2.83 (3H, m, CH2Arb and CH2SH), 2.21-2.14 
(1H, m, PRO-3a-H), 1.93 (2H, d, J 5.5, PRO-4-H), 1.86-1.70 (1H, m, PRO-
3b-H); δC (75 MHz, D2O): 174.7 (TYR-C=O), 173.1 (PRO-C=O), 166.7 (CYS-
C=O), 154.6 (C4’), 130.7 (C6’ and C2’), 128.3 (C1’), 115.5 (C5’ and C3’), 
60.7 (PRO-CH), 54.3 (CYS-CH), 50.9 (TYR-CH), 48.0 (C5), 35.7 (CH2Ar), 
29.2 (C3), 24.7 (CH2SH), 23.7 (C4); νmax/ cm
-1 (solid): 3241, 3013, 2921, 
1723, 1660, 1515, 1174, 1131; LCMS: (Tr = 1.27, m/z (ES): (Found: MH+, 
381.1. C17H23N3O5S requires MH, 381.1)). [α]D = + 47.8° (c 0.10, H2O). 
D-Pro-D-Cys-Phe (6.28) 
Preparation was via the general method outlined in 
Section 10.5.1. The title compound (6.28) was formed 
as colourless microcrystals (39 mg, 0.11 mmol, 78%). 
m.p.: 202.1-203.4 °C; Rf: 0.15 (19:1 DCM−MeOH). δH 
(500 MHz, D2O): 7.41-7.11 (5H, m, 2’-H, 3’-H, 4’-H, 5’-
H, and 6’-H), 4.72-4.65 (1H, m, PHE-CH), 4.63 (1H, dd, 
J 8.9 and 5.4 CYS-CH), 4.30 (1H, t, J 7.7, PRO-CH), 
3.31 (2H, t, J 7.3 PRO-5-H), 3.21 (1H, dd, J 14.2 and 5.4, CH2Ara), 2.99 (2H, 
dt, J 12.9 and 6.3, CH2Arb and CH2SHa), 2.83 (1H, dd, J 18.1 and 6.4 
CH2SHb), 2.30 (1H, dt, J 20.6 and 7.7, PRO-3a-H), 1.93 (2H, dt, J 20.5 and 
7.7, PRO-4-H), 1.78 (1H, dd, J 20.6 and 7.7 PRO-3b-H); δC (125 MHz, D2O): 
174.5 (PRO-C=O), 170.9 (PHE-C=O), 169.5 (CYS-C=O), 136.6 (C1’), 129.3 
(C6’ and C2’), 128.8 (C5’ and C3’), 127.2 (C4’), 59.6 (PRO-CH), 54.1 (CYS-
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CH), 52.9 (PHE-CH), 46.7 (C5), 39.0 (CH2Ar), 36.8 (C4), 29.9 (CH2SH), 23.8 
(C3); νmax/ cm
-1 (solid): 3326, 3255, 3096, 2958, 1671, 1539, 1175; LCMS: 
(Tr = 1.50, m/z (ES): (Found: MH+, 365.0. C17H23N3O4S requires MH, 
365.1)). [α]D = + 51.0° (c 0.10, H2O). 
10.6 Synthesis of de novo designed inhibitors 
10.6.1 Synthesis of ‘first generation’ de novo designed inhibitors 
of NDM-1 
Synthesis of 5-phenyl-1,3-dihydo-2-benzofuranone (7.6) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and phenyl 
boronic acid (0.32 g, 2.58 mmol) to afford the title 
compound (7.6) as a cream coloured powder which was 
used without further purification (0.33 g, 1.58 mmol, 67%) m.p.: 124.4-125.8 
°C; Rf: 0.5 (2:1 Petrol–EtOAc); δH (300 MHz, CDCl3): 7.98 (1H, d, J 7.6, 3-H), 
7.75 (1H, d, J 7.6, 4-H), 7.68 (1H, s, 6-H), 7.62 (2H, d, J 7.1, 2’-H and 6’-H), 
7.47 (2H, app. t, J 7.1, 3’-H and 5’-H) 7.45 (1H, t, J 7.1, 4’-H),  5.38 (2H, s, 
CH2O); δC (75 MHz, CDCl3): 147.5 (C=O), 147.3 (C1), 139.6 (C3), 129.1 
(C3’’ and C5’), 128.6 (C2), 128.5 (C5),127.5 (C2’ and C6’) 126.1 (C4’), 124.5 
(C1’), 120.6 (C6),  69.9 (CH2O); νmax/ cm
-1 (solid): 3473, 3070, 2924, 1747, 
1615, 1452; HPLC: Tr= 3.00 (100% rel. area); m/z (ES): (Found: MNa+, 
233.0573. C14H10O2 requires MNa, 223.0570).  
Synthesis of 2-hydroxymethyl-4-phenylbenzoic acid (7.4) 
Preparation was via general method B using 5-phenyl-
1,3-dihydo-2-benzofuranone (7.6) (0.30 g, 1.43 mmol) 
to afford the title compound (7.4) as an off-white solid 
which was used without further purification (0.26 g, 1.04 
mmol, 73%) m.p.: 121.3-121.8 °C; Rf: 0.95 (19:1 DCM–MeOH); δH (300 
MHz, DMSO-d6): 8.11 (1H, d, J 1.6, 3-H), 7.96 (1H, d, J 8.2, 6-H), 7.72 (2H, 
d, J 7.1, 6’-H and 2’-H), 7.64 (1H, dd, J 8.2  and J 1.6, 5-H), 7.52 (2H, app. t, 
J 7.1, 5’-H and 3’-H), 7.42 (1H, t, J 7.1, 4’-H), 4.90 (2H, s, CH2OH); δC (75 
MHz, DMSO-d6): 168.0 (C=O), 145.2 (C2), 143.4 (C4), 139.4 (C1’), 124.8 
(C3), 124.4 (C5), 131.0 (C6), 129.0 (C3’ and C5’), 128.1 (C4’), 126.8 (C2’ 
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and C6’), 61.2 (CH2OH); νmax/ cm
-1 (solid): 3472, 3063, 1753, 1681, 1356; 
HPLC: Tr= 2.42 (96% rel. area); m/z (ES): (Found: [M-H]
-, 227.0714. 
C14H12O3 requires [M-H], 227.0717).  
Synthesis of 5-(3-chlorophenyl)-1,3-dihydo-2-benzofuranone (7.14) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.20 g, 0.94 mmol) and 3-
chlorophenyl boronic acid (0.16 g, 1.03 mmol) to afford 
the title compound (7.14) as yellow plates which was 
used without further purification (0.14 g, 0.58 mmol, 62%) 
m.p.: 150.7-151.2 °C; Rf: 0.47 (2:1 Petrol–EtOAc); δH (300 MHz, CDCl3):  
7.94 (1H, d, J 8.2, 3-H), 7.72 (1H, d, J 8.2, 4-H), 7.66 (1H, s, 6-H), 7.61 (1H, 
s, 2’-H), 7.50 (1H, app. t, J 7.7, 5’-H), 7.43 (2H, m, 4’-H and 6’-H), 5.39 (2H, 
s, CH2O); δC (75 MHZ, CDCl3): 180.7 (C=O), 147.4 (C1), 145.9 (C1’), 141.5 
(C5), 135.1 (C3’), 130.3 (C5’), 128.6 (C3’), 127.7 (C6’), 126.3 (C3), 125.7 
(C4), 125.1 (C2), 120.7 (C6), 69.6 (CH2O); νmax/ cm
-1 (solid): 3490, 3069, 
1747, 1350; HPLC: Tr= 3.37 (95% rel. area); m/z (ES): (Found: MNa
+, 
267.0183. C14H9ClO2 requires MNa, 267.0162).  
Synthesis of 4-(3-chlorophenyl)-2-(hydroxymethyl) benzoic acid (7.7) 
Preparation was via general method B using 5-(3-
chlorophenyl)-1,3-dihydo-2-benzofuranone (7.14) (0.15 
g, 0.75 mmol) to afford the title compound (7.7) as an 
off-white solid which was used without further 
purification (0.16 g, 0.74 mmol, 99%) m.p.: 134.5-135.6 
°C; Rf: 0.12 (19:1 DCM–MeOH); δH (300 MHz, DMSO-d6): 8.00 (1H, d, J 1.1, 
3-H), 7.96 (1H, d, J 7.7, 6-H), 7.78 (1H, d, J 1.6, 2’-H), 7.67 (2H, m, 5-H and 
4’-H), 7.58 (1H, app. t, J 8.2, 5’-H), 7.50 (1H, dd, J 8.2 and 1.6  6’-H), 4.91 
(2H, s, CH2OH);  δC (75 MHz, DMSO-d6): 167.9 (C=O), 145.2 (C2), 141.7 
(C4), 141.5 (C1’), 133.8 (C3’), 131.0 (C5’), 130.9 (C6), 127.9 (C3), 127.6 
(C1), 126.5 (C2’), 125.6 (C4’), 124.9 (C6’), 124.7 (C5), 61.2 (CH2OH); νmax/ 
cm-1 (solid): 3456, 3015, 1738, 1716, 1221; HPLC: Tr= 2.77 (100% rel. area); 
m/z (ES): (Found: [M-H]-,  261.0330. C14H11ClO3 requires [M-H], 261.0324).  
 
 
- 195 - 
Synthesis of 5-(furan-2-yl)-1,3-dihydo-2-benzofuranone (7.15) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 2-
furanboronic acid (0.29 g, 2.58 mmol) to afford the title 
compound (7.15) as yellow plates which was used without 
further purification (0.19 g, 0.97 mmol, 41%) m.p.: 153.8-154.3 °C; Rf: 0.51 
(2:1 Petrol–EtOAc); δH (300 MHz, CDCl3): 7.96 (1H, d, J 8.2, 3-H), 7.82 (1H, 
d, J 8.2, 4-H), 7.73 (1H, s, 6-H), 7.53 (1H, d, J 2.2, 5’-H), 6.91 (1H, d, J 3.3,  
3’-H), 6.55 (1H, dd, J 3.3 and 2.2, 4’-H), 5.37 (2H, s, CH2O); δC (75 MHz, 
CDCl3): 180.3 (C=O), 147.4 (C2’), 143.7 (C1), 135.0 (C5), 133.8 (C2), 126.1 
(C5’), 124.7 (C3), 116.6 (C4), 112.3 (C6), 108.3 (C3’ and C4’), 69.6 (CH2O); 
νmax/ cm
-1 (solid): 3472, 3110, 1740, 1602, 1446, 1352; HPLC: Tr= 2.65 (92% 
rel. area); m/z (ES): (Found: MNa+, 223.0366. C12H8O3 requires MNa, 
223.0350). 
Synthesis of 4-(furan-2-yl)-2-(hydroxymethyl) benzoic acid (7.8) 
Preparation was via general method B using 5-(furan-2-
yl)-1,3-dihydo-2-benzofuranone (7.15) (0.15 g, 0.75 
mmol) to afford the title compound (7.8) as an off-white 
solid which was used without further purification (0.16 g, 
0.74 mmol, 99%) m.p.: 137.7-138.3 °C; Rf: 0.96 (19:1 DCM–MeOH); δH 
(300MHz, DMSO-d6): 8.16 (1H, d, J 1.6, 3-H), 7.92 (1H, d, J 7.7, 6-H), 7.83 
(1H, d, J 1.6, 5’-H), 7.66 (1H, dd, J 7.7 and 1.6, 5-H), 7.18 (1H, d, J 3.3, 3’-
H), 6.62 (1H, dd, J 3.3 and 1.6, 4’-H), 4.88 (2H, s, CH2OH); δC (75 MHz, 
DMSO-d6): 167.8 (C=O), 152.3 (C1’), 145.6 (C2) 143.8 (C5’), 133.2 (C4), 
131.1 (C6), 126.4 (C1), 121.1 (C3 and C5), 107.8 (C3’), 61.1 (CH2OH); νmax/ 
cm-1 (solid): 3379, 2970, 1738, 1607, 1377, 1217; HPLC: Tr= 2.13 (94% rel. 
area) m/z (ES): (Found: [M-H]-, 217.0506. C14H10O4 requires [M-H], 
217.0514).  
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Synthesis of 5-(3-ethoxyphenyl)-1,3-dihydo-2-benzofuranone (7.16) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.20 g, 0.94 mmol) and 3-
ethoxyphenyl boronic acid (0.17 g, 1.03 mmol) to afford 
the title compound (7.16) as an off-white solid which was 
used without further purification (0.20 g, 0.80 mmol, 85%) 
m.p.: 89.7-91.5 °C; Rf: 0.43 (2:1 Petrol–EtOAc); δH (300 
MHz, CDCl3): 7.89 (1H, d, J 8.2, 3-H), 7.66 (1H, d, J 8.2, 4-H), 7.58 (1H, s, 
6-H), 7.32 (1H, app. t, J 7.7, 5’-H), 7.10 (1H, dd, J 7.7 and 2.2, 4’-H), 7.05 
(1H, app. t, J 2.2, 2’-H), 6.87 (1H, dd, J 7.7  and J 2.2, 6’-H), 5.29 (2H, s, 
CH2O), 4.02 (2H, q, J 7.1, CH2), 1.35 (3H, t, J 7.1, CH3);  δC (75 MHz, 
CDCl3): 159.5 (C=O), 147.4 (C3’), 147.3 (C1 or C1’), 141.1 (C5), 130.2 (C5’), 
128.5 (C4), 126.1 (C3), 124.5 (C2), 120.6 (C6), 119.8 (C4’), 114.4 (C2’), 
114.0 (C6’), 69.7 (CH2O), 63.6 (CH2), 14.9 (CH3); νmax/ cm
-1 (solid): 3482, 
2970, 1730, 1598, 1352, 1217; HPLC: Tr= 3.34 (96% rel. area); m/z (EI):  
(Found: M+,  254.0947. C16H14O3 requires M, 254.0943).  
Synthesis of 4-(3-ethoxyphenyl)-2-(hydroxymethyl) benzoic acid (7.9) 
Preparation was via general method B using 5-(3-
ethoxyphenyl)-1,3-dihydo-2-benzofuranone (7.16) (0.10 
g, 0.34 mmol) to afford the title compound (7.9) as an 
off-white solid which was used without further 
purification (83 mg, 0.31 mmol, 77%) m.p.: 145.3-146.4 
°C; Rf: 0.12 (19:1 DCM–MeOH); (Found: C, 70.4; H, 
5.85; C16H16O4 requires C, 70.5; H, 5.92%); δH (300 MHz, DMSO-d6): 7.98 
(1H, s, 3-H), 7.95 (1H, d, J 8.2, 6-H), 7.64 (1H, d, J 8.2, 5-H), 7.40 (1H, t, J 
7.7, 5’-H), 7.26 (1H, d, J 7.7, 6’-H), 7.20 (1H, s, 2’-H), 6.97 (1H, dd, J 7.7 and 
2.7, 4’-H), 4.90 (2H, s, CH2OH), 4.11 (2H, q, J 7.1, CH2), 1.34 (3H, t, J 7.1, 
CH3);  δC (75 MHz, DMSO-d6): 168.0 (C=O), 159.0 (C2), 145.1 (C3’), 143.2 
(C1’), 140.9 (C4), 131.0 (C6), 130.2 (C5’), 127.0 (C1), 124.9 (C3), 124.5 
(C5), 119.0 (C6’), 114.1 (C2’), 112.8 (C4’) 63.1 (CH2), 61.2 (CH2OH), 14.6 
(CH3);  νmax/ cm
-1 (solid): 3213, 2520, 2030, 1976, 1688, 1230; HPLC: Tr= 
2.71 (100% rel. area); m/z (ES): (Found: [M-H]-, 271.0976. C16H16O4 
requires [M-H], 271.0798).  
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Synthesis of 5-(4-ethylphenyl)-1,3-dihydo-2-benzofuranone (7.17) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.20 g, 0.94 mmol) and 4-
ethylphenyl boronic acid (0.16 g, 1.03 mmol) to 
afford the title compound (7.17) as yellow plates 
which were used without further purification (0.14 g, 0.57 mmol, 61%) m.p.: 
114.3-115.7 °C; Rf: 0.58 (2:1 Petrol–EtOAc); δH (300 MHz, CDCl3):  7.98 
(1H, d, J 8.2, 3-H), 7.74 (1H, dd, J 8.2 and 1.6, 4-H), 7.66 (1H, d, J 1.6, 6-H), 
7.55 (2H, d, J 8.2, 6’-H and 2’-H), 7.33 (2H, d, J 8.2, 5’-H and 3’-H ), 5.35 
(2H, s, CH2O), 2.72 (2H, q, J 7.7, ethyl CH2), 1.28 (3H, t, J 7.7, ethyl CH3); 
δC (75 MHz, CDCl3): 180.5 (C=O), 147.4 (C5), 147.3 (C1’), 145.1 (C4’), 
141.1 (C1), 132.2 (C2), 128.7 (C3’ and C5’), 128.3 (C4), 127.4 (C2’ and 
C6’), 126.1 (C3), 120.1 (C6), 69.7 (CH2O), 28.6 (CH2), 15.5 (CH3); νmax/ cm
-1 
(solid): 3489, 2968, 1746, 1618, 1347, 1282; HPLC: Tr= 3.51 (100% rel. 
area); m/z (ES): (Found: MNa+, 261.0882. C16H14O2 requires MNa, 
261.0886).  
Synthesis of 4-(4-ethylphenyl)-2-(hydroxymethyl) benzoic acid (7.10) 
Preparation was via general method B using 5-(4-
ethylphenyl)-1,3-dihydo-2-benzofuranone (7.17) 
(0.14 g, 0.57 mmol) to afford the title compound 
(7.10) as an off-white solid which was used without 
further purification (0.16 g, 0.74 mmol, 99%) m.p.: 143.4-145.2 °C; Rf: 0.15 
(19:1 DCM–MeOH); δH (300MHz, DMSO-d6): 7.98 (1H, d, J 2.2, 3-H), 7.96 
(1H, d, J 8.2, 6-H), 7.68 (2H, d, J 8.2, 6’-H and 2’-H), 7.63 (1H, dd, J 8.2 and 
2.2, 5-H), 7.35 (2H, d, J 8.2, 5’-H and 3’-H), 4.90 (2H, s, CH2OH), 2.66 (2H, 
q, J 7.7, ethyl CH2), 1.22 (3H, t, J 7.7, CH3);  δC (75 MHz, DMSO-d6): 168.1 
(C=O), 145.2 (C2), 143.9 (C4’), 143.3 (C4), 136.7 (C1’), 131.0 (C6), 128.4 
(C3’ and C5’), 126.7 (C2’ and C6’), 126.6 (C1), 124.5 (C3), 124.2 (C5), 61.2 
(CH2OH), 27.8 (CH2), 15.5 (CH3); νmax/ cm
-1 (solid): 3365, 3296, 2968, 2551, 
1690, 1608, 1301; HPLC: Tr= 2.88 (100% rel. area); m/z (ES): (Found: 
MNa+, 279.0984. C16H16O3 requires MNa, 279.0992).   
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Synthesis of 5-(2,3-dichlorophenyl)-1,3-dihydo-2-benzofuranone (7.18) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 2,3-
dichlorophenyl boronic acid (0.49 g, 2.58 mmol) to afford 
the title compound (7.18) as an off-white solid which was 
used without further purification (0.46 g, 1.64 mmol, 74%) 
m.p.: 144.6-145.3 °C; Rf: 0.48 (2:1 Petrol–EtOAc); δH (300 MHz, CDCl3): 
7.93 (1H, d, J 8.2, 3-H), 7.51 (1H, s, 6-H), 7.48 (1H, dd, J= 8.2 and 2.2, 4-H), 
7.46 (1H, dd, J 7.7 and 1.6, 4’-H), 7.24 (1H, t, J 7.7, 5-H), 7.19 (1H, dd, J 7.7 
and 1.6, 6’-H), 5.33 (2H, s, CH2O); δC (75 MHz, CDCl3): 181.0 (C=O), 146.6 
(C1), 145.2 (C1’), 141.3 (C5), 134.0 (C3’), 130.7 (C2’), 130.5 (C6 and C4), 
129.3 (C6’), 127.5 (C5’), 125.6 (C3), 125.3 (C2), 123.1 (C4’), 69.6 (CH2O); 
νmax/ cm
-1 (solid): 3506, 3072, 2970, 2325, 1750, 1620, 1365, 1216; HPLC: 
Tr= 3.51 (100% rel. area); m/z (EI): (Found: M
+, 277.9903. C14H8Cl2O2 
requires M, 227.9901).  
Synthesis of 4-(2,3-dichlorophenyl)-2-(hydroxymethyl)benzoic acid 
(7.11) 
Preparation was via general method B using 5-(2,3-
dichlorophenyl)-1,3-dihydo-2-benzofuranone (7.18) 
(0.10 g, 0.36 mmol) to afford the title compound (7.11) 
as an off-white solid which was used without further 
purification (83 mg, 0.31 mmol, 77%) m.p.: 151.2-151.8 
°C; Rf: 0.11 (19:1 DCM–MeOH); δH (300 MHz, DMSO-d6): 7.96 (1H, d, J 8.2, 
6-H), 7.74 (1H, d, J 1.6, 3-H), 7.73 (1H, dd, J 8.2 and 1.6, 5-H), 7.48 (1H, 
app. t, J 7.7, 5’-H), 7.40 (2H, m, 4’-H and 6’-H), 5.30 (1H, brs, OH), 4.89 (2H, 
s, CH2OH); δC (75 MHz, DMSO-d6): 167.9 (C=O), 144.5 (C2), 141.8 (C4), 
141.7 (C1’), 132.4 (C1), 130.1 (C6), 129.9 (C5), 129.4 (C3’), 128.4 (C5’), 
127.8 (C2’), 127.3 (C3) 127.0 (C6’ and C4’), 60.1 (CH2OH); νmax/ cm
-1 (solid): 
3470, 3017, 1717, 1203; HPLC: Tr= 2.90 (100% rel. area); m/z (ES): (Found: 
MNa+, 318.9879 C14H10Cl2O3 requires MNa, 318.9899).   
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Synthesis of 5-(quinolin-3-yl)-1,3-dihydo-2-benzofuranone (7.19) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 3-
quinoline boronic acid (0.45 g, 2.58 mmol) to afford 
the title compound (7.19) as an off-white solid which 
was used without further purification (0.27 g, 1.04 mmol, 44%) m.p.: >250 
°C; Rf: 0.05 (2:1 Petrol–EtOAc); δH (300MHz, CDCl3): 9.25 (1H, d, J 2.2, 2’-
H), 8.40 (1H, d, J 2.2, 4’-H), 8.18 (1H, d, J 8.2, 3-H), 8.06 (1H, d, J 8.2, 4-H), 
7.93 (1H, d, J 8.2, 8’-H), 7.89 (1H, d, J 8.2, 5’-H), 7.83 (1H, s, 6-H), 7.80 (1H, 
app. dd, J 8.2 and 1.6, 6’-H), 7.64 (1H, app. dd, J 8.2 and 1.6, 7’-H), 5.45 
(2H, s, CH2O); δC (75 MHz, CDCl3): 170.0 (C=O), 149.4 (C2’), 147.8 (C9’), 
147.6 (C1), 144.0 (C5), 134.3 (C4’), 132.4 (C10’), 132.1 (C5’), 132.0 (C2), 
130.5 (C6’), 129.4 (C4), 128.7 (C7’), 128.2 (C5’), 127.5 (C3), 126.1 (C6), 
69.6 (CH2O); νmax/ cm
-1 (solid): 3478, 3059, 2970, 1741, 1348; HPLC: Tr= 
1.61 (100% rel. area); m/z (EI): (Found: M+, 261.0765. C17H11NO2 requires 
M, 261.0790).  
Synthesis of 2-(hydroxymethyl)-4-(quinolone-3-yl) benzoic acid (7.12) 
Preparation was via general method B using 5-
(quinolin-3-yl)-1,3-dihydo-2-benzofuranone (7.19) 
(0.15 g, 0.57 mmol) to afford the title compound 
(7.12) as an off-white solid which was used without 
further purification (84 mg, 0.30 mmol, 78%) m.p.: 
>250 °C; Rf: 0.15 (19:1 DCM–MeOH); δH (300MHz, DMSO-d6): 9.36 (1H, d, 
J 2.2, 2’-H), 8.89 (1H, d, J 2.2, 4’-H), 8.23 (1H, s, 3-H), 8.19 (1H, d, J 7.7, 8’-
H), 8.16 (1H, d, J 7.7, 5’-H), 8.02 (1H, d, J 7.7, 6-H), 7.88 (1H, d, J 7.7, 5-H), 
7.86 (1H, app. t, J 7.7, 6’-H), 7.72 (1H, app. t, J 7.7, 7’-H), 5.18 (2H, s, 
CH2OH); δC (75 MHz, DMSO-d6): 167.9 (C=O), 153.9 (C9’), 150.0 (C2), 
148.3 (C2’), 145.5 (C4), 139.6 (C4’), 137.2 (C10’), 137.1 (C3’), 132.2 (C6’), 
131.1 (C6), 130.7 (C1), 128.7 (C7’), 127.9 (C5), 127.7 (C4’), 127.4 (C5’), 
125.4 (C8’), 125.0 (C3), 61.1 (CH2OH); νmax/ cm
-1 (solid): 3448, 2970, 1739, 
1365, 1232; HPLC: Tr= 1.39 (100% rel. area); m/z (ES): (Found: [M-H]
-, 
278.0819. C17H13NO3 requires [M-H], 278.0823).  
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Synthesis of 5-(3,4-dimethoxyphenyl)-1,3-dihydo-2-benzofuranone 
(7.20)  
Preparation was via general method A using 5-
bromophthalide (7.5) (0.20 g, 0.94 mmol) and 3,4-
dimethoxyphenyl boronic acid (0.19 g, 1.03 mmol) to 
afford the title compound (7.20) as yellow plates 
which was used without further purification (0.18 g, 
0.67 mmol, 72%) m.p.: 172.8-174.1 °C; Rf: 0.32 (2:1 Petrol–EtOAc); δH 
(300MHz, CDCl3):  7.98 (1H, d, J 8.2, 3-H), 7.74 (1H, d, J 8.2, 4-H), 7.64 
(1H, s, 6-H), 7.20 (1H, dd, J 8.2 and 2.2, 6’-H), 7.12 (1H, d, J 2.2, 2’-H), 6.98 
(1H, d, J 8.2, 5’-H), 5.38 (2H, s, CH2O), 3.98 (3H, s, CH3-3’), 3.96 (3H, s, 
CH3-4’); δC (75 MHz, CDCl3): 181.1 (C=O), 149.7 (C3’), 149.3 (C4’), 147.4 
(C5), 147.3 (C1’), 132.4 (C2), 128.1 (C4), 126.1 (C3), 124.0 (C1), 120.1 (C6’ 
and C6), 111.5 (C5’), 110.5 (C2’), 69.6 (CH2O), 56.0 (CH3-3’ and CH3-4’); 
νmax/ cm
-1 (solid): 3481, 2944, 1751, 1605, 1226; HPLC: Tr= 2.50 (95% rel. 
area); m/z (ES): (Found: MNa+, 293.0777. C16H14O4 requires MNa, 
293.0784).  
Synthesis of 4-(3,4-dimethoxyphenyl)-2-(hydroxymethyl)benzoic acid 
(7.13) 
Preparation was via general method B using 5-
(3,4-dimethoxyphenyl)-1,3-dihydo-2-benzofuranone 
(7.20) (0.15 g, 0.75 mmol) to afford the title 
compound (7.13) as an off-white solid which was 
used without further purification (0.16 g, 0.74 mmol, 
99%) m.p.: 159.1-159.8 °C; Rf: 0.15 (19:1 DCM–
MeOH); δH (300MHz, DMSO-d6): 7.97 (1H, d, J 1.1, 3-H), 7.91 (1H, d, J 8.2, 
6-H), 7.63 (1H, dd, J 8.2 and 1.1, 5-H), 7.32 (2H, m, 5’-H and 2’-H), 7.27 
(1H, d, J 9.3, 6’-H), 4.89 (2H, s, CH2OH), 3.85 (3H, s, CH3-3’), 3.81 (3H, s, 
CH3-4’); δC (75 MHz, DMSO-d6): 168.1 (C=O), 149.0 (C4’ and C3’), 145.1 
(C4), 143.4 (C1’), 131.9 (C2), 131.0 (C6), 126.2 (C1), 124.4 (C3), 124.1 
(C5), 119.2 (C6’), 112.1 (C5’), 110.3 (C2’), 61.3 (CH2OH), 55.5 (CH3-3’ and 
CH3-4’); νmax/ cm
-1 (solid): 3513, 2940, 2652, 1687, 1605, 1322, 1255; HPLC: 
Tr= 2.05 (89% rel. area); m/z (ES): (Found: MNa
+, 311.0877. C16H16O5 
requires MNa, 311.0890).  
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10.6.2 Thiol-containing inhibitors: route development 
Synthesis of methyl-2-(iodomethyl)-4-phenyl-benzoate (7.22) 
A solution of 5-phenyl-1,3-dihydo-2-benzofuranone 
(7.6) (1.00 g, 4.76 mmol) in DCM (40 ml) was added to 
a stirred solution of 1M boron tribromide in DCM (4.76 
mL, 4.76 mmol), sodium iodide (1.07 g, 7.14 mmol) and 
cat. tetra-n-butly ammonium iodide (20 mg, 0.04 mmol). 
The mixture was stirred at room temperature for 16 h under an atmosphere 
of nitrogen. The reaction mixture was poured into methanol (20 ml) and 
concentrated in vacuo. The crude product was purified using flash column 
chromatography, eluting with chloroform, to afford the title compound (7.22) 
as an off-white solid which was used without further purification (0.52 g, 1.48 
mmol, 31%). m.p.: 79.1-80.5 °C; Rf: 0.73 (CHCl3); δH (300 MHz, CDCl3): 8.05 
(1H, d, J 8.2, 6-H), 7.62 (2H, d, J 7.1, 6’-H and 2’-H), 7.61 (1H, d, J 1.6, 3-H), 
7.54 (1H, dd, J 8.2  and J 1.6, 5-H), 7.48 (2H, app. t, J 7.1, 5’-H and 3’-H), 
7.40 (1H, t, J 7.1, 4’-H), 5.01 (2H, s, CH2I), 3.96 (3H, s, CH3); δC (75 MHz, 
CDCl3): 166.9 (C=O), 145.3 (C2), 141.9 (C4), 139.2 (C1’), 132.2 (C6), 129.7 
(C4’), 129.0 (C5’ and C3’), 128.4 (C5), 127.2 (C6’ and C2’), 126.7 (C1), 
126.5 (C3), 52.3 (CH3), 4.2 (CH2I); νmax/ cm
-1 (solid): 3419, 3060, 2977, 
2584, 1712, 1605, 1293, 1104; HPLC: Tr= 4.10 (96% rel. area); m/z (EI): 
(Found: [M-I]+, 225.0906. C15H13IO2 requires [M-I], 225.0916). 
Synthesis of methyl-4-bromo-2-(iodomethyl)-benzoate (7.23) 
A solution of 5-bromophthalide (7.5) (3.00 g, 14.1 mmol)  
in DCM (50 ml) was added to a stirred solution of 1M 
boron tribromide in DCM (14.1 mL, 14.1 mmol), sodium 
iodide (3.17 g, 21.1 mmol) and cat. tetra-n-butly 
ammonium iodide (52 mg, 0.14 mmol). The mixture was stirred at room 
temperature for 16 h under an atmosphere of nitrogen. The reaction mixture 
was poured into methanol (20 ml) and concentrated in vacuo. The crude 
product was purified using flash column chromatography, eluting with 
chloroform, to afford the title compound (7.23) (1.50 g, 4.23 mmol, 30%) was 
obtained as pale brown plates, m.p: 92.2-93.5 °C; Rf 0.85 (CHCl3); δH (300 
MHz, CDCl3): 7.85 (1H, d, J 8.2, 6-H), 7.59 (1H, s, 3-H), 7.48 (1H, d, J 8.2, 
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5-H), 4.88 (2H, s, CH2), 3.96 (3H, s, CH3); δC (75 MHz, CDCl3): 164.2 (C=O), 
141.2 (C2), 131.9 (C6), 130.9 (C5), 129.0 (C3), 124.9 (C1), 124.9 (C4), 50.3 
(CH3); νmax/ cm
-1 (solid): 3423, 3078, 3055, 2952, 2311, 1939, 1745, 1585, 
1558; HPLC: Tr = 2.05 (100% rel.area); m/z (ES): (Found: MNa
+, 377.8615. 
C9H8IO2 requires MNa, 377.8645). 
Synthesis of 4-bromo-2-([(triphenylmethyl)sulfanyl]methyl)benzoic acid 
(7.24) 
Preparation was via general method D using 4-
bromo-2-(iodomethyl) benzoic acid (7.23) (1.50 g, 
4.24 mmol) to afford the crude compound 4-bromo-
2-(sulfanylmethyl) benzoic acid as colourless 
microcrystals which were re-suspended in THF (30 
mL). Trityl chloride (1.18 g, 4.24 mmol) and Et3N (1.77 mL, 12.7 mmol) were 
added and the reaction stirred at room temperature for 18 h. The reaction 
mixture was concentrated in vacuo. The residue was re-suspended in DCM 
(30 mL), washed with water (3 × 30 mL), dried (MgSO4) and concentrated in 
vacuo. The crude product was purified by flash column chromatography 
eluting with 3:1 Petrol−EtOAc to afford the title compound (7.24) as an off 
white solid (0.65 g, 1.33 mmol, 31%). m.p: 106.2-107.9 °C; Rf 0.31 (DCM); 
δH (300 MHz, CDCl3): 7.92 (1H, d, J 8.2, 6-H), 7.57 (1H, dd, J 8.2 and 1.6, 5-
H), 7.41 (1H, d, J 1.6, 3-H), 7.39 (6H, d, J 7.6, 6-Htrt and 2-Htrt), 7.26 (6H, 
app. t, J 7.6, 5-Htrt and 3-Htrt), 7.20 (3H, t, J 7.6, 4H-trt), 3.74 (2H, s, CH2); 
δC (75 MHz, CDCl3): 169.2 (C=O), 144.3 (C1trt), 138.6 (C2), 133.7 (C5), 
130.9 (C3), 130.2 (C6), 129.4 (C6trt and C2trt), 128.5 (C1), 128.0 (C5trt and 
C3trt), 126.7 (C4trt), 122.6 (C4), 68.3 (C(Ph)3), 35.7 (CH2); νmax/ cm
-1 (solid): 
3078, 2972, 1723, 1521, 1458; HPLC: Tr = 4.21 (100% rel.area); m/z (ES): 
(Found: [M-H]-, 487.0367. C27H21BrO2S requires [M-H], 487.0373). 
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Synthesis of 4-phenyl-2-([(triphenylmethyl)sulfanyl]methyl)benzoic acid 
(7.25) 
 Preparation was via general method A using 4-
bromo-2-([(triphenylmethyl)sulfanyl]methyl) 
benzoic acid (7.24) (0.10 g, 0.20 mmol) and 
phenyl boronic acid (27 mg, 0.22 mmol) to 
afford the title compound (7.25) as an off-white 
solid which was used without further purification (82 mg, 0.17 mmol, 77%). 
m.p: 115.4-117.2 °C; Rf 0.37 (DCM); δH (300 MHz, CDCl3): 8.21 (1H, d, J 
8.3, 6-H), 7.71 (1H, dd, J 8.3 and 1.9, 5-H), 7.62-7.53 (3H, m, 6’-H, 2’-H and 
3-H), 7.46 (2H, app. t, J 7.5, 5’-H and 3’-H), 7.41 (6H, d, J 7.5, 6-Htrt and 2-
Htrt), 7.39 (1H, t, J 7.5, 4’-H), 7.27 (6H, app. t, J 7.2, 5-Htrt and 3-Htrt), 7.20 
(3H, t, J 7.2, 4-Htrt), 3.75 (2H, s, CH2); δC (75 MHz, CDCl3):; νmax/ cm
-1 
(solid): 3065, 2984, 1704, 1521, 1458; HPLC: Tr = 4.03 (100% rel.area); m/z 
(ES): (Found: [M-H]-, 485.1562. C33H26O2S requires [M-H], 485.1581). 
Synthesis of 2-iodomethyl-4-phenyl-benzoic acid (7.26) 
Preparation was via general method C using 5-phenyl-
1,3 dihydro-2-benzofuranone (7.6) (0.20 g, 0.95 mmol) 
to afford the title compound (7.26) as an off-white solid 
which was used without further purification (0.20 g, 0.59 
mmol, 62%) m.p.: 81.3-82.4 °C; Rf: 0.75 (CHCl3); δH (300MHz, DMSO-d6): 
7.94 (1H, d, J 8.3, 6-H), 7.88 (1h, d, J 1.8, 3-H), 7.73 (2H, d, J 7.3, 6’-H and 
2’-H), 7.68 (1H, dd, J 8.3 and 1.8, 5-H), 7.51 (2H, app. t, J 7.3, 5’-H and 3’-
H), 7.44 (1H, t, J 7.3, 4’-H), 5.09 (2H, s, CH2); νmax/ cm
-1 (solid): 2806, 2630, 
1750, 1603, 1257, 909; m/z (ES): (Found: [M+2Na-H]+, 382.9516. C14H11IO2 
requires [M+2Na-H], 382.9515). 
Synthesis of 4-phenyl-2-sulfonylmethylbenzoic acid (7.21) 
Preparation was via general method D using (2-
iodomethyl)-4-phenyl benzoic acid (7.26) (0.65 g, 1.92 
mmol) to afford the crude title compound. The title 
compound (7.21) was isolated as colourless 
microcrystals (0.25 g, 1.01 mmol, 53%). m.p.: 168.2-169.9 °C; Rf: 0.18 (19:1 
DCM−MeOH); δH (300 MHz, DMSO-d6): 7.95 (1H, d, J 8.2, 6-H), 7.77 (1H, 
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d, J 2.0, 3-H), 7.73 (2H, d, J 7.4, 6’-H and 2’-H), 7.65 (1H, dd, J 8.2 and 2.0, 
5-H), 7.52 (2H, app. t, J 7.4, 5’-H and 3’-H), 7.44 (1H, t, J 7.4, 4’-H), 4.13 
(2H, d, J 8.5, CH2), 2.87 (1H, t, J 8.5, SH);  δC (75 MHz, DMSO-d6): 168.0 
(C=O), 144.3 (C4), 143.6 (C1’), 138.7 (C2), 131.5 (C6), 129.0 (C5’ and C3’), 
128.9 (C4’), 128.2 (C5), 127.8 (C1), 126.9 (C6’ and C2’), 124.9 (C3), 26.4 
(CH2); νmax/ cm
-1 (solid): 2976, 1681, 1350, 1278, 756; HPLC: Tr= 2.88 (95% 
rel. area); m/z (ES): (Found: [M-H]-, 243.0477 C14H12O2S requires [M-H], 
243.0485).   
10.6.3 Second generation de novo designed inhibitors  
Synthesis of 5-(2-chlorophenyl)-1,3-dihydo-2-benzofuranone (7.42) 
 Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 2-
chlorophenyl boronic acid (0.40 g, 2.59 mmol) to afford 
the title compound (7.42) as yellow plates which was 
used without further purification (0.43 g, 1.76 mmol, 75%) m.p.: 80.4-81.7 
°C; Rf: 0.40 (4:1 Petrol−EtOAc); δH (300 MHz, CDCl3): 8.01 (1H, d, J 7.9, 3-
H), 7.62 (1H, dd, J 7.9 and 2.2, 4-H), 7.58 (1H, d, J 2.2, 6-H), 7.57-7.50 (1H, 
m, 3’-H), 7.42-7.30 (3H, m, 4’-H, 5’-H and 6’-H), 5.41 (2H, s, CH2); δC (75 
MHz, CDCl3): 170.8 (C=O), 146.5 (C1), 145.4 (C1’), 139.0 (C5), 132.3 (C2’), 
131.1 (C3’), 130.7 (C6’), 130.3 (C6), 129.6 (C4’), 127.1 (C3), 125.5 (C4), 
125.0 (C2), 123.5 (C5’), 69.6 (CH2); νmax/ cm
-1 (solid): 1752, 1351, 1072; 
HPLC: Tr= 2.95 (100% rel. area); m/z (ES): (Found: MNa
+, 267.0186. 
C14H9ClO2 requires MNa, 267.0183). 
Synthesis of 4-(2-chlorophenyl)-2-iodomethyl-benzoic acid (7.50) 
Preparation was via general method C using 5-(2-
chlorophenyl)-1,3 dihydro-2-benzofuranone (7.42) (0.30 
g, 1.23 mmol) to afford the title compound (7.50) as an 
off-white solid which was used without further 
purification (0.24 g, 0.64 mmol, 52%) m.p.: 152.4-153.2 °C; Rf: 0.29 (CHCl3); 
δH (300 MHz, DMSO-d6): 7.91 (1H, d, J 7.9, 6-H), 7.59 (1H, d, J 2.0, 3-H), 
7.54 (1H, dd, J 7.9 and 2.0, 5-H), 7.47-7.37 (4H, m, 6’-H, 5’-H, 4’-H and 3’-
H), 5.03 (2H, s, CH2); νmax/ cm
-1 (solid): 3052, 2197, 1672, 1605, 1439, 1260; 
m/z (ES): (Found: [M-I]+, 245.0365. C14H10ClO2 requires [M-I], 245.0364). 
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Synthesis of 4-(2-chlorophenyl)-2-(sulfonylmethyl) benzoic acid (7.28) 
Preparation was via general method D using 4-(2-
chlorophenyl)-2-(iodomethyl) benzoic acid (7.50) (0.15 
g, 0.40 mmol) to afford the title compound (7.28) as 
colourless needles. (66 mg, 0.24 mmol, 59%). m.p.: 
129.3-130.7 °C; Rf: 0.22 (19:1 DCM−MeOH); δH (300MHz, DMSO-d6): 7.93 
(1H, d, J 8.2, 6-H), 7.62-7.57 (1H, m, 3’-H), 7.52(1H, d, J 1.8, 3-H), 7.46-7.43 
(3H, m, 6’-H, 5’-H and 4’-H), 7.42 (1H, dd, J 8.2 and 1.8, 5-H), 4.11 (2H, d, J 
8.3, CH2), 2.84 (1H, t, J 8.3, SH); δC (75 MHz, DMSO-d6): 168.0 (C=O), 
143.4 (C1’), 142.2 (C2), 38.6 (C4), 131.4 (C6’ and C3’), 131.1 (C2’), 130.6 
(C6), 129.9 (C5), 129.7 (C4’), 128.4 (C1), 127.8 (C5’), 127.6 (C3), 26.2 
(CH2); νmax/ cm
-1 (solid): 2912, 1676, 1438, 1296, 1068; HPLC: Tr= 3.04 
(95% rel. area); m/z (ES): (Found: [M-H]-, 277.0090. C14H11ClO2S requires 
[M-H], 277.0096). 
Synthesis of 4-(3-chlorophenyl)-2-iodomethyl-benzoic acid (7.51) 
Preparation was via general method C using 5-(3-
chlorophenyl-1,3 dihydro-2-benzofuranone (7.14) (0.30 
g, 1.22 mmol) to afford the title compound (7.51) as an 
off-white solid which was used without further 
purification (0.38 g, 1.03 mmol, 84%) m.p.: 167.8-169.9 
°C; Rf: 0.26 (CHCl3); δH (300 MHz, DMSO-d6): 7.90 (1H, d, J 1.8, 3-H), 7.89 
(1H, d, J 8.1, 6-H), 7.77 (1H, t, J 1.4, 2’-H), 7.69-7.63 (2H, app. d, J 8.0, 5-H 
and 4’-H), 7.49 (1H, t, J 8.0, 5’-H), 7.46 (1H, d, J 8.0, 6’-H), 5.03 (2H, s, 
CH2); νmax/ cm
-1 (solid): 3067, 2815, 2521, 1678, 1412, 1253. 
Synthesis of 4-(3-chlorophenyl)-2-(sulfonylmethyl) benzoic acid (7.29) 
Preparation was via general method D using 4-(3-
dichlorophenyl)-2-(iodomethyl) benzoic acid (7.51) (0.19 
g, 0.50 mmol) to afford the title compound (7.29) as 
pale yellow microcrystals. (0.11 g, 0.38 mmol, 77%) 
m.p.: 144.2-145.9 °C; Rf: 0.16 (19:1 DCM-MeOH); δH 
(300 MHz, DMSO-d6): 7.95 (1H, d, J 8.2, 6-H), 7.83 (1H, d, J 1.7, 2’-H), 7.82 
(1H, d, J 1.9, 3-H), 7.72 (1H, dd, J 8.9 and 1.7, 4’-H), 7.69 (1H, dd, J 8.2 and 
1.9, 5-H), 7.53 (1H, app t, J 8.9, 5’-H), 7.49 (1H, dd, J 8.9 and 1.7, 6’-H), 
- 206 - 
4.13 (2H, d, J 8.4, CH2SH), 2.87 (1H, t, J 8.4, SH); δC (75 MHz, DMSO-d6): 
167.9 (C=O), 144.5 (C4), 141.8 (C1’), 140.8 (C2), 133.8 (C3’), 131.6 (C5’), 
130.8 (C6), 129.0 (C2’), 128.4 (C1), 128.1 (C4’), 126.7 (C5) 125.6 (C3), 
125.2 (C6’), 26.3 (CH2);  νmax/ cm
-1 (solid): 2962, 2643, 1762, 1261, 772; 
HPLC: Tr= 2.33 (90% rel. area); m/z (ES): (Found: [M-H]
-, 277.0088 
C14H11ClO2S requires [M-H],  277.0096. 
Synthesis of 5-(4-chlorophenyl)-1,3-dihydo-2-benzofuranone (7.43) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 3-
thienyl boronic acid (0.40 g, 2.59 mmol) to afford the 
title compound (7.43) as yellow plates which was 
used without further purification (0.43 g, 1.76 mmol, 75%) m.p.: 186.6-187.4 
°C; Rf: 0.32 (4:1 Petrol−EtOAc); δH (300 MHz, CDCl3): 7.91 (1H, d, J 8.0, 6-
H), 7.63 (1H, dd, J 8.0 and 1.5, 5-H), 7.57 (1H, d, J 1.5, 3-H), 7.48 (2H, d, J 
8.4, 6’-H and 2’-H), 7.39 (2H, d, J 8.4, 5’-H and 3’-H), 5.30 (2H, s, CH2); δC 
(75 MHz, CDCl3): 170.7 (C=O), 147.5 (C1), 146.2 (C1’), 138.2 (C5), 135.0 
(C4’), 129.3 (C5’ and C3’), 128.8 (C6’ and C2’), 128.3 (C6), 126.3 (C3), 
124.9 (C2), 120.5 (C4), 69.6 (CH2); νmax/ cm
-1 (solid): 1747, 1614, 1321, 
1112; HPLC: Tr= 3.07 (100% rel. area); m/z (ES): (Found: MH
+, 245.0356. 
C14H10ClO2 requires MH, 245.0364). 
Synthesis of 4-(4-chlorophenyl)-2-iodomethyl-benzoic acid (7.52) 
Preparation was via general method C using 5-(4-
chlorophenyl)-1,3 dihydro-2-benzofuranone (7.43) 
(0.30 g, 1.23 mmol) to afford the title compound 
(7.52) as an off-white solid which was used without 
further purification (0.33 g, 0.87 mmol, 71%) m.p.: 181.5-187.1 °C; Rf: 0.21 
(CHCl3); δH (300 MHz, DMSO-d6): 7.91 (1H, d, J 8.1, 6-H), 7.86 (1H, d, J 
1.8, 3-H), 7.74 (2H, d, J 8.5, 6’-H and 2’-H), 7.66 (1H, dd, J 8.3 and 1.8, 5-
H), 7.53 (2H, d, J 8.7, 5’-H and 3’-H), 5.04 (2H, s, CH2); νmax/ cm
-1 (solid): 
3065, 2649, 1676, 1318, 1190. 
 
 
 
- 207 - 
Synthesis of 4-(4-chlorophenyl)-2-(sulfonylmethyl) benzoic acid (7.30) 
Preparation was via general method D using 4-(4-
chlorophenyl)-2-(iodomethyl) benzoic acid (7.52) 
(0.30 g, 0.81 mmol) to afford the title compound 
(7.30) as pale yellow microcrystals. (0.17 g, 0.59 
mmol, 73%). m.p.: 215.0-216.6 °C; Rf: 0.05 (19:1 DCM−MeOH); δH (300 
MHz, DMSO-d6): 7.95 (1H, d, J 8.2, 6-H), 7.78 (1H, d, J 2.0, 3-H), 7.77 (2H, 
d, J 8.6, 6’-H and 2’-H), 7.66 (1H, dd, J 8.2 and 2.0, 5-H), 7.57 (2H, d, J 8.6, 
5’-H and 3’-H), 4.13 (2H, d, J 8.4, CH2), 2.87 (1H, t, J 8.4, SH); δC (75 MHz, 
DMSO-d6): 167.9 (C=O), 144.4 (C4), 142.1 (C1’), 137.5 (C2), 133.1 (C4’), 
131.6 (C6), 129.0 (C5’ and C3’), 128.8 (C5), 128.6 (C6’ and C2’), 128.1 
(C1), 124.9 (C3), 26.3 (CH2)  νmax/ cm
-1 (solid):  3225, 1698, 1650, 1302, 
1008; HPLC: Tr= 3.23 (90% rel. area); m/z (ES): (Found: [M-H]
-,  277.0089. 
C14H11ClO2S requires [M-H], 277.0096). 
Synthesis of 5-(3-fluorophenyl)-1,3-dihydo-2-benzofuranone (7.44) 
 Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 3-
flurorophenyl boronic acid (0.36 g, 2.59 mmol) to afford 
the title compound (7.44) as yellow plates which was 
used without further purification (0.32 g, 1.42 mmol, 60%) 
m.p.: 126.6-127.6 °C; Rf: 0.33 (4:1 Petrol−EtOAc); δH (300 MHz, CDCl3): 
8.00 (1H, d, J 8.7, 3-H), 7.73 (1H, d, J 8.7, 4-H), 7.66 (1H, s, 6-H), 7.46 (1H, 
dd, J 7.8 and 1.6, 2’-H), 7.40 (1H, dt, J 7.8 and 1.6, 6’-H), 7.32 (1H, dt, J 7.8 
and 1.6, 5’-H), 7.14 (1H, dd, J 7.8 and 1.6, 4’-H), 5.39 (2H, s, CH2); δC (75 
MHz, CDCl3): 170.7 (C=O), 164.8 (C3’), 147.4 (C1), 146.1 (C1’), 141.8 (C5), 
130.6 (C5’), 128.4 (C6), 126.3 (C3), 125.1 (C2), 123.2 (C4), 120.7 (C6’), 
115.5 (C4’), 114.5 (C2’), 69.6 (CH2); νmax/ cm
-1 (solid): 3077, 1748, 1506, 
1079; HPLC: Tr= 2.75 (98% rel. area); m/z (ES): (Found: MH
+, 229.0708. 
C14H9FO2 requires MH, 229.0659). 
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Synthesis of 4-(3-fluorophenyl)-2-iodomethyl-benzoic acid (7.53) 
Preparation was via general method C using 5-(3-
fluorophenyl)-1,3 dihydro-2-benzofuranone (7.44) (0.25 
g, 1.10 mmol) to afford the title compound (7.53) as an 
off-white solid which was used without further 
purification (0.31 g, 0.87 mmol, 79%) m.p.: 176.1-177.9 
°C; Rf: 0.24 (CHCl3); δH (300 MHz, DMSO-d6): 7.90 (1H, d, J 8.1, 6-H), 7.89 
(1H, d, J 2.0, 3-H), 7.68 (1H, dd, J 8.1 and 1.9, 5-H), 7.58 (1H, app. s, 2’-H), 
7.58 (1H, d, J 1.8, 6’-H), 7.49 (1H, app. q, J 6.5, 5’-H), 7.22 (1H, app. t, J 
8.1, 4’-H), 5.02 (2H, s, CH2); νmax/ cm
-1 (solid): 3063, 2632, 1687, 1557, 
1205, 792. 
Synthesis of 4-(3-fluorophenyl)-2-(sulfonylmethyl) benzoic acid (7.31) 
Preparation was via general method D using 4-(3-
fluorophenyl)-2-(iodomethyl) benzoic acid (7.53) (0.25 
g, 0.70 mmol) to afford the title compound (7.31) as 
pale yellow microcrystals. (73 mg, 0.28 mmol, 40%). 
m.p.: 167.0-168.9 °C; Rf: 0.16 (19:1 DCM−MeOH); δH 
(300 MHz, DMSO-d6): 7.94 (1H, d, J 8.2, 6-H), 7.82-7.76 (2H, m, 6’-H and 
2’-H), 7.75 (1H, d, J 1.6, 3-H), 7.64 (1H, dd, J 8.2 and 1.6, 5-H), 7.34 (2H, 
app.t, J 8.9, 5’-H and 4’-H), 4.12 (2H, d, J 8.3, CH2), 2.87 (1H, t, J 8.3, SH); 
δC (75 MHz, DMSO-d6): 167.9 (C=O), 163.1 (C3’), 144.4 (C4), 142.4 (C1’), 
138.5 (C2), 131.6 (C5’), 128.9 (C6’ and C6), 128.8 (C5), 128.3 (C1), 127.7 
(C3), 115.8 (C4’), 111.5 (C2’), 26.3 (CH2); νmax/ cm
-1 (solid): 3415, 1681, 
1490, 1295; HPLC: Tr= 2.93 (81% rel. area); m/z (ES): (Found: [M-H]
-, 
261.0389  C14H11FO2S requires [M-H], 261.0391).   
Synthesis of 5-(4-fluorophenyl)-1,3-dihydo-2-benzofuranone (7.45) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 4-
fluorophenyl boronic acid (0.36 g, 2.59 mmol) to afford 
the title compound (7.45) as yellow plates which was 
used without further purification (0.21 g, 0.94 mmol, 40%) m.p.: 172.4-173.8 
°C; Rf: 0.32 (4:1 Petrol−EtOAc); δH (300 MHz, CDCl3): 7.98 (1H, d, J 8.2, 3-
H), 7.70 (1H, d, J 8.2, 4-H), 7.63 (1H, s, 6-H), 7.59 (2H, dd, J 8.7 and 1.2, 2’-
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H and 6’-H), 7.19 (2H, t, J 8.7, 3’-H and 5’-H), 5.38 (2H, s, CH2); δC (75 MHz, 
CDCl3):170.8 (C=O), 165.3 (C4’), 147.4 (C1),146.5 (C5), 139.8 (C1’), 131.3 
(C60, 129.3 (C2’ and C6’), 128.5 (C3), 126.2 (C4), 124.9 (C2), 120.7 (C3’ 
and C5’), 69.6 (CH2); νmax/ cm
-1 (solid): 3064, 2977, 1746, 1438, 1295; 
HPLC: Tr= 2.73 (98% rel. area); m/z (ES): (Found: MH
+,  229.0706. 
C14H9FO2 requires MH, 229.0659). 
Synthesis of 4-(4-fluorophenyl)-2-iodomethyl-benzoic acid (7.54) 
Preparation was via general method C using 5-(4-
fluorophenyl)-1,3 dihydro-2-benzofuranone (7.45) 
(0.15 g, 0.66 mmol) to afford the title compound 
(7.54) as an off-white solid which was used without 
further purification (0.19 g, 0.52 mmol, 79%) m.p.: 177.4-178.5 °C; Rf: 0.21 
(CHCl3); δH (300 MHz, DMSO-d6): 7.95 (1H, d, J 8.3, 6-H), 7.88 (1h, d, J 1.8, 
3-H), 7.80 (2H, dd, J 8.8 and 5.4, 6’-H and 2’-H), 7.62 (1H, dd, J 8.1 and 1.8, 
5-H), 7.35 (2H, app. t, J 8.9, 5’-H and 3’-H), 5.09 (2H, s, CH2); νmax/ cm
-1 
(solid): 3068, 2639, 1678, 1235, 1168. 
Synthesis of 4-(4-fluorophenyl)-2-(sulfonylmethyl) benzoic acid (7.32) 
Preparation was via general method D using 4-(4-
fluorophenyl)-2-(iodomethyl) benzoic acid (7.54) 
(0.30 g, 0.84 mmol) to afford the title compound 
(7.32) as pale yellow microcrystals. (92 mg, 0.35 
mmol, 42%) m.p.: 156.4-157.8 °C; Rf: 0.14 (19:1 DCM−MeOH); δH (300 
MHz, DMSO-d6): 7.94 (1H, d, J 8.1, 6-H), 7.79 (2H, dd, J 8.9 and 5.6, 6’-H 
and 2’-H), 7.75 (1H, d, J 1.8, 3-H), 7.63 (1H, dd, J 8.1 and 1.8, 5-H), 7.34 
(2H, app. t, J 8.9, 5’-H and 3’-H), 4.13 (1H, d, J 8.4, CH2), 2.85 (1H, t, J 8.4, 
SH); δC (75 MHz, DMSO-d6): 167.9 (C=O), 160.0 (C4’), 144.4 (C4), 142.5 
(C1), 135.2 (C1’), 131.6 (C6), 128.9 (C6’, C2’ and C5), 127.7 (C1), 124.9 
(C3), 115.8 (C5’ and C3’); νmax/ cm
-1 (solid): 2980, 1680, 1558, 1294, 1219; 
HPLC: Tr= 2.25 (90% rel. area); m/z (ES): (Found: [M-H]
-, 261.0390. 
C14H11FO2S requires [M-H], 261.0391). 
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Synthesis of 4-(2,3-dichlorophenyl)-2-iodomethyl-benzoic acid (7.55) 
Preparation was via general method C using 5-(2,3-
dichlorophenyl-1,3 dihydro-2-benzofuranone (7.18) 
(0.30 g, 1.08 mmol) to afford the title compound (7.55) 
as an pale brown solid which was used without further 
purification (0.44 g, 1.07 mmol, 99%) m.p.: 154.3-155.7 
°C; Rf: 0.26 (CHCl3); δH (300 MHz, DMSO-d6): 7.92 (1H, d, J 8.1 6-H), 7.70 
(1H, dd, J 7.7 and 2.1 5-H), 7.59 (1H, d, J 1.9 3-H), 7.45 (2H, d, J 7.8, 6’-H 
and 4’-H), 7.38 (1H, td, J 7.8 and 2.2 5’-H), 5.02 (2H, s, CH2); νmax/ cm
-1 
(solid): 3363, 2973, 2653, 1771, 1378, 1268. 
Synthesis of 4-(2,3-dichlorophenyl)-2-(sulfonylmethyl) benzoic acid 
(7.33) 
Preparation was via general method D using 4-(2,3-
dichlorophenyl)-2-(iodomethyl) benzoic acid (7.55) (0.15 
g, 0.57 mmol) to afford the title compound (7.33) as 
pale yellow microcrystals. (98 mg, 0.31 mmol, 55%). 
m.p.: 154.1-155.7 °C; Rf: 0.38 (19:1 DCM−MeOH) δH 
(300 MHz, DMSO-d6): 7.94 (1H, d, J 8.0, 6-H), 7.71 (1H, dd, J 8.0 and 1.4, 
5-H), 7.52 (1H, d, J 1.4, 3-H), 7.47(1h, d, J 7.7, 4’-H), 7.47-7.70 (2H, m, 6’-H 
and 5’-H), 4.10 (2H, d, J 7.5, CH2), 2.84 (1H, t, J 7.5, SH); δC (75 MHz, 
DMSO-d6): 167.8 (C=O), 143.5 (C1’), 142.0 (C4), 141.5 (C2), 139.1 (C3’), 
132.4 (C5’), 131.3 (C6), 130.9 (C5), 130.7 (C6’), 129.2 (C2’), 128.8 (C1), 
128.4 (C4’), 127.6 (C3), 26.1 (CH2); νmax/ cm
-1 (solid): 2750, 1680, 1247, 
1020, 759; HPLC: Tr=  2.57 (100% rel. area); m/z (ES): (Found: [M-H]
-, 
310.9707. C14H10Cl2O2S requires [M-H], 310.9706) 
Preparation of 5-[3,5-bis(trifluoromethyl)phenyl]-1,3-dihydro-2-
benzofuran-1-one (7.46) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 3,5-
bis-(trifluoromethyl)phenyl boronic acid (0.49 g, 2.59 
mmol) to yield the title compound (7.46) as a yellow 
solid (0.39 g, 1.13 mmol, 48%); m.p.: 167-171 °C; Rf: 
0.51 (4:1 Petrol–EtOAc); δH (300 MHz, DMSO-d6): 8.46 (2H, s, 6`-H and 2`-
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H), 8.22 (2H, s, 6-H and 4`H), 8.12 (1H, d, J 8.1, 3-H), 7.98 (1H, d, J 8.1, 4-
H), 5.50 (2H, s, CH2); δC (75 MHz, DMSO-d6): 170.3 (C=O), 147.7 (C1), 
144.2 (C1`), 141.9 (C5), 132.8 (C6`), 132.5 (C2`), 132.3 (C5`), 128.6 (C3`), 
127.7 (C4), 126.8 (C6), 126.2 (C2), 124.2 (C3), 122.3 (CF3 × 2), 121.1 (C4’), 
69.5 (CH2); νmax/ cm
-1 (solid): 3071, 2922 1758, 1681; HPLC: Tr= 2.78 (100% 
rel. area); m/z (ES) (Found: MNa+,  369.0312. C16H8F6O2 requires MNa, 
369.0321). 
Preparation of 4-[3,5-bis(trifluoromethyl)phenyl]-2-(iodomethyl)benzoic 
acid (7.56) 
Preparation was via general method C using 5-
[3,5-bis(trifluoromethyl)phenyl]-1,3-dihydro-2-
benzofuranone (7.46) (0.30 g, 0.86 mmol) to yield 
the title compound (7.56) as a grey solid (0.39 g, 
0.82 mmol, 95%); m.p.: 156.2-157.9 °C; Rf: 0.88 
(19:1 DCM−MeOH); δH (300 MHz, DMSO-d6): 8.43 (2H, s, 6`-H and 2`-H), 
8.22-8.13 (2H, m, 3-H and 4`H), 7.99 (1H, d, J 8.2, 6-H), 7.91 (1H, d, J 8.2, 
5-H), 5.09 (2H, s, CH2); νmax/ cm
-1 (solid): 2818, 2635, 1763, 1688. 
Preparation of 4-[3,5-bis(trifluoromethyl)phenyl]-2-
(sulfanylmethyl)benzoic acid (7.34) 
Preparation was via general method D using 4-
[3,5-bis(trifluoromethyl)phenyl]-2-(iodomethyl) 
benzoic acid (7.56) (0.30 g, 0.81 mmol) to yield the 
title compound (7.34) as a colourless solid (0.15 g, 
0.39 mmol, 55%); m.p.: 147-151 °C; Rf: 0.10 (19:1 
DCM−MeOH); δH (300 MHz, DMSO-d6): 8.31 (2H, s, 6`-H and 2`-H), 8.07 
(1H, s, 6-H), 7.88 (2H, d, J 7.8, 3-H and 4`-H), 7.78 (1H, d, J 7.6, 5-H), 4.04 
(2H, d, J 8.5, CH2), 2.82 (1H, J 8.3, SH); δC (75 MHz, DMSO-d6): 168.0 
(C=O), 144.6 (C1`), 141.0 (C2), 139.5 (C4), 132.3 (C5’ and C3’), 131.6 
(C6`), 129.5 (C2`), 127.6 (C6), 125.7 (C3), 125.4 (C5), 123.1 (CF3 × 2), 
121.6 (C4`), 26.2 (CH2); νmax/ cm
-1 (solid): 2965, 2651, 1763, 1690; m/z (ES) 
(Found: [M-H]+, 379.0232. C16H10F6O2S requires [M-H], 379.0306). 
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Preparation of 5-(naphthalen-2-yl)-1,3-dihydro-2-benzofuran-1-one 
(7.47) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 2-
napthalene boronic acid (0.45 g, 2.59 mmol) to yield 
the title compound (7.47) as a colourless powder 
(0.34 g, 1.31 mmol, 56%); m.p.: 204-206 °C; Rf: 0.36 (3:1 Petrol–EtOAc); δH 
(300 MHz, CDCl3): 8.10 (1H, s, 1`-H), 8.03 (1H, d, J 8.1, 3-H), 7.98 (1H, d, J 
8.9, 5`-H), 7.94-7.86 (3H, m, 3’-H, 8`-H and 3-H), 7.83 (1H, s, 6-H), 7.75 (1H, 
dd, J 9.0 and 1.8, 3`-H), 7.61-7.52 (2H, m, 7`-H and 6`-H), 5.42 (2H, s, CH2); 
δC (75 MHz, CDCl3): 171.5 (C=O), 147.4 (C1), 137.0 (C5), 133.5 (C2`), 
133.2 (C8`a and C4`a),129.0 (C4), 128.7 (C4`), 128.4 (C8`), 127.7 (C5`), 
126.8 (C7`), 126.7 (C3`), 126.2 (C6` and C2), 125.2 (C6 and C3`), 120.8 
(C1), 69.6 (CH2); νmax/ cm
-1 (solid): 3056, 2942, 2872, 1740, 1610; HPLC: Tr= 
2.93 (100% rel. area); m/z (ES) (Found: MH+, 261.0918. C18H12O2 requires 
MH, 261.0871). 
Preparation of 2-(iodomethyl)-4-(naphthalen-2-yl)benzoic acid (7.57) 
Preparation was via general method C using 5-
(napthalen-2-yl)-1,3-dihydro-2-benzofuranone 
(7.47) (0.30 g, 1.15 mmol) to yield the title 
compound (7.57) as a brown solid (0.33 g, 0.85 
mmol, 74%); m.p.: 174-178 °C; Rf: 0.50 (19:1 DCM−MeOH); δH (300 MHz, 
DMSO): 8.33 (1H, d, J 8.1, 6-H), 8.29–8.20 (1H, m, 8`-H), 8.14 (1H, d, J 7.5, 
5`-H), 8.06-7.95 (2H, m, 3-H, 1`-H), 7.90 (1H, dd, J 8.7 and 1.9, 4`-H), 7.84 
(1H, dd, J 8.1 and 2.0, 5-H), 7.55 (1H, d, J 8.7, 3`-H), 7.49–7.43 (2H, m, 7`-H 
and 6`H), 5.12 (2H, s, CH2); νmax/ cm
-1 (solid): 2957, 2646, 1679, 1600. 
Preparation of 4-(naphthalen-2-yl)-2-(sulfanylmethyl)benzoic acid (7.35) 
Preparation was via general method D using 2-
(iodomethyl)-4-(naphthalene-2-yl) benzoic acid 
(7.57) (0.30 g, 0.81 mmol) to yield the title 
compound (7.35) as a colourless solid (0.13 g, 
0.44 mmol, 63%); m.p.: 163-165 °C; Rf: 0.33 (19:1 DCM−MeOH); δH (300 
MHz, DMSO): 13.30 (1H, s, OH), 8.32 (1H, s, 6-H), 8.04-8.04 (1H, m, 4`-H), 
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8.03-8.02 (1H, m, 7`H), 8.01-7.99 (2H, m, 3`-H and 3-H), 7.97 (1H, d, J 1.0, 
8`-H), 7.80 (1H, dd, J 7.8 and 2.6, 5-H), 7.57 (1H, d, J 1.8, 1`-H), 7.56-7.54 
(2H, m, 5`-H and 6`H), 4.15 (2H, d, J 8.6, CH2), 2.88 (1H, t, J 8.4, SH); δC 
(75 MHz, DMSO): 168.0 (C=O), 144.5 (C2), 143.3 (C4), 136.0 (C2`), 133.20 
(C8a`), 132.6 (C4a`), 131.7 (C6), 129.1 (C3), 128.6 (C5), 128.3 (C8`), 127.8 
(C5`), 127.5 (C1), 126.6 (C7`), 125.8 (C1`), 125.2 (C6`), 124.8 (C3`), 26.5 
(CH2); νmax/ cm
-1 (solid): 3057, 2968, 2647, 2557, 1759, 1682, 1605; HPLC: 
Tr= 2.71 (100% rel. area); m/z (ES) (Found: [M-H]
-, 293.0647. C18H14O2S 
requires [M-H], 293.0715). 
Preparation of 4-(furan-2-yl)-2-(iodomethyl)benzoic acid (7.58) 
Preparation was via general method C using 5-(furan-2-
yl)-1,3-dihydro-2-benzofuranone (7.15) (0.23 g, 1.15 
mmol) to yield the title compound (7.58) as a brown 
solid which was used without further purification (0.37 g, 
1.12 mmol, 98%); m.p.: 149.1-150.4 °C; Rf: 0.81 (19:1 DCM−MeOH); δH 
(300 MHZ, DMSO): 7.91 (1H, d, J 8.2, 6-H), 7.87 (1H, d, J 1.7, 5`-H), 7.85 
(1H, d, J 1.8, 3-H), 7.67 (1H, dd, J 8.2 and 1.8, 5-H), 7.14 (1H, d, J 3.4, 3`-
H), 6.66 (1H, dd, J 3.2 and 1.7, 4`-H), 5.04 (2H, s, CH2); νmax/ cm
-1 (solid): 
2796, 2634, 1681, 1607.  
Preparation of 4-(furan-2-yl)-2-(sulfanylmethyl)benzoic acid (7.36) 
Preparation was via general method D using 4-(furan-2-
yl)-2-(iodomethyl) benzoic acid (7.58) (0.30 g, 0.90 
mmol) to yield the title compound (7.36) as a colourless 
solid (0.10 g, 0.43 mmol, 48%); m.p.: 154.9-157.3 °C; 
Rf: 0.22 (19:1 DCM−MeOH); δH (300 MHz, DMSO): 13.16 (1H, s, OH), 7.91 
(1H, d, J 8.1, 6-H), 7.82 (1H, s, 5`-H), 7.76 (1H, s, 3-H), 7.64 (1H, d, J 8.1, 5-
H), 7.11 (1H, d, J 5.1, 3`-H), 6.66 (1H, d, J 5.1, 6, 4`-H), 4.08 (2H, d, J 8.4, 
CH2), 2.83 (1H, t, J 8.4, SH); δC (75 MHz, DMSO): 167.7 (C=O), 151.8 (C1`), 
144.5 (C3`), 144.0 (C6), 133.4 (C2), 131.7 (C3), 127.4 (C4), 125.2 (C5), 
121.6 (C1), 112.4 (C4`), 108.1 (C5`), 26.4 (CH2); νmax/ cm
-1 (solid): 2941, 
2809, 2634, 2540, 1762 and 1680; HPLC: Tr= 2.52 (91% rel. area); m/z (ES) 
(Found: [M-H]-, 233.0277, C12H10O3S requires [M-H], 233.0351). 
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Synthesis of 4-(4-ethylphenyl)-2-iodomethyl-benzoic acid (7.59) 
Preparation was via general method C using 5-(4-
ethylphenyl-1,3 dihydro-2-benzofuranone (7.16) 
(0.30 g, 1.26 mmol) to afford the title compound 
(7.59) as an off-white solid which was used without 
further purification (0.19 g, 0.51 mmol, 41%) m.p.: 164.1-165.7 °C; Rf: 0.24 
(CHCl3); δH (300 MHz, DMSO-d6): 7.85 (1H, d, J 8.4, 6-H), 7.78 (1H, d, J 
1.8, 3-H), 7.57 (3H, app. d, J 8.3, 5-H, 2’-H and 6’-H), 7.26 (2H, d, J 8.3, 5’-H 
and 3’-H), 5.01 (2H, s, CH2I), 2.58 (2H, q, J 7.8, CH2), 1.13 (3H, t, J 7.6 
CH3); νmax/ cm
-1 (solid): 2970, 2631, 1669, 1572, 1252, 828; m/z (ES): 
(Found: [M-I]+, 239.1068. C16H15IO2 requires [M-I], 239.1067). 
Synthesis of 4-(4-ethylphenyl)-2-(sulfonylmethyl) benzoic acid (7.37) 
Preparation was via general method D using 4-(4-
ethylphenyl)-2-(iodomethyl) benzoic acid (7.59) 
(0.15 g, 0.41 mmol) to afford the title compound 
(7.37) as pale yellow microcrystals. (65 mg, 0.22 
mmol, 55%) m.p.: 139.2-140.5 °C; Rf: 0.20 (19:1 
DCM−MeOH); δH (300 MHz, DMSO-d6): 7.95 (1H, d, J 8.2, 6-H), 7.74 (1H, 
d, J 2.2, 3-H), 7.66 (2H, d, J 8.2, 6’-H and 2’-H), 7.62 (1H, dd, J 8.2 and 2.2, 
5-H), .34 (2H, d, J 8.2, 5’-H and 3’-H), 4.12 (2H, d, J 8.5, CH2SH), 2.85 (1H, 
t, J 8.5, SH), 2.66 (2H, q, J 7.4, CH2CH3), 1.21 (3H, t, J 7.4, CH3); δC (75 
MHz, DMSO-d6): 168.0 (C=O), 144.3 (C4), 144.0 (C4’), 143.5 (C2), 136.1 
(C1’), 131.5 (C6), 128.5 (C5), 128.4 (C5’ and C3’), 127.8 (C1), 126.7 (C6’ 
and C2’), 124.7 (C3), 27.8 (CH2CH3), 26.4 (CH2SH), 15.5 (CH3); νmax/ cm
-1 
(solid): 2942, 1673, 1274, 830; HPLC: Tr= 2.61 (91% rel. area); m/z (ES): 
(Found: [M-H]-, 271.0790 C16H16O2S requires [M-H], 271.0798). 
Synthesis of 5-(thiophen-3-yl)-1,3-dihydo-2-benzofuranone (7.48) 
 Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.35 mmol) and 3-thienyl 
boronic acid (0.33 g, 2.59 mmol) to afford the title 
compound (7.48) as yellow plates which was used without 
further purification (0.23 g, 1.08 mmol, 46%) m.p.: 171.7-173.4 °C; Rf: 0.30 
(4:1 Petrol−EtOAc); δH (300 MHz, CDCl3): 7.96 (1H, d, J 8.1, 3-H), 7.78 (1H, 
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dd, J 8.1 and 1.6, 4-H), 7.70 (1H, d, J 1.6, 6-H), 7.63 (1H, dd, J 2.9 and 1.5, 
5’-H), 7.49 (1H, dd, J 5.0 and 2.9, 2’-H), 7.45 (1H, dd, J 5.0 and 1.5, 4’-H), 
5.39 (2H, s, CH2); δC (75 MHz, CDCl3):170.9 (C=O), 147.5 (C1), 141.6 (C3’), 
140.8 (C5), 127.6 (C6), 127.2 (C4), 126.1 (C5’ and C3), 124.2 (C2), 122.8 
(C4’), 119.6 (C2’), 69.5 (CH2); νmax/ cm
-1 (solid): 3095, 1768, 1747, 1366, 
1046; HPLC: Tr= 2.54 (100% rel. area); m/z (ES): (Found: MNa
+,  239.0141. 
C12H8NaO2S requires MNa, 239.0137). 
Synthesis of 4-(thien-3-yl)-2-iodomethyl-benzoic acid (7.60) 
Preparation was via general method C using 5-(thien-3-
yl)-1,3 dihydro-2-benzofuranone (7.48) (0.30 g, 1.39 
mmol) to afford the title compound (7.60) as an off-white 
solid which was used without further purification (0.38 g, 
1.10 mmol, 79%) m.p.: 168.9-170.7 °C; Rf: 0.18 (CHCl3); δH (300 MHz, 
DMSO-d6): 8.05 (1H, app. s, 4’-H), 7.93 (1H, d, J 1.8, 3-H), 7.90 (1H, d, J 
8.1, 6-H), 7.74-7.68 (2H, m, 5-H and 2’-H), 7.64 (1H, dd, J 5.6 and 2.0, 4’-H), 
5.04 (2H, s, CH2); νmax/ cm
-1 (solid): 3405, 2505, 1665, 1600, 1248, 786; m/z 
(ES): (Found: [M-I+Na]+, 239.0137. C12H8NaO2S requires [M-I+Na], 
239.0137. 
Synthesis of 4-(thiophen-3-yl)-2-(sulfonylmethyl) benzoic acid (7.38) 
Preparation was via general method D using 4-
(thiophen-3-yl)-2-(iodomethyl) benzoic acid (7.60) (0.30 
g, 0.87 mmol) to afford the title compound (7.38) as 
colourless microcrystals. (0.12 g, 0.48 mmol, 54%). 
m.p.: 171.5-173.2 °C; Rf: 0.21 (19:1 DCM−MeOH); δH (300 MHz, DMSO-d6): 
8.04 (1H, dd, J 5.0 and 2.9, 5’-H), 7.90 (1H, d, J 8.2, 6-H), 7.82 (1H, d, J 1.4, 
3-H), 7.72-7.68 (2H, m, 5-H and 2’-H), 7.64 (1H, dd, J 7.9 and 2.9, 4’-H), 
4.10 (2H, d, J 8.4, CH2), 2.84 (1H, t, J 8.4, SH); δC (75 MHz, DMSO-d6): 
167.9 (C=O), 144.4 (C1’), 140.1 (C2), 138.5 (C4), 131.6 (C6), 128.1 (C3), 
127.4 (C4’), 127.1 (C1), 126.1 (C5), 124.3 (C3’), 122.7 (C5’), 26.4 (CH2); 
νmax/ cm
-1 (solid): 1675, 1607, 1281, 772; HPLC: Tr= 2.74 (100% rel. area); 
m/z (ES): (Found: [M-H]-, 248.9522. C12H10O2S2 requires [M-H], 249.0049). 
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Synthesis of 4-(3-ethoxyphenyl)-2-iodomethyl-benzoic acid (7.61) 
Preparation was via general method C using 5-(3-
ethoxyphenyl)-1,3 dihydro-2-benzofuranone (7.16) 
(0.30 g, 1.18 mmol) to afford the title compound (7.61) 
as an off-white solid which was used without further 
purification (86 mg, 0.23 mmol, 19%) m.p.: 145.8-146.4 
°C; Rf: 0.15 (CHCl3); δH (300 MHz, DMSO-d6): 8.18 
(1H, d, J 8.3, 6-H), 7.68 (1H, d, J 1.8, 3-H), 7.59 (1H, dd, J 8.3 and 1.8, 5-H), 
7.39 (1H, t, J 8.1, 5’-H), 7.23 (1H, dd, J 8.1 and 1.9, 4’-H), 7.17 (1H, t, J 1.8, 
2’-H), 6.96 (1H, dd, J 8.1 and 1.9, 6’-H), 5.08 (2H, s, CH2I), 4.25 (2H, q, 
CH2), 1.37 (3H, t, CH3); νmax/ cm
-1 (solid): 2980, 1676, 1597, 1305, 1262. 
Synthesis of 4-(3-ethoxyphenyl)-2-(sulfonylmethyl) benzoic acid (7.39) 
Preparation was via general method D using 4-(3-
ethoxyphenyl)-2-(iodomethyl) benzoic acid (7.61) (0.30 
g, 0.79 mmol) to afford the title compound (7.39) as 
colourless microcrystals. (84 mg, 0.29 mmol, 37%). 
m.p.: 128.0-129.8 °C; Rf: 0.21 (19:1 DCM−MeOH); 
(Found: C, 66.8; H, 5.60; C16H16O3S requires C, 66.6; 
H, 5.59%); δH (300 MHz, DMSO-d6): 7.93 (1H, d, J 8.1, 6-H), 7.77 (1H, d, J 
1.6, 3-H), 7.65 (1H, dd, J 8.1 and 1.6, 5-H), 7.40 (1H, app. t, J 7.9, 5’-H), 
7.29 (1H, d, J 7.9, 6’-H), 7.26 (1H, d, J 1.4, 2’-H), 6.98 (1H, dd, J 7.9 and 
1.4, 4’-H), 4.20-4.03 (4H, m, CH2CH3 and CH2SH), 2.86 (1H, t, J 8.3, SH), 
1.36 (3H, t, J 7.0, CH3); δC (75 MHz, DMSO-d6): 168.0 (C=O), 159.1 (C3’), 
144.3 (C1’), 143.4 (C2), 140.2 (C4), 131.5 (C5’), 130.1 (C6), 128.9 (C5), 
127.8 (C1), 125.0 (C3), 119.0 (C6’), 114.2 (C4’), 112.9 (C2’), 63.1 (CH2CH3), 
26.4 (CH2S), 14.6 (CH3); νmax/ cm
-1 (solid): 3045, 1650, 1541, 1301, 952; 
HPLC: Tr= 3.11 (100% rel. area); m/z (ES): (Found: [M-H]
-, 287.0675. 
C16H16O3S requires [M-H], 287.0747). 
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Synthesis of 5-(2-trifluoromethylphenyl)-1,3-dihydo-2-benzofuranone 
(7.49) 
Preparation was via general method A using 5-
bromophthalide (7.5) (0.50 g, 2.30 mmol) and 3-
nitrophenyl boronic acid (0.49 g, 2.60 mmol) to afford the 
title compound (7.49) as an off-white solid which was 
used without further purification (0.45 g, 1.61 mmol, 70%); m.p.: 87-89 °C; 
Rf: 0.41 (4:1 Petrol–EtOAc); δH (300 MHz, CDCl3): 7.87 (1H, d, J 7.9, 3-H), 
7.71 (1H, dd, J 7.4 and 0.9, 4-H), 7.65-7.51 (2H, m, 5`-H and 4`-H), 7.42 
(1H, d, J 7.6, 6`-H), 7.38 (1H, d, J 0.9, 6-H), 7.29 (1H, d, J 7.6, 3`-H), 5.30 
(2H, s, CH2); δC (75 MHz, CDCl3): 170.7 (C=O), 146.2 (C5), 145.9 (C1`), 
139.6 (C1), 131.6 (C4`), 131.5 (C5`), 130.3 (C6), 128.4 (C6`), 128.0 (C2`), 
126.4 (C4), 125.2 (C3), 125.0 (C2), 125.0 (CF3), 122.7 (C3`), 69.5 (CH2); 
νmax/ cm
-1 (solid): 2967, 1758, 1619; HPLC: Tr= 2.85 (100% rel. area); m/z 
(ES) (Found: MH+, 279.0617. C15H9F3O2 requires MH, 279.0555). 
Synthesis of 4-(2-trifluoromethylphenyl)-2-iodomethyl-benzoic acid 
(7.62) 
Preparation was via general method C using 5-(2-
trifluoromethylphenyl)-1,3 dihydro-2-benzofuranone 
(7.49) (0.30 g, 1.08 mmol) to afford the title compound 
(7.62) as an off-white solid which was used without 
further purification (0.32 g, 0.78 mmol, 72%) m.p.: 149.5-151.0 °C; Rf: 0.27 
(CHCl3); δH (300 MHz, DMSO-d6): 7.86 (1H, d, J 8.0, 6-H), 7.81 (1H, d, J 
7.3, 3’-H), 7.70 (1H, app. t, J 7.3, 5’-H), 7.61 (1H, app. t, J 7.3, 4’-H), 7.44 
(1H, d, J 1.7, 3-H), 7.37 (1H, d, J 7.3, 6’-H), 7.27 (1H, dd, J 8.0 and 1.7, 5-
H), 4.83 (2H, s, CH2); νmax/ cm
-1 (solid): 2855, 1690, 1678, 1254, 1085.  
Synthesis of 4-(2-trifluoromethylphenyl)-2-(sulfonylmethyl) benzoic 
acid (7.40) 
Preparation was via general method D using 4-(2-
trifluoromethyl)-2-(iodomethyl) benzoic acid (7.62) (0.25 
g, 0.61 mmol) to afford the title compound (7.40) as 
pale yellow microcrystals. (79 mg, 0.25 mmol, 42%). 
m.p.: 114.4-115.9 °C; Rf: 0.20 (19:1 DCM−MeOH); δH (300MHz, DMSO-d6): 
7.91 (1H, d, J 8.0, 6-H), 7.86 (1H, d, J 7.4, 3’-H), 7.76 (1H, app. t, J 7.4, 5’-
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H), 7.66 (1H, app. t, J 7.4, 4’-H), 7.45 (1H, app. d, J 7.4, 6’-H), 7.41 (1H, d, J 
1.8, 3-H), 7.30 (1H, dd, J 8.0 and 1.8, 5-H), 4.09 (2H, d, J 8.5, CH2), 2.80 
(1H, t, J 8.5, SH); δC (75 MHz, DMSO-d6):  169.0 (C=O), 143.1 (C1’), 142.9 
(C4), 139.4 (C2), 132.4 (C4’ and C2’), 131.8 (C5’), 130.9 (C6’ and C1), 
130.3 (C3’), 128.5 (C6 and C5), 128.6 (CF3), 127.3 (C3), 126.1 (C6’), 26.1 
(CH2); νmax/ cm
-1 (solid): 3066, 1677, 1413, 1167, 1093; HPLC: Tr= 3.11 
(100% rel. area); m/z (ES): (Found: [M-H]-, 311.0207. C15H11F3O2S requires 
[M-H], 311.0210). 
Preparation of 4-bromo-2-(iodomethyl) benzoic acid (7.63) 
Preparation was via general method C using 5-
bromophthalide (7.5) (0.30 g, 1.40 mmol) to yield the title 
compound (7.63) as a yellow solid (0.26 g, 0.76 mmol, 
55%); m.p.: 154-157 °C; Rf: 0.79 (19:1 DCM−MeOH); δH (300 MHz, DMSO-
d6): 7.81 (1H, d, J 2.0, 6-H), 7.71 (1H, d, J 8.4, 3-H), 7.58 (1H, dd, J 8.4 and 
2.0, 5-H), 4.97 (2H, s, CH2); νmax/ cm
-1 (solid): 2797, 2632, 1675 and 1584. 
Preparation of 4-bromo-2-(sulfanylmethyl)benzoic acid (7.41) 
Preparation was via general method D using 4-bromo-2-
(iodomethyl) benzoic acid (7.63) (0.23 g, 0.67 mmol) to 
yield the title compound (7.41) as a colourless solid (62 
mg, 0.25, mmol, 37%); m.p.: 134-137 °C; Rf: 0.14 (5% MeOH–DCM); δH 
(300 MHz, DMSO-d6): 7.78 (1H, d, J 8.3, 6-H), 7.70 (1H, d, J 2.0, 3-H), 7.58 
(1H, dd, J 8.3 and 2.0, 5-H), 4.02 (2H, d, J 8.5, CH2), 2.90 (1H, t, J 8.5, SH); 
δC (75 MHz, DMSO-d6): 167.5 (C=O), 146.0 (C2), 133.1 (C3), 132.7 (C6), 
129.9 (C5), 128.3 (C1), 125.6 (C4), 25.7 (CH2); νmax/ cm
-1 (solid): 2956, 
2809, 2646, 2525, 1673 and 1585; HPLC: Tr= 2.12 (100% rel. area); m/z 
(ES) (Found: MH+, 246.9250. C8H7BrO2S requires 246.9350). 
Synthesis of 5-phenyl-1,3-dihydro-2-benzothiophen-1-one (7.64) 
 4-(phenyl)-2-(sulfanylmethyl) benzoic acid (7.21) (50 mg, 
0.20 mmol) was dissolved in TFA (5 mL). The reaction 
was heated to reflux for 1 h. The reaction mixture was 
allowed to cool to room temperature before being 
concentrated in vacuo to afford the title compound (7.64) as off-white 
microcrystals. (45 mg, 0.20 mmol, 99%). m.p.: 114.3-115.7 °C; Rf: 0.48 (4:1 
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Petrol−EtOAc); δH (300 MHz, DMSO-d6): 7.95 (1H, s, 6-H), 7.78 (1H, d, J 
7.4, 4-H), 7.75-7.30 (3H, m, 3-H, 6’-H and 2’-H), 7.46 (2H, app. t, J 7.3, 5’-H 
and 3’-H), 7.41 (1H, t, J 7.3, 4’-H), 4.67 (2H, s, CH2);  δC (75 MHz, DMSO-
d6): 189.7 (C=O), 148.7 (C5), 145.3 (C1’), 138.6 (C1), 133.8 (C2), 129.2 
(C6’ and C2’), 128.7 (C4), 127.3 (C5’ and C3’), 126.8 (C3), 125.1 (C4’), 
123.4 (C6), 34.5 (CH2); νmax/ cm
-1 (solid): 3481, 1657, 1138, 870; HPLC: Tr= 
2.57 (100% rel. area); m/z (ES): (Found: MH+,  227.0518. C14H10OS requires 
MH, 227.0525). 
Synthesis of 3H-benzo[b]thiophene-2-one (7.66) 
To a stirred solution of thianapthene-2-boronic acid (7.65) 
(0.25 g, 1.40 mmol) in ethanol (1 mL) was added dropwise 
hydrogen peroxide solution (0.46 mL, 1.74 mmol). The 
mixture was stirred at room temperature for 24 h. The solution was diluted 
with water (5 mL). The aqueous mixture was extracted with chloroform (3 × 5 
mL). The combined organics were dried and concentrated in vacuo. The 
crude product was purified by flash column chromatography eluting with 19:1 
Petrol−EtOAc to afford the title compound (7.66) as pale pink needles. (0.20 
g, 1.36 mmol, 97%) Rf: 0.35 (19:1 Petrol–EtOAc); (Found: C, 64.1; H, 4.05; 
S, 21.2; C8H6OS requires C, 63.9; H, 4.03; S, 21.4%); δH (300 MHz, CDCl3):  
7.36-7.19 (4H, m, 5-H and 2-H); δC (75 MHz, CDCl3): 203.1 (C=O), 137.1 
(C6), 132.2 (C1), 128.4 (C3), 126.2 (C5), 124.8 (C4), 123.1, (C2), 47.3 
(CH2); νmax/ cm
-1 (solid): 3410, 2926, 1714, 1466, 1387; HPLC: Tr= 2.64 
(100% rel. area); m/z (EI): (Found: M+, 150.0114 C8H6OS requires M, 
150.0139).  
Synthesis of 2-(2 sulfanylphenyl)acetic acid (7.67) 
3H-benzo[b]thiophene-2-one (7.66) (0.10 g, 0.67 mmol) was 
dissolved in methanol (10 mL) and to this was added 2M 
NaOH (aq) (5 mL). The reaction was refluxed under nitrogen 
for 16 h. The reaction mixture was concentrated in vacuo. The residue was 
re-suspended in water (5 mL) and the mixture acidified to ~pH1 with 2M HCl 
(aq). The resulting precipitate was isolated to afford the title compound (7.67) 
as pale brown plates. (0.10 g, 0.62 mmol, 93%) m.p: 98.9-100.9 °C Rf: 0.38 
(19:1 DCM−MeOH); δH (300 MHz, DMSO-d6): 7.42 (1H, t, J 7.7 4-H), 7.20 
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(3H , m, 6-H, 5-H and 3-H), 3.82 (2H, s, CH2), 3.50 (1H, s, SH); δC (75 MHz, 
DMSO-d6): 176.8 (C=O), 133.3 (C2), 132.3 (C4), 131.0 (C5), 130.8 (C1), 
128.3 (C3), 127.0 (C6), 39.9 (CH2); νmax/ cm
-1 (solid): 3063-2637, 1696, 
1467, 1232; HPLC: Tr= 2.48 (88% rel. area); m/z (ES): (Found: [M-H]
-, 
167.0187 C8H8O2S requires [M-H], 167.0172).   
Synthesis of 2-(([(2-carboxy-5-phenylphenyl)methyl]disulfanyl)methyl)-
4-phenylbenzoic acid176 (7.27) 
 A solution of 4-(phenyl)-2-(sulfanylmethyl) 
benzoic acid (7.21) (50 mg, 0.20 mmol) in 
EtOH (2 mL) was cooled to 0 °C. To the 
mixture was added iodine (0.5 M in ethanol) 
until the colour of the solution turned red. The 
reaction was stirred at 0 °C for 1 h. Sodium 
thiosulfate (0.5M in H2O) was added to the mixture until the colour changed 
from red to white. The EtOH was removed in vacuo and the resulting 
precipitate was isolated by filtration. The product was washed (H2O) and 
dried to afford the title compound (7.27) as colourless microcrystals. (46 mg, 
0.09 mmol, 95%). m.p.: 234.2-235.9 °C; Rf: 0.15 (19:1 DCM−MeOH); δH 
(300 MHZ, DMSO-d6): 8.00 (2H, d, J 8.2, 6-H), 7.70 (2H, dd, J 8.2 and 1.2, 
5-H), 7.69 (4H, d, J 7.5, 6’-H and 2’-H), 7.56 (2H, d, J 1.2, 3-H), 7.52-7.39 
(6H, m, 5’-H, 4’-H and 3’-H), 4.25 (4H, s, CH2); δC (75 MHz, DMSO-d6): 
167.9 (C=O), 143.1 (C4), 139.9 (C1’), 138.5 (C2), 131.9 (C6), 129.8 (C5), 
129.1 (C5’ and C3’), 128.3 (C4’), 128.2 (C1), 126.8 (C6’ and C2’), 125.6 
(C3), 40.6 (CH2); νmax/ cm
-1 (solid): 2931, 1681, 1450, 1166; HPLC: Tr= 2.70 
(100% rel. area); m/z (ES): (Found: [M-H]-, 485.0884. C28H22O4S2 requires 
[M-H], 485.0887). 
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10.6.4 Synthesis of cephalosporin / inhibitor co-drug 
Synthesis of (6R,7R)-3-(([(2-carboxy-5-
phenylphenyl)methyl]sulfanyl)methyl)-8-oxo-7-[2-(thiophen-2-
yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
(7.72) 
To a solution containing 
cephalotin sodium salt (7.71) 
(0.20 g, 0.48 mmol) in HPLC 
grade H2O (10 mL) was added 
4-(phenyl)-2-(sulfanylmethyl) benzoic acid (7.21) (0.12 g, 0.48 mmol). The 
pH was adjusted to pH 7.0 by the drop wise addition of 1M NaOH(aq) and the 
solution was stirred at 65 °C for 6 h. The pH was kept at pH 7.0 throughout 
the reaction. After cooling to room temperature the reaction was extracted 
with EtOAc (2 × 10 mL). The aqueous was then acidified to ~pH 4 using 1M 
HCl(aq) and extracted with EtOAC (3 × 10 mL). The organics were 
concentrated in vacuo and the residue re-dissolved in NaHCO3 (10 mL). The 
aqueous was slowly acidified to pH 2 by the addition of 1M HCl(aq). The 
acidified aqueous was extracted with EtOAc (3 × 10 mL). The organics were 
dried (MgSO4) and concentrated to give a crude brown powder. The crude 
product was purified by mass directed HPLC to afford the title compound 
(7.72) as off-white plates. (72 mg, 0.12 mmol, 26%). m.p.: 114.7-115.3 °C; 
Rf: 0.02 (19:1 DCM−MeOH); δH (500 MHz, MeOD-d4): 7.92 (1H, d, J 8.1, 3-
HAr), 7.62 (2H, d, J 7.4, 6’-HAr and 2’-HAr), 7.61 (1H, d, J 2.0, 6-HAr), 7.53 
(1H, dd, J 8.1 and 2.0, 5-HAr), 7.38 (2H, app.t, J 7.4, 5’-HAr and 3’-HAr), 
7.30 (1H, t, J 7.4, 4’-H), 7.16 (1H, dd, J 4.8 and 1.6, Thio-5-H), 6.86-6.82 
(2H, m, Thio-4-H and Thio-3-H), 5.32 (1H, d, J 4.7, 7a-H), 4.68 (1H, d, J 4.7, 
6a-H), 4.21 (1H, d, J 12.9, 3c-H), 3.98 (1H, d, J 12.9, 3c-H), 3.83 (1H, d, J 
13.8, 3a-H), 3.68 (2H, dd, J 3.5 and 0.6, 7c-H), 3.50 (1H, d J 13.8, 3a-H), 
3.41 (1H, d, J 17.7, 4-H), 3.28 (1H, d, J 17.7, 4-H); δC (125 MHz, MeOD-d4): 
172.7 (HNC=O), 170.1 (COOH), 165.7 (Lactam C=O, Lactam COOH), 145.8 
(C4-Ar), 140.3 (C1’-Ar), 137.1 (C2-Ar), 133.3 (C2), 133.2 (C2-Thio), 133.1 
(C3-Ar), 130.5 (C5-Ar), 130.0 (C5’-Ar and C3’-Ar), 129.3 (C4’-Ar), 129.1 (C1-
Ar), 128.1 (C4-Thio and C3-Thio), 127.7 C6’-Ar and C2’-Ar), 126.7 (C3), 
126.4 (C6-Ar), 125.7 (C5-Thio), 60.6 (C7a), 59.4 (C6a), 31.7 (C7c), 36.0 
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(C3c), 35.9 (C3a), 28.8 (C4);  νmax/ cm
-1 (solid): 3330, 1750, 1686, 1019; 
HPLC: Tr= 2.30 (100% rel. area); m/z (ES): (Found: MH
+, 581.0870. 
C28H24N2O6S3 requires MH, 581.0869). [α]D = + 92.5 ° (c 0.10, MeOH). 
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10.7 General computational procedures 
All computational dockings were conducted on a LINUX computer using the 
CentOS 6.6 operating system. Parallel docking was conducted on the Milin6 
cluster housed at the University of Leeds. 
10.7.1 PBD pre-processing 
All PDBs were sourced from the RCSB PDB databank. Standard PDBs used 
for molecular docking are NDM-1: 3Q6X, VIM-2: 1KO3, IMP-1: 1JJT, SPM-1: 
2FHX. Each PDB complex was first opened in Maestro Version 9.9.013 
where they were visually inspected. If more than one protein molecule was 
present in the asymmetric unit, one was removed to generate a monomer 
and all water molecules were removed from the structure. 
10.7.2 SPROUT de novo design 
All SPROUT de novo design was conducted using SPROUT v6.4.10. Each 
pre-processed PDB complex was opened in the SPROUT Cangaroo module 
where the cavity was defined and receptor was defined as a 10Å cut around 
the cavity. The sites were explored by Hippo and Hydrophobic sites created. 
Fragments selected in the Elefant module came from the built in Fragment 
library. Fragments were joined in Spider using spacer templates restricted to 
carbon, nitrogen, oxygen, 5 and 6 membered aromatic rings. Suggested 
molecules were scored using Alligator. The top 1000 molecules were then 
analysed using the complexity analysis tool. The top 500 were then re 
scored and visually inspected. From this the top 10-20 were selected for re-
docking with AutoDock. 
10.7.3 AutoDock dockings 
All AutoDock dockings were conducted using AutoDock 4.2 and the results 
were visualised with AutoDockTools v1.5.6. The receptor used for docking 
was the receptor previously defined in SPROUT. 10 or 20 dockings were 
conducted per ligand. The results were scored and ranked based upon the 
most populated cluster from the graphical output. 
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Appendix 
Assay Conditions 
A1.1 Enzymatic assays 
The experiments were performed by using a NovaStar microplate reader 
(using path length correction) and were performed at r.t. (24-25 °C). All 
enzymes and substrates were dissolved in the assay buffer: 50 mM HEPES-
NaOH buffer (pH 7.2) supplemented with 1 µg / mL BSA (to minimize the 
denaturation of the enzyme), 1 µM ZnSO4 and 0.01% Triton 100.  
Hydrolysis of nitroceﬁn, CENTA, imipenem and Fluorogenic compound, was 
monitored by following the variation in absorbance at 492, 405 and 300 nm 
or fluorescence at excitation 380 nm and emission at 460 nm, respectively. 
In all cases 96 well flat bottom plates: µClear half area black plate for 
fluorescence (675096) and UV-STAR Microplate (655801) or Micro assay 
Plate (655095) for absorbance from Greiner Bio-One were used. 
The kinetic values reported in this study are the means from at least three 
independent measurements. At least six different concentrations of the 
substrate or inhibitor were used to determinate the kinetic parameters (KM, 
kcat and IC50). Determination of the steady state kinetic parameters for the 
hydrolysis of different substrates (KM and kcat) was performed by fitting the 
initial velocity data to the Michaelis-Menten equation using the software 
package Graph Prism 5.01. The IC50 values were determined from the plot 
of activity (steady state rate) versus inhibitor concentration using the same 
software. 
IC50 values (concentration required to affect 50% inhibition of enzyme 
activity) were determined by preincubation of the appropriate amount of 
enzyme with the desired compound in the assay buffer for 10 min at r.t. prior 
to the initiation of the assay by the addition of the substrate. The compounds 
for inhibition study were prepared in 1 to 100 mM DMSO stock solutions. 
Additional tests verified that the low concentration of DMSO (0.5%) present 
in the reaction mixture had no inhibition effects.  
A1.2 MIC recovery determination 
Minimal inhibitory concentration (MIC) values were determined by broth 
microdilution in cation adjusted Mueller Hinton broth (Sigma) according to 
Clinical Laboratory Standards Institute (CLSI) guidelines. Briefly, bacteria 
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were grown overnight on Mueller-Hinton agar and several colonies 
resuspended in broth to give an optical density at 600 nm equivalent to a 0.5 
McFarland standard. 20 L of a 1 in 20 dilution of this suspension was 
inoculated into microtitre plates (Corning) containing medium plus 
meropenem (Sequoia Research Products, Pangbourne, U.K.) and inhibitors 
as appropriate. The total assay volume was 200 L. Inhibitors were 
dissolved in dimethyl sulphoxide (DMSO) to 10 mg / mL and diluted in broth 
to a final concentration of 100 g / mL. The concentration of DMSO in the 
assay was 1%. For inhibitors that were not soluble under these conditions 
stocks were prepared at 1 mg/mL in 50 % DMSO, giving a final DMSO 
concentration in the assay of 5 %. Control experiments carried out in the 
absence of inhibitors confirmed that susceptibility to meropenem was 
unaffected by DMSO at these concentrations. Plates were incubated 
overnight at 37 °C for 18 – 24 h and absorbance at 600 nm read on a 
Polarstar Omega (BMG LabTech) plate reader. 
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AutoDock vHTS results 
A2.1 ChemBridge 
Cat. No Structure 
AutoDock 
Score 
SPROUT 
Score 
clogP 
5185088 
 
-9.65 -6.54 5.08 
5482935 
 
-10.60 -6.70 4.61 
5670808 
 
-9.53 -6.69 3.24 
5918981 
 
-9.80 -6.77 2.93 
6240983 
 
-9.59 -6.41 4.20 
7691782 
 
-9.70 -6.94 2.18 
9072094 
 
-9.45 -6.94 3.03 
9151689 
 
-9.50 -7.19 3.49 
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A2.2 Peakdale 
Cat. No Structure 
AutoDock 
Score 
SPROUT 
Score 
clogP 
1011074 
 
-9.62 -6.69 3.52 
1012076 
 
-10.40 -7.05 4.29 
1017178 
 
-9.62 -6.10 2.12 
1019464 
 
-9.67 -7.02 4.42 
3001659 
 
-9.60 -7.00 3.08 
3002632 
 
-9.65 -7.08 4.78 
1015266 
 
-9.58 -6.00 1.58 
1007423 
 
-9.50 -6.58 3.59 
3001861 
 
-10.40 -6.19 1.99 
3001851 
 
-9.50 -5.76 3.85 
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Peptide library generation  
A3.1 Python script to generate SMILES strings 
import sys 
import itertools 
resi1=[         'A', 
                'R', 
                'N', 
                'D', 
                'C', 
                'E', 
                'Q', 
                'G', 
                'H', 
                'I', 
                'L', 
                'K', 
                'M', 
                'F', 
                'P', 
                'S', 
                'T', 
                'W', 
                'Y', 
                'V', 
        ] 
resi2=resi3=resi1 
print 'resi1', len(resi1) 
print 'resi2', len(resi2) 
print 'resi3', len(resi3) 
 
listoflists=[resi1,resi2,resi3] 
print 'listoflists', len(listoflists) 
crude=list(itertools.product(*listoflists)) 
print len(crude) 
 
singleC=[] 
for comb in crude: 
        Ccheck=0 
        for resi in comb: 
                if resi=='C': Ccheck+=1 
        if Ccheck==1: singleC.append(comb) 
print singleC 
print len(singleC) 
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#for comb in singleC: 
#       if comb[0]=='C' and comb[1]=='D' and comb[2]=='D': 
#               print comb 
 
aminodict={     'A':'C(=O)[C@H](C)N', 
                'C':'C(=O)[C@H](CS)N', 
                'D':'C(=O)[C@H](CC(=O)O)N', 
                'E':'C(=O)[C@H](CCC(=O)O)N', 
                'F':'C(=O)[C@H](C(c1ccccc1))N', 
                'G':'C(=O)CN', 
                'H':'C(=O)[C@H](C(C1=CN=CN1))N', 
                'I':'C(=O)[C@H]([C@@H](C)(CC))N', 
                'K':'C(=O)[C@H](CCCCN)N', 
                'L':'C(=O)[C@H](CC(C)C)N', 
                'M':'C(=O)[C@H](CCSC)N', 
                'N':'C(=O)[C@H](CC(=O)N)N', 
                'P':'C(=O)[C@@H]1CCCN1', 
                'Q':'C(=O)[C@H](CCC(=O)N)N', 
                'R':'C(=O)[C@H](CCCNC(=N)N)N', 
                'S':'C(=O)[C@H](CO)N', 
                'T':'C(=O)[C@H]([C@@H](C)O)N', 
                'V':'C(=O)[C@H](C(C)(C))N', 
                'W':'C(=O)[C@H](Cc1cNc2ccccc21)N', 
                'Y':'C(=O)[C@H](Cc1ccc(O)cc1)N', 
} 
 
final=[] 
for sequence in singleC: 
        final.append(list(sequence)) 
 
for item in final: 
        for n,letter in enumerate(item): 
                if letter in aminodict.keys(): 
                        item[n]=aminodict[letter] 
                else: 
                        print 'ERRRRRRORRRRRR' 
                        sys.exit() 
 
print final 
 
peptides=[] 
for smiles in final: 
        molecule=(''.join(smiles)) 
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        add_acid=(molecule[0:5]+'(O)'+molecule[5:]) 
        peptides.append(add_acid) 
 
print peptides 
print len(peptides) 
 
output=open('output.smi', 'w+') 
for molecule in peptides: 
        output.write(molecule) 
        output.write('\n') 
 
print 'output.smi written' 
The output of this program generates the SMILES strings below: 
C(=O)(O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CS)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CN 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C(C1=CN=CN1))N 
C(=O)(O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)(CC))N 
… 
Total: 1,083 peptide SMILES strings 
A3.2 Conversion of SMILES to 2D structures using Babel 
babel -in output.smi -out output.sdf 
A3.3 Conversion of 2D structures to 3D structures using Omega 
omega –in output.sdf -strict -progress percent -maxconfs 1 -out 3D-
trimers.sdf 
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In silico peptide selection 
A4.1 Top trimer sequences 
Amino Acid 
Sequence 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses /20a 
Pro-Ile-Cys -7.40 -4.35 12 
Asn-Pro-Cys -7.00 -6.13 15 
Pro-Pro-Cys -7.50 -4.99 10 
Pro-Trp-Cys -8.40 -5.56 3 
Pro-Cys-Phe -7.76 -3.49 3 
Cys-Pro-Phe -7.30 -4.58 13 
Cys-Gly-Trp -7.60 -5.73 6 
Cys-Pro-Trp -7.60 -5.07 5 
Cys-Phe-Tyr -7.50 -4.5 4 
Cys-Pro-Tyr -7.20 -4.02 7 
 
A4.2Top scoring tetramers 
Amino Acid 
Sequence 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses /20a 
Cys-Pro-Asp-Ala -8.00 -5.35 7 
Pro-Pro-Gly-Cys -8.00 -5.73 5 
Pro-Trp-Gly-Cys -8.50 -5.53 4 
Pro-Gly-Trp-Cys -7.70 -4.62 5 
Ser-Cys-Val-Glu -7.80 -4.61 7 
Pro-Cys-Phe-Gly -7.80 -3.17 5 
Gly-Cys-Pro-Phe -7.70 -5.94 7 
Pro-Cys-Asp-Pro -7.50 -3.6 7 
Pro-Pro-Cys-Pro -7.80 -3.17 7 
Cys-Pro-Glu-Pro -7.60 -4.34 8 
 
A4.3 Top Scoring Dimers 
Amino Acid 
Sequence 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses /20a 
Asp-Cys -7.00 -6.29 14 
Glu-Cys -7.05 -5.91 10 
Gln-Cys -6.45 -4.87 16 
His-Cys -6.40 -4.96 13 
Phe-Cys -6.44 -5.67 6 
Pro-Cys -6.68 -3.64 19 
Trp-Cys -7.80 -7.18 14 
Tyr-Cys -6.67 -3.80 14 
Cys-Phe -6.30 -3.77 6 
Cys-Trp -6.70 -6.38 9 
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A4.4 Worst Scoring Trimers 
Amino Acid 
Sequence 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses /20a 
Cys-Arg-Arg -3.00 -2.98 2 
Arg-Cys-Arg -2.42 -1.89 2 
Gln-Cys-Arg -3.50 -2.34 2 
Lys-Cys-Arg -3.19 -4.08 1 
Asp-Cys-Asp -3.75 -4.57 1 
Arg-Arg-Cys -3.00 -2.46 2 
Cys-Lys-Glu -3.75 -3.41 2 
Cys-Arg-Glu -3.91 -5.42 3 
Lys-Cys-Gln -3.62 -2.38 2 
Arg-Cys-Tyr -3.41 -3.33 3 
 
A4.5 Top Scoring D-L Combinations 
Amino Acid 
Sequence 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses /20a 
D-Cys-D-Phe-D-Tyr -8.40 -5.49 5 
D-Pro-D-Trp-D-Cys -8.10 -3.71 6 
D-Cys-D-Pro-D-Tyr -8.00 -4.65 10 
D-Pro-D-Cys-D-Phe -8.00 -4.43 8 
 
a 
Number of AutoDock poses out of the 20 dockings conducted for each ligand which are in 
the most populated cluster relating to the displayed AutoDock score.   
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In silico assay evaluation 
A5.1 Substrate 
Enzyme Substrate 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses / 10b 
IMP-1 Nitrocefin -11.00 -7.95 2 
  Imipenem -6.75 -6.04 7 
  Fluorogenic -10.10 -7.63 2 
 CENTA -9.05 -8.03 1 
NDM-1 Nitrocefin -6.70 -5.11 6 
  Imipenem -6.15 -4.25 10 
  Fluorogenic -8.00 -5.69 3 
 CENTA -7.10 -4.49 2 
SPM-1 Nitrocefin 2.00 -4.01 5 
  Imipenem -3.75 -2.95 3 
  Fluorogenic 7.50 -4.57 2 
 CENTA 2.50 -3.96 2 
VIM-2 Nitrocefin -6.00 -4.46 5 
  Imipenem -7.40 -3.39 6 
  Fluorogenic -8.00 -5.08 2 
 CENTA -7.00 -3.61 5 
A5.2 Tetrahedral intermediate 
Enzyme Substrate 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses / 10b 
IMP-1 Nitrocefin -9.20 -6.61 3 
  Imipenem -6.92 -6.68 5 
  Fluorogenic -8.50 -6.20 2 
 CENTA -7.60 -8.54 2 
NDM-1 Nitrocefin -6.25 -5.64 1 
  Imipenem -5.40 -4.73 10 
  Fluorogenic -7.10 -6.26 2 
 CENTA -7.25 -6.06 3 
SPM-1 Nitrocefin 8.00 0.96 3 
  Imipenem -3.90 0.65 6 
  Fluorogenic 10.00 0.81 1 
 CENTA 2.85 -4.07 1 
VIM-2 Nitrocefin -4.50 -3.69 2 
  Imipenem -6.30 -3.51 5 
  Fluorogenic -10.00 -6.32 1 
 CENTA -3.00 -3.98 2 
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A5.3 Hydrolysis product 
Enzyme Substrate 
AutoDock 
Score 
SPROUT 
Score  
Number of AutoDock 
poses / 10b 
IMP-1 Nitrocefin -9.00 -8.23 1 
  Imipenem -6.20 -4.21 1 
  Fluorogenic -8.50 -7.57 2 
 CENTA -7.50 -6.79 2 
NDM-1 Nitrocefin -7.90 -7.00 3 
  Imipenem -5.50 -3.79 1 
  Fluorogenic -8.50 -7.34 1 
 CENTA -7.75 -5.38 2 
SPM-1 Nitrocefin 1.00 1.27 1 
  Imipenem -4.00 0.89 3 
  Fluorogenic 0.00 1.12 1 
 CENTA 8.00 -3.83 1 
VIM-2 Nitrocefin -5.00 -4.86 1 
  Imipenem -7.25 -4.29 4 
  Fluorogenic -8.00 -5.13 2 
 CENTA -7.00 -6.17 2 
 
b 
Number of AutoDock poses out of the 10 dockings conducted for each ligand which are in 
the most populated cluster relating to the displayed AutoDock score.   
 
 
 
